

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

This Page Blank (uspto)

Result No.	Score	Query	Match	Length	DB	ID	Description
1	3013	100.0	601	8	ADO19021		Ado19021 Full-length Ado19023 C-terminal Aar1016 Polypept1
2	3034.5	95.8	580	8	ADO19023		Aar101679 NS5B prot
3	3027	95.6	3010	2	ARR3016		Aaw01679 NS5B prot
4	3016	95.2	591	2	AAW01679		Aaw01680 HCV NS2-N
5	3016	95.2	2201	2	AAW01680		Aar20111 Non-A, no
6	3016	95.2	3010	2	AAR20111		Aar20091 Non-A, no
7	3016	95.2	3010	7	ADP88597		AdF88597 Hepatitis Aaw88022 Infection
8	3015	95.2	3010	2	AAW01679		Aaw88022 Infectiou
9	3015	95.2	3010	4	AAB31170		Ado1170 Amino aci
10	3015	95.2	3010	8	ADO36227		Ado36227 Hepatitis
11	3015	95.2	3010	8	AD079401		Ado79401 Hepatitis
12	3014	95.2	592	8	AD036215		Ado36215 Hepatitis
13	3014	95.2	592	8	AD079389		Ado79389 Hepatitis
14	3014	95.2	3010	2	AAY06423		Aay06423 Non-A, no
15	3013	95.1	3010	2	AAY06423		Aar8864 Hepatitis
16	3013	95.1	591	4	AB60130		Aab0130 Hepatitis
17	3012	95.1	591	6	AA026416		Aao6416 Protein d
18	3012	95.1	1985	6	ABU09575		Abu09575 HCV Met-N
19	3012	95.1	3010	2	ABR68622		Aar8622 HCV prote
20	3011	95.1	591	5	AGG79560		Aag79560 HCV NS5B
21	3011	95.1	621	5	AGG79556		Aag79556 HCV decree
22	3011	95.1	621	5	AAB18903		Aab18903 Hepatitis
23	3011	95.1	621	6	ABP71699		Abp71699 HCV NS5B
24	3011	95.1	621	6	ABR41892		Abr41892 Hepatitis

Copyright (c) 1993 - 2005 Compugen Ltd.	GenCore version 5.1.6	Abp97967 Amino aci
OM protein - protein search, using sw model		AAG79561 HCV decree
Run on: September 22, 2005, 14:39:13 ; Search time 169 Seconds (without alignments)	1375.402 Million cell updates/sec	ADG19078 NS5B
Title: US-10-712-479-2		Aar82694 Partial H
Perfect score: 3167		Aao18001 Hepatitis
Sequence: 1 MASMSMSYTWTGALITPCAA.....LLSGVGIVYLPPNRHHHHH 601		Aae15729 Hepatitis
Scoring table: BLOSUM62		Aae15731 Hepatitis
Gapext 0 , Gapext 0.5		Aae15720 Hepatitis
Searched: 2105692 seqs, 386760381 residues	2105692	Aae15717 Hepatitis
Total number of hits satisfying chosen parameters:		Aae15727 Hepatitis
Minimum DB seq length: 0		Aae15728 Hepatitis
Maximum DB seq length: 2000000000		Aae15722 Hepatitis
Post-processing: Minimum Match 0% Maximum Match 100%		Aae15730 Hepatitis
Database : Listing first 45 summaries		ADJ57846 HCV repli
		Abg30591 Hepatitis
		Abg30600 Hepatitis
		Abg30581 Hepatitis
		Abg30586 Hepatitis
		Abg30593 Hepatitis
		Abg30582 Hepatitis
		ALIGMENTS
		RESULT 1
		ID ADO19021
		XX ADO19021 standard; protein; 601 AA.
		XX ADO19021;
		XX DT 12-AUG-2004 (first entry)
		XX DE Full-length HCV NS5B polymerase, FL NS5B.
		XX KW RNA polymerase activity; continuous-read assay; HCV infection; Polymerase; NSSB;
		XX KW Hepatitis C virus infection; Polymerase; carcinoma; cardiovascular disease;
		XX KW bone mineral disease; osteoporosis; carcinoma; cardiovascular disease;
		XX KW diabetes; ocular disorder; renal dysfunction; lymphoma;
		XX KW lymphoproliferative disorder; metabolic disorder; arthritis;
		XX KW sleep disorder; thyroid disorder; antinflammatory; hepatotropic;
		XX KW virucide; osteopathic; cytotoxic; antidiabetic; ophthalmological;
		XX KW nephrotropic; antiarthritic; enzyme.
		XX OS Hepatitis C virus.
		XX PN WO2004044228-A2.
		XX XX 27-MAY-2004.
		XX PF 13-NOV-2003 ; 2003WO-US036465.
		XX PR 13-NOV-2002 ; 2002US-04225981P.
		XX XX (PFIZER INC.
		XX PI Yagi Y, Sheets MP, Wells PA, Shelly JA, Poorman RA, Epps DE;
		XX PI Morgan AG;
		XX XX WPI ; 2004-420337/39.
		XX DR N-PSDB ; ADO19020.
		XX PR Detecting RNA polymerase activity in a continuous-read manner, useful in
		PR treating osteoporosis, carcinoma, cardiovascular disease, ocular
		PR disorders or arthritis, by contacting an RNA polymerase with an
		PR oligonucleotide template.
		XX XX Claim 5 ; SEQ ID NO 2 ; 46pp ; English.
		CC The present invention relates to a method for detecting RNA polymerase
		CC activity in a continuous-read manner. The method comprises contacting an RNA polymerase with an oligonucleotide template in a reaction mixture
		CC comprising an assay buffer, under conditions in which the RNA polymerase

CC is active, adding a fluorescent dye capable of binding double-stranded CC nucleic acid molecules to the reaction mixture, and measuring the CC fluorescence of the reaction mixture. The RNA polymerase is the Hepatitis CC virus (HCV) polymerase, NS5B. The method is useful for treating HCV CC infection, bone mineral diseases like osteoporosis, carcinomas, CC cardiovascular diseases, diabetes, ocular disorders, metabolic disorders, CC lymphomas, lymphoproliferative disorders, metabolic disorders, arthritis, CC sleep disorders and thyroid disorders. The present sequence represents CC a full-length HCV NS5B polymerase (designated FL NS5B).

XX Sequence 601 AA;

Query Match 100.0%; Score 3167; DB 8; Length 601;
 Best Local Similarity 100.0%; Pred. No. 4e-294;
 Matches 601; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MASMSMSYTWTGALITPCAAEESKLPINALNSLRLRHNLYSTTSRSASLRQKVKTEFR 60
 Db 1 MASMSMSYTWTGALITPCAAEESKLPINALNSLRLRHNLYSTTSRSASLRQKVKTEFR 60
 Qy 61 LQVLDHYDVKEMKAKASTVKAKLISVERBACKLTPHSAKSKFGYGAQDVSLSPPAV 120
 Db 61 LQVLDHYDVKEMKAKASTVKAKLISVERBACKLTPHSAKSKFGYGAQDVSLSPPAV 120
 Qy 121 NHIRSYWKDQLEDDTPIQTTIMAKNEVPCVQPKGGKPKPARLIVPPDGLVYCEKMYL 180
 Db 121 NHIRSYWKDQLEDDTPIQTTIMAKNEVPCVQPKGGKPKPARLIVPPDGLVYCEKMYL 180
 Qy 181 DVVSTLPQAVMGSSYGFQYSPKQREFLYNTWAKKCPMGFSDTRCPDSTTENDRVE 240
 Db 181 DVVSTLPQAVMGSSYGFQYSPKQREFLYNTWAKKCPMGFSDTRCPDSTTENDRVE 240
 Qy 241 ESIYOCQCDLAPEAQDAAIRSLETERLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Db 241 ESIYOCQCDLAPEAQDAAIRSLETERLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Qy 301 LKAAAACRAAKLQDCTMLANGDDLVICSGASQTBDAASLRVFTTEAMTRYSAQPGDPPQ 360
 Db 301 LKAAAACRAAKLQDCTMLANGDDLVICSGASQTBDAASLRVFTTEAMTRYSAQPGDPPQ 360
 Qy 361 EYDLELITSCSNSVVAHDASGRKVYLTRDPTPLARAAWETARHTPPNSLGNINI MYA 420
 Db 361 EYDLELITSCSNSVVAHDASGRKVYLTRDPTPLARAAWETARHTPPNSLGNINI MYA 420
 Qy 421 PTIWMARLMLTHFFSILLAOEQLQEQLDQYQYACYSIEPLDLPQITRLHGSAPSLSH 480
 Db 421 PTIWMARLMLTHFFSILLAOEQLQEQLDQYQYACYSIEPLDLPQITRLHGSAPSLSH 480
 Qy 481 YSPGEINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGGRALCGKYLFLNWAVRTKLL 540
 Db 481 YSPGEINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGGRALCGKYLFLNWAVRTKLL 540
 Qy 541 TPIPASRUDLSGMFVAGYSGGDIYHSLSRPRWFMLLUSVGVGYLLPNRHHHH 600
 Db 541 TPIPASRUDLSGMFVAGYSGGDIYHSLSRPRWFMLLUSVGVGYLLPNRHHHH 600
 Qy 601 H 601
 Db 601 H 601

RESULT 2
 ID AD019023 Standard; protein: 580 AA.

XX AD019023;
 AC
 XX DT 12-AUG-2004 (First entry)
 DE C-terminally truncated HCV NS5B polymerase, Cde1ta21 NS5B.
 KW RNA polymerase activity; continuous-read assay;
 KW Hepatitis C virus infection; HCV infection; polymerase; NS5B;
 KW 181 DVSTLPQAVMGSSYGFQYSPKQREFLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Db 181 DVSTLPQAVMGSSYGFQYSPKQREFLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Qy 121 NHRSWVKDQLEDDTPIQTTIMAKNEVPCVQPKGGKPKPARLIVPPDGLVYCEKMYL 180
 Db 121 NHRSWVKDQLEDDTPIQTTIMAKNEVPCVQPKGGKPKPARLIVPPDGLVYCEKMYL 180
 Qy 61 LQVLDHYDVKEMKAKASTVKAKLISVERBACKLTPHSAKSKFGYGAQDVSLSPPAV 120
 Db 61 LQVLDHYDVKEMKAKASTVKAKLISVERBACKLTPHSAKSKFGYGAQDVSLSPPAV 120
 Qy 121 NHRSWVKDQLEDDTPIQTTIMAKNEVPCVQPKGGKPKPARLIVPPDGLVYCEKMYL 180
 Db 121 NHRSWVKDQLEDDTPIQTTIMAKNEVPCVQPKGGKPKPARLIVPPDGLVYCEKMYL 180
 Qy 181 ESIYOCQCDLAPEAQDAAIRSLETERLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Db 181 ESIYOCQCDLAPEAQDAAIRSLETERLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Qy 241 ESIYOCQCDLAPEAQDAAIRSLETERLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Db 241 ESIYOCQCDLAPEAQDAAIRSLETERLYVGPMTNSKGKQNGCYRCCRASGVLTTSQGNTLTCY 300
 Qy 301 LKAAAACRAAKLQDCTMLANGDDLVICSGASQTBDAASLRVFTTEAMTRYSAQPGDPPQ 360

		SQ	Sequence 3010 AA;	Query Match	Score 3027;	DB 2;	Length 3010;
Db	301 IKAACAAACRAAKLQDCTMLVNGDDLVVICESAGTQEDASLRVFTTEAMTRYSAPPDPQP 360			Best Local Similarity 95.6%;	Pred. No. 1.3e-279;		
Qy	361 YDYLELITCSNSVYAHDAKGKRYYLTRPPTVPLARAWEWAHTTPNSWLNNTIMYA 420			Matches 572; Conservative 9;	Missmatches 10;	Indels 0;	Gaps 0;
Db	361 YDYLELITCSNSVYAHDAKGKRYYLTRPPTVPLARAWEWAHTTPNSWLNNTIMYA 420						
Qy	421 PTIWLARMILATHFFESTLIAQQLPEKALDCQIYGACYSIEPLDLPQIERTHLGLSPLHS 480			5 SMSYTWTGALITPCAAEESKLPTNALSNSLRLRHNLVYSTSRSASLROKVTFDRQLV 64			
Db	421 PTIWLARMILATHFFESTLIAQQLPEKALDCQIYGACYSIEPLDLPQIERTHLGLSPLHS 480			Db 2420 SMSYTWTGALITPCAAEESKLPTNALSNSLRLRHNLVYSTSRSASLROKVTFDRQLV 2479			
Qy	481 YSPGBINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGRAAICGKYLFWAVRTKLKL 540			Qy 65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSFKFGYGAKDVRSLSSRAVNRH 124			
Db	481 YSPGBINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGRAAICGKYLFWAVRTKLKL 540			Db 2480 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSFKFGYGAKDVRSLSSRAVNRH 2539			
Qy	541 TPIPAASRLDLSGWFVAGYSSGCDIYHSLSRSPRFMLCILLLSSTGVGTYLLPQRHHHH 600			Qy 125 SWKDLLEDIDTPPIQTTIMAKNEVCPQPKGGRKPKPARLIVFPDQGVRVCEKMAIYDVS 184			
Db	541 TPIPAASRLDLSGWFVAGYSSGCDIYHSLSRSPRFMLCILLLSSTGVGTYLLPQRHHHH 600			Db 2540 SWKDLLEDIDTPPIQTTIMAKNEVCPQPKGGRKPKPARLIVFPDQGVRVCEKMAIYDVS 2599			
Qy	601 H 601			Qy 185 TLPOAVMGSSYGFOSPKORVEFLVNTWAKKCPMGFSYDTRCFDSTVTDNDIVREESIY 244			
Db	601 H 601			Db 2600 TLPOAVMGSSYGFOSPKORVEFLVNTWAKKCPMGFSYDTRCFDSTVTDNDIVREESIY 2659			
Qy	580 H 580			Qy 245 QCCDLAPBARQAIISLTERLYVGPMTNSKGQNCYRRCASGVLTTSCGNTLTCYKAA 304			
Db	580 H 580			Db 2660 QCCDLAPBARQAIISLTERLYVGPMTNSKGQNCYRRCASGVLTTSCGNTLTCYKAA 2719			
RESUL T 3				Qy 305 AACRAAKLQDQCTMLVNGDDLVICESAGTQEDASLRVFTTEAMTRYSAPPGDPPPEYDL 364			
AAR30616				Db 2720 AACRAAKLQDQCTMLVNGDDLVICESAGTQEDASLRVFTTEAMTRYSAPPGDPPPEYDL 2779			
ID AAR30616	standard; protein; 3010 AA.			Qy 365 ELITSCSSNSVVAIDASGKRYVYLTRDPTVPLARAWEETARHTPNSWLNNTIMAPTLW 424			
XX				Db 2780 ELITSCSSNSVVAIDASGKRYVYLTRDPTVPLARAWEETARHTPNSWLNNTIMAPTLW 2839			
AC AAR30616;				Qy 425 ARMLMTPHPSILLAQEQLEKALDCQIYGACYSIEPLDLPQIERTHLGLSAFSLHSSPG 484			
XX				Db 2840 ARMLMTPHPSILLAQEQLEKALDCQIYGACYSIEPLDLPQIERTHLGLSAFSLHSSPG 2899			
KW KHCV-LBC1; diagnosis; vaccine.				Qy 485 BINRVASCIRKLGVPPLRWRHRSVRAKLLSQGRAAICGKYLFWAVRTKLKLTPIP 544			
DT 27-AUG-2003 (revised)				Db 2900 BINRVASCIRKLGVPPLRWRHRSVRAKLLSQGRAAICGKYLFWAVRTKLKLTPIP 2959			
DT 25-MAR-2003 (revised)				Qy 545 AASRLDLSGMFVAGYSGDDIYHSLSRAPRFMLCLLISVGVGYLPLNIR 595			
DT 19-MAY-1993 (first entry)				Db 2960 AASRLDLSGMFVAGYSGDDIYHSLSRAPRFMLCLLISVGVGYLPLNIR 3010			
XX	Polypeptide coded by Korean HCV full cDNA sequence LBC1.			RESULT 4			
DE				ID AAW01679 standard; protein; 591 AA.			
XX				XX AAW01679;			
KW	KHCV-LBC1; diagnosis; vaccine.			AC AAW01679;			
XX				XX DT 17-OCT-2003 (revised)			
OS Hepatitis C virus.				XX DT 25-MAR-2003 (revised)			
XX				XX DT 19-AUG-1997 (first entry)			
PN EP521318-A2.				XX XX Hepatitis C virus; strain BK.			
XX				XX XX Hepatitis C virus; HCV; non-structural protein; NSSB; polyprotein;			
PD 07-JAN-1993.				XX XX RNA dependent RNA polymerase; RDRP; terminal nucleotidyl transferase;			
XX				XX XX TNAse; method; assay; in vitro activity; therapy; inhibitor.			
PP 10-JUN-1992;	92EP-00109753.			XX XX			
XX				XX XX			
PR 10-JUN-1991;	91KR-00009510.			XX XX			
PR 06-AUG-1991;	91KR-00013601.			XX XX			
XX				XX XX			
PA (LUCK-) LUCKY LTD.				XX XX			
XX				XX XX			
PI Cho JM, Lee YB, Park YW, Lim KJ, Choi DY, So HS, Kim CH;				XX XX			
PI Kim ST, Yang JY;				XX XX			
XX				XX XX			
DR WPI: 1993-001883/01.				XX XX			
DR N-PSDB; AAQ33282.				XX XX			
XX				XX XX			
PT DNA and polypeptide(s) from a new type of hepatitis C virus (KHCV) - for				XX XX			
PT diagnosing and vaccinating against KHCV infections.				XX XX			
PS Disclosure; Fig 2; 119pp; English.				XX XX			
XX				XX XX			
CC The polypeptide is that encoded by the full cDNA sequence of Korean				XX XX			
CC hepatitis C virus (KHCV) CDNA, KHCV-LBC1. It or its fragments may be used				XX XX			
CC in a specific and accurate method for detecting KHCV antibodies in the				XX XX			
CC serum of hepatitis C patients. Antibodies directed against these				XX XX			
CC polypeptides are useful for the purification of KHCV antigens and for the				XX XX			
CC development of an improved diagnostic to detect KHCV antigens in a				XX XX			
CC sample. The polypeptides may also be used in a vaccine for treatment and				XX XX			
CC prevention of KHCV infection at a dosage of 5-200 ug/peptide. (Updated on				XX XX			
CC 25-MAR-2003 to correct PN field.) (Updated on 27-AUG-2003 to correct OS				XX XX			
CC field.)				XX XX			

Qy	5	SMSYTWTGALITPCAAEBSKIPINALNSLJRHMLVYSTSRSASLROCKVTPDRQLV	64	PT	Protein	1615. .1862
Db	1611	SMSYTWTGALITPCAAEBSKIPINALNSLJRHMLVYSTSRSASLROCKVTPDRQLV	1670	PT	Protein	/label= NS4a
Qy	65	DDHYDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSRAVNHIR	124	PT	Protein	1863. .2012
Db	1671	DDHYDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSRAVNHIR	1730	PT	Protein	/label= NS4b
Qy	125	SWKQDILEDTPDITPIQTTIMARNEVCPQPEKGRKPARLIVFDLGVRVCEKMLDYVVS	184	PT	Protein	2013. .3010
Db	1731	SWKQDILEDTPDITPIQTTIMARNEVCPQPEKGRKPARLIVFDLGVRVCEKMLDYVVS	1790	XX	XX	/label= NS5
Qy	185	TLPOQAWMGSSYGFQISPKORVEFLINTWKAKKCPNGFSYDTRCPFDSTVENDIVBESY	244	PT	Protein	EP463848-A.
Db	1791	TLPOQVMGSSYGFQISPKORVEFLINTWKAKKCPNGFSYDTRCPFDSTVENDIVBESY	1850	XX	XX	XX
Qy	245	QCCDLAPEARQAISSITERLYVGPMNTNSKGQNCGYRRCASGVLTSCCTNLTCYKAA	304	PR	25-JUN-1990;	02-JAN-1992.
Db	1851	QCCDLAPEARQAISSITERLYVGPMNTNSKGQNCGYRRCASGVLTSCCTNLTCYKAA	1910	PR	25-JUN-1990;	02-JUN-1991;
Qy	305	AACRAAKLQDQDTMLVNGDDLVVICESAGTOADAASLRVFTTEAMTRYSAPEGDPPPEYDL	364	PR	31-AUG-1990;	02-JUN-1992.
Db	1911	AACRAAKLQDQDTMLVNGDDLVVICESAGTOADAASLRVFTTEAMTRYSAPEGDPPPEYDL	1970	PR	09-NOV-1990;	02-JUN-1992.
Qy	365	BLITSCSSNSVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPNSMIGNINMYAPTWW	424	PR	28-DEC-1990;	02-JUN-1992.
Db	1971	BLITSCSSNSVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPNSMIGNINMYAPTWW	2030	PR	08-MAY-1991;	02-JUN-1992.
Qy	425	ARMILMTHPFSSILLAQEQLKALDCQIYGACYSIRPLDQLQIIEHLHGSAPSLSHSSYSPG	484	PR	14-MAY-1991;	02-JUN-1992.
Db	2031	ARMILMTHPFSSILLAQEQLKALDCQIYGACYSIRPLDQLQIIEHLHGSAPSLSHSSYSPG	2050	PA	PA (OSAU) UNIV OSAKA.	(REMI-) RES FOUND MICROBIAL.
Qy	485	EINRVASCLRLKGVPPLRVHRARSVRAKLQSQGRAAICKGYLNFNVAVRKTLKTPIP	544	PS	Disclosure; Fig 2; 89pp; English.	
Db	2091	EINRVASCLRLKGVPPLRVHRARSVRAKLQSQGRAAICKGYLNFNVAVRKTLKTPIP	2150	DR	WPI: 1992-009412/02.	
Qy	545	AASRLDLSGMVAGYGGDIIYHSLSRARPWFMCLLISVGVGYLLPNR	595	DR	N-PSDB; AAQ20268.	
Db	2151	AASRLDLSGMVAGYGGDIIYHSLSRARPWFMCLLISVGVGYLLPNR	2201	CC	Non-A, non-B hepatitis virus (NANBV) particles - as vaccines, immuno- diagnostics and screening agents for NANBV, and to remove NANBV from blood.	
Qy	2000	5 SMSYTWTGALITPCAAEBSKIPINALNSLJRHMLVYSTSRSASLROCKVTPDRQLV	64	CC	The sequence (SEQ ID NO 1) was deduced from several overlapping from a library prep. from NANBV RNA. Antigenic polypeptides from the sequence can be used as immunoassay reagents, for screening donated blood, and as immunogens for vaccine prodn. Antibodies raised to the peptides can be used in immunoassays to detect or quantify NANBV antigens in liver tissue and blood. Preferred polypeptides include residues 1-30, or 115, or 2012; 47-77; 116-191; 192-207 or -298; 230-238 or -263; 287-300; 293-300; 390-729; 730- 1005; 1006-1614; 1384-1414; 1615-1862; 1737-1767; 1863-2012; and 2013-3010. The sequence is also disclosed in EP-164287 (SEQ ID NO 1). see AAR20091 for details of this specification. (Updated on 25-MAR-2003 to correct PD field.) (Updated on 25-MAR-2003 to correct PA field.)	
Db	2092	5 SMSYTWTGALITPCAAEBSKIPINALNSLJRHMLVYSTSRSASLROCKVTPDRQLV	64	CC	Sequence 3010 AA;	
Qy	2420	DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSRAVNHIR	124	CC	Query Match 95.2%; Score 3016; DB 2; Length 3010;	
Db	2480	DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSRAVNHIR	2539	CC	Best Local Similarity 96.6%; Pred. No. 1.5e-278; Mismatches 9; Indels 0; Gaps 0;	
Qy	65	5 SMSYTWTGALITPCAAEBSKIPINALNSLJRHMLVYSTSRSASLROCKVTPDRQLV	64	CC	5 SMSYTWTGALITPCAAEBSKIPINALNSLJRHMLVYSTSRSASLROCKVTPDRQLV	
Db	2420	DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSRAVNHIR	124	CC	2420 SMSTWTGALITPCAAEBSKIPINALNSLJRHMLVYSTSRSASLROCKVTPDRQLV	
Qy	185	TLPQAVMGSSYGFQYSPIRQEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY	244	CC	65 DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSRAVNHIR	
Db	2480	TLPQAVMGSSYGFQYSPIRQEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY	2659	CC	2480 DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSRAVNHIR	
Qy	125	QCCDLAPBARQATRSLTLERLYVGGMFTMNSKGONGCYRGRASGVLTSCCTNLTCYKAA	384	CC	125 SWWDLLEDTPDITPIQTTIMAKNIVFCVQPEKGGRKPARLIVFPDGLVRYCEKMLDYVVS	
Db	2540	QCCDLAPBARQATRSLTLERLYVGGMFTMNSKGONGCYRGRASGVLTSCCTNLTCYKAA	2599	CC	2540 SWWDLLEDTPDITPIQTTIMAKNIVFCVQPEKGGRKPARLIVFPDGLVRYCEKMLDYVVS	
Qy	185	TLPQAVMGSSYGFQYSPIRQEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY	2659	CC	185 TLPQAVMGSSYGFQYSPIRQEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY	
Db	2600	TLPQAVMGSSYGFQYSPIRQEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY	2719	CC	2600 TLPQAVMGSSYGFQYSPIRQEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY	
Qy	245	QCCDLAPBARQATRSLTLERLYVGGMFTMNSKGONGCYRGRASGVLTSCCTNLTCYKAA	304	CC	245 QCCDLAPBARQATRSLTLERLYVGGMFTMNSKGONGCYRGRASGVLTSCCTNLTCYKAA	
Db	2660	QCCDLAPBARQATRSLTLERLYVGGMFTMNSKGONGCYRGRASGVLTSCCTNLTCYKAA	3729	CC	2660 QCCDLAPBARQATRSLTLERLYVGGMFTMNSKGONGCYRGRASGVLTSCCTNLTCYKAA	
Qy	305	AACRAAKLQDQDTMLVNGDDLVVICESAGTOEADASLRVFTTEAMTRYSAPEGDPPPEYDL	364	CC	305 AACRAAKLQDQDTMLVNGDDLVVICESAGTOEADASLRVFTTEAMTRYSAPEGDPPPEYDL	
Db	2720	AACRAAKLQDQDTMLVNGDDLVVICESAGTOEADASLRVFTTEAMTRYSAPEGDPPPEYDL	2779	CC	2720 AACRAAKLQDQDTMLVNGDDLVVICESAGTOEADASLRVFTTEAMTRYSAPEGDPPPEYDL	

Qy	365 ELITSCSSNVVAHDASGKRVVYLTIDPTPLARAATETARHTPVNSLGNIMYAPTLW 424	PT New DNA from non-A, non-B hepatitis virus - and derived antigenic polypeptide(s) useful for diagnostic, blood screening and in vaccines.
Db	2780 ELITSCSSNVVAHDASGKRVVYLTIDPTPLARAATETARHTPVNSLGNIMYAPTLW 2339	XX PS Claim 3; Fig 2; 89pp; English.
Qy	425 ARMLMTHFFSILLAQEQLKALDQIYGACYSTEPLDLPLQIETRLHGLSASFSLHHSYSPG 484	CC The sequence was deduced from several overlapping "BK" cDNA clones obt. by "gene walking" using a cDNA clone isolated from a library prep. from NANB RNA. Antibiotic polypeptides from the sequence can be used as immunogens for screening donated blood, and as immunogens for immunoassay reagents for screening donated blood, and as immunogens for vaccine prodn. Antibodies raised to the peptides can be used in immunoassays to detect or quantify NANB antigens in liver tissue and blood. Preferred polypeptides are include residues 1-30; -115, or 2012; 47-77; 116-191; 192-207 or -298; 230-238 or -263; 287-300; 291-330; 390-729; 730-1005; 1006- 1614; 1384-1414; 1615-1862; 1737-1767; 1863-212; and 2013-3030. The sequence is also disclosed in EP-463848 (SEQ ID NO 1) in which a virus particle contg. antigens encoded by the sequence is claimed. See AAR2011 for details of this specification. (Updated on 25-MAR-2003 to correct PA field.)
Db	2840 ARMLMTHFFSILLAQEQLKALDQIYGACYSTEPLDLPLQIETRLHGLSASFSLHHSYSPG 2899	XX PS Claim 3; Fig 2; 89pp; English.
Qy	485 BINRVASCLRKLGPPPLRWRARSVRAKLGSQGRAGAICGKYLENVAWTKLKLTPP 544	CC
Db	2900 BINRVASCLRKLGPPPLRWRARSVRAKLGSQGRAGAICGKYLENVAWTKLKLTPP 2959	CC
Qy	545 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMCLLUSVGIVYLLPNR 595	CC
Db	2960 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMCLLUSVGIVYLLPNR 3010	CC
RESULT 7		
AAR20091 standard; protein; 3010 AA.		
XX		Sequence 3010 AA;
AC	AAR20091;	Query Match 95.2%; Score 3016; DB 2; Length 3010;
XX		Best Local Similarity 96.6%; Pred. No. 1..5e-278; Indels 0; Gaps 0;
DT	25-MAR-2003 (revised)	Matches 571; Conservative 11; Mismatches 9;
DT	01-MAY-1992 (first entry)	Indels 0; Gaps 0;
XX		DB 2420 SMSYTTWGLITPQAAEBSKLPIINALSNSLRLRHNLYVSTTSASLHQKVKTFDRLQVL 2479
DE	Non-A, non-B viral genome product.	Qy 5 SMSYTTWGLITPQAAEBSKLPIINALSNSLRLRHNLYVSTTSASLHQKVKTFDRLQVL 64
XX		DB 2480 DDHYRDVILKEMKAKASTYRAKLLSVEEACKLTPPHSAKSFKFGYGAOKDVRSLSSRAVNHHIR 124
KW	NANBV; vaccine; immunodiagnosis; antigen; antibody.	Qy 65 DDHYRDVILKEMKAKASTYRAKLLSVEEACKLTPPHSAKSFKFGYGAOKDVRSLSSRAVNHHIR 124
XX		DB 2480 DDHYRDVILKEMKAKASTYRAKLLSVEEACKLTPPHSAKSFKFGYGAOKDVRSLSSRAVNHH 2539
OS	Non-A.	Qy 125 SWKNDLLEDIDTPDPTQTTMAKNEVCFVCEPKGKPKPLIVEFDLGVYVCEKMAHYDVS 184
XX		DB 2540 SWKNDLLEDIDTPDPTQTTMAKNEVCFVCEPKGKPKPLIVEFDLGVYVCEKMAHYDVS 2599
FH	Key	FT 185 TLPAVMSGSYGQYSQPCREVLVNTWKAKCPGMPFYTDTCPDSTTENDTREVESYY 244
FT	Protein	FT 2600 TLQPVYMGSSYGFQYSQPCREVELVNTWKSKNPMGFYDTRCFDSTTENDTREVESYY 2659
FT	Protein	FT 245 QCCDLAPEARQARQARSLTTERLYVGPMTNISKGONGCYRRCRASGVLTISCGNTLTCYKAA 304
FT	Protein	FT 2660 QCCDLAPEARQARQAKSLTTERLYIGPLTNISKGONGCYRRCRASGVLTISCGNTLTCYKAS 2719
FT	Protein	FT 305 AACRAAKLQDCTMLVNGDLYVICESACTQDAAASLRFTTEAMTRYSAPPGDPQPETDL 364
FT	Protein	FT 2720 AACRAAKLQDCTMLVNGDLYVICESACTQDAAASLRFTTEAMTRYSAPPGDPQPETDL 2779
FT	Protein	FT 365 ELTSCSSNVSVADASGKRVYLTRDSTVPLARAATWTAHTPVNSLGNIMYAPTLW 424
FT	Protein	FT 2780 ELTSCSSNVSVADASGKRVYLTRDSTVPLARAATWTAHTPVNSLGNIMYAPTLW 2839
FT	Protein	FT 425 ARMLMTHFFSILLAQEQLKALDQIYGACYSTEPLDLPLQIETRLHGLSASFSLHHSYSPG 484
FT	Protein	FT 2840 ARMLMTHFFSILLAQEQLKALDQIYGACYSTEPLDLPLQIETRLHGLSASFSLHHSYSPG 2899
XX	PN EP464287-A.	Qy 485 EINRVASCLRKLGPPPLRWRARSVRAKLGSQGRAGAICGKYLENVAWTKLKLTPP 544
XX		DB 2900 EINRVASCLRKLGPPPLRWRARSVRAKLGSQGRAGAICGKYLENVAWTKLKLTPP 2959
PD	08-JAN-1992.	Qy 545 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMCLLUSVGIVYLLPNR 595
XX	PP 28-DEC-1990;	DB 2950 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMCLLUSVGIVYLLPNR 3010
XX	(OSAU) UNTV OSAKA.	RESULT 8
XX	PR 25-JUN-1990;	ADP88597
PR	31-AUG-1990;	ADP88597 standard; protein; 3010 AA.
PR	09-NOV-1990;	XX
PR	17-JUN-1991;	AC
XX	91EP-00401604.	XX
XX		DR DR88597;
DR	WPI: 1992-009617/02.	XX
DR	N-PSDB; AAQ21829.	DT 26-FEB-2004 (first entry)
XX		

XX	ADO36227;	QY	245	QCCDLAPEARQAIRSLTERLYVGGPMNTISKONGGYYRGRASGVLTTCGNTLTCYKAA	304
AC		Db	2660	QCCDLAPEARQAIRSLTERLYVGGPMNTISKONGGYYRGRASGVLTTCGNTLTCYKAA	2719
XX	26-AUG-2004 (first entry)	QY	305	AACRAAKLQDCTMLVNGDDLVICSAQTOEDAASLRVTEAMTRYSAPGDPOPEYD	364
DB	Hepatitis C virus (HCV) J4L6 wild-type polyprotein.	Db	2720	AACRAAKLQDCTMLVNGDDLVICSAQTOEDAALRAATEAMTRYSAPGDPOPEYD	2779
XX	hepatotrophic; viruside; gene therapy; vaccine; core protein; HCV infection; vaccination; polyprotein.	QY	365	ELITSCSSNSVVAHDASGRKVYLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTLW	424
KW	Hepatitis C virus; HCV; core protein.	Db	2780	ELITSCSSNSVVAHDASGRKVYLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTLW	2839
XX	OS	QY	425	ARMILMTHFPTSLILQAEQLEKALDCQIYGACYSTEPLDLQPIERLHGLSAFSLHHSYSPG	484
OS	Hepatitis C virus.	Db	2840	ARMILMTHFPTSLILQAEQLEKALDCQIYGACYSBPLDQPIERLHGLSAFTHHSYSPG	2899
PN	WO2004046175-A1.	QY	485	EINRVASCLRKLGYPPLTRWHRARSVRAKLLSGGRAICGKYLFWNAVRTRKLTLP	544
XX	03-JUN-2004.	Db	2900	EINRVASCLRKLGYPPLTRWHRARSVRAKLLSGGRAATCGRLFWNAVRTRKLTLP	2959
XX	PP	QY	545	AASRLDLSGMFVAGYSGGDLYHSSLRARRPRWFMLCLLILSFGVGYIYLNR	595
XX	13-NOV-2003; 2003WO-EP012793.	Db	2960	AASOLDLSGMFVAGYSGGDLYHSSLRARRPRWFPLCLLILSFGVGYIYLPNR	3010
PR	15-NOV-2002; 2002GB-00026722.				
XX	(GLAX) GLAXO GROUP LTD.				
XX	Brett S, Hamblin PA, Ogilvie L;				
PI					
DR	WPI; 2004-420613/39.				
DR	N-PSDB; ADO36222.				
XX	PT	RESULT 12			
XX	New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes the polypeptide sequences of the HCV core and at least one other HCV protein, for use in medicine, particularly for manufacturing a medicament for treating HCV.	AD079401			
XX	PS	AD079401 standard; protein; 3010 AA.			
XX	Disclosure: Fig 6; 78pp; English.	AC			
XX	The invention describes a polynucleotide vaccine comprising a polynucleotide sequence (S1) encoding the Hepatitis C virus (HCV) Core protein and at least 1 other HCV protein, and causes expression of the proteins in cells (in which (S1) has been mutated or positioned relative to the polynucleotide sequence encoding the other HCV protein, so that the negative effect of the core protein on expression of the other HCV protein is reduced). Also described are: a method of preventing or treating an HCV infection in a mammal, comprising administering the vaccine cited above to a mammal; and a method of vaccination of an individual, comprising taking a polynucleotide vaccine as cited above, coating the polynucleotide onto gold beads and delivering the gold beads into the skin. HCV nucleic acids, peptides, host cells, vectors and antibodies used in the methods, are also disclosed. The polynucleotide vaccine is useful in the manufacture of a medicament for the treatment of HCV. This is the amino acid sequence of the wild type HCV polyprotein.	XX			
XX	Sequence 3 010 AA;	XX			
XX	Query Match 95.2%; Score 3015; DB 8; Length 3010;	XX			
XX	Best Local Similarity 95.9%; Pred. No. 1.9e-278; Mismatches 16; Indels 0; Gaps 0;	XX			
XX	Matches 567; Conservative 16;	XX			
QY	5	SMSTWTGALITPCKAABEBSLPIALNSLILRHNLVYSTTSRASLRQKTFDRLQVL	64		
Db	2420	SMSTWTGALITPCKAABEBSLPIALNSLILRHNLVYSTTSRASLRQKTFDRLQVL	2479		
QY	65	DDHYRDVLKEMKAKASTVKAKLISVERACKLTPPHSAKSKEKGAKDVRSLSSRAVNHR	124		
Db	2480	DDHYRDVLKEMKAKASTVKAKLISVERACKLTPPHSAKSKEKGAKDVRSLSSRAVNHR	2339		
QY	125	SMVQDLLEDTPQFTTQTIMAKNEVFCQPEKGKRPARLIVFPDLGVRCERKALYDVVS	184		
Db	2540	SMVQDLLEDTPQFTTQTIMAKNEVFCQPEKGKRPARLIVFPDLGVRCERKALYDVVS	2599		
QY	185	TPQAVMGMGSYGFQYSPKRVFVNTRAKCFCMGEFSYDTRCPDSTVENDRVEESY	244		
Db	2600	TPQAVMGSYGFQYSPKRVFVNTRAKCFCMGEFSYDTRCPDSTVENDRVEESY	2659		

New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes the polypeptide sequences of the HCV core, NS3, NS4B and NS5B proteins for use in medicine, in particular for manufacturing a medicament for the treatment of HCV.

Disclosure: Fig 6; 78pp; English.

The present sequence is the hepatitis C virus (HCV) J4L6 genome wild-type polyprotein sequence. HCV DNA vaccines of the invention comprise a polynucleotide that encodes the HCV Proteins Core, NS3, NS4B and NS5B, and does not encode the NS4A and NS5A Proteins. Preferably, the codon usage of the polynucleotide sequence resembles that of highly expressed human genes. The polynucleotides may encode individual proteins or fusion proteins. Preferred fusions include double fusions between NS4B and NS5B and between Core and NS3. The vaccines are useful for the treatment or prevention of an HCV infection.

Sequence 3 010 AA;

WPI; 2004-420614/39.
N-PSDB; AD079396.

New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes the polypeptide sequences of the HCV core, NS3, NS4B and NS5B proteins for use in medicine, in particular for manufacturing a medicament for the treatment of HCV.

The present sequence is the hepatitis C virus (HCV) J4L6 genome wild-type polyprotein sequence. HCV DNA vaccines of the invention comprise a polynucleotide that encodes the HCV Proteins Core, NS3, NS4B and NS5B, and does not encode the NS4A and NS5A Proteins. Preferably, the codon usage of the polynucleotide sequence resembles that of highly expressed human genes. The polynucleotides may encode individual proteins or fusion proteins. Preferred fusions include double fusions between NS4B and NS5B and between Core and NS3. The vaccines are useful for the treatment or prevention of an HCV infection.

Sequence 3 010 AA;

Query	Match	Score 95.2%; Best Local Similarity 95.9%; Mismatches 16; Matches 56; Conservatve 16; Pred. No. 1.9e-278; Mismatches 8; Indels 0; Gaps 0;	DB 8; Length 3010; DB 8; Length 3010;
Db	5 SMSYTWTGALITPCAAEESKLPINALNSLRLRHNLNYSTTSRSASLRQKKTFRDQLV 64	DR N-PSDB; ADO36226.	WPI; 2004-420613/39.
Db	2420 SMSYTWTGALITPCAAEESKLPINPLNSLRLHNMVATTSRSASLRQKKTFRDQLV 2479	XX	New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes the polypeptide sequences of the HCV core and at least one other HCV protein, for use in medicine, particularly for manufacturing a medicament for treating HCV.
Qy	65 DHDYRDLKEMKAKASTYKAKLISVEACKLTPPHSAKSFKGYAKDVSLSRAVNHR 124	XX	Example 2; Page 27; 78pp; English.
Db	2480 DHDYRDLKEMKAKASTYKAKLISVEACKLTPPHSAKSFKGYAKDVSLSRAVNHR 2539	CC	The invention describes a polynucleotide vaccine comprising a polynucleotide sequence (S1) encoding the Hepatitis C virus (HCV) Core protein and at least 1 other HCV protein, and causes expression of the proteins in cells (in which (S1) has been mutated or positioned relative to the polynucleotide sequence encoding the other HCV protein, so that the negative effect of the Core protein on expression of the other HCV protein is reduced). Also described are: a method of preventing or treating an HCV infection in a mammal, comprising administering the vaccine cited above to a mammal; and a method of vaccination of an individual, comprising taking a polynucleotide vaccine as cited above, coating the polynucleotide onto Gold beads, and delivering the Gold beads into the skin. HCV nucleic acids, polypeptides, host cells, vectors and antibodies used in the methods, are also disclosed. The polynucleotide vaccine is useful in the manufacture of a medicament for the treatment of HCV. This is the amino acid sequence of the HCV NS5B protein.
Qy	125 SWKDLLEDITPIQTTIMAKNEVFCVQPEKGKPKPARLIVPDGLYRCEKMAVLYDVS 184	XX	XX
Db	2540 SWKDLLEDITPIQTTIMAKNEVFCVQPEKGKPKPARLIVPDGLYRCEKMAVLYDVS 2599	CC	XX
Qy	185 TLPQAVMGSSYGFQSPKORVEFLVNTWAKAKCPCMGFSYDTRCFDSTVTEIDIRVEESIV 244	CC	XX
Db	2600 TLPQAVMGSSYGFQSPKORVEFLVNTWAKCPCMGFSYDTRCFDSTVTEIDIRVEESIV 2659	CC	XX
Qy	245 QCCDLAPEARQAISLTERTLYVGPMNTSKGQNGQYCRASAGVLTISCGNTLTCYKAA 304	CC	XX
Db	2660 QCCDLAPEARQAISLTERTLYVGPMNTSKGQNGQYCRASAGVLTISCGNTLTCYKAT 2719	CC	XX
Qy	305 AACEAKAKLQDCTMLVNGDILVVICESAGTQEDASLRVTEAMTRYSAPPGDPPQPEYDL 364	CC	XX
Db	2720 AACRAKQDCTMLVNGDILVVICESAGTQEDASLRVTEAMTRYSAPPGDPPQPEYDL 2779	CC	Sequence 592 AA;
Qy	365 ELITSCSSNVSAHDASGKRVYTLTRDPTVPLARAAMETARTHTPVNSLGNITIMAPTLW 424	CC	Query Match 95.2%; Score 3014; DB 8; Length 592;
Db	2780 ELITSCSSNVSAHDASGKRVYTLTRDPTVPLARAAMETARTHTPVNSLGNITIMAPTLW 2839	CC	Best Local Similarity 96.1%; Pred. No. 1.8e-279; Matches 569; Conservative 14; Mismatches 9; Indels 0; Gaps 0;
Qy	425 ARMLTMTHPSLILAQEQLKALDQIYACYSIPELDLQPIERLQHLSPLHSSPG 484	Db	4 MSMSYTWTGALITPCAAEESKLPINALNSLRLRHNLNYSTTSRSASLRQKKTFRDQLV 63
Db	2840 ARMLTMTHPSLILAQEQLKALDQIYACYSIPELDLQPIERLQHLSPLHSSPG 2899	Db	1 MSMSYTWTGALITPCAAEESKLPINPLNSLRLRHNMVATTSRSASLRQKKTFRDQLV 60
Qy	485 EINRVASCLRKLGYPPLRTRHRSVRAKLSSGRRAAICGCKLFWAVRTRKLKLTIP 544	Qy	64 LDHYRDLKEMKAKASTYKAKLISVEACKLTPPHSEKSKFSGYAKDVSLSRSRAVNTI 123
Db	2900 EINRVASCLRKLGYPPLRTRHRSVRAKLSSGRRAAICGCKLFWAVRTRKLKLTIP 2959	Db	61 LDHYRDLKEMKAKASTYKAKLISVEACKLTPPHSEKSKFSGYAKDVSLSRSRAVNTI 120
Qy	545 AASPLDLSCWFWVAGYSGGDIYHSLSRARPRFWMLCLLISVGYIYLPNR 595	Qy	124 RSWKDLLEDITPIQTTIMAKNEVFCVQPEKGKPKPARLIVPDGLYRCEKMAVLYDVS 183
Db	2960 AASPLDLSCWFWVAGYSGGDIYHSLSRARPRFWMLCLLISVGYIYLPNR 3010	Db	121 RSWKDLLEDITPIQTTIMAKNEVFCVQPEKGKPKPARLIVPDGLYRCEKMAVLYDVS 180
Qy	RESULT 13	Qy	184 STLPOAVNGSSYGFQSPKORVEFLVNTWAKAKCPCMGFSYDTRCFDSTVTEIDIRVESTI 243
AD036215	AD036215 standard; protein; 592 AA.	Db	181 STLPOAVNGSSYGFQSPKORVEFLVNTWAKAKCPCMGFSYDTRCFDSTVTEIDIRVESTI 240
ID	AD036215	Qy	244 YQCCDLAPEARQAISLTERTLYVGPMNTSKGQNGQYCRASAGVLTISCGNTLTCYKAA 303
DE	Hepatitis C virus (HCV) NS5B protein.	Db	241 YQCCDLAPEARQAISLTERTLYVGPMNTSKGQNGQYCRASAGVLTISCGNTLTCYKAA 300
XX	hepatotropic; viricide; vaccine; gene therapy; vaccine; vaccination; NS5B.	Qy	304 AACRAKQDCTMLVNGDILVVICESAGTQEDASLRVTEAMTRYSAPPGDPPQPEYD 363
XX	26-AUG-2004 (first entry)	Db	361 LELITSCSSNVSAHDASGKRVYTLTRDPTVPLARAAMETARTHTPVNSLGNITIMAPTL 420
DE	Hepatitis C virus (HCV) NS5B protein.	Qy	424 WAMILMTHFFSLLAQEQLDCQYACYSIPELDLQPIERLQHLSPLHSSPG 483
XX	XX	Db	421 WAMILMTHFFSLLAQEQLDCQYACYSIPELDLQPIERLQHLSPLHSSPG 480
KW	KW Hepatitis C virus; HCV; core protein; HCV infection; vaccination; NS5B.	Qy	484 GEINRVASCLRKGVPPVWRHRSVRAKLSSGRRAAICGCKLFWAVRTRKLKLTIP 543
XX	XX	Db	481 GEINRVASCLRKGVPPVWRHRSVRAKLSSGRRAAICGCKLFWAVRTRKLKLTIP 540
OS	OS Hepatitis C virus.	Qy	544 PAASRLDLSGWFWVAGYSGGDIYHSLSRARPRFWMLCLLISVGYIYLPNR 595
PN	PN WO0046175-A1.	Db	541 PANSQLDLSGWFWVAGYSGGDIYHSLSRARPRFWMLCLLISVGYIYLPNR 592
XX	XX	XX	XX
PD	PD 03-JUN-2004.	XX	XX
XX	XX	XX	XX
PF	PF 13-NOV-2003; 2003WO-EP012793.	XX	XX
XX	XX	XX	XX
PR	PR 15-NOV-2002; 2002GB-00026722.	XX	XX
PA	PA (GLAX) GLAXO GROUP LTD.	XX	XX
PI	PI Brett S, Hamblin PA, Ogilvie L;	XX	XX

RESULT 14	304 AACRAAKLQDCTMLYNGDLYVICESAGTQDAAISLRVFTAMTRYSAPPGDPPOPEYD	363
ADO79389	301 TAACRAAKLQDCTMLYNGDLYVICESAGTQDAAISLRVFTAMTRYSAPPGDPPOPEYD	360
AC	ADO79389;	
26-AUG-2004	(first entry)	
XX	Hepatitis C virus NSSB protein.	
XX	HCV; NSSB; vaccine; DNA immunisation; hepatotropic; virucide; mutant; mutein.	
XX	Hepatitis C virus.	
XX	Synthetic.	
XX	WO2004046176-A1.	
03-JUN-2004.		
XX	13-NOV-2003; 2003WO-EPO12830.	
XX	15-NOV-2002; 2002GB-00026722.	
XX	(GLAXO) GLAXO GROUP LTD.	
XX	Brett S, Hamblin PA, Ogilvie L;	
XX	WPI; 2004-420614/39.	
XX	N-PSDB; AD079400.	
XX	New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes the polypeptide sequences of the HCV core, NS3, NS4B and NS5B proteins, for use in medicine, in particular for manufacturing a medicament for the treatment of HCV.	
XX	Example 2; Page 27; 79pp; English.	
XX	The present sequence is that of the NS5B protein of hepatitis C virus (HCV). The sequence is the translation sequence of a polynucleotide in which codon usage was altered to resemble that of highly expressed human genes. HCV vaccines of the invention comprise a polynucleotide that encodes the HCV proteins Core, NS3, NS4B and NS5B, and does not encode the NS4A and/or NS5A proteins. The proteins may be expressed as individual proteins or as fusion proteins. Preferred fusions include double fusions between NS4B and NS5B and between Core and NS3. The vaccines are useful for the treatment or prevention of an HCV infection.	
XX	Sequence 592 AA;	
Q	Query Match 95.2%; Score 3014; DB 8; Length 592;	
Best Local Similarity 96.1%; Pred. No. 1.8e-279;		
Matches 569; Conservative 14; Mismatches 9; Indels 0; Gaps 0;		
YY	4 MSMSTWTGALITPCAAEESKLPINALNSLIRHNLVYSTTSRSASLRQKVTFDRQV 63	
bb	1 NSMSWTWTGALITPCAAEESKLPINPNSLIRHNMVATTSRSASLRQKVTFDRQV 60	
YY	64 LDDHYRDYLKEMKAKASTVKAKLSSVEACKLTTPHSASAKSKFGYGAQDVSILSSRAVNHI 123	
bb	61 LDDHYRDYLKEMKAKASTVKAKLSSVEACKLTTPHSASAKSKFGYGAQDVSILSSRAVNHI 120	
YY	124 RSWKDLLEDPTPQTTIMAKNEVCPQPEKGKRPARLIVFPLDGVRCERKMLYDV 183	
bb	121 RSWEDDLEDPTPDTTMAKSEFVCPQPEKGKRPARLIVFPLDGVRCERKMLYDV 180	
YY	184 STLPQAWGSSYGFQTSPKQRVEFLYNTWAKKCPMGFSYDTRCFDSTVENDIRVEESI 243	
bb	181 STLPQAWGSSYGFQTSPKQRVEFLYNTWAKKCPMGFSYDTRCFDSTVENDIRVEESI 240	
YY	244 YCCDLAPEAOAISLTERLYVGGMNTNSKGQNCGYRRCASGVLTTSCGNTCTCYLK 303	
PA	(OSAU) UNIV OSAKA.	
PA	241 YCCDLAPEAOAISLTERLYVGGMNTNSKGQNCGYRRCASGVLTTSCGNTCTCYLK 300	
PI	Okayama H, Fukui I, Mori C, Takamizawa A, Yoshida I;	

XX WPI: 1999-407152/35.
DR N-PSDB; AAX59394.

XX PT New hepatitis virus polypeptides, useful for diagnosing and treating
PT hepatitis infections.

XX PS Claim 2; Fig 2 (1) - (16); 56pp; English.

XX This sequence represents the non-A, non-B hepatitis virus (NANBV) polypeptide, as predicted from cDNA (see AAX59394) containing the entire open reading frame of the NANBV genome. To obtain this cDNA, NANBV RNAs were extracted directly from NANBV particles contained in whole blood of a patient having NANB hepatitis, or from a resected liver of a patient having NANB hepatitis and liver cancer. The RNA was then converted to double-stranded cDNA. A cDNA library was produced and screened using serum from a convalescent patient having acute NANB hepatitis and serum from a patient having chronic NANB hepatitis. The isolated cDNA allows recombinant production of NANBV antigen polypeptides in microbial or eukaryotic cell culture. The method provides the safe production of NANBV antigens with high purity on a large scale at low cost without the biohazard associated with multiplying virus in animals. Claimed NANBV nucleotide sequences are useful for the recombinant production of polypeptides useful as antigens for vaccines, and as diagnostic reagents. (Updated on 20-MAR-2003 to correct PR field.) (Updated on 20-MAR-2003 to correct PR field.)

XX SQ Sequence 3010 AA;

Query	Match	Score	Length
QY	95.2%; Best Local Similarity	3014; Pred. No. 2.3e-278;	3010;
Db	57; Matches	10; Mismatches	0; Indels 0; Gaps 0;
QY	5 SMTSTWGTALITPCGAEEKLPIPNALNSLIRHNLVSTTSRASLROKVKTFDRLQLV	64	
Db	2420 SMTSTWGTALITPCGAEEKLPIPNALNSLIRHNMVATTSRAGLROKVKTFDRLQLV	2479	
QY	65 DHYRDVLKEMKAKASTVKAHLSSVEACKLTPPHSAKSFKPGYAKDVRSLSSRAVHNIR	124	
Db	2480 DHYRDVLKEMKAKASTVKAHLSSVEACKLTPPHSAKSFKPGYAKDVRSLSSRAVHNIR	25339	
QY	125 SWKDLDEDTPIOTTIMAKNEYFCVQPEKGRKPARLIVFPLGIVRCEKMAHYDVS	184	
Db	2540 SWKDLDEDTPIOTTIMAKNEYFCVQPEKGRKPARLIVFPLGIVRCEKMAHYDVS	2599	
QY	185 TLPOAVMGSSYQFOVSPKORVEFLVNTWKAKKCPMGFSYDTRCPDSTVENDIVRSY	244	
Db	2600 TLPOVUMGSSYQFOVSPQRFVFLVNTWISKKNPMGFSYDTRCPDSTVENDIVRSY	2659	
QY	245 QCCDLAPEARQAIISLTERIYVGGMNTNSKGQNCYRRCRASGVLTTSCGNTLTCYKAA	304	
Db	2660 QCCDLAPEARQAIISLTERIYGGLNTNSKGQNCYRRCRASGVLTTSCGNTLTCYKAA	2719	
QY	305 AACRAAKLQDQTMLYNGDDLVVICESAGTOEADAASLRVFTTEAMTRYSAPPGDPPEPEYDL	364	
Db	2720 AACRAAKLQDQTMLYNGDDLVVICESAGTOEADAASLRVFTTEAMTRYSAPPGDPPEPEYDL	2779	
QY	365 BLITSCSSNYVAHDASGKRVYLTQDPTPLARAWEATRHTPNWGNIMYAPLW	424	
Db	2780 BLITSCSSNYVAHDASGKRVYLTQDPTPLARAWEATRHTPNWGNIMYAPLW	2839	
QY	425 ARMLIMTHFFSILLAQEQLERKALDCQIYGAQSYIEPLDLFQIIERLHGLSALSFLHSYSFG	484	
Db	2840 ARMLIMTHFFSILLAQEQLERKALDCQIYGAQSYIEPLDLFQIIERLHGLSALSFLHSYSFG	2899	
QY	485 EINRVASCLRKLGYPPLRVWRHARSVRAKLSSQGGRAATCGKYLFLNVAVTRKLUKLTPIP	544	
Db	2900 EINRVASCLRKLGYPPLRVWRHARSVRASLSSQGRAATCGKYLFLNVAVTRKLUKLTPIP	2959	
QY	545 AASRLDLSGMFVAGYSGGDTYHSLSRARPWMLCLLISVGCVYLLNR	595	
Db	2960 AASRLDLSGMFVAGYSGGDTYHSLSRARPWMLCLLISVGCVYLLPNR	3010	

Search completed: September 22, 2005, 14:47:11
Job time : 172 secs

Qy	125 SWVQDILEDTPIQOPTIMMANEVFCVQPEGGKPARLTYFPDLGVRCKMAYDVVS	184	Qy	65 DDEHYDYLKEMKAKASTYKAKLSSVEACKLTPPHSAKSFKGAKDVRSLSSRAHNHR 124	
Db	2540 SWWEDLEDTPIDTTIMANEVFCVQPEGGKPARLTYFPDLGVRCKMAYDVVS	2599	Db	2480 DDEHYDYLKEMKAKASTYKAKLSSVEACKLTPPHSAKSFKGAKDVRSLSSRAHNHR 2539	
Qy	185 TLPOAVMGSSYGFQYSPKORVEFLNTWKAKKCPMGFSYDTRCFDSTVENDIRVEESIV	244	Qy	125 SWWQDILEDTPIQOPTIMMANEVFCVQPEGGKPARLTYFPDLGVRCKMAYDVVS 184	
Db	2600 TLPOAVMGSPSGQYSPKORVEFLNTWKAKKCPMGFSYDTRCFDSTVENDIRVEESIV	2659	Db	2540 SWWQDILEDTPIQOPTIMMANEVFCVQPEGGKPARLTYFPDLGVRCKMAYDVVS 2599	
Qy	245 QCCDLAPEARQAISSITERLYGGPMNTNSKCONCGYRCCRASGLTSCGNTLTCYLKAA	304	Qy	185 TLPOAVMGSSYGFQYSPKORVEFLNTWKAKKCPMGFSYDTRCFDSTVENDIRVEESIV	244
Db	2660 QCCDLAPEARQAISSITERLYGGPMNTNSKCONCGYRCCRASGLTSCGNTLTCYLKAT	2719	Db	2600 TLPOAVMGSSYGFQYSPKORVEFLNTWKAKKCPMGFSYDTRCFDSTVENDIRVEESIV	2659
Qy	305 AACRAAKLQDQDTMLYGGDLYVVICESAGTOADASLRVFTAMTRYSAPPDPPOPEYDL	364	Qy	245 QCCDLAPEARQAISSITERLYGGPMNTNSKCONCGYRCCRASGLTSCGNTLTCYLKAA	304
Db	2720 AACRAAKLQDQDTMLYGGDLYVVICESAGTOADASLRVFTAMTRYSAPPDPPOPEYDL	2779	Db	2660 TLPOAVMGSSYGFQYSPKORVEFLNTWKAKKCPMGFSYDTRCFDSTVENDIRVEESIV	2719
Qy	365 BLITSCSSNNSVAHDASGKRVVYLTRDPTVPLARAANETARHTPVNSWIGNIMYAPTILW	424	Qy	305 AACRAAKLQDQDTMLYGGDLYVVICESAGTOADASLRVFTAMTRYSAPPDPPOPEYDL	364
Db	2780 BLITSCSSNNSVAHDASGKRVVYLTRDPTVPLARAANETARHTPVNSWIGNIMYAPTILW	2839	Db	2720 AACRAAKLQDQDTMLYGGDLYVVICESAGTOADASLRVFTAMTRYSAPPDPPOPEYDL	2779
Qy	425 ARMLMTHFFSILLAQEOLEKALDQIYGAQCYSTEPLDLPQIERTHLGLSFSLHSYSPG	484	Qy	365 BLITSCSSNNSVAHDASGKRVVYLTRDPTVPLARAANETARHTPVNSWIGNIMYAPTILW	424
Db	2840 ARMLMTHFFSILLAQEOLEKALDQIYGAQCYSTEPLDLPQIERTHLGLSFSLHSYSPG	2899	Db	2780 BLITSCSSNNSVAHDASGKRVVYLTRDPTVPLARAANETARHTPVNSWIGNIMYAPTILW	2839
Qy	485 EINRVASCLRLGVPPLRVWRHRARSYRALKLQSGERAATCGKYLFLNWAIVTRKLKLTPIP	544	Qy	425 ARMLMTHFFSILLAQEOLEKALDQIYGAQCYSTEPLDLPQIERTHLGLSFSLHSYSPG	484
Db	2900 EINRVASCLRLGVPPLRVWRHRARSYRALKLQSGERAATCGKYLFLNWAIVTRKLKLTPIP	2959	Db	2840 ARMLMTHFFSILLAQEOLEKALDQIYGAQCYSTEPLDLPQIERTHLGLSFSLHSYSPG	2899
Qy	545 AASRLDLSGMVFGYSGGDIYTHSLSRARPWFMCLLSSVGVIYLLPNR	595	Qy	485 EINRVASCLRLGVPPLRVWRHRARSYRALKLQSGERAATCGKYLFLNWAIVTRKLKLTPIP	544
Db	2960 AASRLDLSGMVFGYSGGDIYTHSLSRARPWFMCLLSSVGVIYLLPNR	3010	Db	2900 EINRVASCLRLGVPPLRVWRHRARSYRALKLQSGERAATCGKYLFLNWAIVTRKLKLTPIP	2959
RESULT 2					
Genome polyprotein - hepatitis C virus					
N;contains: capsid protein C; envelope protein M; hepacivirin (EC 3.4.21.98) (nonstructural protein NS4a); nonstructural protein NS4b; nonstructural protein NS5					
C;species: hepatitis C virus					
C;date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 09-Jul-2004					
C;accession: A38465					
A;Title: Structure and organization of the hepatitis C virus genome isolated from human J. Virol. 65, 1105-1113, 1991					
A;Reference number: A38465; MUID:91140698; PMID:1847440					
A;Accession: A34465					
A;Molecule type: genomic RNA					
A;Residues: 1-3010 <TAN>					
A;Cross-references: UNIPROT: P26662; EMBL: M58335; NID: 9329770; PID: 932977					
C;Keywords: ATP; capsid protein; envelope protein; glycoprotein; hydrolase; nonstructural protein; hepacivirin					
C;Key-words: ATP; capsid protein; envelope protein; glycoprotein; hydrolase; nonstructural protein; hepacivirin					
F;2-115/Product: capsid protein C #status predicted <CPC>					
F;2-116/19/1/Region: envelope protein M #status predicted <EPM>					
F;2-116/19/1/Region: envelope protein M #status predicted <EPM>					
F;190-79/Product: nonstructural protein NS1 #status predicted <NS1>					
F;1007-1615/Region: hepacivirin #status predicted <NS3>					
F;120-1237/Region: nucleotide-binding motif A (P-loop)					
F;1311-1319/Region: nucleotide-binding motif B					
F;1312-1313/Region: nucleotide-binding motif B					
F;1316-1313/Region: DBX motif					
F;1616-1862/Region: nonstructural protein NS4a #status predicted <N4a>					
F;1616-1862/Region: nonstructural protein NS4b #status predicted <N4b>					
F;1730-1006/Region: nonstructural protein NS1 #status predicted <NS1>					
F;1007-1615/Region: hepacivirin #status predicted <NS2>					
F;1230-1237/Region: nucleotide-binding motif A (P-loop)					
Query Match 95.2%: Score 3016; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					
Query Match 94.8%: Score 3003; DB 1; Length 3010;					
Best Local Similarity 96.6%; Pred. No. 3.8e-223;					
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;					

Best Local Similarity 95.9%; Pred. No. 3.8e-222; Matches 567; Conservative 15; Mismatches 9;	Indels 0; Gaps 0;	Query Match 93.7%; Score 2968; DB 1; Length 3010; Best Local Similarity 94.9%; Pred. No. 1.9e-219; Matches 561; Conservative 15; Mismatches 15;	Indels 0; Gaps 0;
5 SMSYTWTGALITPCAAEBSKPINALNSLIRHNLVYSTTSRSASLROCKVTFDRLQVL 64		5 SMSYTWTGALITPCAAEBSKPINALNSLIRHNLVYSTTSRSASLROCKVTFDRLQVL 64	
Db 2420 SMSYTWTGALITPCAAEBSKPINALNSLIRHNLVYSTTSRSASLROCKVTFDRLQVL 2479		Db 2420 SMSYTWTGALITPCAAEBSKPINALNSLIRHNLVYSTTSRSASLROCKVTFDRLQVL 2479	
Qy 65 DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSKEFYGAKDVRSLSSRAVNHIR 124		Qy 65 DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSKEFYGAKDVRSLSSRAVNHIR 124	
Db 2480 DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSKEFYGAKDVRSLSSRAVNHIR 2539		Db 2480 DDHYRDVLKEMKAKASTVKAKLISVEACKLTPPHSAKSKEFYGAKDVRSLSSRAVNHIR 2539	
Qy 125 SWKDLLEDTPIDTTGKPEKGRKPARLIVPDLGVRCKMAYDVS 184		Qy 125 SWKDLLEDTPIDTTGKPEKGRKPARLIVPDLGVRCKMAYDVS 184	
Db 2540 SWKDLLEDTPIDTTGKPEKGRKPARLIVPDLGVRCKMAYDVS 2599		Db 2540 SWKDLLEDTPIDTTGKPEKGRKPARLIVPDLGVRCKMAYDVS 2599	
Qy 245 QCCDLAPEARQDAIRSSTERLYUGGPMNTNSKGQNCGYRRCRASGLLTISCGNTLICYLKAA 304		Qy 185 TLQQAIVMGSSYGFQYSPKQREFLVNTWAKKCPNGFSDTRCFDSTVENDIRVYESIY 244	
Db 2660 QCCDLAPEARQDAIRSSTERLYUGGPMNTNSKGQNCGYRRCRASGLLTISCGNTLICYLKAA 2719		Db 2600 TLQQAIVMGSSYGFQYSPKQREFLVNTWAKKCPNGFSDTRCFDSTVENDIRVYESIY 2659	
Qy 305 AACRAKLOQDQDTMLVNGDDLVVICSAQGDTQDAASLRLVFTETAMTRYSAPPDQPOPEYDL 364		Qy 245 QCCDLAPEARQDAIRSSTERLYUGGPMNTNSKGQNCGYRRCRASGLLTISCGNTLICYLKAA 304	
Db 2720 AACRAKLOQDQDTMLVNGDDLVVICSAQGDTQDAASLRLVFTETAMTRYSAPPDQPOPEYDL 2779		Db 2660 QCCDLAPEARQDAIRSSTERLYUGGPMNTNSKGQNCGYRRCRASGLLTISCGNTLICYLKAA 2719	
Qy 365 ELITCSSNSVSAHDAISGRVYVLTQDPLPQIILVPLARAWETARHTPNSLGNNTIYAPTLW 424		Qy 305 AACRAKLOQDQDTMLVNGDDLVVICSAQGDTQDAASLRLVFTETAMTRYSAPPDQPOPEYDL 364	
Db 2780 ELITCSSNSVSAHDAISGRVYVLTQDPLPQIILVPLARAWETARHTPNSLGNNTIYAPTLW 2819		Db 2720 AACRAKLOQDQDTMLVNGDDLVVICSAQGDTQDAASLRLVFTETAMTRYSAPPDQPOPEYDL 2779	
Qy 425 ARMLMTHPFSILLAQEQLKALDQIYGAQSYSTEPLDLQPIIQLHGLSAPSFLHSYSPG 484		Qy 365 ELITCSSNSVSAHDAISGRVYVLTQDPLPQIILVPLARAWETARHTPNSLGNNTIYAPTLW 424	
Db 2840 ARMLMTHPFSILLAQEQLKALDQIYGAQSYSTEPLDLQPIIQLHGLSAPSFLHSYSPG 2899		Db 2780 ELITCSSNSVSAHDAISGRVYVLTQDPLPQIILVPLARAWETARHTPNSLGNNTIYAPTLW 2839	
Qy 485 EINRYASCLRKLGPPPLRVWRHRSVRAKILSQQGRAAICGKYLFWAVTRKULTP 544		Qy 425 ARMLMTHPFSILLAQEQLKALDQIYGAQSYSTEPLDLQPIIQLHGLSAPSFLHSYSPG 484	
Db 2900 EINRYASCLRKLGPPPLRVWRHRSVRAKILSQQGRAAICGKYLFWAVTRKULTP 2959		Db 2840 ARMLMTHPFSILLAQEQLKALDQIYGAQSYSTEPLDLQPIIQLHGLSAPSFLHSYSPG 2899	
Qy 545 AASRDLSSGMFVAGYGGDIYHSLSRARPFWMCLLISVGVGYLLPNR 595		Qy 485 EINRYASCLRKLGPPPLRVWRHRSVRAKILSQQGRAAICGKYLFWAVTRKULTP 544	
Db 2960 AASRDLSSGMFVAGYGGDIYHSLSRARPFWMCLLISVGVGYLLPNR 3010		Db 2900 EINRYASCLRKLGPPPLRVWRHRSVRAKILSQQGRAAICGKYLFWAVTRKULTP 2959	
RESULT 4		Qy 545 AASRDLSSGMFVAGYGGDIYHSLSRARPFWMCLLISVGVGYLLPNR 595	
GNWVTVW		Db 2960 AASRDLSSGMFVAGYGGDIYHSLSRARPFWMCLLISVGVGYLLPNR 3010	
N; Contains: capsid protein C; envelope protein M; hepatitis C virus (strain Taiwan)		RESULT 5	
protein NS4a; nonstructural protein NS4b; nonstructural protein NS5		S18030	
C; Species: hepatitis C virus		Genome polyprotein - hepatitis C virus (isolate JK1)	
A; Note: host Homo sapiens (man)		N; Contains: capsid protein C; envelope protein M; hepatitis C virus (strain Taiwan)	
C; Species: hepatitis C virus		protein NS4a; nonstructural protein NS4b; nonstructural protein NS5	
A; Cross-references: UNIPROT: P29846; GB: M84754		C; Species: hepatitis C virus	
A; Title: The Taiwanese hepatitis C virus genome: sequence determination and mapping the genome polyprotein - hepatitis C virus (strain Taiwan)		A; Variety: isolate JK1	
A; Reference number: A40244; PMID: 9230506; PMID: 1314449		C; Date: 19-May-2000 #sequence_revision 19-May-2000 #text_change 09-Jul-2004	
A; Molecule type: genomic RNA		R; Accession: S18030; S33570; A48232; S18029	
A; Residues: 1-3010 <CHB>		R; Honda, M.; Kaneko, S.; Maasaki, U.; Kobayashi, K.; Murakami, S.	
A; Cross-references: UNIPROT: P29846; GB: M84754		A; Experimental source: isolate JK1 from an individual	
C; Superfamily: hepatitis C virus genome polyprotein		R; Honda, M.; Kaneko, S.; Unoura, M.; Kobayashi, K.; Murakami, S.	
C; Keywords: Atp; capsid protein; envelope protein; glycoprotein; hydrolase; nonstructural protein NS4a; nonstructural protein NS4b; nonstructural protein NS5		Arch. Virol. 128, 163-169, 1993	
A; Molecule type: genomic RNA		A; Reference number: S18028	
F: 1-115/Product: capsid protein C #status predicted <CPC>		A; Molecule type: genomic RNA	
F: 116-191/Product: envelope protein M #status predicted <BPM>		A; Residues: 1-3010 <HON>	
F: 192-389/Product: major envelope protein M #status predicted <MEB>		A; Cross-references: UNIPROT: Q68949; EMBL: X61596; NID: 959478; PMID: CAA43793.1; PID: 959479	
F: 390-1006/Product: nonstructural protein NS1 #status predicted <NS1>		A; Experimental source: isolate JK1 from an individual	
F: 1007-1615/Product: nonstructural protein NS2 #status predicted <NS2>		R; Honda, M.; Kaneko, S.; Unoura, M.; Kobayashi, K.; Murakami, S.	
F: 1230-1237/Region: nucleotide-binding motif A (P-loop)		A; Title: Sequence analysis of putative structural regions of hepatitis C virus isolated from a single patient	
F: 1312-1317/Region: nucleotide-binding motif B		A; Reference number: A48332; PMID: 9311927; PMID: 8380322	
F: 1316-1862/Product: nonstructural protein NS4a #status predicted <N4a>		A; Accession: S33570	
F: 1616-1862/Product: nonstructural protein NS4a #status predicted <N4a>		A; Molecule type: genomic RNA	

A;Residues: 1-547, 'T', 549-621, 'V', 623-624, 'S', 626-652, 'D', 655-761, 'T', 763-782 <HOW>	C;Date: 19-May-2000 #sequence_revision 19-May-2000 #text_change 09-Jul-2004
A;Cross-references: EMBL:X6191	R;Okamoto, H
A;Note: this sequence is inconsistent with the nucleotide translation	R;Okamoto, H
A;Note: the authors translated the codon AGG for residue 43 as Pro, TGG for residue 320	R;Okamoto, H
A;Note: the authors translated the codon AGG for residue 71 as Ser	R;Okamoto, H
A;Note: sequence extracted from NCBIN:121747, NCBI:121748	R;Okamoto, H
C;Superfamily: hepatitis C virus genome polyprotein	R;Okamoto, H
C;Keywords: ATP; Glycoprotein; hydrolyase; nucleotide binding; P-loop; polyprotein; serin	R;Okamoto, H
F;2-115/Product: capsid protein C #status predicted <CPC>	R;Okamoto, H
F;116-191/Product: envelope protein M #status predicted <BPM>	R;Okamoto, H
F;192-289/Product: major envelope protein E #status predicted <ME>	R;Okamoto, H
F;300-729/Product: nonstructural protein NS1 #status predicted <NS1>	R;Okamoto, H
F;730-1066/Product: nonstructural protein NS2 #status predicted <NS2>	R;Okamoto, H
F;1067-1515/Product: hepacivirin #status predicted <NS3>	R;Okamoto, H
F;1230-1237/Region: nucleotide-binding motif A (P-loop)	R;Okamoto, H
F;1312-1317/Region: nucleotide-binding motif B	R;Okamoto, H
F;1316-1319/Region: DEXH motif	R;Okamoto, H
F;1616-1862/Product: nonstructural protein NS4a #status predicted <N4A>	R;Okamoto, H
F;1683-2013/Product: nonstructural protein NS4b #status predicted <N4B>	R;Okamoto, H
F;2014-3010/Product: nonstructural protein NS5 #status predicted <NS5>	R;Okamoto, H
F;196,209,234,250,305,417,423,448,532,540,556,576,623,645/Binding site: carbohydrate	R;Okamoto, H
Query Match Score 2944; DB 1; Length 3010;	Best Local Similarity 93.9%; Pred. No. 1.3e-217; Mismatches 17; Indels 0; Gaps 0;
Db 2416 VACCSMSYTWTGALITPCAAEESKLPIKNLNSLRLPHNLYVYSTSPRSASLQQKVTEDR 60	Db 2416 VACCSMSYTWTGALITPCAAEESKLPIKNLNSLRLPHNLYVYSTSPRSASLQQKVTEDR 60
Db 2475 LQVLDHYDVLKEMKAKASTVAKLISVEACKLTPHSAKSFSKFGYAKDVSLSRAV 120	Db 2475 LQVDPDHYDVLKEMKAKASTVAKLISVEACKLTPHSAKSFSKFGYAKDVSLSRAV 120
Db 2476 1QVDPDHYDVLKEMKAKASTVAKLISVEACKLTPHSAKSFSKFGYAKDVSLSRAV 2535	Db 2476 1QVDPDHYDVLKEMKAKASTVAKLISVEACKLTPHSAKSFSKFGYAKDVSLSRAV 2535
Qy 1 MASMMSMSYTWTGALITPCAAEESKLPIKNLNSLRLPHNLYVYSTSPRSASLQQKVTEDR 60	Qy 1 MASMMSMSYTWTGALITPCAAEESKLPIKNLNSLRLPHNLYVYSTSPRSASLQQKVTEDR 60
Db 2536 NHIHSWWDLLEDTPIDTMAKNEVFCVQPEXGKRPARLTVPEGLVRCYKMLY 180	Db 2536 NHIHSWWDLLEDTPIDTMAKNEVFCVQPEXGKRPARLTVPEGLVRCYKMLY 180
Db 2595 DVVSTLPOAIVMGSSYGFQSPKORYVEFLVNTWKAKCPMPGFSYDTRCFDSTVENDIRVE 240	Db 2595 DVVSTLPOAIVMGSSYGFQSPKORYVEFLVNTWKAKCPMPGFSYDTRCFDSTVENDIRVE 240
Db 2596 DVVSTLPOAIVMGSSYGFQSPQGVRFYFLVNAWSKRNPKGFAYCTRCPDSTVENDIRVE 2555	Db 2596 DVVSTLPOAIVMGSSYGFQSPQGVRFYFLVNAWSKRNPKGFAYCTRCPDSTVENDIRVE 2555
Qy 241 ESIYQCCDLAPEAROAIRSLTTERLYVGGPMNTSKQGNCYRCRASGLTTSCGNTLTCY 300	Qy 241 ESIYQCCDLAPEAROAIRSLTTERLYVGGPMNTSKQGNCYRCRASGLTTSCGNTLTCY 300
Db 2656 ESIYQCCDLAPEAROQYTRSLTTERLYVGGPMNTSKQGNCYRCRASGLTTSCGNTLTCY 2715	Db 2656 ESIYQCCDLAPEAROQYTRSLTTERLYVGGPMNTSKQGNCYRCRASGLTTSCGNTLTCY 2715
Qy 301 LKAAACRAKMLQDCTMLVNGDDLVVICSEGTQDAAISLRVFTTEAMTRYSAPPGDPQP 360	Qy 301 LKAAACRAKMLQDCTMLVNGDDLVVICSEGTQDAAISLRVFTTEAMTRYSAPPGDPQP 360
Db 2716 LKAAACRAKMLQDCTMLVCGDDLVVICESAGTQDAAISLRVFTTEAMTRYSAPPGDPQP 2775	Db 2716 LKAAACRAKMLQDCTMLVCGDDLVVICESAGTQDAAISLRVFTTEAMTRYSAPPGDPQP 2775
Qy 361 EYDLELTITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEARHTPWNLMGNITMYA 420	Qy 361 EYDLELTITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEARHTPWNLMGNITMYA 420
Db 2776 EYDLELTITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEARHTPWNLMGNITMYA 2835	Db 2776 EYDLELTITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEARHTPWNLMGNITMYA 2835
Qy 421 PTIWMARMLTMTHFFSIIQIAQOLEKALDQIYQGACYSIPLDLQIIEHLGLSAFSLMS 480	Qy 421 PTIWMARMLTMTHFFSIIQIAQOLEKALDQIYQGACYSIPLDLQIIEHLGLSAFSLMS 480
Db 2836 PTIWMARMLTMTHFFSIIQIAQOLEKALDQIYQGACYSIPLDLQIIEHLGLSAFSLMS 2895	Db 2836 PTIWMARMLTMTHFFSIIQIAQOLEKALDQIYQGACYSIPLDLQIIEHLGLSAFSLMS 2895
Qy 541 TPIPASRUDLSGMWVAGYSGDLYHSLSSRARPWEMLCLLSSVYGYIPLPNR 595	Qy 541 TPIPASRUDLSGMWVAGYSGDLYHSLSSRARPWEMLCLLSSVYGYIPLPNR 595
Db 2956 TPIPASQDLSGMWVAGYSGDLYHSLSSRARPWEMCILLLSSVYGYIPLPNR 3010	Db 2956 TPIPASQDLSGMWVAGYSGDLYHSLSSRARPWEMCILLLSSVYGYIPLPNR 3010
RESULT 6	
S40770 genome polyprotein - hepatitis C virus	
N;Contains: capsid protein C; envelope protein M; hepacivirin (BC 3.4.21.98) (nonstructural protein NS4a); nonstructural protein NS4b; nonstructural protein NS5	
Q;Species: hepatitis C virus	

Qy	125	SWVKDILEDTPICOTTIMAKNEVFCQPEKGGRKPARLIVFPDLGVRCERKVALDYDVS	184	5	SMSYTWTGALITPOAEESSKLPINALNSLRLRHNLVYSTTSRSASLQKQKTFDRLQVL	64
Db	2541	SWVKDLEDSTVTPIDTMARNEFCVQPEKGGRKPARLIVFPDLGVRCERKVALDYDVS	2600	2424	SMSYTWTGALITPOAEESSKLPINALNSLRLRHNLVYSTTSRSASLQKQKTFDRLQVL	2483
Qy	185	TLPOAVMGSSYGEQYSPKQRFVETVNTWAKKCPMGSYDTRCPDSTVENDIRVEESTY	244	65	DDHYRDVYKEMKAXASTYTKAKLISVBEACKLTTPHSAAKSKFGYGAQDVRSLSSRAVNHR	124
Db	2601	KLPLAVMGSSYGEQYSPKQRFVETVNTWAKKCPMGSYDTRCPDSTVENDIRVEESTY	2660	2484	DDHYREVDEMRKLASKVTKARLPLEEAGLTTPHSAAKSKFGYGAQDVRSLSSRAVNHR	2543
Qy	245	QCCDLAPEARQAISSLTERLYVGGMPTNSKGQNGYRRCRASCGVLTSGNTUTCYLAA	304	125	SWVKDILEDTPICOTTIMAKNEVFCQPEKGGRKPARLIVFPDLGVRCERKVALDYDVS	184
Db	2661	QCCDLDPQARVAISLTERLYVGGMPTNSKGQNGYRRCRASCGVLTSGNTUTCYLAA	2720	2544	GIVQDQLDDSDTPDLPPTTMAKNEVFAVESPCKGSKKPKPARLIVYDGLGVRCERKVALDYDVS	2603
Qy	305	AACRAAKLQCDTMLVNGDDLVICESAGTOBDAASLRVFTTEAMTRYSAPPGDPROPEYDL	364	185	TLPOAVMGSSYGEQYSPKQRFVETVNTWAKKCPMGSYDTRCPDSTVENDIRVEESTY	244
Db	2721	AACRAGLQCDTMLVCGDDLVICESAGTOBDAASLRVFTTEAMTRYSAPPGDPROPEYDL	2780	2604	KLFPLMPSYQGQSPQRVDFLWAKLPMAPYDTRCPDSTVENDIRVEESTY	2663
Qy	365	ELITSCSSNVSAHDAASGKRVYYLTDRDPTVPLARAASWETARTHTPVNSMLGNITIMAPTLW	424	245	QCCDLAPEARQATRSLSLTERLYVGGMPTNSKGONGYRRCRASCGVLTSGNTUTCYLAA	304
Db	2781	ELITSCSSNVSAHDAASGKRVYYLTDRDPTVPLARAASWETARTHTPVNSMLGNITIMAPTLW	2840	2664	QSCDLQBARVATRSLSLTERLYVGGMPTNSKGONGYRRCRASCGVLTSGNTUTCYLAA	2723
Qy	425	ARMLMTHFSSILLAQBOLEKALDQIYACYSIEPDLPQIYERLGLSAPSFLHSSPG	484	305	AACRAAKLQCDTMLVNGDDLVICESAGTOBDAASLRVFTTEAMTRYSAPPGDPROPEYDL	364
Db	2841	ARMLMTHFSSILLAQBOLEKALDQIYACYSIEPDLPQIYERLGLSAPSFLHSSPG	2900	2724	ASCARAKLDRDCTLVCQGDLVAICESQTHEDASLRAFTAEANTRYSAPPGDPROPEYDL	2783
Qy	485	EINRVAASCLRKLGVPBLRVRHARSVRAKLLSQSGRAAIQGKYLFWAVRTKLKLTP	544	365	ELITSCSSNVSAHDAASGKRVYYLTDRDPTVPLARAASWETARTHTPVNSMLGNITIMAPTLW	424
Db	2901	EINRVAACLRKLGVPBLRVRHARSVRAKLLSQSGRAAIQGKYLFWAVRTKLKLTP	2960	2784	ELITSCSSNVSAHDAASGKRVYYLTDRDPTVPLARAASWETARTHTPVNSMLGNITIMAPTLW	2843
Qy	545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595	425	ARMILMTHFSSILLAQBOLEKALDQIYACYSIEPDLPQIYERLGLSAPSFLHSSPG	484
Db	2961	AAGRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	3011	2844	ARTVLTMHFFPSVLSQSQEKTIAFEMGSVTSVTPLLPAIQRLHGLSAPSFLHSSPG	2903
Qy	9	RESULTS 9		485	EINRVAASCLRKLGVPBLRVRHARSVRAKLLSQSGRAAIQGKYLFWAVRTKLKLTP	544
Db	2904	JC5620 genome polyprotein - hepatitis C virus (isolate EUH1480)		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		Contains: capsid protein C; envelope protein M; hepatitis C virus (strain HC-J8)		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		protein NS4a; nonstructural protein NS4b; nonstructural protein NS5		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		Species: hepatitis C virus		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		Date: 19-May-2000 #sequence_revision 19-May-2000 #Text_change 09-Jul-2004		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		C:Sequence: hepatitis C virus		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		C:Accession: JC5620		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Title: The complete coding sequence of hepatitis C virus genotype 5a, the predominant		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		R;Chamberlain, R.W.; Adams, N.J.; Taylor, L.A.; Simmonds, P.; Elliott, R.M.		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		Biochem. Biophys. Res. Commun. 236, 44-49, 1997		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Reference number: JC5620; PMID:97366593; PMID:9223423		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Accession: JC5620		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Molecule type: mRNA		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Cross-references: UNIPROT:Q39928; GB:Y13184		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Experimental source: hypervariable #status predicted <ME>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		F:192-389/Region: major envelope protein E #status predicted <ME>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		F:384-408/Region: hypervariable #status predicted		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		F:390-730/Region: nonstructural protein NS4b #status predicted <NS4b>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		F:311-1007/Region: nonstructural protein NS5 #status predicted <NS5>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		F:1008-1616/Region: hepatitis C virus type and its phylogenetic relationship to e, interferon sensitivity determining #status predicted <NS3>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		F:123-1238/Region: nucleotide-binding motif A (P-loop)		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		F:1313-1318/Region: nucleotide-binding motif B		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		F:1317-1320/Region: DEH motif		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		F:1617-1863/Region: nonstructural protein NS4a #status predicted <NS4a>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		F:1864-2014/Region: nonstructural protein NS4b #status predicted <NS4b>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		F:2015-2014/Region: nonstructural protein NS5 #status predicted <NS5>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		F:2210-2249/Region: interferon sensitivity determining #status predicted		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		Query Match 79.3%; Score 2511; DB 1; Length 3014;		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		Best Local Similarity 78.8%; Pred. No. 2.9e-184; Mismatches 53; Gaps 0;		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		Matches 466; Conservative 53; Mismatches 72; Indels 0;		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Residues: 1-3033 <OAA>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Cross-references: UNIPROT:P26661; GB:Y13184		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Experimental source: isolate E-b12		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		R;Chm, S.W.; McOmisch, F.; Holmes, E.C.; Dow, B.; Peutherford, J.F.; Pollitt, E.; Yap, P.L.		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		J. Gen. Virol. 73, 1131-1141, 1992		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		R;Okamoto, K.; Kurai, K.; Okada, S.I.; Yamamoto, K.; Lizuka, H.; Tanaka, T.; Fukuda, S.; Virology 188, 331-341, 1992		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Title: Full-length sequence of a hepatitis C virus genome having poor homology to reported hepatitis C virus		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		C:Accession: A40250		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Accession: A40250		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Molecule type: genomic RNA		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Residues: 1-3033 <OAA>		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Cross-references: DDBJ:01034		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Experimental source: isolate E-b12		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		R;Kato, N.; Ootsuyama, Y.; Ohkoshi, S.; Nakazawa, T.; Mori, S.; Hijikata, M.; Shimotohno, K.		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		Biochem. Biophys. Res. Commun. 181, 279-285, 1991		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Title: Analysis of a new hepatitis C virus type and its phylogenetic relationship to e, hepatitis C virus		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Reference number: P0393; PMID:1316939		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Accession: P0397		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Molecule type: genomic RNA		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Qy		A:Residues: 2678-2754		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595
Db		A:Cross-references: DDBJ:2678-2754		545	AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISVGGYIYLPPN	595

A;Cross-references: GB:D10562; GB:D90518; NID:g221523; PIDN:BAA01418.1; PID:g221524	A;Reference number: JQ1303; MUID:92044440; PMID:1658196
C;Superfamily: hepatitis C virus genome polyprotein	A;Molecule type: genomic RNA
C;Keywords: AVE; capsid protein; envelope protein; glycoprotein; hydrolase; nonstructure	A;Residues: 1-3033 <OKA>
F;115-191/Product: capsid protein C #status predicted <CPC>	A;Cross-references: UNIPROT:P26660; GB:D00344; NID:921650; PIDN:BAA00792.1; PID:g221651
F;116-189/Product: envelope protein E #status predicted <EPM>	A;Experimental source: isolate HC-J6 from a Japanese individual
F;192-389/Product: envelope protein M #status predicted <ME>	C;Superfamily: hepatitis C virus genome polyprotein
F;390-733/Product: major envelope protein E #status predicted <NS1>	C;Keywords: AMP; glycoprotein; hydrolase; P-loop; polyprotein; serine proteinase; transme
F;734-1010/Product: nonstructural protein NS1 #status predicted <NS1>	F;2-115/Product: capsid protein C #status predicted <CPC>
F;1011-1619/Product: nonstructural protein NS2 #status predicted <NS2>	F;116-191/Product: envelope protein M #status predicted <EPM>
F;1234-1321/Region: nucleotide-binding motif A (P-loop)	F;192-389/Product: major envelope protein E #status predicted <ME>
F;1311-1323/Region: nucleotide-binding motif B	F;390-733/Product: nonstructural protein NS1 #status predicted <NS1>
F;1320-1323/Region: DEXH motif	F;734-1010/Product: nonstructural protein NS2 #status predicted <NS2>
F;1867-2017/Product: nonstructural protein NS4a #status predicted <NA4>	F;1011-1619/Product: hepatitis C virus (strain J4) (fragment)
F;1867-2017/Product: nonstructural protein NS4b #status predicted <NA4>	C;Species: hepatitis C virus
F;2018-3033/Product: nonstructural protein NS5 #status predicted <NS5>	C;Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004
F;196,209,233,299,305,417,423,430,448,477,534,542,558,578,627,649,1091,1217,1259,2038,23	C;Accession: JQ1303
Query Match 5 SMTWTGALTIPCAAEESKLPIALNSNLRRHNLVYSTTSRASLRQKVKTPDRQLV 64	RESULT 11
Best Local Similarity 75.5%; Score 2392; DB 1; Length 3033;	JQ1303
Matches 446; Conservative 59; Mismatches 86; Indels 0; Gaps 0;	RESULTS
Qy 65 DDHYRDVLEKMAKASTVRAKLLSVEACKLTPHSAKSFRSLRAKKTVDRQVL 124	5 SMSWTWTGALTIPCAAEESKLPIALNSNLRRHNLVYSTTSRASLRQKVKTPDRQLV 64
Db 2443 SMSWTWTGALTIPCAAEESKLPIALNSNLRRHNLVYSTTSRASLRQKVKTPDRQVL 2502	Qy 65 DDHYRDVLEKMAKASTVRAKLLSVEACKLTPHSAKSFRSLRAKKTVDRQVL 124
Qy 125 SWKDLLEDTDPICOTTIMAKNEVFCVQPEKGRKPARLIVPDLGVRVCEKRALYDV 184	Db 2443 SMSWTWTGALTIPCAAEESKLPIALNSNLRRHNLVYSTTSRASLRQKVKTPDRQVL 2502
Db 2563 SWKDLLEDTDPICOTTIMAKNEVFCVQPEKGRKPARLIVPDLGVRVCEKRALYDIAQ 2622	Qy 65 DDHYRDVLEKMAKASTVRAKLLSVEACKLTPHSAKSFRSLRAKKTVDRQVL 124
Qy 185 TLPQAVMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCPDSTVENDRVEESTY 244	Db 2563 SWKDLLEDTDPICOTTIMAKNEVFCVQPEKGRKPARLIVPDLGVRVCEKRALYDIAQ 2622
Db 2623 KLPKAIMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCPDSTVENDRVEESTY 2682	Qy 185 TLPQAVMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCPDSTVENDRVEESTY 244
Qy 245 QCCDLAPEARQAIIRSLLTLYVGGPMFTNSKGQNCYRRCTASGVLTTSCGNTLTCYKAA 304	Db 2623 KLPKAIMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCPDSTVENDRVEESTY 2682
Db 2683 QACSLPQEARTVHSLLTLYVGGPMFTNSKGQNCYRRCTASGVLTTSCGNTLTCYKAA 2742	Qy 245 QCCDLAPEARQAIIRSLLTLYVGGPMFTNSKGQNCYRRCTASGVLTTSCGNTLTCYKAA 304
Qy 305 AACRAAKLQDQCTMLYGDDLVVICESAGTOADAASLRVTEAMTRYSAPPDPFPQPEYDL 364	Db 2683 RACSLPQEARTVHSLLTLYVGGPMFTNSKGQNCYRRCTASGVLTTSCGNTLTCYKAA 2742
Db 2743 AACRAAGIVDPVMLVCGDDLVIVSSEQNEEDERNLRAFTTEAMTRYSAPPDPFPQPEYDL 2802	Qy 305 AACRAAKLQDQCTMLYGDDLVVICESAGTOADAASLRVTEAMTRYSAPPDPFPQPEYDL 364
Qy 365 BLITSCSSNYSVAHDASGKRYVYLTRDPTVPLABAETPARHTPVNSWGNITMYAPTW 424	Db 2743 AACRAAGIVDPVMLVCGDDLVIVSSEQNEEDERNLRAFTTEAMTRYSAPPDPFPQPEYDL 2802
Db 2803 BLITSCSSNYSVAHDASGKRYVYLTRDPTVPLABAETPARHTPVNSWGNITMYAPTW 2862	Qy 365 BLITSCSSNYSVAHDASGKRYVYLTRDPTVPLABAETPARHTPVNSWGNITMYAPTW 424
Qy 425 ARMLMTHFFSILLAQOLEKALDQIYQGACSYLEPLDQIQLRLHGSASLHSYSG 484	Db 2803 BLITSCSSNYSVAHDASGKRYVYLTRDPTVPLABAETPARHTPVNSWGNITMYAPTW 2862
Db 2863 VRM7IMTHFFSILLAQDTLNQNLNPFEMYGAVYSVNPPLDPLPATTIQLHGLEAFSLHTYSPH 2922	Qy 425 ARMLMTHFFSILLAQOLEKALDQIYQGACSYLEPLDQIQLRLHGSASLHSYSG 484
Qy 485 EINRYASCURKLGVPPLRVWRHRSVRALKLSQGGAATCKGYLFENWAVRKLKLTP1P 544	Db 2863 ARMLMTHFFSILLAQOLEKALDQIYQGACSYLEPLDQIQLRLHGSASLHSYSG 484
Db 2923 ELSRVATURKLGAPPRLAWSRARAVALSIAQARAAICGRYLFENWAVKTKLTP1P 2982	Qy 485 EINRYASCURKLGVPPLRVWRHRSVRALKLSQGGAATCKGYLFENWAVRKLKLTP1P 544
Qy 545 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMLCLLISVGIVYLPNR 595	Db 2923 ELSRVATURKLGAPPRLAWSRARAVALSIAQARAAICGRYLFENWAVKTKLTP1P 2982
Db 2983 EASRLDLSGMFVAGYSGGDIYHSLSRARPRWMLCLLISVGIVYLPNR 3033	Qy 545 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMLCLLISVGIVYLPNR 595
RESULT 11	Db 2983 EASRLDLSGMFVAGYSGGDIYHSLSRARPRWMLCLLISVGIVYLPNR 3033
genome polyprotein - hepatitis C virus (isolate HC-J6)	RESULTS
N;contains: capsid protein C; envelope protein M; hepatitis C virus (BC 3.4.21.98) (nonstructure	12
protein NS4a; nonstructural protein NS4b; nonstructural protein NS5	JQ0879
C;Species: hepatitis C virus	NS5 protein - hepatitis C virus
C;Accession: JQ1303	C;Species: hepatitis C virus
R;Okamoto, H.; Okada, S.; Sugiyama, Y.; Kurai, K.; Iizuka, H.; Machida, A.; Miyakawa, Y.	C;Accession: JQ0879
J. Gen. Virol. 72, 2697-2704, 1991	R;Okamoto, H.
A;Title: Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a hum	

submitted to JIPID, January 1991	Db	121 SAPPDPQPEYDLELITSCSSNTSVADASGRKVVYLTRDPTVPLARAAMETARHTPVN 180
A;Description: The 5'-terminal and 3'-terminal sequences of the genomic RNA of hepatitis C virus genome polyprotein	Qy	411 SWLGNITIMAPTIWARMILMTHFFSILLAQEQLKALDCQIYGACYSTEPLDIFQITRL 470
A;Accession: JQ0879	Db	181 SWLGNITIMAPTIWARMILMTHFFSILLAQEQLKALDCQIYGACYSTEPLDIFQITRL 240
A;Molecule type: genomic RNA	Qy	471 HGLSAFSLHSYSPGEINRVAACLKLGPPRLQWRHRARSVRAKILSQQGRAAICGKYL 530
A;Residues: 1-365 <OKA>	Db	241 HGLSAFSLHSYSPGEINRVAACLKLGPPRLQWRHRARSVRAKILSQQGRAAICGKYL 300
A;Cross-references: UNIPROT:Q81717	Qy	531 NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDLYHSSLRARPWEMCLLISVGVGY 590
A;Experimental source: strain J4	Db	301 NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDLYHSSLRARPWEMCLLISVGVGY 360
C;Superfamily: hepatitis C virus genome polyprotein	Qy	231 TWTENDIRVEESIYQCCDIAPEAROAIRSUTERLYVGGMTNSKGQNCYRCBASGVLT 290
Query Match 59.6%; Score 1886; DB 2; Length 365;	Db	1 1 TWTENDIRVEESIYQCCDIAPEAROAIRSUTERLYVGGMTNSKGQNCYRCBASGVLT 60
Best Local Similarity 96.7%; Pred. No. 2.1e-137;	Qy	291 TSGCTNLTCYKAAACRAKQLQDCTMLVNGDLYVVICSAGTQDAAASLRVFTTEAMTRY 350
Matches 353; Conservative 9; Mismatches 3; Indels 0; Gaps 0;	Db	61 TSGCTNLTCYKAAACRAKQLQDCTMLVNGDLYVVICSAGTQDAAASLRVFTTEAMTRY 120
Db	61 LLPNR 595	
Qy	361 LLPNR 365	
RESULT 14	Qy	JQ0883 genome polyprotein - hepatitis C virus (strain J7) (fragments)
Db	121 SAPPDPQPEYDLELITSCSSNTSVADASGRKVVYLTRDPTVPLARAAMETARHTPVN 410	
Qy	411 SWLGNITIMAPTIWARMILMTHFFSILLAQEQLKALDCQIYGACYSTEPLDIFQITRL 470	
Db	181 SWLGNITIMAPTIWARMILMTHFFSILLAQEQLKALDCQIYGACYSTEPLDIFQITRL 240	
Qy	471 HGLSAFSLHSYSPGEINRVAACLKLGPPRLQWRHRARSVRAKILSQQGRAAICGKYL 530	
Db	241 HGLSAFSLHSYSPGEINRVAACLKLGPPRLQWRHRARSVRAKILSQQGRAAICGKYL 300	
Qy	531 NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDLYHSSLRARPWEMCLLISVGVGY 590	
Db	301 NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDLYHSSLRARPWEMCLLISVGVGY 360	
Qy	591 LLPNR 595	
Db	361 LLPNR 365	
RESULT 15	Qy	JQ0883 genome polyprotein - hepatitis C virus (strain J7) (fragments)
Db	121 SAPPDPQPEYDLELITSCSSNTSVADASGRKVVYLTRDPTVPLARAAMETARHTPVN 410	
Qy	411 SWLGNITIMAPTIWARMILMTHFFSILLAQEQLKALDCQIYGACYSTEPLDIFQITRL 470	
Db	181 SWLGNITIMAPTIWARMILMTHFFSILLAQEQLKALDCQIYGACYSTEPLDIFQITRL 240	
Qy	471 HGLSAFSLHSYSPGEINRVAACLKLGPPRLQWRHRARSVRAKILSQQGRAAICGKYL 530	
Db	241 HGLSAFSLHSYSPGEINRVAACLKLGPPRLQWRHRARSVRAKILSQQGRAAICGKYL 300	
Qy	531 NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDLYHSSLRARPWEMCLLISVGVGY 590	
Db	301 NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDLYHSSLRARPWEMCLLISVGVGY 360	
Qy	591 LLPNR 595	
Db	361 LLPNR 365	
RESULT 16	Qy	Query Match 46.5%; Score 1471.5; DB 2; Length 874;
Db	Best Local Similarity 70.0%; Pred. No. 5.6e-105;	
Qy	Matches 202; Conservative 40; Mismatches 64; Indels 17; Gaps 3;	
Db	195 YGFOYSPKORVEPLVNTWAKKCPMPGF-SYDTRCFD-STVTVENDIRVPESTIYQCCDIAPE 252	
Qy	487 YCHYHPPK-----PCGTVSAKTVGPPVTVTEIRDITBESIYQCCSLLPQE 531	
Db	253 ARAQIRSLSTERLYGGPMTNSKGQNCYRCRASGVLTSGCNTLTCVIKAAAACRAKCL 312	
Qy	532 ARAQHSSTERLYGGPMTNSKGQNCYRCRASGVFTSGCMTKALAAACKAGI 591	
Db	333 QDCTMLVNGDDLVVTCBAGTQDAAASRVFTAMTRVSSAPPDPPQBYDLELITSSS 372	
Qy	592 KDPIMLVCDDLVVISESGNEEDERNIRAFTEAMTRVSSAPPDLPQBYDLELITSSS 651	
Db	373 NVSYAHDASGRKVVYLTRDPTVPLARAAMETARHTPVN 410	
Qy	652 NVSYAHDASGRKVVYLTRDPTVPLARAAMETARHTPVN 410	
Db	652 NVSYAHDASGRKVVYLTRDPTVPLARAAMETARHTPVN 410	
Qy	433 FFSLLAQEQLKALDCQIYGACYSTEPLDIFQITRLHGLSAFSLHSYSPGEINRVAASC 492	
Db	712 FFNLLAQDPLNQNLNFPEYVGAATSYVNPIDLPATIERTHGLDASLUTYSPHLSRVAT 771	
Qy	493 LRGKGVPLRVWRHRARSVRAKILSQQGRAAICGKYLNWAVRTKLKLTPIPASRLDLS 552	
Db	772 LRGKGVPLRVWRHRARSVRAKILSQQGRAAICGKYLNWAVRTKLKLTPIPASRLDLS 831	
Qy	553 GWFVAGYSGGDLYHSSLRARPWEMCLLISVGVGYLLPNR 595	
Db	832 GWFVAGYSGGDLYHSSLRARPWEMCLLISVGVGYLLPNR 874	
Qy	231 TWTENDIRVEESIYQCCDIAPEAROAIRSUTERLYVGGMTNSKGQNCYRCBASGVLT 290	
Db	1 TWTENDIRVEESIYQCCDIAPEAROAIRSUTERLYVGGMTNSKGQNCYRCBASGVLT 60	
Qy	291 TSGCTNLTCYKAAACRAKQLQDCTMLVNGDLYVVICSAGTQDAAASLRVFTTEAMTRY 350	
Db	61 TSGCTNLTCYKAAACRAKQLQDCTMLVNGDLYVVICSAGTQDAAASLRVFTTEAMTRY 120	
Qy	351 SAPPDPQPEYDLELITSCSSNTSVADASGRKVVYLTRDPTVPLARAAMETARHTPVN 410	

RESULT 15

JQ0881 Genome polyprotein - hepatitis C virus (strain J6) (Fragments)

N; Contains: NSS protein

C; Species: hepatitis C virus

C; Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004

C; Accession: JQ0881

R; Okamoto, H.

Submitted to JVID, January 1991

A; Description: The 5'-terminal and 3'-terminal sequences of the genomic RNA of hepatitis

A; Reference number: JQ0879

A; Accession: JQ0881

A; Molecule type: genomic RNA

A; Residues: 1-974 <OKA>

A; Cross-references: UNIPROT:Q7LZY5

A; Experimental source: strain J6

C; Superfamily: hepatitis C virus genome polyprotein

C; Keywords: polyprotein

F; S10-874/Product: NSS protein (Fragment) #status predicted <NS5>

Query Match 45.5%; Score 1412; DB 2; Length 874;

Best Local Similarity 74.2%; Pred. No. 1e-102;

Matches 271; Conservative 36; Mismatches 58; Indels 0; Gaps 0;

Db 510 TTVTDIRTDIRTBSITVRSITRASLPEATAHSITRERLGGPMNSIGQTCYRCRASGVLT 569

Qy 231 TTYTDIRTDIRTBSITVRSITRASLPEATAHSITRERLGGPMNSIGQTCYRCRASGVLT 290

Db 510 TTVTDIRTDIRTBSITVRSITRASLPEATAHSITRERLGGPMNSIGQTCYRCRASGVLT 569

Qy 291 TSGCNTLTCYKAAACRAAKLQDCITMLYNGDLVWICSGTQDAAASLRVFTTEAMTRY 350

Db 570 TSMGNTTTCYTKAALACKAAGGTTAAPTMLYCGDLVWVSISSQGTEDERNLRAFTTEAMTRY 629

Qy 351 SAPPGDPQQPEYDLELITSGSSNSVVAHDASGKRVYVLTRDPTVPLARAWEWAHTRHPPN 410

Db 630 SAPPGDPQQPEYDLELITSGSSNSVVALGPQGRYYLTTRDPTVPLARAWEWAHTRHPPN 689

Qy 411 SWLGNITMAYPTLWARMILMTHFFSILLACQLEKALDCOYGACYSIEPLDLPIQIIERL 470

Db 690 SWLGNITQAYPTLWARMVMLMTHFFSILLMAQTLDDNLPFMYGAVYVSEPLDLPAIIERL 749

Qy 471 HGLSAFSLHSYSPGEINRYASCLRKLGVPPLRWRHRSYRAKLLSQGRRALCGKYL 530

Db 750 HGLDAFSLHTYTPHLTRVASALRKLGAPPRLRANKSRAVRSILSREGRAAVCGRYLF 809

Qy 531 NWAVRTKLKLTPIPASRDLISGNWAGYSGDLYHSLSRARPWFMLCLLUSVGVITY 590

Db 810 NWAVRTKLKLTPIPASRDLISGNWAGYSGDLYHHSVSRAARPLLGLLFFVGVLIF 869

Qy 591 LLPNR 595

Db 870 LLPAR 874

This Page Blank (uspto)

DR	InterPro; IPR007095; RNA_pol DS PS.	OS Hepatitis C virus.
DR	Pfam; PF01543; HCV_core_1.	CC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
DR	Pfam; PF01542; HCV_core_1.	OC Hepatitis C virus.
DR	Pfam; PF01542; HCV_core_1.	OX Hepatitis C virus.
DR	Pfam; PF01539; HCV_env_1.	RN Hepatitis C virus.
DR	Pfam; PF01560; HCV_NS1_1.	SEQUENCE FROM N_A.
DR	Pfam; PF01538; HCV_NS2_1.	RC STRAIN=MD12;
DR	Pfam; PF02907; HCV_NS3_1.	RA Nagayama K., Kuroasaki M., Enomoto N., Miyasaka Y., Marumo F., Sato C.;
DR	Pfam; PF00006; HCV_NS4a_1.	RA Submitted (NOV-1999) to EMBL/GenBank/DBJ databases.
DR	Pfam; PF01001; HCV_NS4b_1.	DR EMBL; AF207753; AAF65943.1; -.
DR	Pfam; PF01506; HCV_NS5a_1.	DR PIR; A61196; A61196.
DR	Pfam; PF02271; Helicase_C_1.	DR PIR; PQ0246; PQ0246.
DR	Pfam; PF00998; Viral_RRNP_1.	DR PIR; PS0329; PS0329.
DR	SMART; SMO0487; DEXDC_1.	DR HSSP; Q8JY51; 1C9X.
DR	SMART; SMO0490; HELICC_1.	DR GO; GO:00016021; C: integral to membrane; IEA.
DR	PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.	DR GO; GO:00019038; C: viral capsid; IEA.
KW	AP-binding; Coat protein; Envelope protein; Glycoprotein; Helicase;	DR GO; GO:00019031; C: viral envelope; IEA.
KW	Hydrolyase; Nonstructural protein; Polypeptide; Transmembrane.	DR GO; GO:0005524; P: ATP binding; IEA.
SEQUENCE	3010 AA;	DR GO; GO:0008046; P: ATP-dependent helicase activity; IEA.
SO	327043 MW;	DR GO; GO:0003723; P: RNA-directed RNA polymerase activity; IEA.
Db	2420 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 2479	DR GO; GO:0003658; P: RNA-directed RNA polymerase activity; IEA.
Db	2480 SWKQDLEPDTPIQTTIMAKNEVCFQPEKGKPKPARLIVPDLGIVRCEKNAQLYDVS 2539	DR InterPro; IPR00045; C:tc,_name_BS.
Qy	5 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 64	DR InterPro; IPR00110; DEAD.
Qy	125 SWKQDLEPDTPIQTTIMAKNEVCFQPEKGKPKPARLIVPDLGIVRCEKNAQLYDVS 184	DR InterPro; IPR001545; DEAD/DEAH_N.
Db	2540 SWKQDLEPDTPIQTTIMAKNEVCFQPEKGKPKPARLIVPDLGIVRCEKNAQLYDVS 2599	DR InterPro; IPR002522; HCV_capsid.
Qy	185 TLPAQAVMGSSYGIQKSPKQRFVLYNTWKAKCPGMFSYDTRCPDSTVENDRVEEY 244	DR InterPro; IPR002521; HCV_core.
Db	2600 TLPAQAVMGSSYGIQKSPKQRFVLYNTWKAKCPGMFSYDTRCPDSTVENDRVEEY 2659	DR InterPro; IPR002519; HCV_env.
Qy	245 QCCDLAPEARQAISSLTELYVGGPMNTSKQNGQYRRCRASGVLTSGNTLTCYKAA 304	DR InterPro; IPR002511; HCV_NS1.
Db	2660 QCCDLAPEARQAISSLTELYVGGPMNTSKQNGQYRRCRASGVLTSGNTLTCYKAT 2719	DR InterPro; IPR000945; HCV_NS2.
Qy	305 AACTAAKQLODCTMVLNGDDLVVICESACTQDASLRYVETAACTRYSAPPGDPQPEYD 364	DR InterPro; IPR002518; Pept_U39_HCV_NS3.
Db	2720 AACTAAKQLODCTMVLNGDDLVVICESACTQDASLRYVETAACTRYSAPPGDPQPEYD 2779	DR InterPro; IPR007095; RNA_pol_DS_P5.
Qy	365 ELITSCSSNVVAQDAASGKRVVYLTRDPTVPLARAATWTAHPTPVNSLGNLIMYAPTLW 424	DR InterPro; IPR007094; RNA_pol_PSVir.
Db	2780 ELITSCSSNVVAQDAASGKRVVYLTRDPTVPLSPAATWTAHPTPVNSLGNLIMYAPTLW 2839	DR Pfam; PF01543; HCV_capsid; 1.
Qy	425 ARMLTMTHFFSILLAAQEQLKALDQIYACYSTBPDLQPIERLHGISAFLHSYSPG 484	DR Pfam; PF01544; HCV_core; 1.
Db	2840 ARMLTMTHFFSILLAAQEQLKALDQIYACYSTBPDLQPIERLHGISAFLHSYSPG 2899	DR Pfam; PF01539; HCV_env; 1.
Qy	485 EINRVASCLRKLGVPPLRWRHARSVRAKLSSGGRGAIQGKYLEWAVRTKLKLTP 54	DR Pfam; PF01560; HCV_NS1; 1.
Db	2900 EINRVASCLRKLGVPPLRWRHARSVRAKLSSGGRGAIQGKYLEWAVRTKLKLTP 2959	DR Pfam; PF00277; Helicase_C; 1.
Qy	545 AASPLDLSGWPMVAGYSSGGDIYHSLSRARPRWFLCILLLSGVGYIYLPNR 595	DR Pfam; PF00938; Viral_RRNP; 1.
Db	2960 AASPLDLSGWPMVAGYSSGGDIYHSLSRARPRWFLCILLLSGVGYIYLPNR 3010	DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
Qy	5 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 64	KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
Db	2420 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 2479	KW Polyprotein; Transmembrane.
Qy	65 DDHYRDVNLKEMKAKASTVAKLSSVVEACKLTPPHSAAKSKEFGYAKDVSLSRAVNIR 124	SEQUENCE 3010 AA;
Db	2480 DDHYRDVNLKEMKAKASTVAKLSSVVEACKLTPPHSAAKSKEFGYAKDVSLSRAVNIR 2539	326693 MW; 074098DB305AFA19 CRC64;
Qy	Query Match 96.0%; Score 3040; DB 2; Length 3010;	Query Match 96.0%; Score 3040; DB 2; Length 3010;
	Best Local Similarity 97.3%; Pred. No. 6.3e-228; Mismatches 7; Indels 0; Gaps 0;	Best Local Similarity 97.3%; Pred. No. 6.3e-228; Mismatches 7; Indels 0; Gaps 0;
Qy	5 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 64	Qy 5 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 64
Db	2420 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 2479	Db 2420 SWSITWTGALITPAAEBSKPNALNSLRLRHNLVSTTSRASLQRQKTFDRLQVL 2479

RESULT 2
Q9J310 ID Q9J310 PRELIMINARY; PRT; 3010 AA.
AC DT 01-OCT-2000 (TREMBLrel. 15, Created)
DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
QB Polyprotein.

Qy	125 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	184	DR	InterPro; IPR001410; DEAD.
Db	2540 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	2599	DR	InterPro; IPR011545; DEAD/DEAH_N.
Qy	185 TLPOAVMGSSYGFQYSKPQKVERFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY	244	DR	InterPro; IPR002521; HCV core.
Db	2600 TLPOAVMGSSYGFQYSKPQKVERFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY	2659	DR	InterPro; IPR002519; HCV_env.
Qy	245 QCCDLAPEARQAIRSLTERLYVGPMNTSKQNCYRRCRASGVLTTSGNTLTCYLKAA	304	DR	InterPro; IPR000745; HCV_NSA.
Db	2660 QCCDLAPEARQAIRSLTERLYVGPMNTSKQNCYRRCRASGVLTTSGNTLTCYLKAA	2719	DR	InterPro; IPR014907; HCV_NSAb.
Qy	305 AACRAKQLOQCTMLDVLVICESAGTODAASLRVFTETAMTRYSAPPDPPQPEYDL	364	DR	InterPro; IPR02868; HCV_NSSa.
Db	2720 AACRAKQLOQCTMLDVLVICESAGTODAASLRVFTETAMTRYSAPPDPPQPEYDL	2779	DR	InterPro; IPR002166; HCV_RdRP.
Qy	365 BLITSCSSNVSYAHDASGKRYVYLTRDPTVPLARAWEETARHTPVNSWLGNITMYAPTLW	424	DR	InterPro; IPR001650; Helicase_C.
Db	2780 BLITSCSSNVSYAHDASGKRYVYLTRDPTVPLARAWEETARHTPVNSWLGNITMYAPTLW	2839	DR	InterPro; IPR004109; Peptidase_S9.
Qy	425 ARMLMTHFSSILLAQOLEKALDQIYGACYSLEPLDIPQIIEPLHGLUSAFLSHYSFG	484	DR	InterPro; IPR009003; Pept_Ser_Cys.
Db	2840 ARMLMTHFSSILLAQOLEKALDQIYGACYSLEPLDIPQIIEPLHGLUSAFLSHYSFG	2899	DR	InterPro; IPR002518; Pept_U59_HCV_NSS2.
Qy	485 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNVAVTKLKLTPIP	544	DR	InterPro; IPR007095; RNA_pol_DS.
Db	2900 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNVAVTKLKLTPIP	2959	DR	InterPro; IPR007094; RNA_pol_PSVir.
Qy	545 AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISLSSVGCVYILLPNR	595	DR	Pfam; PF01543; HCV_capsid_1.
Db	2960 AASRLDLSGMWVAGYSGGDIYHSLSRARPWFMCLLISLSSVGCVYILLPNR	3010	DR	Pfam; PF01542; HCV_core_1.
Qy	546 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNVAVTKLKLTPIP	644	DR	Pfam; PF01539; HCV_env_1.
Db	2961 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNVAVTKLKLTPIP	3011	DR	Pfam; PF01560; HCV_NS1.
Qy	65 DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR	124	DR	Pfam; PF00271; Helicase_C.
Db	2480 DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR	2539	DR	Pfam; PF00998; Viral_RdRP.
Qy	125 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	184	DR	SMART; SM00487; DEXDC_1.
Db	2540 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	2599	DR	PROSITE; PS0019; CYTOCHROME_C; UNKNOWN_1.
Qy	185 TLPOAVMGSSYGFQYSKPQKVERFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY	244	Db	Coat_protein; Envelope_protein; Glycoprotein.
Db	2420 TLPOAVMGSSYGFQYSKPQKVERFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY	2479	Qy	KW_Polyprotein; Transmembrane.
Qy	65 DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR	124	Db	SEQUENCE 3010 AA; 327352 MW; 888BBA102A733390 CRC64;
Qy	125 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	184	Qy	Query Match 96.0%; Score 3039; DB 2; Length 3010;
Db	2540 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	2599	Qy	Best local similarity 97.6%; Pred. No. 7.5e-228; Mismatches 7; Indels 0; Gaps 0;
Qy	5 SMSYTWTGALITPCAAEESKLPIINALSNSLIRHNLVYSTTSRGASLRQKVKTPDRLQVL	64	Qy	Matches 577; Conservative 7;
Db	2420 SMSYTWTGALITPCAAEESKLPIINALSNSLIRHNLVYSTTSRGASLRQKVKTPDRLQVL	2479	Db	DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR 124
Qy	65 DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR	124	Qy	DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR 2539
Db	2480 DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR	2539	Qy	DDHYRDVLCEMKAKASTVAKLLSVEEACKLTPHSAKSQKPGYAKDVSLSRAVNHIR 2539
Qy	125 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	184	Qy	QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA 304
Db	2540 SWVKDLEDTPPIOTTIMAKRNEVFCVQPEKGGRKPARLIVFPDILGVRVCEKMLDYDVS	2599	Db	QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA 304
Qy	185 TLPOAVMGSSYGFQYSKPQKVERFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY	244	Qy	QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA 304
Db	2600 TLPOAVMGSSYGFQYSKPQKVERFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY	2659	Db	QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA 304
Qy	245 QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA	304	Qy	QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA 304
Db	2660 QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA	2719	Db	QCDCLAPERQAIKSLLPELYVGGMGFTSKQONGCYRRCASGVLTSCNTLTCYLKAA 2719
Qy	305 AACRAAKLQDCTMLVNGDILWVICSAGTOQDASLRVTEAMTRYSAPGDPPOPEYDL	364	Qy	305 AACRAAKLQDCTMLVNGDILWVICSAGTOQDASLRVTEAMTRYSAPGDPPOPEYDL
Db	2720 AACRAAKLQDCTMLVNGDILWVICSAGTOQDASLRVTEAMTRYSAPGDPPOPEYDL	2779	Db	2720 AACRAAKLQDCTMLVNGDILWVICSAGTOQDASLRVTEAMTRYSAPGDPPOPEYDL
Qy	365 ELITSCSNSVSYVAHDASGKRVYLTRDPTVPLARAWEETARHTPVNSLGNINMYAPTILW	424	Qy	365 ELITSCSNSVSYVAHDASGKRVYLTRDPTVPLARAWEETARHTPVNSLGNINMYAPTILW
Db	2780 ELITSCSNSVSYVAHDASGKRVYLTRDPTVPLARAWEETARHTPVNSLGNINMYAPTILW	2839	Db	2780 ELITSCSNSVSYVAHDASGKRVYLTRDPTVPLARAWEETARHTPVNSLGNINMYAPTILW
Qy	425 ARMLMTHFSSILLQSGQRAATCGKYLFLNWAVTKLKLTPIP	544	Qy	425 ARMLMTHFSSILLQSGQRAATCGKYLFLNWAVTKLKLTPIP
Db	2840 ARMLMTHFSSILLQSGQRAATCGKYLFLNWAVTKLKLTPIP	2959	Db	2840 ARMLMTHFSSILLQSGQRAATCGKYLFLNWAVTKLKLTPIP
Qy	485 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNWAVTKLKLTPIP	544	Qy	485 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNWAVTKLKLTPIP
Db	2900 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNWAVTKLKLTPIP	2959	Db	2900 EINRVAASCLRKLGVPPLRWRHARSVRAKLQSGQRAATCGKYLFLNWAVTKLKLTPIP
Qy	InterPro; IPR000345; CytC_heme_BS.			

Qy	545 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMCLLISVGVGIYLPLNR 595	DR SMART; SM00487; DEXDC; 1.
Db	2960 BASQDLSGMFVAGYSGGDIYHSLSRARPRWMCLLISVGVGIYLPLNR 3010	DR PROSITE; PS00190; CYTOCHOME C; UNKNOWN 1.
		DR Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
		KW Polyprotein; Transmembrane.
		KW
		SEQUENCE 3010 AA;
		SEQ 326780 MW: 6680FFEA5FEC3658 CRC64;
RESULT 4		Query Match 95.9%; Score 3038; DB 2; Length 3010;
Q9DT89	PRELIMINARY;	Best Local Similarity 96.8%; Pred. No. 9e-228;
ID		Matches 572; Conservative 13; Mismatches 6; Indels 0; Gaps 0;
AC		
DT	01-MAR-2001 (TREMBLrel. 16, Created)	Qy 5 SMSYTWTGALITPCAAEBSKLPINALISHLRHNLYSTSRSASLRSOKKTFDRQVL 64
DT	01-MAR-2004 (TREMBLrel. 16, Last sequence update)	Db 24220 SMSYTWTGALITPCAAEBSKLPINALISHLRHNLYSTSRSASLRSOKKTFDRQVL 2479
DT	01-MAR-2004 (TREMBLrel. 26, Last annotation update)	
DE		
DE		
OS	Hepatitis C virus.	Qy 65 DDAYRDVLEKMKAKASTYKAKLISVEACKLTTPHSAKSKEKGAKDVSISSSPAVNNIR 124
OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;	Db 2480 DDEAYRDVLEKMKAKASTYKAKLISVEACKLTTPHSAKSKEKGAKDVSISSSPAVNNIR 2539
OC	Hepadnaviruses.	
OX	NCBI_TaxID=11103;	
RN	SEQUENCE FROM N.A.	Qy 125 SWKDLLEDIDTP1QTTMAKNEVPCVQPEKGGRKPARLIVFPDLGTVYCEKADLYDVS 184
RC	TGSSKE-Serum;	Db 2540 SWKDLLEDIDTP1QTTMAKNEVPCVQPEKGGRKPARLIVFPDLGTVYCEKADLYDVS 2599
RA	Takahashi K., Iwata K., Matsumoto M., Nakao K.,	
RA	Hatahara T., Ohta Y., Kanai K., Baba K., Hijikata M.,	Qy 185 TLPOAVMGSYSGROYSPKORVEFLVNTKAKKCEMGFSYDTRCDFSTVENDIRVEESIY 244
RA	Misniro S.,	Db 2600 TLPOAVMGSYSGROYSPGROVEFLVNTKSKCCEMGFSYDTRCDFSTVENDIRVEESIY 2659
RT	"Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited."	
RT	with hepatocellular carcinoma: the 'progression score' revisited."	Qy 245 QCCDLAPRQARQATPSLTPBLYQGAPMTNSKGONGQGYRCRASGVLTTSQGNTLTCLYKRA 304
RL	Hepatol. Res. 20:161-171 (2001).	Db 2660 QCCDLAPRQARQATPSLTPBLYQGAPMTNSKGONGQGYRCRASGVLTTSQGNTLTCLYKAS 2719
DR	EMBL; AB049098; BAB18801.1; -.	
DR	PIR; A61196; A61196.	Qy 305 AACRAAKLQDCTMLVNGDDLVVCEAGTQDASLRLFTTEAMTRYSAPPGDPPQPEVDL 364
DR	PIR; P00246; P00246.	Db 2720 AACRANKQDCTMLVNGDDLVVCEAGTQDASLRLFTTEAMTRYSAPPGDPPQPEVDL 2779
DR	PIR; PQ0804; PQ0804.	
DR	PIR; PS0329; PS0329.	Qy 365 ELITSCSSNVNSVADASGSKRYYLTTRDPVPLARAATRHTPVNSLGNNIYMAPTILW 424
DR	HSSP; Q9Y1SL_1CWX.	Db 2780 ELITSCSSNVNSVADASGSKRYYLTTRDPVPLARAATRHTPVNSLGNNIYMAPTILW 2839
DR	GO_00016021; C-viral to membrane; IEA.	
DR	GO_00019028; C-viral capsid; IEA.	Qy 425 APMILMTFSTILIAQEQLEKALDCQIYGACYSTEPLDLPQITERLHLSAFSLHSYSPG 484
DR	GO_00019031; C-viral envelope; IEA.	Db 2840 APMILMTFSTILIAQEQLEKALDCQIYGACYSTEPLDLPQITERLHLSAFSLHSYSPG 2899
DR	GO_000190524; P-ATP binding; IEA.	
DR	GO_00018026; P-ATP-dependent helicase activity; IEA.	Qy 485 EINRVASCLRKLYPPPLTRWHRARSRAKLLSGGRAICGKYLENVAVRTKLLKLTPIP 544
DR	GO_00018026; P-ATP-dependent helicase activity; IEA.	Db 2900 EINRVASCLRKLYPPPLTRWHRARSRAKLLSGGRAICGKYLENVAVRTKLLKLTPIP 2959
DR	GO_000190723; F-RNA binding; IEA.	
DR	GO_00039658; F-RNA-directed RNA polymerase activity; IEA.	Qy 545 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMCLLISVGVGIYLPLNR 595
DR	GO_0008236; P-serine-type peptidase activity; IEA.	Db 2960 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWMCLLISVGVGIYLPLNR 3010
DR	GO_00065048; P-structural molecule activity; IEA.	
DR	GO_00066350; P-protocolysis and peptidolysis; IEA.	
DR	GO_00066350; P-transcription; IEA.	
DR	GO_00119087; P-viral genome replication; IEA.	
DR	InterPro; IPR000345; Cys-C_heme_BS.	RESULT 5
DR	InterPro; IPR001410; DEAD.	Qb1760 PRELIMINARY; PRT; 3010 AA.
DR	InterPro; IPR011545; DEAD/DEAH_N.	
DR	InterPro; IPR00522; HCV_capsid.	Qb1760; 081760; PRELIMINARY; PRT; 3010 AA.
DR	InterPro; IPR002521; HCV_core.	AC 081760; 01-Nov-1996 (TREMBLrel. 01, Created)
DR	InterPro; IPR002519; HCV_env.	DT 01-Nov-1996 (TREMBLrel. 01, Last sequence update)
DR	InterPro; IPR00531; HCV_NS1.	DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DR	InterPro; IPR00745; HCV_NS4a.	DB Polyprotein.
DR	InterPro; IPR001490; HCV_NS4b.	OS Hepatitis C virus.
DR	InterPro; IPR00668; HCV_NS5a.	OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
DR	InterPro; IPR002166; HCV_RdRp.	OC Hepacivirus.
DR	InterPro; IPR001630; Helicase_C.	NCBI TaxID=11103;
DR	InterPro; IPR004109; Peptidase_S29.	[1] SEQUENCE FROM N.A.
DR	InterPro; IPR002518; Pept_Ser_Cys.	RX MEDLINE=9335897; PubMed=8394876;
DR	InterPro; IPR002518; Pept_U39_HCV_NS2.	RA Wang Y., Okamoto H., Tsuda F., Nagayama R., Tao Q.M., Mishiro S.;
DR	InterPro; IPR007055; RNA_pol_DS_P6.	RT "Prevalence, genotypes, and an isolate (HC-C2) of hepatitis C virus in Chinese patients with liver disease.";
DR	Pfam; PF01543; HCV_capsid_1.	RL J. Med. Virol. 40:254-260 (1993).
DR	Pfam; PF01542; HCV_core_1.	DR EMBL; D1.0934; BAA01728.1; -.
DR	Pfam; PF01539; HCV_env_1.	DR PIR; A61196; A61196.
DR	Pfam; PF01560; HCV_NS1_1.	DR PIR; PQ0246; PQ0246.
DR	Pfam; PF01538; HCV_NS2_1.	DR
DR	Pfam; PF01006; HCV_NS4a_1.	
DR	Pfam; PF01001; HCV_NS4b_1.	
DR	Pfam; PF01506; HCV_NS5a_1.	
DR	Pfam; PF00271; Helicase_C_1.	
DR	Pfam; PF00998; Viral_RdRp_1.	
DR	Pfam; PF00998; RNA_pol_PsVr.	

DR	PIR; P00254; PQ00254;	2660	QCQDLAPEAKOAIKSLSLTERLYIGGPLTNSKGQNCYRRCRASGVLTSCGNTLTCYLKAS	2719
DR	PIR; PQ0804;	3 305	AACRAAKLQDCTMLVNGDLIVICESAGTOEDAASLRVFTTEAMTRYSAPPGDPPPEYDL	364
DR	HSSP; Q8ATYS1; 1CWX.			
DR	GO; GO:0016021; C: integral membrane; IEA.			
DR	GO; GO:0019028; C: viral capsid; IEA.			
DR	GO; GO:0019031; C: viral envelope; IEA.			
DR	GO; GO:000524; ATP binding; IEA.			
DR	GO; GO:0008026; F: ATP-dependent helicase activity; IEA.			
DR	GO; GO:000350; P: proteolysis and peptidolysis; IEA.			
DR	GO; GO:0006350; P: transcription; IEA.			
DR	GO; GO:0003723; F: RNA binding; IEA.			
DR	GO; GO:0009686; F: RNA-directed RNA polymerase activity; IEA.			
DR	GO; GO:0008236; F: serine-type peptidase activity; IEA.			
DR	GO; GO:0005198; P: structural molecule activity; IEA.			
DR	GO; GO:0005200; P: proteolysis and peptidolysis; IEA.			
DR	GO; GO:0019079; P: viral genome replication; IEA.			
DR	GO; GO:0019087; P: viral genome transformation; IEA.			
DR	InterPro; IPR000345; CysC_heme_BS.			
DR	InterPro; IPR011410; DEAD.			
DR	InterPro; IPR011545; DEAD/DEAH_N.			
DR	InterPro; IPR002522; HCV capsid.			
DR	InterPro; IPR002521; HCV core.			
DR	InterPro; IPR002519; HCV_env.			
DR	InterPro; IPR002519; HCV_NS1.			
DR	InterPro; IPR002865; HCV_NS4b.			
DR	InterPro; IPR002865; HCV_RdRp.			
DR	InterPro; IPR002166; HCV_RdRp.			
DR	InterPro; IPR001650; Helicase_C.			
DR	InterPro; IPR004109; Peptidase_S29.			
DR	InterPro; IPR009003; Pept_Ser_Cys.			
DR	InterPro; IPR002518; Pept_U39_HCV_NS2.			
DR	InterPro; IPR011545; RNA_Pol_Dis_P5.			
DR	InterPro; IPR007094; RNA_Pol_P5V1.			
DR	Pfam; PF01543; HCV_capsid_1.			
DR	Pfam; PF01542; HCV_core_1.			
DR	Pfam; PF01539; HCV_env_1.			
DR	Pfam; PF01560; HCV_NS1_1.			
DR	Pfam; PF01538; HCV_NS2_1.			
DR	Pfam; PF02907; HCV_NS3_1.			
DR	Pfam; PF0106; HCV_NS4a_1.			
DR	Pfam; PF01001; HCV_NS4b_1.			
DR	Pfam; PF01506; HCV_NS5a_1.			
DR	Pfam; PF02271; Helicase_C_1.			
DR	Pfam; PF00998; Viral_RdRp_1.			
DR	SMART; SM00487; DEAD/C_1.			
DR	SMART; SM00487; DEAD/C_1.			
KW	Coat protein; Envlope protein; Glycoprotein; Nonstructural protein;			
KW	Polypeptide; Transmembrane.			
SEQNCE	3010 AA; 326857 MW; EA7D3064BA2E224 CRC64;			
Query Match	95.8%; Score 3034; DB 2; Length 3010;			
Best Local Similarity	96.6%; Pred. No. 1.8e-227;			
Matches 571; Conservative	14; Mismatches 6; Indels 0; Gaps 0;			
Qy	5 SMSITWTGALITPCMAEESKPLNALSNSLRRHNLVYSTTSRSASLROKKNTEDRQLV 64			
Db	2420 SMSITWTGALITPCMAEESKPLNPLNSLRRHNLVYSTTSRSASLROKKNTEDRQLV 2479			
Qy	65 DHYRDVLKEMKAKASTVKAKLISVBEACKLTPHSIAKSFKGYAKDVSLSRAVNHR 124			
Db	2480 DHYRDVLKEMKAKASTVKAKLISVBEACKLTPHSIAKSFKGYAKDVSLSRAVNHR 2539			
Qy	125 SWKDLLEDTPICOTTIMANKEVPCQPEKGGRPARLIVPDLGVRCYCEKNAKYDVS 184			
Db	2540 SWKDLLEDTPICOTTIMANKEVPCQPEKGGRPARLIVPDLGVRCYCEKNAKYDVS 2599			
Qy	185 TLPQAVMGSSYGRQYSPKRQVRELYVNTWKSKKCPNGFSYDTRCPDSTVENDRVEESTY 244			
Db	2600 TLPQAVMGSSYGRQYSPKRQVRELYVNTWKSKKCPNGFSYDTRCPDSTVENDRVEESTY 2659			
Qy	245 QCQDLAPEAKOAIKSLSLTERLYIGGPLTNSKGQNCYRRCRASGVLTSCGNTLTCYLKA 304			

DR	InterPro; IPR004109; Peptidase S29.	RESULT 7
DR	InterPro; IPR00903; Pept_Ser_Cys.	Q69285 PRELIMINARY;
DR	InterPro; IPR002518; Pept_U9_HCV_NS2.	Q69285; PRT; 3010 AA.
DR	InterPro; IPR007095; RNA_Pol_DS_P5.	AC
DR	InterPro; IPR007094; RNA_Pol_P5vir.	DT 01-NOV-1996 (TREMBLrel. 01. Created)
DR	Pfam; PRO1543; HCV_capped_1.	DT 01-MAR-1996 (TREMBLrel. 01. Last sequence update)
DR	Pfam; PRO1542; HCV_core_1.	DT 01-MAR-2004 (TREMBLrel. 26. Last annotation update)
DR	Pfam; PRO1539; HCV_env_1.	DE Polyprotein.
DR	Pfam; PRO1560; HCV_NS1_1.	OS Hepatitis C virus.
DR	Pfam; PRO1538; HCV_NS2_1.	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
DR	Pfam; PRO2007; HCV_NS3_1.	OC Hepatitis C virus.
DR	Pfam; PRO1006; HCV_NS4a_1.	OC Hepacivirus.
DR	Pfam; PRO1001; HCV_NS4b_1.	NCBI_TaxID=11103;
DR	Pfam; PRO1506; HCV_NS5a_1.	RN [1]
DR	Pfam; PRO0998; Vi-Tail_RNP; 1.	RP
DR	SMART; SMC0487; DEADIC_1.	Cho J., Park Y., Lee Y., Yang J., Ryu W.; RIA
DR	PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.	Submitted (OCT-1994) to the EMBL/GenBank/ DDBJ databases.
KW	Coat_protein; Envelope_protein; Glycoprotein; Nonstructural_protein;	EMBL; U16362; AAA22748.1; -.
KW	Polyprotein; Transmembrane.	DR
FT	CHAIN 730 1006	PIR; A61196; A61196.
FT	CHAIN 1007 1615	HSRP; Q81755; 1DXP.
FT	CHAIN 1 191	DR; GO:0016021; C-integral to membrane; IEA.
FT	CHAIN 1616 2013	DR; GO:0019038; C-viral capsid; IEA.
FT	CHAIN 2014 3010	DR; GO:0019031; C-viral envelope; IEA.
FT	CHAIN 192 383	DR; GO:0005524; P-ATP binding; IEA.
FT	CHAIN 384 729	DR; GO:0008046; F-ATP-dependent helicase activity; IEA.
SQ	SEQUENCE 3010 AA; 326959 MW; 93D455263EADP8 CRC64;	DR; GO:0003723; F-RNA-directed RNA Polymerase activity; IEA.
QY	5 SMTSYWTGAIJTPCAAEESKIPNLTNALNSLIRHHLNLYSTTTSRSASLROKKTTEDRQLV 64	DR; GO:0003988; F-RNA-directed RNA Polymerase activity; IEA.
Db	2420 SMTSYWTGAIJTPCAAEESKIPNLTNALNSLIRHHLNLYSTTTSRSASLROKKTTEDRQLV 2479	DR; GO:0008236; F-serine-type peptidase activity; IEA.
QY	65 DHYRDVLKEMKAKSTKAKLISVBEAKLTTPHSAKSKEGAKDVSRSLSRAVNHR 124	DR; GO:0006508; F-structural molecule activity; IEA.
Db	2480 DHYRDVLKEMKAKSTKAKLISVBEAKLTTPHSAKSKEGAKDVSRSLSRAVNHR 2539	DR; GO:0006350; P-transcription; IEA.
QY	125 SWDLDLEDTPIDTTIMAKNEVCFQPKGKXPRLVTPDGLVYCEKQALYDVVS 184	DR; GO:0019079; P-viral genome replication; IEA.
Db	2540 SWDLDLEDTPIDTTIMAKNEVCFQPKGKXPRLVTPDGLVYCEKQALYDVVS 2599	DR; GO:0019087; P-viral transformation; IEA.
QY	185 TLPOAVMGSSYGFQYSPKORFVFLVNTWKAKKCPMGFSYDTRCFDSTVTVENDIRVEESTY 244	DR; InterPro; IPR00345; Cyt_C_Theme_BS.
Db	2600 TLPOAVMGSSYGFQYSPKORFVFLVNTWKAKKCPMGFSYDTRCFDSTVTVENDIRVEESTY 2659	DR; InterPro; IPR01410; DEAD.
QY	245 QCCDLAPEARQAIISLTERLYGGPMTNSKGQNCYRRCAQVLTTSQNTLTCYLKA 304	DR; InterPro; IPR011545; DEAD/DEAH_N.
Db	2660 QCCDLAPEARQAIISLTERLYGGPMTNSKGQNCYRRCAQVLTTSQNTLTCYLKA 2719	DR; InterPro; IPR02522; HCV_capsid.
QY	305 ACRAAKLQDCTMLVNGDDLVVICESAGTOEAAALRVTEAMTRYSAPPDQQPEYDL 364	DR; InterPro; IPR002521; HCV_core.
Db	2720 ACRAAKLQDCTMLVNGDDLVVICESAGTOEAAALRVTEAMTRYSAPPDQQPEYDL 2779	DR; InterPro; IPR002519; HCV_env.
QY	365 ELITSCSSNVSYVAHDASGKRVVYLTRDPTVPLARAIAWETARHTPVNSLGNIMYAPTW 424	DR; InterPro; IPR02531; HCV_NS1.
Db	2780 ELITSCSSNVSYVAHDASGKRVVYLTRDPTVPLARAIAWETARHTPVNSLGNIMYAPALW 2839	DR; InterPro; IPR00745; HCV_NS2.
QY	425 ARMLMTHPFSILLAQEQLKALCQIXGACYCSTEPLDLPLQIILERLHGLSASFLHSYSPG 484	DR; InterPro; IPR007095; RNA_pol_DS_P5.
Db	2840 ARMLMTHPFSILLAQEQLKALCQIXGACYCSTEPLDLPLQIILERLHGLSASFLHSYSPG 2959	DR; InterPro; IPR007094; RNA_pol_P5vir.
QY	485 EINRYASCLRKLGVPPLRWRARSVRKLQLSGQGRAICGKYLFLNVAWRKLUKTLP 544	DR; InterPro; IPR01543; HCV_capsid.
Db	2900 EINRYASCLRKLGVPPLRWRARSVRKLQLSGQGRAICGKYLFLNVAWRKLUKTLP 595	DR; InterPro; IPR01542; HCV_core.
QY	545 AASRLDLSGMFVAGYSGGDIYHSLSRPWRFLCLLUSVGVGYLLPNR 3010	DR; InterPro; IPR01541; HCV_NS4a.
Db	2960 AASRLDLSGMFVAGYSGGDIYHSLSRPWRFLCLLUSVGVGYLLPNR 3010	DR; InterPro; IPR01540; HCV_NS4b.
Query Match 95.6%; Score 3027; DB 2; Length 3010;		
Best Local Similarity 96.8%; Pred. No. 6.5e-227;		
Matches 572; Conservative 9; Mismatches 10; Indels 0; Gaps 0;		
SEQUENCE 3010 AA; 326915 MW; 29B306FC5B8EBC9B CRC64;		
5 SMTSYWTGAIJTPCAAEESKIPNLTNALNSLIRHHLNLYSTTTSRSASLROKKTTEDRQLV 64		

Db	2420	SMSYTWTGALITPCAAEESKIPINPLNSLRLRHNMYATTSRAGLROKVTFDRLQLV	2479	
Qy	65	DDHYRDVLKENKAKASTVKAKLISVEBACKTTPPSAKSKFGYAKDVRSLSSRAVNHIR	124	
Db	2480	DDHYRDVLKENKAKASTVKAKLISVEBACKTTPPSAKSKFGYAKDVRSLSSRAVNHIR	2539	
Qy	125	SWWDQDLEDTPITPIOTTIMAKNEVFCVQPEKGKPARLIVFPLDGVRYCEKXMAKYDVVS	184	
Db	2540	SWWDQDLEDTPITPIOTTIMAKNEVFCVQPEKGKPARLIVFPLDGVRYCEKXMAKYDVVS	2599	
Qy	185	TLPOAVMGSSYFQOYSPKQYRVEFLINTWKAKKCPNGFSYDTRCPDSTVENDIRVEESITY	244	
Db	2600	TLPOAVMGSSYFQOYSPKQYRVEFLINTWKAKKCPNGFSYDTRCPDSTVENDIRVEESITY	2659	
Qy	245	QCCDLAPEAARAIRSILTERLVGGPMTNSKGQNTSYRRCRASGVLTTSCTNTLCYLKAA	304	
Db	2660	QCCDLAPEAARAIRSILTERLVGGPMTNSKGQNTSYRRCRASGVLTTSCTNTLCYLKAT	2719	
Qy	305	AACRAAKLQDCTMLYNGDDLVVICSAAGTQDAASLRVFTAMTRYSAPPGDPPPEYDYL	364	
Db	2720	AACRAAKLQDCTMLYNGDDLVVICSAAGTQDAASLRVFTAMTRYSAPPGDPPPEYDYL	2779	
Qy	365	ELITSCSSNVSAHDAKGKRVYVLTDRDPTVPLARAWEETARHTPYNSWLMGNINIMAPTLW	424	
Db	2780	ELITSCSSNVSAHDAKGKRVYVLTDRDPTVPLARAWEETARHTPYNSWLMGNINIMAPTLW	2839	
Qy	425	ARMILMTHPFSILLAQBLKALDQIYQGACYSTIEPLDQLPQIYERLHGJSAFSLHSYSPG	484	
Db	2840	ARMILMTHPFSILLAQBLKALDQIYQGACYSTIEPLDQLPQIYERLHGJSAFSLHSYSPG	2899	
Qy	485	EINRVAACLRLGVPLRVYRHRARSVRAKLLSOGRAATCCKYLFLNWAVTRKLUKTPTP	544	
Db	2900	EINRVAACLRLGVPLRVYRHRARSVRAKLLSOGRAATCCKYLFLNWAVTRKLUKTPTP	2959	
Qy	545	AASRLDLSGMFVAQGGDIYTHSLSRARPRWMLCILLLSVGVGTLLPNR	595	
Db	2960	AASRLDLSGMFVAQGGDIYTHSLSRARPRWMLCILLLSVGVGTLLPNR	3010	
RESULT 8:				
Q81825	1D	PRELIMINARY;	PRT;	3010 AA.
AC	081825;			
DT	01-NOV-1996	(TREMBLrel. 01, Created)		
DT	01-NOV-1996	(TREMBLrel. 01, Last sequence update)		
DE	01-MAR-2004	(TREMBLrel. 26, Last annotation update)		
OS		MRNA, complete cds.		
OC		Viruses; sRNA positive-strand viruses, no DNA stage; Flaviviridae;		
OC		Hepacivirus		
OX		NCBL_TaxID=11103;		
RN	[1]	SEQUENCE FROM N.A.		
RA	Cho J.-M.;			
RL	Submitted (JUN-1993) to the EMBL/GenBank/DBJ databases.			
DR		PIR: A61196; A61198.		
DR		PIR: PS0329.		
DR		HSSP; Q81755; 1DXP.		
DR		GO; GO:0016021; C: integral to membrane; IEA.		
DR		GO; GO:0019028; C: viral capsid; IEA.		
DR		GO; GO:0019031; C: viral envelope; IEA.		
DR		GO; GO:00105524; F: ATP binding; IEA.		
DR		GO; GO:0008026; F: ATP-dependent helicase activity; IEA.		
DR		GO; GO:0003723; F: RNA binding; IEA.		
DR		GO; GO:0003968; F: RNA-directed RNA polymerase activity; IEA.		
DR		GO; GO:0008236; F: serine-type peptidase activity; IEA.		
DR		GO; GO:0005198; F: structural molecule activity; IEA.		
DR		GO; GO:0006508; F: proteolysis and peptidolysis; IEA.		
DR		GO; GO:0016350; F: transcription; IEA.		
DR		GO; GO:0019079; P: viral genome replication; IEA.		
DR		DR: GO:0019087; P: viral transformation; IEA.		
DR		InterPro; IPR000345; Cyt_C_heme_BS.		

DR		InterPro; IPR001410; DEAD.		
DR		InterPro; IPR011545; DEAD/DEAH_N.		
DR		InterPro; IPR002522; HCV capsid.		
DR		InterPro; IPR002521; HCV core.		
DR		InterPro; IPR00519; HCV env.		
DR		InterPro; IPR002531; HCV NS1.		
DR		InterPro; IPR000745; HCV NS4a.		
DR		InterPro; IPR00190; HCV NS4b.		
DR		InterPro; IPR002868; HCV NS5a.		
DR		InterPro; IPR002166; HCV RdRP.		
DR		InterPro; IPR00150; Helicase_C.		
DR		InterPro; IPR004109; Peptidase_S29.		
DR		InterPro; IPR009003; Pept_Ser_Cys.		
DR		InterPro; IPR00510; Pept_Ser_Cys.		
DR		InterPro; IPR007095; RNA pol_DS_Ps.		
DR		InterPro; IPR007094; RNA pol_PstVir.		
DR		PF01543; HCV capsid; 1.		
DR		PF01542; HCV core; 1.		
DR		PF01539; HCV env; 1.		
DR		PF01530; HCV NS1; 1.		
DR		PF01538; HCV NS2; 1.		
DR		PF02907; HCV NS3; 1.		
DR		PF01006; HCV NS4a; 1.		
DR		PF01001; HCV NS4b; 1.		
DR		PF01506; HCV NS5a; 1.		
DR		PF00071; Helicase_C.		
DR		PF00998; Viral_RdRp; 1.		
DR		SMART; SM00487; DEAD_C; 1.		
DR		PROSITE; PS00190; CYTOCHOME_C; UNKNOWN_1.		
KW		Coat protein; Envelope protein; Glycoprotein; Nonstructural protein; Polypeptide; Transmembrane.		
SQ		SEQUENCE 3010 AA; 326925 MW; PE997D54BB05142B CRC44;		
Qy		Query Match 95.6%; Score 3027; DB 2; Length 3010;		
Qy		Best Local Similarity 96.8%; Pred. No. 6.5e-27; Mismatches 9; Indels 0; Gaps 0;		
Qy		Matches 572; Conservative 572; Score 5; S		
Db		2420 SMSYTWTGALITPCAAEESKIPINPLNSLRLRHNLYTSTSRSASLQRKKVTFDRLQLV	64	
Db		2420 SMSYTWTGALITPCAAEESKIPINPLNSLRLRHNLYTSTSRSASLQRKKVTFDRLQLV	2479	
Qy		65 DDHYRDVLKENKAKASTVKAKLISVEBACKTTPPSAKSKFGYAKDVRSLSSRAVNHIR	124	
Db		65 DDHYRDVLKENKAKASTVKAKLISVEBACKTTPPSAKSKFGYAKDVRSLSSRAVNHIR	2539	
Qy		2780 ELITSCSSNVSAHDAKGKRVYVLTDRDPTVPLARAWEETARHTPYNSWLMGNINIMAPTLW	2839	
Db		2780 ELITSCSSNVSAHDAKGKRVYVLTDRDPTVPLARAWEETARHTPYNSWLMGNINIMAPTLW	2899	
Qy		425 ARMILMTHPFSILLAQBLKALDQIYQGACYSTIEPLDQLPQIYERLHGJSAFSLHSYSPG	484	
Db		425 ARMILMTHPFSILLAQBLKALDQIYQGACYSTIEPLDQLPQIYERLHGJSAFSLHSYSPG	544	
Qy		2840 ARMILMTHPFSILLAQBLKALDQIYQGACYSTIEPLDQLPQIYERLHGJSAFSLHSYSPG	2899	
Qy		485 EINRVAACLRLGVPLRVYRHRARSVRAKLLSOGRAATCCKYLFLNWAVTRKLUKTPTP	544	
Db		485 EINRVAACLRLGVPLRVYRHRARSVRAKLLSOGRAATCCKYLFLNWAVTRKLUKTPTP	2959	
Qy		545 AASRLDLSGMFVAQGGDIYTHSLSRARPRWMLCILLLSVGVGTLLPNR	595	
Db		545 AASRLDLSGMFVAQGGDIYTHSLSRARPRWMLCILLLSVGVGTLLPNR	3010	

SQ	SEQUENCE	3010 AA:	327098 MW:	737BEP31EBC2B2BD	CRG64;
	Query Match	95.5%;	Score 3026;	DB 2;	Length 3010;
	Best Local Similarity	96.3%;	Pred. No. 7.8e-27;		
	Matches 569;	Conservative 14;	Mismatches 8;	Indels 0;	Gaps 0;
Qy	5	SMSTTWGALITPCRAEESKLPINALNSNLLRHNLWSTTSRASLROKKTVDLQLVL	64		
Db	2420	SMSTTWGALITPCRAEESKLPINALNSNLLRHNMWSTTSRASLROKKTVDLQLVL	2479		
Qy	65	DDHYRDVLKEMKAVASTWAKLJSVEACKLTTPPHSAKSFKFGKAQDVRSLSSRAVNHIR	124		
Db	2480	DDHYRDVLKEMKAVASTWAKLJSVEACKLTTPPHSAKSFKFGKAQDVRSLSSRAVNHIR	2539		
Qy	125	SWWDLLEDTPDPIOTIMAKNEVFCVQPEKGRKPARLIVEPDOLGVRCEKMALYDVY	184		
Db	2540	SWWDLLEDTPDPIPTTVWAKNEVFCVQPEKGRKPARLIVEPDOLGVRCEKMALYDVY	2599		
Qy	185	TLPQAMGSSYGFQYSPKQREVFLYNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIV	244		
Db	2600	TLPQAMGSSYGFQYSPKQREVFLYNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIV	2659		
Qy	245	QCCDLAPEARQATRSLTERLYVGGMNTSKGQNCYRRCRASGVLTSCGNTLTCYLKAA	304		
Db	2660	QCCDLAPEAKLAIKSLLTERLYVGGMNTSKGQNCYRRCRASGVLTSCGNTLTCYLKAA	2719		
Qy	305	AACRAKLQDCTMLVNGDDLVICSEAGTOQEDAASLRVTEAMTRYSAAPPGDPPQPEYDL	364		
Db	2720	AACRAKLQDCTMLVNGDDLVICSEAGTOQEDAASLRVTEAMTRYSAAPPGDPPQPEYDL	2779		
Qy	365	ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAWEATARHTPVNSWGNLIMAPTLW	424		
Db	2780	ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAWEATARHTPVNSWGNLIMAPTLW	2839		
Qy	425	ARMILMTHFFSILIAQEQOLEKALDQOIQGACYSTEPLDLQPIITERLHGLSAFSLHSYSPG	484		
Db	2840	ARMILMTHFFSILIAQEQOLEKALDQOIQGACYSTEPLDLQPIITERLHGLSAFSLHSYSPG	2899		
Qy	485	EINRVAASCLRKLGIVPPRLWHRARSVRAKLLSQGGRRAACGKYLFWNNAVRTKLKLTPI	544		
Db	2900	EINRVAASCLRKLGIVPPRLWHRARSVRAKLLSQGGRRAACGKYLFWNNAVRTKLKLTPI	2959		
Qy	545	AASRLDLSGMFVAGYSGGDIYHSLRARPWFMLCLLUSVGVGYIYLLPVR 595			
Db	2960	AASRLDLSGMFVAGYGGDIYHVSARPRWFMLCLLUSVGVGYIYLLPVR 3010			
RESULT 10					
	Q9Q1X6	PRELIMINARY;	PRT;	3010 AA.	
	ID	Q9Q1X6			
	AC	Q9Q1X6;			
	DT	01-MAY-2000	(TREMBLrel. 13, Created)		
	DT	01-MAY-2000	(TREMBLrel. 13, Last sequence update)		
	DT	01-MAR-2004	(TREMBLrel. 26, Last annotation update)		
	DB				
	RA				
	OS				
	OS				
	OS				
	OC				
	OC				
	OX				
	NCBI_TaxID=11103;				
	[1]				
	RN	SEQUENCE FROM N.A.			
	RP				
	RC	STRANM=M0B-1;			
	RX	MEDLINE=2013325; PubMed=10544098; DOI=10.1006/viro.1999.9924;			
	RA	Nagayama K., Kuroasaki M., Enomoto N., Maekawa S.Y., Miyasaka Y.,			
	RA	Marumo F., Sato C.;			
	RA	"Time-related changes in full-length hepatitis C virus and hepatitis			
	RT	activity";			
	RT	Virology 263:244-253 (1999);			
	RL	PIR; A61196; A61196.			
	DR	PIR; P00246; P00246.			
	DR	PIR; P00254; P00254.			
	DR	PIR; P00804; P00804.			

DR	PIR; PS0329; PS0329.	QY	305 AACRAAKLQDCTMLVNGDLIVICESATGTOBDAASLRVFTTEAMTRYSAPPGDPPPEYD 364
DR	HSSP; Q8JTS1; 1CWX.	DR	2720 AACRAAKLQDCTMLVNGDLIVICESATGTOBDAASLRVFTTEAMTRYSAPPGDPPPEYD 2779
DR	MEPRO; S29_002;	DR	365 ELITSCSNSVVAHDASGRVYILTRDPITPLARAWETARHTPNSWLGNNTIMYAPTLW 424
DR	C: integral to membrane;	DR	2780 ELITSCSNSVVAHDASGRVYILTRDPITPLARAWETARHTPNSWLGNNTIMYAPTLW 2839
DR	GO; GO:0016021; C: integral to membrane;	DR	425 ARMLTMHFTSILLAQEQLEKALDQCIQYGRACYSTEPLDIPQITERLGHISAFSLHISPG 484
DR	GO; GO:0019028; C:viral capsid;	DR	2840 ARMLTMHFTSILLAQEQLEKALDQCIQYGRACYSTEPLDIPQITERLGHISAFSLHISPG 2899
DR	GO; GO:0019031; C:viral envelope;	DR	485 EINRVAASCLRKLGVPPLRIVWRHRSVRAXLSSQGGRAAICGKYLFLNWAVRTKLKLTPIP 544
DR	GO; GO:0005524; F: ATP binding;	DR	2900 EINRVAASCLRKLGVPPLRIVWRHRSVRAXLSSQGGRAAICGKYLFLNWAVRTKLKLTPIP 2959
DR	GO; GO:0008026; F: ATP-dependent helicase activity;	DR	545 AASRLDLSGMFVAGYSGDLYHSLSRARPPWFMLCLLSSVGVGYLLPWR 595
DR	GO; GO:0006508; F: proteolysis and peptidolysis;	DR	2960 AASRLDLSGMFVAGYSGDLYHSLSRARPPWFMLCLLSSVGVGYLLPWR 3010
DR	GO; GO:0013723; F:RNA binding;	DR	RESULT 11
DR	GO; GO:0019068; F:RNA-directed RNA polymerase activity;	DR	Q9QIX5 PRELIMINARY; PRT; 3010 AA.
DR	GO; GO:0008236; F: serine-type peptidase activity;	DR	Q9QIX5 ID: Q9QIX5; AC: Q9QIX5; DT: 01-MAY-2000 (TREMBLrel. 13, Created)
DR	GO; GO:0005198; F: structural molecule activity;	DR	RA Nagayama K., Kurobaki M., Enomoto N., Maekawa S.Y., Miyasaka Y., Tazawa J.I., Izumi N., Marumo F., Sato C.; DB: Polyprotein.
DR	GO; GO:0006508; F: proteolysis and peptidolysis;	DR	RT "Time-related changes in full-length hepatitis C virus and hepatitis C virus; ssRNA positive-strand viruses, no DNA stage; Flaviviridae; Hepacivirus." RT activity;" RA
DR	GO; GO:0016350; P: transcription;	DR	VL virology 263:244-253 (1999) DR EMBL; AP165060; ADD5195.1; PIR; A61196; A61103; RN [1] _ TAXID:11103;
DR	InterPro; IPR002519; HCV env.	DR	NCBI TAXID:11103; RN
DR	InterPro; IPR002531; HCV NS1.	DR	RP SEQUENCE FROM N.A.
DR	InterPro; IPR000745; HCV NS4a.	DR	RC STRAIN=MD8-2;
DR	InterPro; IPR001490; HCV NS4b.	DR	RX MEDLINE=20013325; PubMed=10544098; DOI=10.1006/viro.1999.9924;
DR	InterPro; IPR002868; HCV NS5a.	DR	RA Nagayama K., Kurobaki M., Enomoto N., Maekawa S.Y., Miyasaka Y., Tazawa J.I., Izumi N., Marumo F., Sato C.; DB: Polyprotein.
DR	InterPro; IPR002166; HCV RdrP.	DR	RT "Time-related changes in full-length hepatitis C virus and hepatitis C virus; ssRNA positive-strand viruses, no DNA stage; Flaviviridae; Hepacivirus." RT activity;" RA
DR	InterPro; IPR001650; Helicase C.	DR	VL virology 263:244-253 (1999) DR EMBL; AP165060; ADD5195.1; PIR; A61196; A61103; RN [1] _ TAXID:11103;
DR	InterPro; IPR004109; Peptidase S29.	DR	DR PIR; P00246; P00246.
DR	InterPro; IPR009003; Peptidase S29.	DR	DR PIR; P00254; P00254.
DR	InterPro; IPR002518; Pept_U39_HCV_NS2.	DR	DR PIR; P00804; P00804.
DR	InterPro; IPR007095; RNA_Pol_Ds_Ps.	DR	DR PIR; P03029; P03029.
DR	InterPro; IPR007094; RNA_Pol_Fsvr.	DR	DR HSSP; Q8BYYS1; 1CWX.
DR	Pfam; PF01543; HCV capsid; 1.	DR	DR MEROPS; S29_002; -.
DR	Pfam; PF01542; HCV core; 1.	DR	DR GO; GO:0016021; C:integral to membrane; IEA.
DR	Pfam; PF01539; HCV env; 1.	DR	DR GO; GO:0019028; C:viral capsid; IEA.
DR	Pfam; PF01560; HCV NS1; 1.	DR	DR GO; GO:0019031; C:viral envelope; IEA.
DR	Pfam; PF01538; HCV NS2; 1.	DR	DR GO; GO:0005524; F:ATP-dependent helicase activity; IEA.
DR	Pfam; PF01537; HCV NS3; 1.	DR	DR GO; GO:0008056; F:RNA directed RNA polymerase activity; IEA.
DR	Pfam; PF01561; HCV NS4a; 1.	DR	DR GO; GO:0008326; F:RNA directed peptide activity; IEA.
DR	Pfam; PF01530; HCV NS4b; 1.	DR	DR GO; GO:0005198; F:serine-type peptidase activity; IEA.
DR	Pfam; PF01506; HCV NS5a; 1.	DR	DR GO; GO:0006508; F:structural molecule activity; IEA.
DR	Pfam; PF01501; HCV NS5b; 1.	DR	DR GO; GO:0006350; F:transcription; IEA.
DR	Pfam; PF00271; Helicase C; 1.	DR	DR GO; GO:0019079; F:viral genome replication; IEA.
DR	Pfam; PF01998; viral_RdRp; 1.	DR	DR InterPro; IPR00345; CrtC_heme_BS.
DR	SMART; SM00487; DEAD; 1.	DR	DR InterPro; IPR01410; DEAD.
DR	PROSITE; PS00190; CYTOCHROME C; UNKNOWN 1.	DR	DR InterPro; IPR011545; DEAD/DEAH N.
KW	Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;	DR	DR InterPro; IPR02522; HCV_capsid.
KW	Polyprotein; Transmembrane protein; Unknown 1.	DR	DR InterPro; IPR02521; HCV_core.
KW	SEQUENCE 3010 AA; 327468 MW; 4613744EC4DA013 CRC64;	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
QY	Query Match 95.5%; Score 3025; DB 2; Length 3010;	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Matches 570; Conservative 15; Mismatches 6; Indels 0; Gaps 0;	Best Local Similarity 96.4%; Pred. No. 9.3e-227;	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Db	5 SMTSYTWTGALLTPTCAABEESKPLNALSNSLRLHNLVYSTSRSASLRLRKVTFDRLQLV 64	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Db	2420 SMTSYTWTGALLTPTCAABEESKPLNPLNSLRLHNLVYSTSRSASLRLRKVTFDRLQLV 2479	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Qy	65 DHYDVLKEMKAKASTVKAKLLSVBEACKLTPPHSAKSFKGYAKDVKRSLSSRAVNHR 124	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Db	2480 DHYDVLKEMKAKASTVKAKLLSVBEACKLTPPHSAKSFKGYAKDVKRSLSSRAVNHR 2539	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Qy	125 SWWDLLEDTPITQTTIMAKNEVCPQPKGKPKPARLIVFDLGVRCEKMLAYDVS 184	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Db	2540 SWWEDLLEDTPITQTTIMAKNEVCPQPKGKPKPARLIVFDLGVRCEKMLAYDVS 2599	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Qy	185 TLQQAQMGSYFQYSPKQKVEFLYNTWKAKKCPNGFSYDTRCFDSVTEENDVVEESIY 244	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Db	2600 TLQQAQMGSYFQYSPKQKVEFLYNTWKAKKCPNGFSYDTRCFDSVTEENDVVEESIY 2659	DR	DR InterPro; IPR019087; P: viral transformation; IEA.
Qy	245 QCCDLAPEARQAIRSLLTERLYGGPMNTSKQNGCYRRCPASGVLTSCGNTLTCYLK 304	DR	DR InterPro; IPR002531; HCV env.
Db	2660 QCCDLAPEARQAIRSLLTERLYGGPMNTSKQNGCYRRCPASGVLTSCGNTLTCYLK 2719	DR	DR InterPro; IPR00745; HCV_ns4a.

DR	InterPro; IPR002868; HCV_NSS5a.	AC PB9966;
DR	InterPro; IPR002166; HCV_RdRP.	DT 01-MAY-1997 (TREMBLref); 03, Created)
DR	InterPro; IPR001650; HeliCase_C.	DT 01-MAY-1997 (TREMBLref); 03, Last sequence update)
DR	InterPro; IPR004109; Peptidase_S29.	DT 01-MAR-2004 (TREMBLref); 26, Last annotation update)
DR	InterPro; IPR009003; Pept_Ser_Cys.	DE RNA for Polyprotein, complete cds.
DR	InterPro; IPR002518; Pept_U39_HCV_NS2.	OS Hepatitis C virus
DR	InterPro; IPR007059; RNA_Pol_DS_P5.	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae
DR	InterPro; IPR007059; RNA_Pol_P5vir.	OC Hepacivirus.
DR	Pfam; PF01543; HCV_Capsid_1.	OC HCV.
DR	Pfam; PF0142; HCV_core_1.	NCBI_TaxID=1103;
DR	Pfam; PF01539; HCV_env_1.	RN [1];
DR	Pfam; PF01560; HCV_NS1_1.	RN SEQUENCE FROM N.A.
DR	Pfam; PF01528; HCV_NS2_1.	RC STRAIN=Type 1b;
DR	Pfam; PF01507; HCV_NS3_1.	RN TANAKA T.;
DR	Pfam; PF01006; HCV_NS4a_1.	RN Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.
DR	Pfam; PF01001; HCV_NS4b_1.	RN [2];
DR	Pfam; PF01506; HCV_NS5a_1.	RN SEQUENCE FROM N.A.
DR	Pfam; PF010271; HeliCase_C_1.	RA Tanaka T.
DR	Pfam; PF00998; Viral_RdRP_1.	RN Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
DR	SMART; SMO0487; DE04C_1.	RN EMBL; BA14035.1; -.
DR	PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.	DR PIR; A61196; A61196.
KW	Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;	DR PIR; P00804; P00804.
KW	Polyprotein; Transmembrane.	DR PIR; PS0329; PS0329.
SQ	SEQUENCE 3010 AA; 327295 MW; 8B99PTEBAGA50F56 CRC64;	DR HSSP; QB1755; IDRP.
Query Match 95.5%; Score 3024; DB 2; Length 3010;		
Best Local Similarity 96.4%; Pred. No. 1.1e-226;		
Matches 570; Conservative 14; Mismatches 7; Indels 0; Gaps 0;		
QY	5 SMSYTWGALTIPCAAEESKLPINALNSLRLRHNLYSTTTSRSASLRQKKTFRDLQYL 64	DR GO; GO:0016021; C: integral to membrane; IEA.
Db	2420 SMSYTWGALTIPCAAEESKLPINALNSLRLRHNLYSTTTSRSASLRQKKTFRDLQYL 2479	DR GO; GO:0019028; C: viral capsid; IEA.
QY	65 DHYRDVLEKMAKASTVKAQLLSEPAKTLTPPHSAKSFKGAKDVKRSLLSSPAVNEIR 124	DR GO; GO:0008024; F: ATP-dependent helicase activity; IEA.
Db	2480 DHYRDVLEKMAKASTVKAQLLSEPAKTLTPPHSAKSFKGAKDVKRSLLSSPAVNEIR 2539	DR GO; GO:0008373; F: RNA binding; IEA.
QY	125 SWKDLDEDTPICTTINAKNEYVCQPEKGGRKPARLIVPDLGVRYCEKQALYDV 184	DR GO; GO:000836; F: serine-type Peptidase activity; IEA.
Db	2540 SWKDLDEDTPICTTINAKYEIVCQPEKGGRKPARLIVPDLGVRYCEKQALYDV 2539	DR GO; GO:0051598; F: structural molecule activity; IEA.
QY	185 TLPOQAVMGSSYGFOQSPKORVEFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY 244	DR GO; GO:0006508; F: proteolysis and peptidolysis; IEA.
Db	2600 TLPOQAVMGSSYGFOQSPKORVEFLVNTWKAKKCPMGFSYDTRCPDSTVENDIRVEESTY 2659	DR GO; GO:0006350; F: transcription; IEA.
QY	245 QCCDLAPEARQAISSLTERLYVGPFMTNSKGONGYRRCRASGVLTTSCGNTLTCYLKA 304	DR GO; GO:0019079; F: viral genome replication; IEA.
Db	2660 QCCDLAPEARQAISSLTERLYVGPFMTNSKGONGYRRCRASGVLTTSCGNTLTCYLKA 2719	DR GO; GO:0019079; F: viral transformation; IEA.
QY	305 AACRAAKLQDCTMLVNGDDLVICESAGTQDAAASLRVTEAMTRYSAPPGDPQQPYD 364	DR InterPro; IPR002531; HCV_NS1.
Db	2720 AACRAAKLQDCTMLVNGDDLVICESAGTQDAAASLRVTEAMTRYSAPPGDPQQPYD 2779	DR InterPro; IPR001410; DEAD_N.
QY	365 ELITSCSSNVSYVAHDASKRKYVYLTRDPTPVLARAWETARHTPVNSWLGNIMYAPTLW 424	DR InterPro; IPR002522; HCV_capsid.
Db	2780 ELITSCSSNVSYVAHDASKRKYVYLTRDPTPVLARAWETARHTPVNSWLGNIMYAPTLW 2839	DR InterPro; IPR002521; HCV_core.
QY	425 ARMLMTHFFSILLQOLEKALDQIYQGACYSTEPLDLQIITERLHGSLSAFLHSYSFG 484	DR InterPro; IPR002519; HCV_env.
Db	2840 ARMLMTHFFSILLQOLEKALDQIYQGACYSTEPLDLQIITERLHGSLSAFLHSYSFG 2839	DR InterPro; IPR002518; HCV_NS1.
QY	485 EINRYASCLRLGVPLRVRHRARSVRKLSQSGRAATGCKYLFLNAVTRKLTP 544	DR InterPro; IPR007095; RNA_Ds_P5.
Db	2900 EINRYASCLRLGVPLRVRHRARSVRKLSQSGRAATGCKYLFLNAVTRKLTP 2959	DR InterPro; IPR007094; RNA_Ds_P5vir.
QY	545 AASRLDLSGMWVAGYSGGDIYHSLSRARPFWMCLLISVGVYLLPNR 595	DR Pfam; P001006; HCV_NS3;
Db	2960 AASRLDLSGMWVAGYSGGDIYHSLSRARPFWMCLLISVGVYLLPNR 3010	DR Pfam; P001542; HCV_core; 1.
RESULT 12 PRELIMINARY; PRT; 3010 AA.		
P89966		KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
ID		KW Polyprotein; Transmembrane.
		SEQUENCE 3010 AA; 32704 MW; E075BD9CFD8D1261 CRC64;
		Query Match 95.4%; Score 3022; DB 2; Length 3010;

Best Local Similarity 96.4%; Pred. No. 1.6e-226; Matches 570; Conservative 12; Mismatches 9; Indels 0; Gaps 0;	DR GO; GO:0005524; F:ATP binding; IEA.
Qy 5 SMTYTWTGALITPCAAEBSKPLNALSNSLRKQKTFPRLQLV 64	DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
Db 2420 SMTYTWTGALITPCAAEBSKPLNALSNSLRKQKTFPRLQLV 2479	DR GO; GO:0003723; F:DNA binding; IEA.
Qy 65 DDHYRVLKEMKAKASTVKAKLISUBEACKLTPPHSAKSKEGYAKDVSLSRAVNHR 124	DR GO; GO:0003968; F:RNA-directed polymerase activity; IEA.
Db 2480 DDHYRVLKEMKAKASTVKAKLISUBEACKLTPPHSAKSKEGYAKDVSLSRAVNHR 2539	DR GO; GO:000236; F:serine-type peptidase activity; IEA.
Qy 125 SSWDLEDTPDPIOPTIMANKEVCPQPKGGKPARLIVPDLGVRVCKMAYDVVS 184	DR GO; GO:0005198; F:structural molecule activity; IEA.
Db 2540 SSWDLEDTPDPIOPTIMANKEVCPQPKGGKPARLIVPDLGVRVCKMAYDVVS 2599	DR GO; GO:0006508; F:proteolysis and peptidolysis; IEA.
Qy 185 TLPOAQTMGSSYGFQTSKPKOREFLNTWKAKKCPMGFSYDTRCPFSTVENDIVTESITY 244	DR GO; GO:0019079; F:transcription; IEA.
Db 2600 TLPOAQTMGSSYGFQTSKPKOREFLNTWKAKKCPMGFSYDTRCPFSTVENDIVTESITY 2659	DR GO; GO:0019087; F:viral genome replication; IEA.
Qy 245 QCCDLAPEARQDARSISTERLYGGPMNTNSKGQNCGYRRCRASGVLTTSCTNTLTCYLKAA 304	DR InterPro; IPR001410; DEAD/C-heme_BS.
Db 2660 QCCDLAPEARQDARSISTERLYGGPMNTNSKGQNCGYRRCRASGVLTTSCTNTLTCYLKAT 2719	DR InterPro; IPR001445; DEAD/DEAH_N.
Qy 305 AACRAKLQDCTMLVNGDDLVVICESAGTQDAAASLRVFTBAMTRYSAPPDPPOPEYDL 364	DR InterPro; IPR001490; HCV_NS4b.
Db 2720 AACRAKLQDCTMLVNGDDLVVICESAGTQDAAASLRVFTBAMTRYSAPPDPPOPEYDL 2779	DR InterPro; IPR001496; HCV_NS5a.
Qy 365 ELITSCSSNTSYVAHDASGRKVVYLTRDPTVPLARAWEVHTPNSWGNINMYAPTW 424	DR InterPro; IPR001666; HCV_RdRp.
Db 2780 ELITSCSSNTSYVAHDASGRKVVYLTRDPTVPLARAWEVHTPNSWGNINMYAPTW 2839	DR InterPro; IPR002519; HCV_env.
Qy 425 ARMLMLTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLQPIIERTHLGLSAFLSHSYSPG 484	DR InterPro; IPR002521; HCV_core.
Db 2840 ARMLMLTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLQPIIERTHLGLSAFLSHSYSPG 2899	DR InterPro; IPR002531; HCV_NS4.
Qy 485 EINRYASCLRKLGVPPLRWRHARSVRAKLSQSGRAATGKYLFWNVRKULTPIP 544	DR InterPro; IPR002745; HCV_NS4.
Db 2900 EINRYASCLRKLGVPPLRWRHARSVRAKLSQSGRAATGKYLFWNVRKULTPIP 2959	DR InterPro; IPR002745; HCV_NS4b.
Qy 545 AASRLDLSGMFVAGYGGDLYTHSLSRARPWFMLCLLISVGVGYLLPNR 595	DR InterPro; IPR002745; HCV_NS5.
Db 2960 AASRLDLSGMFVAGYGGDLYTHSLSRARPWFMLCLLISVGVGYLLPNR 3010	DR InterPro; IPR002745; HCV_NS5a.
RESULT 13	DR InterPro; IPR002745; HCV_NS5b.
Q9DTB0 PRELIMINARY; PRT; 3014 AA.	DR InterPro; IPR002745; HCV_NS5c.
ID Q9DTB0	DR InterPro; IPR002745; HCV_NS5d.
AC Q9DTB0;	DR InterPro; IPR002745; HCV_NS5e.
DT 01-MAR-2001 (TrEMBLrel. 16, Created)	DR InterPro; IPR002745; HCV_NS5f.
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)	DR InterPro; IPR002745; HCV_NS5g.
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)	DR InterPro; IPR002745; HCV_NS5h.
DE Polyprotein.	DR InterPro; IPR002745; HCV_NS5i.
OS Hepatitis C virus.	DR InterPro; IPR002745; HCV_NS5j.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;	DR InterPro; IPR002745; HCV_NS5k.
OC Hepacivirus.	DR InterPro; IPR002745; HCV_NS5l.
NCBI_TaxID=11103;	DR InterPro; IPR002745; HCV_NS5m.
RN [1]	DR InterPro; IPR002745; HCV_NS5n.
RP SEQUENCE FROM N.A.	DR InterPro; IPR002745; HCV_NS5o.
RC TISSUE=Serum;	DR InterPro; IPR002745; HCV_NS5p.
RA Takahashi K., Iwata K., Matsumoto M., Nakao K.,	Qy 185 TLPOAVMGSSYGFQSPKORVEFLNTWKAKKCPMGFSYDTRCPDSTVENDIVTESITY 64
RA Hatahara T., Ohta Y., Kanai K., Maruo H., Baba K., Hijikata M.,	Db 2424 SMTYTWTGALITPCAAEBSKPLNALSNSLRKQKTFPRLQLV 2483
RA Miahiro S.,	Qy 65 DDHYRDLKEMKAKASTVKAKLISVEACKLTPPHSAKSKEGYAKDVSLSRAVNHR 124
RT "Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited."	Db 2484 DDHYRDLKEMKAKASTVKAKLISVEACKLTPPHSAKSKEGYAKDVSLSRAVNHR 2543
RT with hepatocellular carcinoma.	Qy 125 SWWDLEDTPDQTTIMARNEVFCVQPEKGKPARLIVFPDLGVRVCERMALYDVVS 184
RT with hepatitis C virus.	Db 2544 SWWDLEDTPDQTTIMARNEVFCVQPEKGKPARLIVFPDLGVRVCERMALYDVVS 2603
OS Hepatitis C virus.	Qy 185 TLPOAVMGSSYGFQSPKORVEFLNTWKAKKCPMGFSYDTRCPDSTVENDIVTESITY 244
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;	Db 2604 TLPOAVMGSSYGFQSPKORVEFLNTWKAKKCPMGFSYDTRCPDSTVENDIVTESITY 2663
OC Hepacivirus.	Qy 245 QCCDLAPEARQAIRSLTERLYVGPMNTNSKGQNCGYRRCRASGVLTTSCTNTLTCYLKAA 304
NCBI_TaxID=11103;	Db 2664 QCCDLAPEARQAIRSLTERLYVGPMNTNSKGQNCGYRRCRASGVLTTSCTNTLTCYLKAS 2723
RN SEQUENCE FROM N.A.	Qy 305 AACRAKLQDCTMLVNGDDLVVICESAGTQDAAASLRVFTBAMTRYSAPPGDPPPEYDL 364
RC TISSUE=Serum;	DR MEROPE; S2155; IDXp.
RA Takahashi K., Iwata K., Matsumoto M., Nakao K.,	DR GO; GO:0016021; C: integral to membrane; IEA.
RA Hatahara T., Ohta Y., Kanai K., Maruo H., Baba K., Hijikata M.,	DR GO; GO:0019028; C:viral capsid; IEA.
RA Miahiro S.,	DR GO; GO:0019031; C:viral envelope; IEA.
RT "Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited."	DR GO; GO:0016021; C: integral to membrane; IEA.
RT with hepatitis C virus.	DR GO; GO:0019028; C:viral capsid; IEA.
OS Hepatitis C virus.	DR GO; GO:0019031; C:viral envelope; IEA.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;	DR GO; GO:0019031; C:viral envelope; IEA.
OC Hepacivirus.	DR GO; GO:0019031; C:viral envelope; IEA.

Db	2784	ELITSCSSNNVAHDASGGRVYYLTRDPTPIAAWETARHTEVNSWLGNIIMYAPTLW	2843	DR	Pfam; PF01539; HCV_env; 1.
Qy	425	ARMILMTHFSSLIAQBOLEKALDQIYGACYSIEPLDPIIERLHGLSAPSFLHSYSPG	484	DR	Pfam; PF01560; HCV_NS1; 1.
Db	2844	ARMILMTHFSSLIAQBOLEKALDQIYGACYSIEPLDPIIERLHGLSAPSFLHSYSPG	2903	DR	Pfam; PF01588; HCV_NS2; 1.
Qy	485	EINRVASCLRLKGVPPLRVHRARSVRAKLLSQGRAITCGYKLENWAVRTKLTKLTP	544	DR	Pfam; PF01006; HCV_NS3; 1.
Db	2904	EINRVASCLRLKGVPPLRVHRARSVRAKLLSQGRAITCGYKLENWAVRTKLTKLTP	2963	DR	Pfam; PF01001; HCV_NS4b; 1.
Qy	545	AASRLDLSGNFVAGYSGGDIYHSLSRARPWFMCLLISVGCVIYLPPN	595	DR	Pfam; PF01504; HCV_NS5a; 1.
Db	2964	AASRLDLSGNFVAGYSGGDIYHSLSRARPWFMCLLISVGCVIYLPPN	3014	DR	Pfam; PF00271; Helicase_C; 1.
				DR	Pfam; PF00938; Viral_RdRP; 1.
				DR	SMART; SM00487; DEXDC; 1.
				DR	PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
				KW	Coat protein; Envelope protein; Glycoprotein; Nonstructural protein; Polypeptide; Transmembrane.
				KW	
				SEQUENCE	3010 AA; 327265 MW; 4324643E6A1D5CE4 CRC64;
				Query Match	95.4%; Score 3021; DB 2; Length 3010;
				Best Local Similarity	96.3%; Pred. No. 1.9e-226;
				Matches	569; Conservative 14; Mismatches 8; Indels 0; Gaps 0;
				Qy	5 SMSYTWTGALITPCAAEBSKLPIINALSNSLRRHNLVYSTSSASLRQKTVFDRLOVL 64
				Db	2420 SMSYTWTGALITPCAAEBSKLPIINALSNSLRRHNLVYSTSSASLRQKTVFDRLOVL 2479
				Qy	65 DDHYRDVKEMKAKASTYKAKLSSVERACKLTPPHSAKSFKFGYGAOKDVRSLSSRAVNHHR 124
				Db	2480 DDHYRDVKEMKAKASTYKAKLSSVERACKLTPPHSAKSFKFGYGAOKDVRNLSSRAVNHIR 2539
				Qy	125 SWKDLLEDDTDP1QTTIMAKNEVCP1QEKPGKPKDPLIVFPLGVRVCEKMLYDVS 184
				Db	2540 SWNDLLETTETP1D7T1MAKSEVFVCP1QEKPGKPKDPLIVFPLGVRVCEKMLYDVS 2599
				Qy	185 TLPOAVMGSSYGGYPOYSKPCQRBPLVNTAKKCPMGFSYDTRCDSTENDRVEESLY 244
				Db	2600 TLPOAVMGSSYGGYPOYSKPCQRBPLVNTAKKCPMGFSYDTRCDSTENDRVEESLY 2659
				Qy	245 QCCDLAPAROAIRSLTBRLYGGPMTNSKGONGYGRCRASGLTTSCGNTLTCYKKA 304
				Db	2650 QCCDLAPAROAIRSLTBRLYGGPMTNSKGONGYGRCRASGLTTSCGNTLTCYKKA 2719
				Qy	305 AACRAAKLQDCTMLVNGDDLVVIESAGTQEDASLRFTTEAMTRSSAPPGDPQPPEVDL 364
				Db	2720 AACRAAKLQDCTMLVNGDDLVVIESAGTQEDASLRFTTEAMTRSSAPPGDPQPPEVDL 2779
				Qy	365 ELITSCSSNNVSAHDASGKRVYLTRDTPLVPLARAWEETARHTPVNSLQGNIMYAPTLW 424
				Db	2780 ELITSCSSNNVSAHDASGKRVYLTRDTPLVPLARAWEETARHTPVNSLQGNIMYAPTLW 2839
				Qy	425 ARMLMTMFFSLLAQBOLEKALDCQIYGACTSPLDPLQIETRLHGLSAFSLHSYFG 484
				Db	2840 ARMLMTMFFSLLAQBOLEKALDCQIYGACTSPLDPLQIETRLHGLSAFSLHSYFG 2899
				Qy	495 EINRVASCLRLKGVPPLRVHRARSVAKLSSOGGRAIGKRYLENVAVRTKLTKLTPP 544
				Db	2900 EINRVASCLRLKGVPPLRVHRARSVAKLSSOGGRAIGKRYLENVAVRTKLTKLTPP 2959
				Qy	545 AASRLDLSGNFVAGYSGGDIYHSLSRARPWFMCLLISVGCVIYLPPN 595
				Db	2960 AASRLDLSGNFVAGYSGGDIYHSLSRARPWFMCLLISVGCVIYLPPN 3010
				RESULT	15
				ID	039930 PRELIMINARY; PRT; 591 AA.
				AC	039930; 039930 PRELIMINARY;
				DT	01-JAN-1998 (TREMBLrel. 05, Created)
				DT	01-JAN-1998 (TREMBLrel. 05, Last sequence update)
				DT	01-OCT-2003 (TREMBLrel. 25, Last annotation update)
				DE	RNA-dependent RNA-polymerase (Fragment).
				GN	Name=NS5b;
					Hepatitis C virus.
					Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
					Replicaviruses.
					NCBI_TaxID=11103;
					OX

[1]

RN SEQUENCE FROM N.A.
RP MEDLINE=9801363; PubMed=9341198;
RX Lohmann V.; Körner F.; Herian U.; Bartenschlager R.;
RT "Biochemical properties of hepatitis C virus NSSB RNA-dependent RNA
polymerase and identification of amino acid sequence motifs essential
for enzymatic activity";
RT RL EMBL; Z97730; CAB10747.; -;
DR PDB; 1NHF; X-ray; A/B=1.570.
DR PDB; 1NHF; X-ray; A/B=1.570.
DR GO; GO:0010524; F:ATP binding; IEA.
DR GO; GO:0003723; F:RNA binding; IEA.
DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0016350; F:transcription; IEA.
DR GO; GO:0019079; P:virial genome replication; IEA.
DR InterPro; IPR002166; HCV_RdRP.
DR InterPro; IPR007059; RNA_pol_DS_RS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF00998; Viral_RdRP; 1.
FT NON_TER 1 1

SQ SEQUENCE 591 AA; 65753 MW; 6PA9C2970260349 CRC64;

Query Match 95.4%; Score 3050; DB 2; Length 591;
Best Local Similarity 96.6%; Pred. No. 2.5e-227;
Matches 571; Conservative 12; Mismatches 8; Indels 0; Gaps 0;

Qy 5 S M S T T W T G A L I T P C R A E E S K P I N A L S N S L R H N L V S T T S R E A S L R Q K V T F D R L Q V L 64
Db 1 S M S T T W T G A L I T P C R A E E S K P I N A L S N S L R H N M V A T T S R E A S L R Q K V T F D R L Q V L 60

Qy 65 D D H Y R D V L K E M K A K A S T V K A K L L S V E R A C K L T P P H S A K S K P G Y G A K D V R S L S R A V H I R 124
Db 61 D D H Y R D V L K E M K A K A S T V K A K L L S V E R A C K L T P P H S A K S K P G Y G A K D V R N L S R A V H I R 120

Qy 125 S W W D L L E D T P I Q T T I M A K E N E F C V Q D P P E R G G K P A R L I V F P D L G V R C E R M A L Y D V S 184
Db 121 S W W D L L E D T P I Q T T I M A K N E V P C V Q D P P E R G G K P A R L I V F P D L G V R C E R M A L Y D V S 180

Qy 185 T L P Q A V M G S Y G F O Y S P K O R V E P L V N T W A K K C P M G F S T D T R C P D S T V T E N D R V E R S Y 244
Db 181 T L P Q A V M G S Y G F O Y S P G O R V E P L V N T W A S K C K C P M G F S T D T R C P D S T V T E N D R V E R S Y 240

Qy 245 Q C C D L A P E A R Q A I R S L T E R L Y V G G P M T N S K G Q N G G Y R R C A S G U L T T S C G N T T T C Y L K A 304
Db 241 Q C C D L A P E A R Q A I R S L T E R L Y V G S P L T N S K G Q N G G Y R R C A S G U L T T S C G N T T T C Y L K A S 300

Qy 305 A C R A A K L Q D C T M V L V N G D D L V I V C S A G T Q D A A S L R V T E A M T R Y S A P P G D P P Q P E Y T D L 364
Db 301 A C R A A K L Q D C T M V L V C G D D L V I V C S A G T Q D A A S L R A F T A M T R Y S A P P G D P P Q P E Y T D L 360

Qy 365 E L I T S C S S N V S V A H D A S G R V Y Y T T R D P T V P L A R A A W E T A R P V N S W G N T T M Y A P T L W 424
Db 361 E L I T S C S S N V S V A H D A S G R V Y Y T T R D P T V P L A R A A W E T A R P V N S W G N T T M Y A P T L W 420

Qy 425 A R M I L M T H F S I I I A Q B Q L E K A L D C Q I Y G A C Y S I E P L D I P Q I I E R L H G L S A F S I H S Y S P G 484
Db 421 A R M I L M T H F S I I I A Q B Q L E K A L D C Q I Y G A C Y S I E P L D I P Q I I O R L H G L S A F S I H S Y S P G 480

Qy 485 E I N R V A S C U R K L G Y P P L R T W R H A R S V R A K L L S Q G R A I C G Y L E N V A V T K L K L P I P 544
Db 481 E I N R V A S C U R K L G Y P P L R T W R H A R S V R A R L L S Q G R A T G C Y L E N V A V T K L K L P I P 540

Qy 545 A A S I D L S S W F V A G Y S G G D I Y H S L S R A R P W M C L L I S V G Y I Y L P N R 595
Db 541 A A S O D L S S W F V A G Y S G G D I Y H S L S R A R P W M C L L I S V G Y I Y L P N R 591

This Page Blank (uspto)

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

DBM protein - protein search, using sw model
 run on: September 22, 2005, 14:39:31 ; Search time 27 Seconds
 (without alignments)
 1661.633 Million cell updates/sec

Title: US-10-712-479-2
 Perfect score: 3167
 Sequence: 1 MA5MSM5YTWTGALITPOAA.....LLS5VGIVYLLPNRHHHHHH 601

Scoring table: BLOSUM62
 Searched: 513545 seqs, 7464964 residues
 Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Issued_Patents_AA.*

1: /cgn2_6/peodata/1/iaa/5A_COMB.pep:*	Sequence 1, App111
2: /cgn2_6/peodata/1/iaa/5B_COMB.pep:*	Sequence 50, App111
3: /cgn2_6/peodata/1/iaa/6A_COMB.pep:*	Sequence 50, App111
4: /cgn2_6/peodata/1/iaa/6B_COMB.pep:*	Sequence 50, App111
5: /cgn2_6/peodata/1/iaa/PECTUS_COMB.pep:*	Sequence 50, App111
6: /cgn2_6/peodata/1/iaa/backfifesi1.pep:*	Sequence 36, App111

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

result No.	Score	Query Match	Length	DB ID	Description
1	3016	95.2	591	3 US-08-952-981A-1	Sequence 1, App111
2	3016	95.2	997	2 US-08-324-977-50	Sequence 50, App111
3	3016	95.2	997	2 US-08-384-616-50	Sequence 50, App111
4	3016	95.2	997	3 US-08-904-886A-50	Sequence 50, App111
5	3016	95.2	997	3 US-08-315-850-50	Sequence 50, App111
6	3016	95.2	2201	3 US-08-552-381A-2	Sequence 2, App111
7	3016	95.2	2621	1 US-08-324-977-36	Sequence 36, App111
8	3016	95.2	2621	2 US-08-384-616-36	Sequence 36, App111
9	3016	95.2	2621	3 US-08-904-886A-36	Sequence 36, App111
10	3016	95.2	2621	3 US-09-315-850-36	Sequence 2, App111
11	3016	95.2	3010	1 US-08-224-977-2	Sequence 2, App111
12	3016	95.2	3010	1 US-08-324-977-14	Sequence 14, App111
13	3016	95.2	3010	2 US-08-384-616-2	Sequence 2, App111
14	3016	95.2	3010	2 US-08-384-616-14	Sequence 14, App111
15	3016	95.2	3010	2 US-08-904-686A-2	Sequence 2, App111
16	3016	95.2	3010	2 US-08-904-686A-14	Sequence 14, App111
17	3016	95.2	3010	3 US-09-15-850-2	Sequence 2, App111
18	3016	95.2	3010	3 US-09-315-850-14	Sequence 14, App111
19	3015	95.2	3010	3 US-09-014-416-3	Sequence 3, App111
20	3014	95.2	593	4 US-09-397-877-23	Sequence 23, App111
21	3011	95.1	621	4 US-09-898-297-1	Sequence 1, App111
22	3011	95.1	621	4 US-09-995-099-1	Sequence 1, App111
23	3011	95.1	621	4 US-10-238-382-1	Sequence 32, App111
24	3011	95.1	2620	1 US-08-324-977-32	Sequence 32, App111
25	3011	95.1	2620	2 US-08-384-616-32	Sequence 2, App111
26	3011	95.1	2620	2 US-09-315-850-32	Sequence 32, App111
27	3011	95.1	2620	3 US-09-315-850-32	Sequence 2, App111

228	3.005	94.9	1985	4	US-09-539-601-9	Sequence 9, App1
229	3.005	94.9	1985	4	US-09-539-601-12	Sequence 12, App1
230	3.005	94.9	1985	4	US-09-539-601-24	Sequence 24, App1
231	3.005	94.9	1985	4	US-09-539-601-6	Sequence 6, App1
232	3.005	94.9	2201	4	US-09-539-601-15	Sequence 15, App1
233	3.005	94.9	2201	4	US-10-029-907-3	Sequence 3, App1
234	3.005	94.9	3.010	4	US-09-539-601-3	Sequence 3, App1
235	3.005	94.9	3.010	4	US-09-539-601-27	Sequence 27, App1
236	3.004	94.9	1985	4	US-09-539-601-18	Sequence 18, App1
237	3.004	94.9	3.010	4	US-09-539-601-21	Sequence 21, App1
238	3.002	94.8	1985	4	US-09-539-601-30	Sequence 30, App1
239	3.002	94.8	3.010	4	US-09-539-601-33	Sequence 33, App1
240	2.993	94.5	591	4	US-09-720-095A-2	Sequence 2, App1
241	2.987	94.3	593	4	US-09-597-777-12	Sequence 15, App1
242	2.927	92.4	590	4	US-09-194-949A-1	Sequence 1, App1
243	2.879	90.9	576	4	US-09-541-990A-1	Sequence 2, App1
244	2.774	88.7	591	3	US-09-208-140-2	Sequence 1, App1
245	2.774	87.6	3011	3	US-09-014-416-1	Sequence 1, App1

Total number of hits satisfying chosen parameters:

Database	Issued Patents AA:
	1: /cgn2_6/.ptodata
	2: /cgn2_6/.ptodata
	3: /cgn2_6/.ptodata
	4: /cgn2_6/.ptodata
	5: /cgn2_6/.ptodata
	6: /cgn2_6/.ptodata

Pred. No. is the number of re-score greater than or equal to and is derived by analysis of and is derived by analysis of

result No.	Score	Query Match	Length	DB	ID
1	3016	95.2	591	3	US
2	3016	95.2	997	1	US
3	3016	95.2	997	2	US
4	3016	95.2	997	2	US
5	3016	95.2	997	3	US
6	3016	95.2	2201	3	US
7	3016	95.2	2621	1	US
8	3016	95.2	2621	2	US
9	3016	95.2	2621	2	US
10	3016	95.2	2621	3	US
11	3016	95.2	3010	1	US
12	3016	95.2	3010	1	US
13	3016	95.2	3010	2	US
14	3016	95.2	3010	2	US
15	3016	95.2	3010	2	US
16	3016	95.2	3010	2	US
17	3016	95.2	3010	3	US
18	3016	95.2	3010	3	US
19	3015	95.2	3010	3	US
20	3014	95.2	593	4	US
21	3011	95.1	621	4	US
22	3011	95.1	621	4	US
23	3011	95.1	621	4	US
24	3011	95.1	2620	1	US
25	3011	95.1	2620	2	US
26	3011	95.1	2620	3	US
27	3011	95.1	2620	3	US

```

RESULT 1
US-08-952-981A-1
; Sequence 1, Application US/08952981A
; GENERAL INFORMATION:
; APPLICANT: DE FRANCESCO, Raffaele
; APPLICANT: TOMEI, Licia
; APPLICANT: BEHRENS, Sven-Erik
; TITLE OF INVENTION: METHOD FOR REPRODUCING IN VITRO THE RNA-DEPENDENT RNA
; POLYMERASE AND TERMINAL NUCLEOTIDYL TRANSFERASE
; TITLE OF INVENTION: ACTIVITIES ENCODED BY HEPATITIS C VIRUS (HCV)
; FILE REFERENCE: IT002P
; CURRENT APPLICATION NUMBER: US/08/952.981A
; CURRENT FILING DATE: 1998-03-23
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO: 1
; LENGTH: 591
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-08-952-981A-1

Query March 95.2%; Score 3016; DB 3; Length 591;
Best Local Similarity 96.6%; Pred. No. 2e-298; 9; Indels 0; Gaps 0;
Matches 571; Conservative 11; Mismatches 9;

Qy 5 SMSYTWTGALITCPAAEBSKLDPNALNSLRRHHNLYVSTTSRSASLRQKCYTFDRIQLV 64
Db 1 SMSYTWTGALITCPAAEBSKLDPNALNSLRRHHNLYVSTTSRSASLRQKCYTFDRIQLV 60
Qy 65 DDHYRDVKEKAKASTVTKAKLSSVPEACKLTPPHSAKSFKPSYGAKDVSRLSSRAVNHIR 124
Db 61 DDHYRDVKEKAKASTVTKAKLSSVPEACKLTPPHSAKSFKPSYGAKDVSRLSSRAVNHIR 120
Qy 125 SWKDLIILEDTDPIQTTIMAKNEVFCYQPEKGRKPARLIVEPDIGYVRCEKMAJYDVVS 184
Db 121 SWKDLIILEDTDPIQTTIMAKNEVFCYQPEKGRKPARLIVEPDIGYVRCEKMAJYDVVS 180
Qy 185 TLPQVNGSSYQGQSSPKQVRQFBLVNTWKAKCCPKMGSYDTRCFDSTVENDIRVSESY 244
Db 181 TLPQVNGSSYQGQSSPKQVRQFBLVNTWKAKCCPKMGSYDTRCFDSTVENDIRVSESY 240
Qy 245 QCCDLAPERQARQAIKSLTERLYYGGPMTNSKGONGCIGTRCRASGLVLTSCGNTLTCYKAA 304
Db 241 QCCDLAPERQARQAIKSLTERLYYGGPMTNSKGONGCIGTRCRASGLVLTSCGNTLTCYKAA 300
Qy 305 AACRAKLUQDCTMLVNGDLDLVVTCBAGTODAASLRVTEAMTRYSAPPGDPPOPEYDL 364
Db 301 AACRAKLUQDCTMLVNGDLDLVVTCBAGTODAASLRVTEAMTRYSAPPGDPPOPEYDL 360

```

Qy 365 ELITSCSSNVSAHDAISGKRVVYLTRDPTVPLARAWEETARHTPVNSLGNIIIMAYPLW 424
 Db 361 ELITSCSSNVSAHDAISGKRVVYLTRDPTVPLARAWEETARHTPVNSLGNIIIMAYPLW 420
 Qy 425 ARMLIMTHFFSIIIAQEQLKALDQIYGACYSTEPLDLFQIITERLHGLSAFSLHSYSPG 484
 Db 421 ARMLIMTHFFSIIIAQEQLKALDQIYGACYSTEPLDLFQIITERLHGLSAFSLHSYSPG 480
 Qy 485 EINRVASCLRKLGPPRLWRHRSRTRAKLISQGRANICGKYLENTAVRTKULITIP 544
 Db 481 EINRVASCLRKLGPPRLWRHRSRTRAKLISQGRANICGKYLENTAVRTKULITIP 540
 Qy 545 AASRDLDSGMVAGYSGGDLYTHSLSRARPFWMFLCLLUSVGVGYLLPNR 595
 Db 541 AASRDLDSGMVAGYSGGDLYTHSLSRARPFWMFLCLLUSVGVGYLLPNR 591

RESULT US-08-324-977-50

SEQUENCE 50, Application US/08324977

PATENT NO. 5747339

GENERAL INFORMATION:

APPLICANT: OKAYAMA, Hiroto
 FUKU, Isao
 MORI, Chisato
 TAKAMIZAWA, Akahisa

APPLICANT: YOSHIDA, Iwao

TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 TITLE OF INVENTION: cDNA AND ANTIGEN POLYPEPTIDE

NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: Armstrong, Westerman, Hattori, McLeland &
 ATTORNEY: Armstrong, Westerman, Hattori, McLeland &
 STREET: 1725 K St. N.W. Suite 1000
 CITY: Washington
 STATE: D.C.
 COUNTRY: U.S.A.
 ZIP: 20006

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 SOFTWARE: ASCII

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/324,977
 FILING DATE: 18-OCT-1994
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: JP 2-167466
 FILING DATE: 25-JUN-1990
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: JP 2-230921
 FILING DATE: 31-AUG-1990
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 08/099,706
 FILING DATE: 30-JUL-1993
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 07/769,996
 FILING DATE: 02-OCT-1991
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 07/635,451
 FILING DATE: 28-DEC-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Stevens-Smith, Theresa M.
 REGISTRATION NUMBER: 36,281
 REFERENCE/DOCKET NUMBER: 90-0703D
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 659-2930
 TELEFAX: (202) 887-0357
 TELEX: 440142

SEQUENCE CHARACTERISTICS:

LENGTH: 997 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-324-977-50

Query Match 95.2%; Score 3016; DB 1; Length 997;
 Best Local Similarity 96.6%; Pred. No. 4.8e-298;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWTGALITCPAAEESKLPINALNSLRLRHNLYVSTTSASLIROKKUTEDRLQVL 64
 Db 407 SMSYTWTGALITCPAAEESKLPINALNSLRLRHNLYVATTSASLIROKKUTEDRLQVL 466

Qy 65 DDHYRDVLKEMKAKASTYKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSKAVNHR 124
 Db 467 DDHYRDVLKEMKAKASTYKAKLISVEACKLTPPHSAKSFKGYGAKDVSLSKAVNHR 526

Qy 125 SWFDLLEDTPDPIQTTIMAKNEVFCVOPKGKRPKPARLIVFPDLGVRYCEKNAHYDVS 184
 Db 527 SWFDLLEDTPDPIQTTIMAKNEFCVOPKGKRPKPARLIVFPDLGVRYCEKNAHYDVS 586

Qy 185 TLPOAVMGSYGGQYSPKQREFLVNTKAKKCPMGFSYDTRCFDSTYENDIRVEESTY 244
 Db 587 TLPOAVMGSYGGQYSPKQREFLVNTKAKKCPMGFSYDTRCFDSTYENDIRVEESTY 646

Qy 245 QCQDLAPRQAIRSLLTPELYVGPPMTNSKGONGYRRCASGLTTCGNTLTCYKKA 304
 Db 647 QCQDLAPRQAIRSLLTPELYVGPPMTNSKGONGYRRCASGLTTCGNTLTCYKRS 706

Qy 305 AACRAAKLQDCTMLVNGDDLVICESAGTQEDASLRVTEAMTRYSPAPPGDPROPEYDL 364
 Db 707 AACRAAKLQDCTMLVNGDDLVICESAGTQEDASLRVTEAMTRYSPAPPGDPROPEYDL 766

Qy 365 ELITSCSSNVSVAHDAISGKRVVYLTRDPTVPLARAWEETARHTPVNSLGNIIIMAYPLW 424
 Db 767 ELITSCSSNVSVAHDAISGKRVVYLTRDPTVPLARAWEETARHTPVNSLGNIIIMAYPLW 826

Qy 425 ARMLIMTHFFSIIAQEQLKALDQIYGACYSTEPLDLFQIITERLHGLSAFSLHSYSPG 484
 Db 827 ARMLIMTHFFSIIAQEQLKALDQIYGACYSTEPLDLFQIITERLHGLSAFSLHSYSPG 886

Qy 485 EINRVASCLRKLGPPRLWRHRSRTRAKLISQGRANICGKYLENTAVRTKULITIP 544
 Db 887 EINRVASCLRKLGPPRLWRHRSRTRAKLISQGRANICGKYLENTAVRTKULITIP 946

Qy 545 AASRDLDSGMVAGYSGGDLYTHSLSRARPFWMFLCLLUSVGVGYLLPNR 595
 Db 947 AASRDLDSGMVAGYSGGDLYTHSLSRARPFWMFLCLLUSVGVGYLLPNR 997

RESULT 3
 US-08-384-616-50
 Sequence 50, Application US/08384616
 GENERAL INFORMATION:
 APPLICANT: OKAYAMA, Hiroto
 FUKU, Isao
 MORI, Chisato
 APPLICANT: TAKAMIZAWA, Akahisa
 APPLICANT: YOSHIDA, Iwao
 TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
 NUMBER OF SEQUENCES: 50
 PATENT NO. 584701
 CORRESPONDENCE ADDRESS:
 ADDRESS: Armstrong, Westerman, Hattori, McLeland &
 ADDRESS: Naughton
 STREET: 1725 K St. N.W. Suite 1000
 CITY: Washington
 STATE: D.C.
 COUNTRY: U.S.A.
 ZIP: 20006

COMPUTER READABLE FORM:
 MEDIUM TYPE: Disquette, 3.5 in, 1.44MB
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/384,616
 FILING DATE: 25-JUN-1990
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 07/769,996
 FILING DATE: 31-AUG-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-167466
 FILING DATE: 02-OCT-1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/635,451
 FILING DATE: 28-DEC-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Stevens-Smith, Theresa M.
 REGISTRATION NUMBER: 36,281
 REFERENCE/DOCKET NUMBER: 900703B
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 659-2930
 TELEFAX: (202) 887-0357
 TELEX: 440142
 INFORMATION FOR SEQ ID NO: 50:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 997 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-384-616-50

Query Match 95.2%; Score 3016; DB 2; Length 997;
 Best Local Similarity 96.6%; Pred. No. 4.8e-298;
 Matches 519; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

5 SMSTWTGALITPCAAEESKLPIINALSNSLRRHHNLYVSTTSRSASIRQKCKVTDRLQLV 64
 407 SMSTWTGALITPCAAEESKLPIINALSNSLRRHHNLYVATTSRSASIRQKCKVTDRLQLV 466

407 SMSTWTGALITPCAAEESKLPIINALSNSLRRHHNLYVATTSRSASIRQKCKVTDRLQLV 466

65 DDHFRDVLKEMKAKSTVAKLLSVEACKLTPPSAKSFRGKAKDVSLSAVNH.R 124
 467 DDHFRDVLKEMKAKSTVAKLLSVEACKLTPPSAKSFRGKAKDVSLSAVNH.R 526

125 SWKDLDEDTPIOTTIMMKNEYFCVQPEKGKRPARI.LVFDLGVRVCEKMLADYVVS 184

527 SWKDLDEDTPIOTTIMMKNEYFCVQPEKGKRPARI.LVFDLGVRVCEKMLADYVVS 586

185 TLQPAVMGSSYGFQSPKQREVELYNTWAKKCPMGFSYDTRCPDSTVENDIVESTY 244
 587 TLQPVVMGSSYGFQSPGQREFLYNTWAKKCPMGFSYDTRCPDSTVENDIVESTY 646

245 QCCDLAPEROAQLSRLTRIYGGMTNSQNCYRRCRASGLTTSGNTLTCYLA 304
 647 QCCDLAPEROAQLSRLTRIYGGMTNSQNCYRRCRASGLTTSGNTLTCYLA 706

305 AACRAKAKLQDCTMLYNGDILVICESAGTOEDAASLRLVTEAMTRYSAPPGDPPOPEYD 364

707 AACRAKAKLQDCTMLYNGDILVICESAGTOEDAASLRLVTEAMTRYSAPPGDPPOPEYD 766

365 ELITSCSSNSVVAHDASGRKVYTLRDPTPLARAWETARHTPNWSGNIMYAPTN 424
 767 ELITSCSSNSVVAHDASGRKVYTLRDPTPLARAAWETARHTPNWSGNIMYAPTN 826

827 ARMLIMTHFFSILLAOEQLAKDQIYGACTSIEPLDPLQIERLHGLSAFSLHSYSPG 886

Db 485 BINRVASCLRKLGVPPLRVWRHRSVRARLISQSGRAATCGKYLNRWAVTKLKTKTPIP 544
 Qy 887 BINRVASCLRKLGVPPLRVWRHRSVRARLISQSGRAATCGKYLNRWAVTKLKTKTPIP 946

Db 545 AASRLDLSGWFVAGSGGDDIYHSLSRAPRFMLCMUULLSFGVGTLYLPPNR 595
 Qy 947 AASRLDLSGWFVAGSGGDDIYHSLSRAPRFMLCMUULLSFGVGTLYLPPNR 997

RESULT 4
 US-08-904-686A-50
 Sequence 50 Application US/08904686A
 ;
 GENERAL INFORMATION:
 ;
 APPLICANT: ORAYAMA, Hiroto
 ;
 APPLICANT: FUJIB, Isao
 ;
 APPLICANT: MORI, Chisato
 ;
 APPLICANT: TAKAMIZAWA, Akahisa
 ;
 APPLICANT: IOSHIDA, Iwao
 ;
 TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 ;
 TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
 ;
 NUMBER OF SEQUENCES: 50
 ;
 CORRESPONDENCE ADDRESS:
 ;
 ADDRESSEE: Armstrong, Westerman, Hattori, McLeland &
 ;
 STREET: 1725 K St. N.W. Suite 1000
 ;
 CITY: Washington
 ;
 STATE: D.C.
 ;
 COUNTRY: U.S.A.
 ;
 ZIP: 20006
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 COMPUTER: IBM PC Compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 ;
 APPLICATION NUMBER: US/08/904,686A
 ;
 FILING DATE: 01-AUG-1997
 ;
 PRIOR APPLICATION DATA:
 ;
 APPLICATION NUMBER: US 08/324,977
 ;
 FILING DATE: 18-OCT-1994
 ;
 PRIOR APPLICATION DATA:
 ;
 APPLICATION NUMBER: JP 2-167466
 ;
 FILING DATE: 25-JUN-1990
 ;
 PRIOR APPLICATION DATA:
 ;
 APPLICATION NUMBER: JP 2-230921
 ;
 FILING DATE: 31-AUG-1990
 ;
 PRIOR APPLICATION DATA:
 ;
 APPLICATION NUMBER: JP 2-305605
 ;
 FILING DATE: 09-NOV-1990
 ;
 PRIOR APPLICATION DATA:
 ;
 APPLICATION NUMBER: US 08/099,706
 ;
 FILING DATE: 30-JUL-1993
 ;
 PRIOR APPLICATION DATA:
 ;
 APPLICATION NUMBER: US 07/769,996
 ;
 FILING DATE: 02-OCT-1991
 ;
 PRIOR APPLICATION DATA:
 ;
 APPLICATION NUMBER: US 07/635,151
 ;
 FILING DATE: 28-DEC-1990
 ;
 ATTORNEY/AGENT INFORMATION:
 NAME: McLeland, Le-Nung
 REGISTRATION NUMBER: 31,541
 REFERENCE/DOCKET NUMBER: 900703G
 ;
 TELECOMMUNICATION:
 (202) 659-2930
 TELEFAX: (202) 887-0357
 ;
 SEQUENCE CHARACTERISTICS:
 LENGTH: 997 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 ;
 425 ARMLIMTHFFSILLAOEQLAKDQIYGACTSIEPLDPLQIERLHGLSAFSLHSYSPG 886

MOLECULE TYPE: protein

Query Match 95.2%; Score 3016; DB 2; Length 997;
Best Local Similarity 96.6%; Pred. No. 4.8e-298;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSTWTGALLTPCAAEESKLPIALNSLRLRHNVYTSRSASLRKKTFDRLQLV 64
Db 407 SMSTWTGALLTPCAAEESKLPIALNSLRLRHNVYTSRSAGLQRKTFDRLQLV 466

Qy 65 DHYRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSFKGCKYCAKDYRSLSSRAVNHR 124
Db 467 DHYRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSFKGCKYCAKDYRNLSSRAVNHR 526

Qy 125 SWVDLLEDTPDQTTIMAKNEFCVQPEKGKPKARLIVFPDLGVRCYCEKMLDYDVS 184
Db 527 SWVDLLEDTPDQTTIMAKNEFCVQPEKGKPKARLIVFPDLGVRCYCEKMLDYDVS 586

Qy 185 TLPOAVMGSSYGFQYSPKORVEFLVNTWAKAKCPNGFSYDTRCFDSTVENDIRVEESTY 244
Db 587 TLQVVMGSSYGFQSPGQVEFLVNTWAKNPMGFSYDTRCFDSTVENDIRVEESTY 646

Qy 245 QCCDLAPEARQAIKSRLTERLYGGPMNTSKQNGCYRRCRASGVLTTSGNTLTCYLKAA 304
Db 647 QCCDLAPEARQAIKSRLTERLYGGPLNTSKQNGCYRRCRASGVLTTSGNTLTCYLKAS 706

Qy 305 AACRAAKLQDCTMLVNGDDLVIVICESAGTOQDASLRLVTEAMTRYSAPPDGPQPEYDL 364
Db 707 AACRAAKLQDCTMLVNGDDLVIVICESAGTOQDASLRLVTEAMTRYSAPPDGPQPEYDL 766

Qy 365 ELITSCSSNVSYVAHDASGKRVYYLTDPTVPLARAAWETARTHPTVNSWLGNNIIMAPTLW 424
Db 767 ELITSCSSNVSYVAHDASGKRVYYLTDPTVPLARAAWETARTHPTVNSWLGNNIIMAPTLW 926

Qy 425 ARMLMTHFFSILLAQEQLKALDCQIYGACYSTEPLDLPQIITERLHGLSASFSLHSSYSPG 484
Db 827 ARMLMTHFFSILLAQEQLKALDCQIYGACYSTEPLDLPQIITERLHGLSASFSLHSSYSPG 885

Qy 485 EINRVASCLRKLGYPPLRWRHRARSVRAKLISQSGRAAIKGKYLFWAVTRKLKLTPTP 544
Db 887 EINRVASCLRKLGYPPLRWRHRARSVRAKLISQSGRAATGKYLFWAVTRKLKLTPTP 946

Qy 545 AASRLDLSGMFVAGYSGGDIYHSLSRPRFMCLLISVGVGIVLLPNR 595
Db 947 AASRLDLSGMFVAGYSGGDIYHSLSRPRFMCLLISVGVGIVLLPNR 997

RESULT 5
US-09-315-850-50
Sequence 50 Application US/09315850
Patent No. 6,178,72
GENERAL INFORMATION:
APPLICANT: OKAYAMA, Hiroto
APPLICANT: FUKE, Isao
APPLICANT: MORI, Chisato
APPLICANT: TAKAMIZAWA, Akahisa
APPLICANT: YOSHIDA, Iwao
TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Armstrong, Westerman, Hattori, Mcleland &
STREET: 1725 K St. N.W. Suite 1000
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20006
COMPUTER READABLE FORM:
MEDIA TYPE: Diskette, 3.5 in, 1.44Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0

SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/315, 850
FILING DATE:
APPLICATION NUMBER: US/08/904, 686
FILING DATE: 01-AUG-1997
APPLICATION NUMBER: US/08/324, 977
FILING DATE: 18-OCT-1994
APPLICATION NUMBER: JP 2-167466
FILING DATE: 25-JUN-1990
APPLICATION NUMBER: JP 2-230921
FILING DATE: 31-AUG-1990
APPLICATION NUMBER: JP 2-305605
FILING DATE: 09-NOV-1990
APPLICATION NUMBER: US/08/099, 706
FILING DATE: 30-JUL-1993
APPLICATION NUMBER: US/07/769, 996
FILING DATE: 02-OCT-1991
APPLICATION NUMBER: US/07/635, 451
FILING DATE: 28-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Mcleland, Le-Nhung
REGISTRATION NUMBER: 31, 541
REFERENCE/DOCKET NUMBER: 900703G
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 659-2930
TELEFAX: (202) 887-0357
INFORMATION FOR SEQ ID NO: 50:
SEQUENCE CHARACTERISTICS:
LENGTH: 997 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-315-850-50

Query Match 95.2%; Score 3016; DB 3; Length 997;
Best Local Similarity 96.6%; Pred. No. 4.8e-298;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSTWTGALLTPCAAEESKLPIALNSLRLRHNVYTSRSASLRKKTFDRLQLV 64
Db 407 SMSTWTGALLTPCAAEESKLPIALNSLRLRHNVYTSRSAGLQRKTFDRLQLV 466

Qy 65 DHYRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSFKGCKYCAKDYRSLSSRAVNHR 124
Db 467 DHYRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSFKGCKYCAKDYRNLSSRAVNHR 526

Qy 125 SWVDLLEDTPDQTTIMAKNEFCVQPEKGKPKARLIVFPDLGVRCYCEKMLDYDVS 184
Db 527 SWVDLLEDTPDQTTIMAKNEFCVQPEKGKPKARLIVFPDLGVRCYCEKMLDYDVS 586

Qy 185 TLPOAVMGSSYGFQYSPKORVEFLVNTWAKAKCPNGFSYDTRCFDSTVENDIRVEESTY 244
Db 587 TLQVVMGSSYGFQSPGQVEFLVNTWAKNPMGFSYDTRCFDSTVENDIRVEESTY 646

Qy 245 QCCDLAPEARQAIKSRLTERLYGGPMNTSKQNGCYRRCRASGVLTTSGNTLTCYLKAA 304
Db 647 QCCDLAPEARQAIKSRLTERLYGGPLNTSKQNGCYRRCRASGVLTTSGNTLTCYLKAS 706

Qy 305 AACRAAKLQDCTMLVNGDDLVIVICESAGTOQDASLRLVTEAMTRYSAPPGDPQPEYDL 364
Db 707 AACRAAKLQDCTMLVNGDDLVIVICESAGTOQDASLRLVTEAMTRYSAPPGDPQPEYDL 766

Qy 365 ELITSCSSNVSYVAHDASGKRVYYLTDPTVPLARAAWETARTHPTVNSWLGNNIIMAPTLW 424
Db 767 ELITSCSSNVSYVAHDASGKRVYYLTDPTVPLARAAWETARTHPTVNSWLGNNIIMAPTLW 826

Qy	425	ARMILMTHFSSILLAQEQLEKALDCQIYGACYSIEPLDLPQIILERHGLSASFSLHSYSPG	484	Db	2091	Einrvasclrklgvpplrvrhrarsvrarllsqgratcgkylenwavktklkltpip	2150	
Db	827	ARMILMTHFSSILLAQEQLEKALDCQIYGACYSIEPLDLPQIILERHGLSASFSLHSYSPG	886	Qy	545	AASRLDLSGMFVAGYSGGDIYHSLSRARPRWFMLCILLLSVGVGTYLPLNR	595	
Qy	485	Einrvasclrklgvpplrvrhrarsvrakllsqgratcgkylenwavrktklkltpip	544	Db	2151	AASRLDLSGMFVAGYSGGDIYHSLSRARPRWFMLCILLLSVGVGTYLPLNR	2201	
Db	887	Einrvasclrklgvpplrvrhrarsvrarllsqgratcgkylenwavrktklkltpip	946					
Qy	545	AASRLDLSGMFVAGYSGGDIYHSLSRARPRWFMLCILLLSVGVGTYLPLNR	595					
Db	947	AASRLDLSGMFVAGYSGGDIYHSLSRARPRWFMLCILLLSVGVGTYLPLNR	997					
RESULT 6				RESULT 7				
	US-08-952-981A-2	Sequence 2, Application US/08952981A	US-08-324-977-36		Sequence 36, Application US/08324977			
	Patent No. 6383768	Patent No. 5747339						
	GENERAL INFORMATION:	GENERAL INFORMATION:						
	APPLICANT: DE FRANCESCO, Raffaele	APPLICANT: OKAYAMA, Hiroto						
	APPLICANT: TOMEI, Licia	APPLICANT: FUKE, Isao						
	APPLICANT: BEHRENS, Seven-Erik	APPLICANT: MORI, Chisato						
	TITLE OF INVENTION: METHOD FOR REPRODUCING IN VITRO THE RNA-DEPENDENT RNA	APPLICANT: TAKIMIZAWA, Akahisa						
	TITLE OF INVENTION: POLYMERASE AND TERMINAL NUCLEOTIDYL TRANSFERASE	APPLICANT: YOSHIDA, Iwao						
	TITLE OF INVENTION: ACTIVITIES ENCODED BY HEPATITIS C VIRUS (HCV)	TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC						
	FILE REFERENCE: ITO002P	NUMBER OF SEQUENCES: 50						
	CURRENT APPLICATION NUMBER: US/08/952,981A	NUMBER OF SEQUENCES: 50						
	CURRENT FILING DATE: 1998-03-23	NUMBER OF SEQUENCES: 50						
	NUMBER OF SEQ ID NOS.: 14	NUMBER OF SEQUENCES: 50						
	SOFTWARE: PatentIn ver. 2.0	NUMBER OF SEQUENCES: 50						
	SEQ ID NO 2	NUMBER OF SEQUENCES: 50						
	LENGTH: 2201	NUMBER OF SEQUENCES: 50						
	TYPE: PRT	NUMBER OF SEQUENCES: 50						
	ORGANISM: cDNA clone PCD (38-9-4)	NUMBER OF SEQUENCES: 50						
	US-08-952-981A-2	NUMBER OF SEQUENCES: 50						
Query Match	95.2%	Score 3016; DB 3; Length 2201;	Query Match	95.2%	Score 3016; DB 1; Length 2617;			
Best Local Similarity	96.6%	Pred. No. 1.8e-297; Mismatches 9; Indels 0; Gaps 0;	Best Local Similarity	96.6%	Pred. No. 1.8e-297; Mismatches 9; Indels 0; Gaps 0;			
Matches	571	Conservative 11; Mismatches 9; Indels 0; Gaps 0;	Matches	571	Conservative 11; Mismatches 9; Indels 0; Gaps 0;			
Qy	5	SMSYTWTGALLTPCAABEKSPLPINALNSLIRHHLVYSTTSRSASLIRQKVKTPDRLQVL	Qy	5	SMSYTWTGALLTPCAABEKSPLPINALNSLIRHHLVYSTTSRSASLIRQKVKTPDRLQVL	Qy	5	SMSYTWTGALLTPCAABEKSPLPINALNSLIRHHLVYSTTSRSASLIRQKVKTPDRLQVL
Db	1611	SMSYTWTGALLTPCAABEKSPLPINALNSLIRHHLVYSTTSRSASLIRQKVKTPDRLQVL	Db	1670	SMSYTWTGALLTPCAABEKSPLPINALNSLIRHHLVYSTTSRSASLIRQKVKTPDRLQVL	Db	1670	SMSYTWTGALLTPCAABEKSPLPINALNSLIRHHLVYSTTSRSASLIRQKVKTPDRLQVL
Qy	65	DHYRDVLKEMKAKASTVRKLLSVBEAKTUPPHSAKSKEFYGAKDVSLSAVNH.R	Qy	65	DHYRDVLKEMKAKASTVRKLLSVBEAKTUPPHSAKSKEFYGAKDVSLSAVNH.R	Qy	65	DHYRDVLKEMKAKASTVRKLLSVBEAKTUPPHSAKSKEFYGAKDVSLSAVNH.R
Db	1671	DHYRDVLKEMKAKASTVRKLLSVBEAKTUPPHSAKSKEFYGAKDVSLSAVNH.H	Db	1671	DHYRDVLKEMKAKASTVRKLLSVBEAKTUPPHSAKSKEFYGAKDVSLSAVNH.H	Db	1671	DHYRDVLKEMKAKASTVRKLLSVBEAKTUPPHSAKSKEFYGAKDVSLSAVNH.H
Qy	125	SYWDKDLLEDTPICOTTIMANNEVFCVQPKGGKPKPARLIVPDLGVRYCEKMKALYDVVS	Qy	125	SYWDKDLLEDTPICOTTIMANNEVFCVQPKGGKPKPARLIVPDLGVRYCEKMKALYDVVS	Qy	125	SYWDKDLLEDTPICOTTIMANNEVFCVQPKGGKPKPARLIVPDLGVRYCEKMKALYDVVS
Db	1731	SYWDKDLLEDTPIDTTIMANNEVFCVQPKGGKPKPARLIVPDLGVRYCEKMKALYDVVS	Db	1731	SYWDKDLLEDTPIDTTIMANNEVFCVQPKGGKPKPARLIVPDLGVRYCEKMKALYDVVS	Db	1731	SYWDKDLLEDTPIDTTIMANNEVFCVQPKGGKPKPARLIVPDLGVRYCEKMKALYDVVS
Qy	185	TLPOAVMGSSYFQYSPKQPKRVEFLINTWAKKCPNGFSYDTRCPDSTVENDIRVEESTY	Qy	185	TLPOAVMGSSYFQYSPKQPKRVEFLINTWAKKCPNGFSYDTRCPDSTVENDIRVEESTY	Qy	185	TLPOAVMGSSYFQYSPKQPKRVEFLINTWAKKCPNGFSYDTRCPDSTVENDIRVEESTY
Db	1791	TLPOVYMGSSYFQYSPGQVTFLYNTWKSCKNPMGFSYDTRCPDSTVENDIRVEESTY	Db	1850	TLPOVYMGSSYFQYSPGQVTFLYNTWKSCKNPMGFSYDTRCPDSTVENDIRVEESTY	Db	1850	TLPOVYMGSSYFQYSPGQVTFLYNTWKSCKNPMGFSYDTRCPDSTVENDIRVEESTY
Qy	245	QCCDIAPEARQAIRSLITERLYVGGMNTNSKGNCQNCYRRCAASGVLITSGCTLTICLKA	Qy	245	QCCDIAPEARQAIRSLITERLYVGGMNTNSKGNCQNCYRRCAASGVLITSGCTLTICLKA	Qy	245	QCCDIAPEARQAIRSLITERLYVGGMNTNSKGNCQNCYRRCAASGVLITSGCTLTICLKA
Db	1851	QCCDIAPEARQAIRSLITERLYVGGMNTNSKGNCQNCYRRCAASGVLITSGCTLTICLKA	Db	1851	QCCDIAPEARQAIRSLITERLYVGGMNTNSKGNCQNCYRRCAASGVLITSGCTLTICLKA	Db	1851	QCCDIAPEARQAIRSLITERLYVGGMNTNSKGNCQNCYRRCAASGVLITSGCTLTICLKA
Qy	305	AACRAAKLQDQTMLYNGDDLVVICSAAGTOADAASLRLVFTeamtrySAPGDPPOPEYDL	Qy	305	AACRAAKLQDQTMLYNGDDLVVICSAAGTOADAASLRLVFTeamtrySAPGDPPOPEYDL	Qy	305	AACRAAKLQDQTMLYNGDDLVVICSAAGTOADAASLRLVFTeamtrySAPGDPPOPEYDL
Db	1911	AACRAAKLQDQTMLYNGDDLVVICSAAGTOADAASLRLVFTeamtrySAPGDPPOPEYDL	Db	1911	AACRAAKLQDQTMLYNGDDLVVICSAAGTOADAASLRLVFTeamtrySAPGDPPOPEYDL	Db	1911	AACRAAKLQDQTMLYNGDDLVVICSAAGTOADAASLRLVFTeamtrySAPGDPPOPEYDL
Qy	365	ELITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPYNSMLGNIMYAPTLM	Qy	365	ELITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPYNSMLGNIMYAPTLM	Qy	365	ELITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPYNSMLGNIMYAPTLM
Db	1971	ELITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPYNSMLGNIMYAPTLM	Db	2030	ELITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPYNSMLGNIMYAPTLM	Db	2030	ELITSCSNVSYVAHDASGKRVVYLTRDPTVPLARAWEATRHTPYNSMLGNIMYAPTLM
Qy	425	ARMILMTHFSSILLAQEQLEKALDCQIYGACYSIEPLDLPQIILERHGLSASFSLHSYSPG	484	Qy	425	ARMILMTHFSSILLAQEQLEKALDCQIYGACYSIEPLDLPQIILERHGLSASFSLHSYSPG	544	
Db	2031	ARMILMTHFSSILLAQEQLEKALDCQIYGACYSIEPLDLPQIILERHGLSASFSLHSYSPG	2090	Qy	485	Einrvasclrklgvpplrvrhrarsvrakllsqgratcgkylenwavrktklkltpip	544	

Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0; PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US 07/769,996
FILING DATE: 02-OCT-1991
APPLICATION NUMBER: JP 2-167466
FILING DATE: 25-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 2-230921
FILING DATE: 31-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 2-305605
FILING DATE: 09-NOV-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/635,451
FILING DATE: 28-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Stevens-Smith, Theresa M.
REGISTRATION NUMBER: 36 281
REFERENCE/DOCKET NUMBER: 900703B
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 659-2930
TELEFAX: (202) 887-0357
TELEX: 440142
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 2621 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-384-616-36

Query Match 95.2%; Score 3016; DB 2; Length 2621;
Best Local Similarity 96.6%; Pred. No. 2.4e-297;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSTWTGALITPGRAEESKLPIINALSNIILRHNLVYSTTSRASLQRKVTFDRQVL 64
Db 2211 QCCDLAPEARQAIISLTERLYGGMINTNSKGQNCYRRGRASGVLTTSGNTLTCYLKA 304
Db 2271 QCCDLAPEARQAIISLTERLYGGMINTNSKGQNCYRRGRASGVLTTSGNTLTCYLKA 2330
Qy 305 AACRAAKLQDQTMLYGDDLVVICESAGTODAASLRVFTTEAMTRYSAPGDPQPOETDL 364
Db 2331 AACRAAKLQDQTMLYGDDLVVICESAGTODAASLRVFTTEAMTRYSAPGDPQPOETDL 2390
Qy 365 ELITSCSSNVSYVAHDASGRKVVYLTRDPTPLBARAWEARTHTPVNSWLNGLNIMYAPTLW 424
Db 2391 ELITSCSSNVSYVAHDASGRKVVYLTRDPTPLBARAWEARTHTPVNSWLNGLNIMYAPTLW 2450
Qy 425 ARMLMTHFFSILLAQEQLKALDQIYGACYSIEPLDLPQIILERLHGSAFSLHSYSRG 484
Db 2451 ARMLMTHFFSILLAQEQLKALDQIYGACYSIEPLDLPQIILERLHGSAFSLHSYSRG 2510
Qy 485 EINRVAASCLRKLGVPPLWRHRARSVRAKLLSOGRAATCGKYLENWAIVTRKLRKTPIP 544
Db 2511 EINRVAASCLRKLGVPPLWRHRARSVRAKLLSOGRAATCGKYLENWAIVTRKLRKTPIP 2570
Qy 545 AASRLDLSGMWVAGYSGGGDIYTHSLSRARPRWMCLLILSVGVGYLLPNR 595
Db 2571 AASRLDLSGMWVAGYSGGGDIYTHSLSRARPRWMCLLILSVGVGYLLPNR 2621

RESULT 8
US-08-384-616-36
Sequence 36, Application US/08384616
Patent No. 547101
GENERAL INFORMATION:
APPLICANT: OKAYAMA, Hiroto
APPLICANT: FUKE, Isao
APPLICANT: MORI, Chisato
APPLICANT: TAKAMIZAWA, Akanisa
TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
TITLE OF INVENTION: DNA AND ANTIGEN POLYPEPTIDE
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Armstrong, Westerman, Hattori, McLeland &
ADDRESSEE: Naughton
STREET: 1725 K St. N.W. Suite 1000
CITY: Washington
STATE: D.C.
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/384,616
FILING DATE:
CLASSIFICATION: 424
Qy 545 AASRLDLSGMWVAGYSGGGDIYHSLSRARPRWMCLLILSVGVGYLLPNR 595
Db 2571 AASRLDLSGMWVAGYSGGGDIYHSLSRARPRWMCLLILSVGVGYLLPNR 2621

RESULT 9

US-08-904-686A-36

Sequence 36 Application US/08904686A

Patent No. 5998130

GENERAL INFORMATION:

APPLICANT: OKAYAMA, Hiroto

APPLICANT: FUKE, Isao

APPLICANT: MORI, Chisato

APPLICANT: TAKAMIZAWA, Akahisa

APPLICANT: YOSHIDA, Iwao

TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC CDNA AND ANTIGEN POLYPEPTIDE

NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: Armstrong, Westerman, Hattori, McLeland & Naughton

STREET: 1725 K St. N.W. Suite 1000

CITY: Washington

STATE: D.C.

ZIP: 20006

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0

SOFTWARE: ASCII

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/904,686A

FILING DATE: 01-AUG-1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/324,977

FILING DATE: 31-AUG-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 2-305605

FILING DATE: 09-NOV-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/099,706

FILING DATE: 30-JUL-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/769,996

FILING DATE: 02-OCT-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/635,451

FILING DATE: 28-DEC-1990

ATTORNEY/AGENT INFORMATION:

NAME: McLeland, Le-Nhung

REGISTRATION NUMBER: 31,541

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 659-2930

TELEFAX: (202) 887-0357

INFORMATION FOR SEQ ID NO: 36:

SEQUENCE CHARACTERISTICS:

LENGTH: 2621 amino acids

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-904-686A-36

Query Match 95 2%; Score 3016; DB 2; Length 2621;

Best Local Similarity 96.6%; Pred. No. 2.4e-297;

Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

5 SMSYTTGALITPCAAEESKIPINAlNSLRLRHNVYSTSRSASLRLQKVTFDRLQVL 64

2031 SMSYTTGALITPCAAEESKIPINAlNSLRLRHNVYSTSRSASLRLQKVTFDRLQVL 2090

65 DDHYRDVLKEMKAKASTVAKLSSVEACKLTPPSAKSKFGYGARDVRSLSSSRAVNHIR 124

Db 2091 DDHYRDVLKEMKAKASTVAKLSSVEACKLTPPSAKSKFGYGARDVRSLSSSRAVNHIR 2150

Qy 125 SWVKOLLEDTPPIOTTIMARNEVPCVQPEKGGRKPARLIVFPDGLVRYCEKMKALYDVVS 184

Db 2151 SWVKOLLEDTPPIOTTIMARNEVPCVQPEKGGRKPARLIVFPDGLVRYCEKMKALYDVVS 2210

Qy 185 TLPOAVMGSSYGFQYSPKQRPVEFLINTVAKKCPMGFSYDTRCPDSTVENDIRVEESIY 244

Db 2211 TLPOVGMGSSYGFQYSPKQRPVEFLINTVAKKCPMGFSYDTRCPDSTVENDIRVEESIY 2270

Qy 245 QCDDIAPEARQAIRSLTERDYGGLTNSKGQNCYRCRASGVLTSGCNTLTCYKAA 304

Db 2271 QCDDIAPEARQAIRSLTERDYGGLTNSKGQNCYRCRASGVLTSGCNTLTCYKAA 2330

Qy 305 AACRAAKLQDCTMLVNGDLIVVICSAGTOQDAASLRVFTTEAMTRYSAPPGDPPPEYDL 364

Db 2331 AACRAAKLQDCTMLVNGDLIVVICSAGTOQDAASLRVFTTEAMTRYSAPPGDPPPEYDL 2390

Qy 365 ELITSCSNVVAHDASGRVYVLTDRDPTVPLARAWETARHTPNSWGNIMVAPTLW 424

Db 2391 ELITSCSNVVAHDASGRVYVLTDRDPTVPLARAWETARHTPNSWGNIMVAPTLW 2450

Qy 425 ARMLTMTHFFSIIQIQQEQLERKDCQIYACYSIEPLDIPQIIERLHGSASFSLHSYSPG 484

Db 2451 ARMLTMTHFFSIIQIQQEQLERKDCQIYACYSIEPLDIPQIIERLHGSASFSLHSYSPG 2510

Qy 485 EINRVASCIKLGVPPLRYMRHRSVRAKLLSGQGRAACIGKYLFWNVAWRTKLKLTPIP 544

Db 2511 EINRVASCIKLGVPPLRYMRHRSVRAKLLSGQGRAACIGKYLFWNVAWRTKLKLTPIP 2570

Qy 545 AASRUDLSGMFVAGYSGGDIYHSLSRARPRWFMLCLLSSVGVGTYLPNR 595

Db 2571 AASRUDLSGMFVAGYSGGDIYHSLSRARPRWFMLCLLSSVGVGTYLPNR 2621

RESULT 10

US-09-315-850-36

sequence 36, Application US/09315850

Patent No. 6217872

GENERAL INFORMATION:

APPLICANT: OKAYAMA, Hiroto

APPLICANT: FUKE, Isao

APPLICANT: MORI, Chisato

APPLICANT: TAKAMIZAWA, Akahisa

APPLICANT: YOSHIDA, Iwao

TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC CDNA AND ANTIGEN POLYPEPTIDE

NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: Armstrong, Westerman, Hattori, McLeland & Naughton

STREET: 1725 K St. N.W. Suite 1000

CITY: Washington

STATE: D.C.

COUNTRY: U.S.A.

ZIP: 20006

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0

SOFTWARE: ASCII

APPLICATION NUMBER: US/09/315850

PRIORITY NUMBER: US 09315850

FILING DATE: 09-NOV-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/099,706

FILING DATE: 30-JUL-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/769,996

FILING DATE: 02-OCT-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/635,451

FILING DATE: 28-DEC-1990

ATTORNEY/AGENT INFORMATION:

NAME: McLeland, Le-Nhung

REGISTRATION NUMBER: 31,541

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 659-2930

TELEFAX: (202) 887-0357

INFORMATION FOR SEQ ID NO: 36:

SEQUENCE CHARACTERISTICS:

LENGTH: 2621 amino acids

TOPOLOGY: linear

MOLECULE TYPE: protein

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US/09/315,850

FILING DATE:

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US/08/904,686

FILING DATE: 01-AUG-1997

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US/08/324,977

FILING DATE: 31-AUG-1990

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: JP 2-305605

FILING DATE: 09-NOV-1990

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US 08/099,706

FILING DATE: 30-JUL-1993

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US 07/769,996

FILING DATE: 02-OCT-1991

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US 07/635,451

FILING DATE: 28-DEC-1990

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-167466
 FILING DATE: 25-JUN-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-230921
 FILING DATE: 31-AUG-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-305605
 FILING DATE: 09-NOV-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/099,706
 FILING DATE: 30-JUL-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/769,996
 FILING DATE: 02-OCT-1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/635,451
 FILING DATE: 28-DEC-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Mcleland, Le-Nhung
 REGISTRATION NUMBER: 31,541
 REFERENCE/DOCKET NUMBER: 900703G
 TELEPHONE: (202) 659-2930
 TELEFAX: (202) 887-0357
 SEQUENCE CHARACTERISTICS:
 LENGTH: 261 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-09-315-850-36

Query Match 95.2%; Score 3016; DB 3; Length 2621;
 Best Local Similarity 96.6%; Pred. No. 2.4e-297;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Query 5 SMTSYWTGALLTPCAAEKSPINALNSLRLRHNLYTTSRASLROKVTEDRQLV 64
 Db 2031 SMTSYWTGALLTPCAAEKSPINALNSLRLRHNLYTTSRAGLROKVTEDRQLV 2090
 Query 65 DDHYRDVLKEMKAKASTVAKRLLSVEACKLTPPHISAKSKFGYAKDVRSLSSRAVHNR 124
 Db 2091 DDHYRDVLKEMKAKASTVAKRLLSVEACKLTPPHISAKSKFGYAKDVRNLSSRAVHNR 2150

Query 125 SWKDLLEDTPICOTTIMAKNEVFCVQDPEKGGKPKPARLIVFDLGVRYCEKMLYDVS 184
 Db 2151 SWKDLLEDTPIDDTIMAKNEVFCVQDPEKGGKPKPARLIVFDLGVRYCEKMLYDVS 2210

Query 185 TLPOQAVMGSSYGFQVSPKQEVFLYNTWAKKCPMGFSYDRCPDSTVENDRVEESTY 244
 Db 2211 TLPOQAVMGSSYGFQVSPKQEVFLYNTWAKKCPMGFSYDRCPDSTVENDRVEESTY 2270

Query 245 QCCDLAPEARQAISSLTERLYGGPMNTSKGQNCYRRCRASGVTTSQCGNTLTCYKAA 304
 Db 2271 QCCDLAPEARQAISSLTERLYGGPLNTSKGQNCYRRCRASGVTTSQCGNTLTCYKAS 2330

Query 305 AACRAAKLQDQCTMLINGDDLVVICESAGTOAAASLRVFTTEAMTRYSAPGDPQPEYDL 364
 Db 2331 AACRAAKLQDQCTMLVNGDDLVVICESAGTOAAASLRVFTTEAMTRYSAPGDPQPEYDL 2390

Query 365 ELITSCSSNVSVAHDASGKRVVYLTRDPTVPLARAWEATRHTPVNSWGNIMYAPTLW 424
 Db 2391 ELITSCSSNVSVAHDASGKRVVYLTRDPTVPLARAWEATRHTPVNSWGNIMYAPTLW 424

Query 425 ARMLMTHFFSILLAQEOLKEALDCQIYGCYSIEPLDQIITERLHGLSAFSLHSSYSPG 484
 Db 2451 ARMLMTHFFSILLAQEOLKEALDCQIYGCYSIEPLDQIITERLHGLSAFSLHSSYSPG 2510

Query Match 95.2%; Score 3016; DB 1; Length 3010;
 Best Local Similarity 96.6%; Pred. No. 3e-297;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Query 485 EINRVAASCLRKLGVPPLRVWRHRSVRACLISQSGRAAICGKYLFWAVRTKLLTPIP 544
 Db 2511 EINRVAASCLRKLGVPPLRVWRHRSVRACLISQSGRAAICGKYLFWAVRTKLLTPIP 2570

Query 545 AASRLDLSGWWFAGYSGGDIYHSLSRAPPRWFMLCLLILSVGVGYIYLPNR 595
 Db 2571 AASRLDLSGWWFAGYSGGDIYHSLSRAPPRWFMLCLLILSVGVGYIYLPNR 2621

RESULT 11
 US-08-324-977-2 ; Sequence 2, Application US/08324977
 ; Patent No. 574339
 GENERAL INFORMATION:
 ; APPLICANT: OKAYAMA, Hiroto
 ; APPLICANT: FUKE, Isao
 ; APPLICANT: MORI, Chiato
 ; APPLICANT: TAKAMIZAWA, Akhisa
 ; APPLICANT: YOSHIDA, Iwao
 ; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 ; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
 ; NUMBER OF SEQUENCES: 50
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Armstrong, Westerman, Hattori, Mcleland &
 ; ADDRESS: Naughton, Armstrong, Westerman, Hattori, Mcleland &
 ; CITY: 1725 K St. N.W. Suite 1000
 ; STATE: Washington
 ; COUNTRY: U.S. A.
 ; ZIP: 20006
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/324,977
 FILING DATE: 18-OCT-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-167466
 FILING DATE: 25-JUN-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-230921
 FILING DATE: 31-AUG-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-305605
 FILING DATE: 09-NOV-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/099,706
 FILING DATE: 30-JUL-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/769,996
 FILING DATE: 02-OCT-1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/324,977
 FILING DATE: 28-DEC-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Stevens-Smith, Theresa M.
 REGISTRATION NUMBER: 36,281
 REFERENCE/DOCKET NUMBER: 900703D
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 659-2930
 TELEFAX: (202) 887-0357
 TELEX: 440142
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 3010 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-324-977-2

Query Match 95.2%; Score 3016; DB 1; Length 3010;
 Best Local Similarity 96.6%; Pred. No. 3e-297;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Query 5 SMSVTWTGALITPCAAEESKPLPINALNSLRLRHNLYTTSRASLROKVTEDRQLV 64
 ; Sequence 2, Application US/08324977
 ; Patent No. 574339
 GENERAL INFORMATION:
 ; APPLICANT: OKAYAMA, Hiroto
 ; APPLICANT: FUKE, Isao
 ; APPLICANT: MORI, Chiato
 ; APPLICANT: TAKAMIZAWA, Akhisa
 ; APPLICANT: YOSHIDA, Iwao
 ; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 ; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
 ; NUMBER OF SEQUENCES: 50
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Armstrong, Westerman, Hattori, Mcleland &
 ; ADDRESS: Naughton, Armstrong, Westerman, Hattori, Mcleland &
 ; CITY: 1725 K St. N.W. Suite 1000
 ; STATE: Washington
 ; COUNTRY: U.S. A.
 ; ZIP: 20006
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/324,977
 FILING DATE: 18-OCT-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-167466
 FILING DATE: 25-JUN-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-230921
 FILING DATE: 31-AUG-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-305605
 FILING DATE: 09-NOV-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/099,706
 FILING DATE: 30-JUL-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/769,996
 FILING DATE: 02-OCT-1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/324,977
 FILING DATE: 28-DEC-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Stevens-Smith, Theresa M.
 REGISTRATION NUMBER: 36,281
 REFERENCE/DOCKET NUMBER: 900703D
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 659-2930
 TELEFAX: (202) 887-0357
 TELEX: 440142
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 3010 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-324-977-2

RESULTS 13

Sequence 2, Application US/08384616

PATENT NO. 5841101

GENERAL INFORMATION:

APPLICANT: OKAYAMA, Hiroto

APPLICANT: FUKE, Isao

APPLICANT: MORI, Chisato

APPLICANT: TAKAMIZAWA, Akahisa

APPLICANT: YOSHIDA, Iwao

TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC DNA AND ANTIGEN POLYPEPTIDE

NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: Armstrong, Westerman, Hattori, Mcleland & STREET: 1725 K St. N.W. Suite 1000

CITY: Washington

STATE: D.C.

ZIP: 20006

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0

SOFTWARE: ASCII

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/384,616

FILING DATE:

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/769,996

FILING DATE: 02-OCT-1991

APPLICATION NUMBER: JP 2-167466

FILING DATE: 25-JUN-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 2-230921

FILING DATE: 31-AUG-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 2-305605

FILING DATE: 09-NOV-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/635,451

FILING DATE: 28-DEC-1990

ATTORNEY/AGENT INFORMATION:

NAME: Stevens-Smith, Theresa M.

REGISTRATION NUMBER: 36,281

REFERENCE/DOCKET NUMBER: 90-070703B

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 659-2930

TELEFAX: (202) 887-0357

TELEX: 440142

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 3010 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

Query Match 95.2%; Score 3016; DB 2; Length 3010;

Best Local Similarity 95.6%; Pred. No. 3e-297;

Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

5 SMYSWTGALITPCAAEEAKPLPINALNSLRLRHHNLVYSTSRSASLRLQKKTFTDRLQVL 64

5 SMYSWTGALITPCAAEEAKPLPINALNSLRLRHHNLVYSTSRSASLRLQKKTFTDRLQVL 2479

65 DDIYRDVLKEMKAKASTVKAKLSSVEACKLTPPHISAKSKFGYGAIDVRSRRAVNHIR 124

2420 SMYSWTGALITPCAAEEAKPLPINALNSLRLRHHNLVYSTSRSASLRLQKKTFTDRLQVL 2479

2480 DDIYRDVLKEMKAKASTVKAKLSSVEACKLTPPHISAKSKFGYGAIDVRSRRAVNHIR 2539

RESULTS 14

US 08-384-616-14

Sequence 14, Application US/08384616

PARENT NO. 5847101

GENERAL INFORMATION:

APPLICANT: OKAYAMA, Hiroto

APPLICANT: FUKE, Isao

APPLICANT: MORI, Chisato

APPLICANT: TAKAMIZAWA, Akahisa

APPLICANT: YOSHIDA, Iwao

TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC DNA AND ANTIGEN POLYPEPTIDE

NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: Armstrong, Westerman, Hattori, Mcleland & STREET: 1725 K St. N.W. Suite 1000

CITY: Washington

STATE: D.C.

COUNTRY: U.S.A.

ZIP: 20006

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0

SOFTWARE: ASCII

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/384,616

FILING DATE:

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/769,996

FILING DATE: 02-OCT-1991

APPLICATION NUMBER: JP 2-167466

FILING DATE: 25-JUN-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 2-230921

FILING DATE: 31-AUG-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 2-305605

FILING DATE: 09-NOV-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/635,451

FILING DATE: 28-DEC-1990

ATTORNEY/AGENT INFORMATION:

NAME: Stevens-Smith, Theresa M.

REGISTRATION NUMBER: 36,281

REFERENCE/DOCKET NUMBER: 90-070703B

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 659-2930

TELEFAX: (202) 887-0357

TELEX: 440142

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 3010 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

Query Match 95.2%; Score 3016; DB 2; Length 3010;

Best Local Similarity 95.6%; Pred. No. 3e-297;

Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

5 SMYSWTGALITPCAAEEAKPLPINALNSLRLRHHNLVYSTSRSASLRLQKKTFTDRLQVL 64

5 SMYSWTGALITPCAAEEAKPLPINALNSLRLRHHNLVYSTSRSASLRLQKKTFTDRLQVL 2479

65 DDIYRDVLKEMKAKASTVKAKLSSVEACKLTPPHISAKSKFGYGAIDVRSRRAVNHIR 124

2420 SMYSWTGALITPCAAEEAKPLPINALNSLRLRHHNLVYSTSRSASLRLQKKTFTDRLQVL 2479

2480 DDIYRDVLKEMKAKASTVKAKLSSVEACKLTPPHISAKSKFGYGAIDVRSRRAVNHIR 2539

Page 11

SEQUENCE LISTING						
SEQUENCE INFORMATION						
APPLICATION NUMBER: JP 2-305605						
FILING DATE: 09-NOV-1990						
PRIOR APPLICATION DATA:						
APPLICATION NUMBER: US 07/635,451						
PRIORITY NUMBER: 900703B						
TELECOMMUNICATION INFORMATION:						
TELEPHONE: (202) 659-2930						
TELEFAX: (202) 887-0357						
TELELEX: 440142						
INFORMATION FOR SEQ ID NO: 14:						
SEQUENCE CHARACTERISTICS:						
LENGTH: 3010 amino acids						
TYPE: amino acid						
TOPOLOGY: linear						
MOLECULE TYPE: protein						
ACCESSION NUMBER: JS-08-384-616-14						
Query Match 95.2%; Score 3016; DB 2; Length 3010;						
Best Local Similarity 96.6%; Pred. No. 3e-297; Mismatches 9; Indels 0; Gaps 0;						
Matches 571; Conservative 11; Gaps 0;						
5 SMSYTGTGALITPQAABESSKLPINALSMSLLRHNLVYSTTSRSASLQQKVTEDRQLVLTG 64						
2420 SMSYTWTGALITPQAABESSKLPINALSMSLLRHNMVATTSSAGLQQKVTEDRQLVLTG 2479						
65 DDEHYDVLKEMKAKASTYKAKLISVEEACKLTTPPHSAKSKEFGAKDVKYRSLSRAVHNIR 124						
2480 DDEHYDVLKEMKAKASTYKAKLISVEEACKLTTPPHSAKSKEFGAKDVKYRSLSRAVHNIR 2539						
125 SWKDLLEDTPDPIQTIMAKNEVFCVPEKGERKPARLIVPPDLGVRVCERMAVLYDVS 184						
2540 SWKDLLEDTPDPIQTIMAKNEVFCVPEKGERKPARLIVPPDLGVRVCERMAVLYDVS 2599						
185 TLPQAVNGSSYGRQYSPKORVPEFLVNTYKAKCCPMGFSYDTRCFDSTTENDIRVEESTY 244						
2600 TLPQVNGSSYGRQYSPQVRFLVNTYKSKNMGFSYDTRCFDSTTENDIRVEESTY 2659						
245 QCCDLAPEARQATRSLTSLRILYVGGPMTNISKGQNCGYRCPGRASSVLTSGNLTCTYKDA 304						
2660 QCCDLAPEARQATKSLTSLRILYVGGPLTNISKGQNCGYRCPGRASSVLTSGNLTCTYKDA 2719						
305 AACRAAKLQDCTMLVNQDGLVVICSEAGTQDASLRVFTTEAMTRYSAPPGDPPQPVYDVL 364						
2720 AACRAAKLQDCTMLVNQDGLVVICSEAGTQDASLRVFTTEAMTRYSAPPGDPPQPVYDVL 2779						
365 ELITSCSSNVYAHDAKGKRVYTLTRDPTVPLARAATWTRATTPVNSWLNIGNITIMAPTLW 424						
2780 ELITSCSSNVYAHDAKGKRVYTLTRDPTVPLARAATWTRATTPVNSWLNIGNITIMAPTLW 2839						
425 ARNMLTMTHFESILLAQOKELEKALDQYQGACYSIEPLDQLQIPLRGLSAAFLHSYSPG 484						
2840 ARNMLTMTHFESILLAQOKELEKALDQYQGACYSIEPLDQLQIPLRGLSAAFLHSYSPG 2899						
485 EINRVAASLKRKGVPYPRWWRHARSTRAKLISQGGRRAICGKYLFWAVTRFLKLTPIP 544						
2900 EINRVAASLKRKGVPYPRWWRHARSTRAKLISQGGRRAICGKYLFWAVTRFLKLTPIP 2959						
545 AASRLDLSGWFVAGYSSGDDIYHSLSRARPRWFMLCLLILISVGIVYLLPNR 595						
2960 AASRLDLSGWFVAGYSSGDDIYHSLSRARPRWFMLCLLILISVGIVYLLPNR 3010						

APPLICANT: MORI, Chisato
 APPLICANT: TAKAMIZAWA, Akahisa
 APPLICANT: YOSHIDA, Iwao
 TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
 NUMBER OF SEQUENCES: 50
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Armstrong, Westerman, Hattori, McLeland &
 STREET: 1725 K St. N.W. Suite 1000
 CITY: Washington
 STATE: D.C.
 COUNTRY: U.S.A.
 ZIP: 20006
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/904,686A
 FILING DATE: 01-AUG-1997
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/324,977
 FILING DATE: 18-OCT-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-167466
 FILING DATE: 25-JUN-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-230921
 FILING DATE: 31-AUG-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-305605
 FILING DATE: 09-NOV-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 2-230921
 FILING DATE: 30-JUL-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/769,996
 FILING DATE: 02-OCT-1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/099,706
 FILING DATE: 28-DEC-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: McLeland, Le Nhung
 REGISTRATION NUMBER: 31,541
 REFERENCE/DOCKET NUMBER: 900703G
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 659-2940
 TELEFAX: (202) 887-0357
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 3010 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-904-686A-2

Query Match 5 Score 95.2%; Score 3016; DB 2; Length 3016
 Best Local Similarity 96.6%; Preed. No. 3e-297; Indels 11
 Matches 571; Conservative 11; Mismatches 9; Indels 11

Qy 5 SWSYTTWCAALITPCAAAESKLPIINALSNSLRRHNNLVYSTSRSASLRLQ
 Db 2420 SWSYTTWCAALITPCAAAESKLPIINALSNSLRRHNNLVYSTSRSASLRLQ

Qy 65 DDIHYRDVLRKEMKAKASTVKAKLVSVEACKTUPPHSAKSKEGYGAKDVR
 Db 2480 DDIHYRDVLRKEMKAKASTVKAKLVSVEACKTUPPHSAKSKEGYGAKDVR

Qy 125 SWKDLJLIEDTDPLOTTIMAKNEVFCVQPEKCGRKDARLIVFDPDLCVYV
 Db 2540 SWKDLJLIEDTDPLOTTIMAKNEVFCVQPEKCGRKDARLIVFDPDLCVYV

QY 185 TLPOAVMGSSYGFQYSKORVEFLVNTWKAKKCPMGFSYDTRCFDSTVENDRVEESIY 244
 Db 2600 TLPOAVMGSSYGFQSPGVEFLVNTWASKNPMGFSYDTRCFDSTVENDRVEESIY 2659
 QY 245 QCCDLAPEARQAISSLTERLYVGGPMTNSKGQONGYRRCRASGVLITSGNTLTCYLKAA 304
 Db 2660 QCCDLAPEARQAISSLTERLYIGSPLTNSKGQONGYRRCRASGVLITSGNTLTCYLKAS 2719
 QY 305 AACRAAKLQDCTMLVNGDDLVVICESAGTQEDAASLRLVFTTEAMTRYSAPPDPPQPEVDL 364
 Db 2720 AACRAAKLQDCTMLVNGDDLVVICESAGTQEDAASLRLVFTTEAMTRYSAPPDPPQPEVDL 2779
 QY 365 ELITSCSSNVSAHADASGRKVYLTTRDPTPLARAAWETARTHTPVNSWLNLTMYAPTLW 424
 Db 2780 ELITSCSSNVSAHADASGRKVYLTTRDPTPLARAAWETARTHTPVNSWLNLTMYAPTLW 2839
 QY 425 ARMLLMTHFSPSILLAQEQLEKALDCQIYGACYSTEPLDPLQOILERLHGSALHSYSPG 484
 Db 2840 ARMLLMTHFSPSILLAQEQLEKALDCQIYGACYSTEPLDPLQOILERLHGSALHSYSPG 2899
 QY 485 EINRVASCLRKLGVPPLRWRHRARSVAKLLSQGRAICGKYLENVAVTKLTKLTPIP 544
 Db 2900 EINRVASCLRKLGVPPLRWRHRARSVAKLLSQGGRATCGCYLENVAVTKLTKLTPIP 2959
 QY 545 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWFMCLLISVGCIYLLPNR 595
 Db 2960 AASRLDLSGMFVAGYSGGDIYHSLSRARPRWFMCLLISVGCIYLLPNR 3010

Search completed: September 22, 2005, 14:47:44
 Job time : 30 secs

Db	61 LQVDDHYDVLKEMKAKASTVAKLILSVEACKLTPPHSAKSKFGYAKDVRSLSSAV	120	Qy	61 LOVLDHYDVLKEMKAKASTVAKLILSVEACKLTPPHSAKSKFGYAKDVRSLSSAV	120
Qy	121 NHIRSWKDLEDTPQTTIMAKNEVEFCVQPKGGKRPARI1LVPDQHVRCEKMLY	180	Db	61 LOVLDHYDVLKEMKAKASTVAKLILSVEACKLTPPHSAKSKFGYAKDVRSLSSAV	120
Db	121 NHIRSWKDLEDTPQTTIMAKNEVEFCVQPKGGKRPARI1LVPDQHVRCEKMLY	180	Qy	121 NHIRSWKDLEDTPQTTIMAKNEVEFCVQPKGGKRPARI1LVPDQHVRCEKMLY	180
Db	181 DVVSTLPQAVMGSSYGFQYSPQRVEFLYNTWAKKCPNGFSYDTRCPDSTVENDIVE	240	Db	121 NHIRSWKDLEDTPQTTIMAKNEVEFCVQPKGGKRPARI1LVPDQHVRCEKMLY	180
Qy	181 DVVSTLPQAVMGSSYGFQYSPQRVEFLYNTWAKKCPNGFSYDTRCPDSTVENDIVE	240	Qy	181 DVVSTLPQAVMGSSYGFQYSPQRVEFLYNTWAKKCPNGFSYDTRCPDSTVENDIVE	240
Db	241 ESYQCCDLAPERQAISSLTERLYVGPMNTSKQNGQYRRCAGVLTSCGNTLTY	300	Do	181 DVVSTLPQAVMGSSYGFQYSPQRVEFLYNTWAKKCPNGFSYDTRCPDSTVENDIVE	240
Qy	241 ESYQCCDLAPERQAISSLTERLYVGPMNTSKQNGQYRRCAGVLTSCGNTLTY	300	Qy	241 ESYQCCDLAPERQAISSLTERLYVGPMNTSKQNGQYRRCAGVLTSCGNTLTY	300
Db	301 LKAAACRAAKLQDCTMLVNGDDLVVICESAGTOEDAASLRLVTEAMTRYSAPGDPQP	360	Do	241 ESYQCCDLAPERQAISSLTERLYVGPMNTSKQNGQYRRCAGVLTSCGNTLTY	300
Qy	301 LKAAACRAAKLQDCTMLVNGDDLVVICESAGTOEDAASLRLVTEAMTRYSAPGDPQP	360	Qy	301 LKAAACRAAKLQDCTMLVNGDDLVVICESAGTOEDAASLRLVTEAMTRYSAPGDPQP	360
Db	361 BYDLELITSSNSVVAHDASGRVYVLTDPYPLARAAWETARHTPNSWGNLIMYA	420	Do	361 BYDLELITSSNSVVAHDASGRVYVLTDPYPLARAAWETARHTPNSWGNLIMYA	420
Qy	361 BYDLELITSSNSVVAHDASGRVYVLTDPYPLARAAWETARHTPNSWGNLIMYA	420	Qy	361 BYDLELITSSNSVVAHDASGRVYVLTDPYPLARAAWETARHTPNSWGNLIMYA	420
Db	421 PTLMARMILMTHFSILIAQEQLEKALDQIYQACYSLEPLDLPQIILERLHGLSAFSLHS	480	Do	361 BYDLELITSSNSVVAHDASGRVYVLTDPYPLARAAWETARHTPNSWGNLIMYA	420
Qy	421 PTLMARMILMTHFSILIAQEQLEKALDQIYQACYSLEPLDLPQIILERLHGLSAFSLHS	480	Qy	421 PTLMARMILMTHFSILIAQEQLEKALDQIYQACYSLEPLDLPQIILERLHGLSAFSLHS	480
Db	481 YSPGRINRVASCLPKGVPLRWNHRARSVRAKULSQGRRAAICGKYLFLNVAVRTKIKL	540	Do	421 PTLMARMILMTHFSILIAQEQLEKALDQIYQACYSLEPLDLPQIILERLHGLSAFSLHS	480
Qy	481 YSPGRINRVASCLPKGVPLRWNHRARSVRAKULSQGRRAAICGKYLFLNVAVRTKIKL	540	Qy	481 YSPGRINRVASCLPKGVPLRWNHRARSVRAKULSQGRRAAICGKYLFLNVAVRTKIKL	540
Db	541 TPIPASRDLSGWNTVAGISGDDIYHSLSRARPWFLCLLISLGVGAYLLPNRHHHH	600	Do	481 YSPGRINRVASCLPKGVPLRWNHRARSVRAKULSQGRRAAICGKYLFLNVAVRTKIKL	540
Qy	541 TPIPASRDLSGWNTVAGISGDDIYHSLSRARPWFLCLLISLGVGAYLLPNRHHHH	600	Qy	541 TPIPASRDLSGWNTVAGISGDDIYHSLSRARPWFLCLLISLGVGAYLLPNRHHHH	600
Db	601 H 601	1	Do	541 TPIPASRDLSGWNTVAGISGDDIYHSLSRARP-----RHHHH	579
Qy	601 H 601	1	Qy	601 H 601	1
Db	601 H 601	1	Do	580 H 580	1
RESULT 2					
US-10-712-479-4					
Sequence 4, Application US/10712479					
; Publication No. US2004/0209283A1					
GENERAL INFORMATION:					
; APPLICANT: Yagi, Yoshihiko					
; APPLICANT: Sheets, Michael P.					
; APPLICANT: Wells, Peter A.					
; APPLICANT: Shelly, John A.					
; APPLICANT: Poorman, Roger A.					
; APPLICANT: Epple, Dennis E.					
TITLE OF INVENTION: A Continuous-Read Assay for the Detection of De Novo HCV RNA Polymerase					
TITLE OF INVENTION: Activity					
FILE REFERENCE: 02-333-A					
CURRENT APPLICATION NUMBER: US/10/712,479					
CURRENT FILING DATE: 2003-11-13					
SEQ ID NO 4					
; SOFTWARE: Patentin version 3.1					
; OTHER INFORMATION: C-terminally truncated HCV NS5B polymerase (C delta 21 NS5B)					
US-10-712-479-4					
Query Match 95.8%; Score 3034.5; DB 16; Length 580;					
Best Local Similarity 96.5%; Pred. No. 4.9e-268; Mismatches 0; Indels 1;					
Matches 580; Conservative 0; Gaps 0;					
Query Match 95.2%; Score 3016; DB 13; Length 591;					
Best Local Similarity 96.6%; Pred. No. 2.5e-266; Mismatches 11; Indels 0; Gaps 0;					
Matches 571; Conservative 11; Gaps 0;					
Query Match 95.2%; Score 3016; DB 13; Length 591;					
Best Local Similarity 96.6%; Pred. No. 2.5e-266; Mismatches 11; Indels 0; Gaps 0;					
Matches 571; Conservative 11; Gaps 0;					

RESULT 4
 US-10-085-476-23
 ; Sequence 2, Application US/10085476
 ; Publication No. US2005016472A1
 ; GENERAL INFORMATION:
 ; APPLICANT: De Francesco, Raffaele
 ; APPLICANT: Tombi, Licia
 ; APPLICANT: Behrens, Sven-Erik
 ; TITLE OF INVENTION: METHOD FOR REPRODUCING IN VITRO THE
 ; TITLE OF INVENTION: RNA-DEPENDENT RNA POLYMERASE AND TERMINAL NUCLEOTIDYL
 ; TITLE OF INVENTION: TRANSFERASE ACTIVITIES ENCODED BY HEPATITIS C VIRUS (HCV)
 ; FILE REFERENCE: IT00021PCA
 ; CURRENT APPLICATION NUMBER: US/110/085,476
 ; CURRENT FILING DATE: 2002-02-27
 ; PRIOR APPLICATION NUMBER: PCT/IT96/00106
 ; PRIOR FILING DATE: 1998-03-23
 ; PRIOR APPLICATION NUMBER: 08/952,981
 ; PRIOR FILING DATE: 1996-05-24
 ; PRIOR APPLICATION NUMBER: RM95A000343
 ; PRIOR FILING DATE: 1995-05-25
 ; NUMBER OF SEQ ID NOS: 14
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO: 2
 ; LENGTH: 2201
 ; TYPE: PRT
 ; ORGANISM: CDNA clone pCD (38-9-4)
 ; Query Match 95.2%; Score 3016; DB 13; Length 2201;
 ; Best Local Similarity 96.6%; Pred. No. 1.7e-265;
 ; Mismatches 11; Gaps 0;
 ; US-10-085-476-23

RESULT 5
 US-10-241-872-23
 ; Sequence 23, Application US/10241872
 ; Publication No. US20030152915A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Hagedorn, Curt H
 ; TITLE OF INVENTION: Recombinant Hepatitis C Virus RNA Replicase
 ; FILE REFERENCE: 76-45C
 ; CURRENT APPLICATION NUMBER: US/10/241,872
 ; CURRENT FILING DATE: 2002-09-12
 ; PRIOR APPLICATION NUMBER: 09/1597,877
 ; PRIOR FILING DATE: 2000-06-20
 ; PRIOR APPLICATION NUMBER: 60/004,383
 ; PRIOR FILING DATE: 1995-09-27
 ; PRIOR APPLICATION NUMBER: 08/722,806
 ; PRIOR FILING DATE: 1996-09-27
 ; PRIOR APPLICATION NUMBER: 09/337,028
 ; PRIOR FILING DATE: 1999-06-25
 ; NUMBER OF SEQ ID NOS: 23
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO: 23
 ; LENGTH: 593
 ; TYPE: PRT
 ; ORGANISM: Hepatitis C virus
 ; US-10-241-872-23

Query Match 95.2%; Score 3014; DB 14; Length 593;
 Best Local Similarity 96.3%; Pred. No. 3.8e-266;
 Matches 569; Conservative 12; Mismatches 10; Gaps 0;
 ; Query 5 SMSYTWGALITPCAAEESKLPIINALNSLRLRHNLVYSTSRSASLROKKTVDRLQVL 64
 ; Db 1611 SMSYTWGALITPCAAEESKLPIINALNSLRLRHNLVYSTSRSASLROKKTVDRLQVL 60
 ; Db 1671 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSFKPGYAKDVRSLSSRAVNHIR 124
 ; Db 1671 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSFKPGYAKDVRNLSSRAVNHIR 1730
 ; Db 125 SWWDOLLEDTPPIOTTIMAKNEVFCQPKGGKPKARLIVPDLGVRYCEKMAKYDVVS 184
 ; Db 121 SWWDOLLEDTPPIOTTIMAKNEVFCQPKGGKPKARLIVPDLGVRYCEKMAKYDVVS 180
 ; Db 185 TLPOQAVMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY 244
 ; Db 181 TLQVVMGSSYGFQYSPGQVEFLVNTWAKKCPMGFSYDTRCPDSTVENDIRVEESIY 240
 ; Db 245 QCCDLAPEAROAIRSLSLTERLYGGPMTNSKGQNCYRRCRASGVLTTSCGNTLTCYLKAA 304
 ; Db 241 QCCDLAPEAROAIRSLSLTERLYGGPMTNSKGQNCYRRCRASGVLTTSCGNTLTCYLKAS 300
 ; Db 305 AACRAAKLQDCTMLVNGDDLVICSAQTODASLRLVTTAEMTRYSAPGDPPOPEYDL 364
 ; Db 301 AACRAAKLQDCTMLVNGDDLVICSAQTODASLRLVTTAEMTRYSAPGDPPOPEYDL 360
 ; Db 365 ELITSCSSNSVVAHDASGRVYLTTRDPTVPLARAAWETARHTPVNSWGNINIYAPTILW 424
 ; Db 361 ELITSCSSNSVVAHDASGRVYLTTRDPTVPLARAAWETARHTPVNSWGNINIYAPTILW 420
 ; Db 425 ARMLTMTHFSILLAQAEQLEKALDCQIYGACYSTEPLDLQPIIERTLHGLSAFSLHSYSPG 484
 ; Db 421 ARMLTMTHFSILLAQAEQLEKALDCQIYGACYSTEPLDLQPIIERTLHGLSAFSLHSYSPG 480
 ; Db 485 EINRVASCLRKLGVPPLRWRHARSVRAKLSSGGRAAICGKYLFWNAVTRKLTLPPIP 544
 ; Db 481 EINRVASCLRKLGVPPLRWRHARSVRAKLSSGGRAAICGKYLFWNAVTRKLTLPPIP 540
 ; Db 545 AASRDLSGWFGVAGYGGDIIYHSLSRAPRWFMLCLLUSVGVTYLPNR 595
 ; Db 541 AASRDLSGWFGVAGYGGDIIYHSLSRAPRWFMLCLLUSVGVTYLPNR 591

RESULT 5
 US-10-241-872-23
 ; Sequence 23, Application US/10241872
 ; Publication No. US20030152915A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Hagedorn, Curt H
 ; TITLE OF INVENTION: Recombinant Hepatitis C Virus RNA Replicase
 ; FILE REFERENCE: 76-45C
 ; CURRENT APPLICATION NUMBER: US/10/241,872
 ; CURRENT FILING DATE: 2002-09-12
 ; PRIOR APPLICATION NUMBER: 09/1597,877
 ; PRIOR FILING DATE: 2000-06-20
 ; PRIOR APPLICATION NUMBER: 60/004,383
 ; PRIOR FILING DATE: 1995-09-27
 ; PRIOR APPLICATION NUMBER: 08/722,806
 ; PRIOR FILING DATE: 1996-09-27
 ; PRIOR APPLICATION NUMBER: 09/337,028
 ; PRIOR FILING DATE: 1999-06-25
 ; NUMBER OF SEQ ID NOS: 23
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO: 23
 ; LENGTH: 593
 ; TYPE: PRT
 ; ORGANISM: Hepatitis C virus
 ; US-10-241-872-23

Query Match 95.2%; Score 3014; DB 14; Length 593;
 Best Local Similarity 96.3%; Pred. No. 3.8e-266;
 Matches 569; Conservative 12; Mismatches 10; Gaps 0;
 ; Query 5 SMSYTWGALITPCAAEESKLPIINALNSLRLRHNLVYSTSRSASLROKKTVDRLQVL 64

3 SMSYTWGALITPCAAEOKLPINALNSLRLRHNMTTATRSRASLRLRKTTFDRLQLV 62
 65 DHYDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKEYGAKDVKRSLSRPAVNHR 124
 63 DHYDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKEYGAKDVRNLSSRAVNHR 122
 125 SWKDLLEDTPLOTTIMAKNEFCVQPEKGKPKARLIVPPDLGVYCEKRALYDV 184
 123 SWKDLLEDTPLOTTIMAKNEFCVQPEKGKPKARLIVPPDLGVYCEKRALYDV 182
 Qy 185 TLPOAVMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCFDSTVENDIRVEESIY 244
 Db 183 TLPOVVMGSSYGFQYSPGQVEFLVNTWAKKCPMGFSYDTRCFDSTVENDIRVEESIY 242
 Qy 125 OCCDLAPRQAQPSLTERLYGGPLTNKGQYRRCRASGLTTSOGNTLTCYKAA 304
 Db 243 QCCDLAPRQAQSLTERLYGGPLTNKGQYRRCRASGLTTSOGNTLTCYKAA 302
 Qy 305 AACRAAKLQDCTMLYNGDLVVICESAGTQDASLRLVTEAMTRYSAPPDGPQPEVDL 364
 Db 303 AACRAAKLQDCTMLYNGDLVVICESAGTQDASLRLVTEAMTRYSAPPDGPQPEVDL 362
 Qy 365 ELITSCSSNVSVAHDASGRVYIYLTRDPTVLARAAWETARHTPVNSWLGNIIIMYAPTLW 424
 Db 363 ELITSCSSNVSVAHDASGRVYIYLTRDPTVLARAAWETARHTPVNSWLGNIIIMYAPTLW 422
 Qy 425 ARMLTMTHFSSILIAQEQLEKAQDQIYGACYSTEPLDQIQLPQIQLHGSALSHSYSPG 484
 Db 423 ARMLTMTHFSSILIAQEQLEKAQDQIYGACYSTEPLDQIQLPQIQLHGSALSHSYSPG 482
 Qy 485 EINRVASCLRKLYGPPLRWHRARSVRAKLSSQGRAGIAGKYLENWAVKTKLTPIP 544
 Db 483 EINRVASCLRKLYGPPLRWHRARSVRAKLSSQGRATGKYLENWAVKTKLTPIP 542
 Qy 545 AASLDLSGMFVAGYSGGDYIYHSLSRARPRWMCLLILSVGVGIVYLLPNR 595
 Db 543 AASQDLSGMFVAGYSGGDYIYHSLSRARPRWMCLLILSVGVGIVYLLPNR 593

RESULT 6

; Sequence 6, Application US/10492178
 ; Publication No. US20040247615A1

GENERAL INFORMATION:

; APPLICANT: Emini, Emilio A.
 ; APPLICANT: Kaslow, David C.
 ; APPLICANT: Bett, Andrew J.
 ; APPLICANT: Shiver, John W.
 ; APPLICANT: Nicosia, Alfredo
 ; APPLICANT: Lahn, Armin
 ; APPLICANT: Iuzzago, Alessandra
 ; APPLICANT: Correse, Riccardo
 ; APPLICANT: Colloca, Stefano
 ; TITLE OF INVENTION: HEPATITIS C VIRUS VACCINE
 ; FILE REFERENCE: ITR0015P
 ; CURRENT APPLICATION NUMBER: US/10/492,178
 ; CURRENT FILING DATE: 2004-04-07
 ; PRIOR APPLICATION NUMBER: PCT/US02/32512
 ; PRIOR FILING DATE: 2002-10-10
 ; PRIOR APPLICATION NUMBER: 60/363,774
 ; PRIOR FILING DATE: 2003-03-13
 ; PRIOR FILING DATE: 2001-10-11
 ; NUMBER OF SEQ ID NOS: 17
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 6
 ; LENGTH: 1985
 ; ORGANISM: Artificial Sequence
 ; FEATURE: Other information: NS sequence
 ; OTHER INFORMATION: NS sequence

Query Match 95.1%; Score 3012; DB 16;
 Best Local Similarity 96.4%; Pred. No. 3.e-265;
 Matches 570; Conservative 12; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWGALITPCAAEOKLPINALNSLRLRHNMTTATRSRASLRLRKTTFDRLQLV 64
 Db 1395 SMSYTWGALITPCAAEOKLPINALNSLRLRHNMTTATRSRASLRLRKTTFDRLQLV 1454
 Qy 65 DHYDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKEYGAKDVKRSLSRAVNHR 124
 Db 1455 DHYDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKEYGAKDVRNLSSRAVNHR 1514
 Qy 125 SWKDLLEDTPLOTTIMAKNEFCVQPEKGKPKARLIVPPDLGVYCEKRALYDV 184
 Db 1515 SWKDLLEDTPLOTTIMAKNEFCVQPEKGKPKARLIVPPDLGVYCEKRALYDV 1574
 Qy 185 TLPOAVMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCFDSTVENDIRVEESIY 244
 Db 1575 TLPOVVMSSYGFQYSPQVEFLVNTWAKKCPMGFSYDTRCFDSTVENDIRVEESIY 1634
 Qy 245 QCCDLAPRQAQSLTERLYGGPLTNKGQYRRCRASGLTTSOGNTLTCYKAA 304
 Db 1635 QCCDLAPRQAQSLTERLYGGPLTNKGQYRRCRASGLTTSOGNTLTCYKAA 304
 Qy 305 AACRAAKLQDCTMLYNGDLVVICESAGTQDASLRLVTEAMTRYSAPPDGPQPEVDL 364
 Db 1695 AACRAAKLQDCTMLYNGDLVVICESAGTQDASLRLVTEAMTRYSAPPDGPQPEVDL 1754
 Qy 365 ELITSCSSNVSVAHDASGRVYIYLTRDPTVLARAAWETARHTPVNSWLGNIIIMYAPTLW 424
 Db 1755 ELITSCSSNVSVAHDASGRVYIYLTRDPTVLARAAWETARHTPVNSWLGNIIIMYAPTLW 1814
 Qy 425 ARMLTMTHFSSILIAQEQLEKAQDQIYGACYSTEPLDQIQLPQIQLHGSALSHSYSPG 484
 Db 1815 ARMLTMTHFSSILIAQEQLEKAQDQIYGACYSTEPLDQIQLPQIQLHGSALSHSYSPG 482
 Qy 485 EINRVASCLRKLYGPPLRWHRARSVRAKLSSQGRAGIAGKYLENWAVKTKLTPIP 544
 Db 1875 EINRVASCLRKLYGPPLRWHRARSVRAKLSSQGRATGKYLENWAVKTKLTPIP 544
 Qy 545 AASRLDLSGMFVAGYSGGDYIYHSLSRARPRWMCLLILSVGVGIVYLLPNR 595
 Db 1935 AASQDLSGMFVAGYSGGDYIYHSLSRARPRWMCLLILSVGVGIVYLLPNR 1985

RESULT 7

US-10-471-164-5
 ; Sequence 5, Application US/10471164
 ; Publication No. US20040110126A1

;

; GENERAL INFORMATION:
 ; APPLICANT: George KUKOLJ and Ginette MCKERCHER
 ; TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY
 ; FILE REFERENCE: 13-094
 ; CURRENT APPLICATION NUMBER: US/10/471-164
 ; CURRENT FILING DATE: 2003-09-05
 ; PRIOR APPLICATION NUMBER: 60/274,374
 ; NUMBER OF SEQ ID NOS: 6
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 5
 ; LENGTH: 591
 ; TYPE: PRT
 ; ORGANISM: HCV
 ; US-10-471-164-5

Query Match 95.1%; Score 3011; DB 16;
 Best Local Similarity 95.9%; Pred. No. 7.1e-266;
 Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;

Qy 5 SMSYTWGALITPCAAEOKLPINALNSLRLRHNMTTATRSRASLRLRKTTFDRLQLV 64
 Db 1 SMSYTWGALITPCAAEOKLPINALNSLRLRHNMTTATRSRASLRLRKTTFDRLQLV 60

;

Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEACKLTPPHSAKSFKFGYAKDVRSLSSRAVNHIR 124
 Db 61 DDHYRDVLKEMKAKASTVKAKLLSVEACKLTPPHSAKSFKFGYAKDVRSLSSRAVNHIR 120

Qy 125 SWKDLLEDTPICHTTMAKNEVECPKGRKPARLTIPDGLVRCERKMALEYDVS 184
 Db 121 SWKDLLEDTPICHTTMAKNEVECPKGRKPARLTIPDGLVRCERKMALEYDVS 180

Qy 185 TLPOQWGMSSYGFQYSPKQRVEFLVNTWAKKCPGMFSYDTRCPDSTVENDIRVEESIY 244
 Db 181 TLPOQWGMSSYGFQYSPKQRVEFLVNTWAKKCPGMFSYDTRCPDSTVENDIRVEESIY 240

Qy 245 QCCDLAPEARQAIRSLLTRELIGPLTNSKGQNCCYRGRASGVLTSCGNTLTCYLKAA 304
 Db 271 QCCDLAPEARQAIRSLLTRELIGPLTNSKGQNCCYRGRASGVLTSCGNTLTCYLKAS 330

Qy 305 AACRAAKLQDCTMLVNGDLVVICESAGTQDAAASLRVFTTEAMTRYSAPPGDPPOPEYDL 364
 Db 331 AACRAAKLQDCTMLVNGDLVVICESAGTQDAAANLRVFTTEAMTRYSAPPGDPPOPEYDL 390

Qy 365 ELITSCSNVVAHDASGRKVYLTRDPTPLARAWEETARHTPWNGLNIMYAPTLW 424
 Db 391 ELITSCSNVVAHDASGRKVYLTRDPTPLARAWEETARHTPWNGLNIMYAPTLW 450

Qy 365 ELITSCSNVVAHDASGRKVYLTRDPTPLARAWEETARHTPWNGLNIMYAPTLW 424
 Db 361 ELITSCSNVVAHDASGRKVYLTRDPTPLARAWEETARHTPWNGLNIMYAPTLW 420

Qy 425 ARMLMTHFFSILLAOBLKDCQIYACYSIEPLDIPQIIEPLHGSAPSLSHYSPG 484
 Db 451 ARMLMTHFFSILLAOBLKDCQIYACYSIEPLDIPQIIEPLHGSAPSLSHYSPG 510

Qy 485 EINRVAICLRLGVPPLRWRHARSVRAKLISOGGRAATCGKYLIPNWAVRTKULKLTP 544
 Db 511 EINRVAICLRLGVPPLRWRHARSVRAKLISOGGRAATCGKYLIPNWAVRTKULKLTP 570

Qy 545 AASRLDLSGMFVAGYSGGGDIYHSLSRARPKWMLCLLSSVGVGTYLLPNR 595
 Db 571 AASRLDLSGMFVAGYNGDIIYHSLSRARPKWMLCLLSSVGVGTYLLPNR 621

RESUL^T 9
 US-10-198-680A-1
 ; Sequence 1, Application US/10198680A
 ; Publication No. US2003017433A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Boehringer Ingelheim (Canada) Ltd.
 ; TITLE OF INVENTION: Viral Polymerase Inhibitors
 ; FILE REFERENCE: 13/095
 ; CURRENT APPLICATION NUMBER: US/10/198,680A
 ; CURRENT FILING DATE: 2002-07-18
 ; PRIOR APPLICATION NUMBER: 60/338,061
 ; PRIOR FILING DATE: 2001-12-07
 ; PRIOR APPLICATION NUMBER: 60/307,674
 ; PRIOR FILING DATE: 2001-07-25
 ; NUMBER OF SEQ ID NOS: 4
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 1
 ; LENGTH: 621
 ; TYPE: PRT
 ; ORGANISM: HCV NSSB
 US-10-198-680A-1

RESUL^T 8
 US-09-898-297-1
 ; Sequence 1, Application US/09898297
 ; Publication No. US20020065418A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BOEHRINGER INGELHEIM (CANADA) LTD.
 ; TITLE OF INVENTION: VIRAL POLYMERASE INHIBITORS
 ; FILE REFERENCE: 13/079
 ; CURRENT APPLICATION NUMBER: US/09/898,297
 ; CURRENT FILING DATE: 2001-07-03
 ; PRIOR APPLICATION NUMBER: 60/216,084
 ; PRIOR FILING DATE: 2000-07-06
 ; PRIOR APPLICATION NUMBER: 60/274,374
 ; PRIOR FILING DATE: 2001-03-08
 ; PRIOR APPLICATION NUMBER: 60/281,434
 ; PRIOR FILING DATE: 2001-04-02
 ; NUMBER OF SEQ ID NOS: 1
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 1
 ; LENGTH: 621
 ; TYPE: PRT
 ; ORGANISM: Hepatitis C Virus
 US-09-898-297-1

Query Match 95.1%; Score 3011; DB 9; Length 621;
 Best Local Similarity 95.9%; Pred. No. 7.6e-266; Indels 0; Gaps 0;
 Matches 567; Conservative 18; Mismatches 6; Delins 0; Gaps 0;

Qy 5 SMSYTWTGALITPCAAEESQPKINALNSLRRHNLVYSTTSRASLROKKVTFDRLQVL 64
 Db 31 SMSYTWTGALITPCAAEESQPKINALNSLRRHNMVYSTTSRASLROKKVTFDRLQVL 90

Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEACKLTPPHSAKSFKFGYAKDVRSLSSRAVNHIR 124
 Db 91 DDHYRDVLKEMKAKASTVKAKLLSVEACKLTPPHSAKSFKFGYAKDVRNLSSRAVDHIR 150

Qy 125 SWKDLLEDTPICHTTMAKNEVECPKGRKPARLTIPDGLVRCERKMALEYDVS 184
 Db 151 SWKDLLEDTPICHTTMAKNEVECPKGRKPARLTIPDGLVRCERKMALEYDVS 210

Qy 185 TLPOQWGMSSYGFQYSPKQRVEFLVNTWAKKCPGMFSYDTRCPDSTVENDIRVEESIY 244
 Db 91 DDHYRDVLKEMKAKASTVKAKLLSVEACKLTPPHSAKSFKFGYAKDVRNLSSRAVDHIR 150

Db	211	TLPOAVMGSSYGFQYSKPQKRVEFLVNAWISKKCPMGFSYDTRCPDSTVTESDIRVEESTY	270	Db	271	QCCDLAPEARQAIKSLLTBLRYYIGGPLTNSKGONGCYRRCRASGVLTSCGNLTLCYLKAS	330
Qy	245	QCCDLAPEARQAIKSLLTBLRYYIGGPLTNSKGONGCYRRCRASGVLTSCGNLTLCYLKAA	304	Qy	305	ACRAAKLQDCTMLVNGDDLVNICESAGTQEDASLRYTEAMTRYSAPPGDPQPEYDL	364
Db	271	QCCDLAPEARQAIKSLLTBLRYYIGGPLTNSKGONGCYRRCRASGVLTSCGNLTLCYLKAS	330	Db	331	ACRAAKLQDCTMLVNGDDLVNICESAGTQEDASLRYTEAMTRYSAPPGDPQPEYDL	390
Db	305	ACRAAKLQDCTMLVNGDDLVNICESAGTQEDASLRYTEAMTRYSAPPGDPQPEYDL	364	Qy	365	ELITSCSNVSVAHDAASGRVYLTTRDPTVPLARAETARHPPVNSLGNIMYAPTLW	424
Db	331	ACRAAKLQDCTMLVNGDDLVNICESAGTQEDASLRYTEAMTRYSAPPGDPQPEYDL	390	Db	391	ELITSCSNVSVAHDAASGRVYLTTRDPTVPLARAETARHPPVNSLGNIMYAPTLW	450
Qy	365	ELITSCSNVSVAHDAASGRVYLTTRDPTVPLARAETARHPPVNSLGNIMYAPTLW	424	Qy	425	ARMLMTTHFSTILLAQEOLAKEALDCQTYGACTSTEPLDLPQITERLHGSAFSLHSSYSPG	484
Db	391	ELITSCSNVSVAHDAASGRVYLTTRDPTVPLARAETARHPPVNSLGNIMYAPTLW	450	Db	451	ARMLMTTHFSTILLAQEOLAKEALDCQTYGACTSTEPLDLPQITERLHGSAFSLHSSYSG	510
Qy	425	ARMLMTTHFSTILLAQEOLAKEALDCQTYGACTSTEPLDLPQITERLHGSAFSLHSSYSG	484	Qy	485	EINRVAASCURKLQGPPLRWRHRSARSKLLSQGGRATCQKYLENWAUTKLTLP	544
Db	451	ARMLMTTHFSTILLAQEOLAKEALDCQTYGACTSTEPLDLPQITERLHGSAFSLHSSYSG	510	Db	511	EINRVAASCURKLQGPPLRWRHRSARSKLLSQGGRATCQKYLENWAUTKLTLP	570
Qy	485	EINRVAASCURKLQGPPLRWRHRSARSKLLSQGGRATCQKYLENWAUTKLTLP	544	Qy	545	AASRLDLSMFWVAGYSGDIYHSLSRAPRPFMCLLILSVGVGIVLLPNR	595
Db	511	EINRVAASCURKLQGPPLRWRHRSARSKLLSQGGRATCQKYLENWAUTKLTLP	570	Db	571	AASRLDLSMFWVAGYSGDIYHSLSRAPRPFMCLLILSVGVGIVLLPNR	621
Qy	545	AASRLDLSMFWVAGYSGDIYHSLSRAPRPFMCLLILSVGVGIVLLPNR	595				
Db	571	AASRLDLSMFWVAGYSGDIYHSLSRAPRPFMCLLILSVGVGIVLLPNR	621				
				RESULT 11			
				US-10-198-259A-1			
				Sequence 1, Application US/10198259A			
				; Sequence 1, Application US/10198259A			
				; Publication No US2003026251A1			
				GENERAL INFORMATION:			
				; APPLICANT: Boehringer Ingelheim (Canada) Ltd.			
				; TITLE OF INVENTION: Viral Polymerase Inhibitors			
				; FILE REFERENCE: 1/089			
				; CURRENT APPLICATION NUMBER: US/10/198-259A			
				; CURRENT FILING DATE: 2002-07-18			
				; PRIOR APPLICATION NUMBER: 60/306,669			
				; PRIOR FILING DATE: 2001-07-20			
				; PRIOR APPLICATION NUMBER: 60/338,324			
				; PRIOR FILING DATE: 2001-12-07			
				; NUMBER OF SEQ ID NOS: 4			
				; SOFTWARE: FastSeq for Windows Version 4.0			
				; SEQ ID NO 1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 18 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: HCV NS5B			
				US-10-198-259A-1			
				RESULT 10			
				Sequence 1, Application US/102386282			
				; Publication No. US20030232016A1			
				GENERAL INFORMATION:			
				; APPLICANT: BOEHRINGER INGELHEIM (CANADA) LTD.			
				; TITLE OF INVENTION: VIRAL POLYMERASE INHIBITORS			
				; FILE REFERENCE: 13/079			
				; CURRENT APPLICATION NUMBER: US/10/238,282			
				; CURRENT FILING DATE: 2002-09-10			
				; PRIOR APPLICATION NUMBER: 60/216,084			
				; PRIOR FILING DATE: 2000-07-06			
				; PRIOR FILING DATE: 2001-01-08			
				; PRIOR APPLICATION NUMBER: 60/281,434			
				; PRIOR FILING DATE: 2001-04-02			
				; NUMBER OF SEQ ID NOS: 1			
				SOFTWARE: FastSeq for Windows Version 4.0			
				; SEQ ID NO 1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
				US-10-238-282-1			
				Query Match 95.1% ; Score 3011 ; DB 15 ; Length 621 ;			
				Best Local Similarity 95.9% ; Pred. No. 7.6e-266 ;			
				Matches 567 ; Mismatches 6 ; Indels 0 ; Gaps 0 ;			
				TYPE: PRT			
				ORGANISM: Hepatitis C Virus			
</td							

Qy	365	ELITCSSNSVVAHDASGRVYLTLDPTPLARAWEARHTPNSWLGNIMMAPTLW	424
Db	391	ELITCSSNSVVAHDASGRVYLTLDPTPLARAWEARHTPNSWLGNIMMAPTLW	450
Qy	425	ARMILMTHFFSIIAQBQLEKALDQIYQACYSIPELDLQIIELRHGSASFSLISYSPG	484
Db	451	ARVLMTHFFSIIAQBQLEKALDQIYQACYSIPELDLQIIELRHGSASFSLISYSPG	510
Qy	485	EINRVAASCLRKLGYPPLRVWRHRSVRAKLSSQGRRACGKYLFLNWAERTKLLKLTPIP	544
Db	511	EINRVAASCLRKLGYPPLRVWRHRSVRAKLSSQGRRACGKYLFLNWAERTKLLKLTPIP	570
Qy	545	AASRLDLSSWMPVAGYSGGDLYHSLSRARPPWFMLCLLSSVGVGJLLPNR	595
Db	571	AASRLDLSSWMPVAGYNGDIYHSLSRARPPWFMLCLLSSVGVGJLLPNR	621
RESULT 12			
US-10-198-384A-1			
Sequence 1, Application US/10198384A			
Publication No. US20040024190A1			
GENERAL INFORMATION:			
APPLICANT: Boehringer Ingelheim (Canada) Ltd.			
TITLE OF INVENTION: Viral Polymerase Inhibitors			
FILE REFERENCE: 13/090			
CURRENT APPLICATION NUMBER: US/10/198,384A			
CURRENT FILING DATE: 2002-07-18			
PRIOR APPLICATION NUMBER: 60/338,061			
PRIOR FILING DATE: 2001-12-07			
PRIOR APPLICATION NUMBER: 60/307,674			
PRIOR FILING DATE: 2001-07-25			
NUMBER OF SEQ ID NOS: 4			
SOFTWARE: FastSEQ For Windows Version 4.0			
SEQ ID NO 1			
LENGTH: 621			
TYPE: PRT			
ORGANISM: HCV NSSB			
US-10-198-384A-1			
Query Match Score 95.1%; Length 621;			
Best Local Similarity 95.9%; Pred. No. 7.6e-266; Length 621;			
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;			
5 SMSYTWGALITPCAAERSKLPINALSNSLVRHNLVYSTSITRSSSLRQKVTFFRLQVL			
31 SMSYTWGALITPCAAERSQQLPINALSNSLVRHNLVYSTSITRSSSLRQKVTFFRLQVL			
65 DDTYDVLKEMKAKASTVAKLSSVTEAKLTPPHSAAKSFRGKGDVTSLSRAVNHIR			
91 DDTYDVLKEMKAKASTVAKLSSVTEAKLTPPHSAAKSFRGKGDVTSLSRAVNHIR			
125 SWKDLLEDTDTPTIQTTIMAKNEYFCYQPEKGRKPARLIVFDPDGVRYCEKMKALYDVS			
151 SWKDLLEDTDTPTIDTTIMAKNEYFCYQPEKGRKPARLIVFDPDGVRYCEKMKALYDVS			
185 TL PQAVMGSSYGFQYSKPKRVEFLVNTWAKKCPMGFSYDTRCPSTVENDIRYTESI			
211 TL PQAVMGSSYGFQYSKPKRVEFLVNTWAKKCPMGFSYDTRCPSTVENDIRYTESI			
245 QCDLAPEAROARSLTTERLYVGSPMTNSKGQNCYRRCRASGVTTSCNTLTYLKA			
271 QCDLAPEAROARSLTTERLYVGSPMTNSKGQNCYRRCRASGVTTSCNTLTYLKA			
305 AACRAKQIQLDTMLVNGDLYVVCESAGTQDQEADASLRVPTTEAMTYSAPGDPDPPPEYDL			
331 AACRAKQIQLDTMLVNGDLYVVCESAGTQDQEADASLRVPTTEAMTYSAPGDPDPPPEYDL			
365 ELITCSSNSVVAHDASGRVYLTLDPTPLARAWEARHTPNSWLGNIMMAPTLW			
391 ELITCSSNSVVAHDASGRVYLTLDPTPLARAWEARHTPNSWLGNIMMAPTLW			
425 ARMILMTHFFSIIAQBQLEKALDQIYQACYSIPELDLQIIELRHGSASFSLISYSPG			

Db	451	ARMILMTHFFSILLAAQBLEKALDQIYGACYSTIEPLDLQIIEHLHGSLSAFSLHSYSPG	510
Qy	485	EINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGRRALCGKYLFWAVRKLKLTPIP	544
Qy	511	EINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGRRATCGKYLFWAVRKLKLTPIP	570
Db	545	AASRLDISGWVAGYGGDIYHSLSRARPWFMLCLLSSVGVGTYLLPVR	595
Qy	571	AASRLDISGWVAGYGGDIYHSLSRARPWFMLCLLSSVGVGTYLLPVR	621
RESULT 13			
US-10-471-164-1			
Sequence 1 Application US/10471164			
Publication No. US20040110126A1			
GENERAL INFORMATION:			
APPLICANT: George KUKOLJ and Ginette MCKERCHER			
TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY			
FILE REFERENCE: 13/094			
CURRENT APPLICATION NUMBER: US/10/471,164			
CURRENT FILING DATE: 2003-09-05			
PRIOR APPLICATION NUMBER: 60/274,374			
PRIOR FILING DATE: 2001-03-08			
NUMBER OF SEQ ID NOS: 6			
SOFTWARE: FastSEQ for Windows Version 4.0			
SEQ ID NO 1			
TYPE: PRT			
ORGANISM: HCV			
US-10-471-164-1			
Qy	Query Match	95.1%	Score 3011; DB 16; Length 621;
Qy	Best Local Similarity	95.3%	Pred. No. 7.6e-266;
Db	Matches	567	Conservative 18; Nismatches 6; Indels 0; Gaps 0;
Qy	5	SMSYTWTGALITPCAREESKPLNALSNSLJRHNLVYSTTSRSALRQKVTDFRLQVL	64
Db	31	SMSYTWTGALITPCAREESQPLNALSNSLVRHNMVYSTTSRSALRQKVTDFRLQVL	90
Qy	65	DDHYRDLKEMKAKASTVKRLLSVEACKLTPPKAASKSFYGAQKDYRSLSSRAVNHIR	124
Db	91	DDHYRDLKEMKAKASTVKRLLSVEACKLTPPKAASKSFYGAQKDYRSLSSRAVNHIR	150
Qy	125	SYWKDILEDTPDPIQTTIMAKNEWFCVQPEKGGRKPARLIVPDLGIVRYCEKMKALYDVY	184
Db	151	SYWKDILEDTPDPIQTTIMAKNEWFCVQPEKGGRKPARLIVPDLGIVRYCEKMKALYDVY	210
Qy	185	TLPOQMGSSTGFOISPKQVNEFLNTWRAKCPMGFSDTRCPDTSVENDIRVEESIY	244
Db	211	TLPOQMGSSTGFOISPKQVNEFLNTWRAKCPMGFSDTRCPDTSVENDIRVEESIY	270
Qy	245	QCCDLAPEAROARISRTLRYVGGMNTNSKGQNCCYRRCRASGVLTISCGNTLTCYLKA	304
Db	271	QCCDLAPEAROARISRTLRYVGGMNTNSKGQNCCYRRCRASGVLTISCGNTLTCYLKA	330
Qy	305	AACRAKQLQDCTMLVNGDDLVVICSAQTOEASLRLVTEAMTRYSAPPGDPPOPEYDL	364
Db	331	AACRAKQLQDCTMLVNGDDLVVICSAQTOEASLRLVTEAMTRYSAPPGDPPOPEYDL	390
Qy	365	BLITSSSNVSAHDSGKRVYLTTRDPTPLRARAETARHTPNSWIGNIIMYATPLW	424
Db	391	BLITSSSNVSAHDSGKRVYLTTRDPTPLRARAETARHTPNSWIGNIIMYATPLW	450
Qy	425	ARMILMTHFFSILLAAQBLEKALDQIYGACYSTIEPLDLQIIEHLHGSLSAFSLHSYSPG	484
Qy	451	ARMILMTHFFSILLAAQBLEKALDQIYGACYSTIEPLDLQIIEHLHGSLSAFSLHSYSPG	510
Qy	485	EINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGRRALCGKYLFWAVRKLKLTPIP	544
Db	511	EINRVAASCLRKLGVPPLRWRHRSVRAKLLSQGRRATCGKYLFWAVRKLKLTPIP	570
Qy	545	AASRLDISGWVAGYGGDIYHSLSRARPWFMLCLLSSVGVGTYLLPVR	595

Db 571 AASRLDLSGMFVAGYNGDIYHSLSLRARPWFMLCLLISVGVGIYLLP.NR 621

RESULT 14 US-10-851-710-1.

; Sequence 1, Application US/10851710

; Publication No. US2004022455A1

; GENERAL INFORMATION:

; APPLICANT: BOEPPINGER INGELHEIM (CANADA) LTD.

; TITLE OF INVENTION: VIRAL POLYMERASE INHIBITORS

; FILE REFERENCE: 13/079

; CURRENT APPLICATION NUMBER: US/10/851,710

; CURRENT FILING DATE: 2004-05-01

; PRIOR APPLICATION NUMBER: US/10/238,282

; PRIOR FILING DATE: 2002-09-10

; PRIOR APPLICATION NUMBER: 60/216,084

; PRIOR FILING DATE: 2000-07-06

; PRIOR APPLICATION NUMBER: 60/274,374

; PRIOR FILING DATE: 2001-03-08

; PRIOR APPLICATION NUMBER: 60/281,434

; PRIOR FILING DATE: 2001-04-02

; NUMBER OF SEQ ID NOS: 1

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 1

; LENGTH: 621

; TYPE: PRT

; ORGANISM: Hepatitis C Virus

; US-10-851-710-1

Query Match 95.1%; Score 3011; DB 16; Length 621;

Best Local Similarity 95.9%; Pred. No. 7.6e-266;

Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;

Qy 5 SMSYTWTGALITPCAAEESKPLNALSILRHNLVYSTTSSAISLQQKVTFDRLQLV 64

Db 31 SMSYTWTGALITPCAAEESKPLNALSILRHNLVYSTTSSAISLQQKVTFDRLQLV 90

Qy 65 DDHYRDVLEKMRKAKASTVAKLISVEACKLTPPHSAAKSKEGYAKDVRSLSSRAVNIR 124

Db 91 DDHYRDVLEKMRKAKASTVAKLISVEACKLTPPHSAAKSKEGYAKDVRSLSSRAVNIR 150

Qy 125 SWKDLLEDTPDPIOTTIMARNEYFCVQPEKGGRKPARLIVFPDLGVRCVCEKMLADYDVS 184

Db 157 SWKDLLEDTPDPIOTTIMARNEYFCVQPEKGGRKPARLIVFPDLGVRCVCEKMLADYDVS 216

Qy 185 TLPOAVMGSYYGFOYSKPKRVEPLVNTKAKICCPGMFSEYDTRCFDSTTENDIRVEESIY 244

Db 217 TLPOAVMGSYYGFOYSKPKRVEPLVNTKAKICCPGMFSEYDTRCFDSTTENDIRVEESIY 276

Qy 185 TLPOAVMGSYYGFOYSKPKRVEPLVNTWAKKCPMGFSYDTRCFDSTTENDIRVEESIY 244

Db 211 TLPOAVMGSYYGFOYSKPKRVEPLVNAWKSKKCPMGFSYDTRCFDSTTENDIRVEESIY 270

Qy 245 QCCDLAPEARQAQFSLITERLYGGNTNTSKQNCYRRCRASGVLTTSCGNTUTCYLKA 304

Db 271 QCCDLAPEARQAQFSLITERLYGGNTNTSKQNCYRRCRASGVLTTSCGNTUTCYLKA 330

Qy 305 AACRAAKLQDCTMLVNGDDLVICESAGTOEDASLRVFTTEAMTRYSAPPGDPQPEYDL 364

Db 337 AACRAAKLQDCTMLVNGDDLVICESAGTOEDANLRFTTEAMTRYSAPPGDPQPEYDL 396

Qy 365 ELITSCSSNVSVAHDAKSRRVYLTTRDPTVPLARAANETRHTPVPNSLGNLIMYAPTLW 424

Db 397 ELITSCSSNVSVAHDAKSRRVYLTTRDPTVPLARAANETRHTPVPNSLGNLIMYAPTLW 456

Qy 425 ARMLTMTHPSILLAQEQLEKALDCQIGACYSTEPLDLPQIIRLHLSAFSLHSYSPG 484

Db 457 ARMLTMTHPSILLAQEQLEKALDCQIGACYSTEPLDLPQIIRLHLSAFSLHSYSPG 516

Qy 485 EINRVASCLRKLGVPPLRWRHARSVRAKLSQGGRAATCGYLFNVAVRTKLUKLTPIP 544

Db 517 EINRVASCLRKLGVPPLRWRHARSVRAKLSQGGRAATCGYLFNVAVRTKLUKLTPIP 576

Qy 545 AASRLDLSGMFVAGYNGDIYHSLSLRARPWFMLCLLISVGVGIYLLP.NR 595

Db 577 AASRLDLSGMFVAGYNGDIYHSLSLRARPWFMLCLLISVGVGIYLLP.NR 627

RESULT 15 US-09-838-386-12

; Sequence 12, Application US/09838386

; Patent No. US20010055756A1

; GENERAL INFORMATION:

; APPLICANT: Pellerin, Charles

; APPLICANT: Kukoli, George

; TITLE OF INVENTION: Internal De No. US20010055756A10 Initiation Sites of the HCV NS5B

; FILE REFERENCE: 1011.2180001

; CURRENT APPLICATION NUMBER: US/09/838-386

; CURRENT FILING DATE: 2001-06-20

; PRIOR APPLICATION NUMBER: US 60/198,793

; PRIOR FILING DATE: 2000-04-21

; NUMBER OF SEQ ID NOS: 25

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 12

; LENGTH: 627

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc feature

; OTHER INFORMATION: Htah5B polymerase

; US-09-838-386-12

Query Match 95.1%; Score 3011; DB 9; Length 627;

Best Local Similarity 95.9%; Pred. No. 7.7e-266;

Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;

Qy 5 SMSYTWTGALITPCAAEESKPLNALSILRHNLVYSTTSSAISLQQKVTFDRLQLV 64

Db 37 SMSYTWTGALITPCAAEESKPLNALSILRHNLVYSTTSSAISLQQKVTFDRLQLV 96

Qy 65 DDHYRDVLEKMRKAKASTVAKLISVEACKLTPPHSAAKSKEGYAKDVRSLSSRAVNIR 124

Db 97 DDHYRDVLEKMRKAKASTVAKLISVEACKLTPPHSAAKSKEGYAKDVRSLSSRAVNIR 156

Qy 125 SWKDLLEDTPDPIOTTIMARNEYFCVQPEKGGRKPARLIVFPDLGVRCVCEKMLADYDVS 184

Db 157 SWKDLLEDTPDPIOTTIMARNEYFCVQPEKGGRKPARLIVFPDLGVRCVCEKMLADYDVS 216

Qy 185 TLPOAVMGSYYGFOYSKPKRVEPLVNTKAKICCPGMFSEYDTRCFDSTTENDIRVEESIY 244

Db 217 TLPOAVMGSYYGFOYSKPKRVEPLVNTKAKICCPGMFSEYDTRCFDSTTENDIRVEESIY 276

Qy 245 QCCDLAPEARQAQFSLITERLYGGNTNTSKQNCYRRCRASGVLTTSCGNTUTCYLKA 304

Db 277 QCCDLAPEARQAQFSLITERLYGGNTNTSKQNCYRRCRASGVLTTSCGNTUTCYLKA 336

Qy 305 AACRAAKLQDCTMLVNGDDLVICESAGTOEDASLRVFTTEAMTRYSAPPGDPQPEYDL 364

Db 337 AACRAAKLQDCTMLVNGDDLVICESAGTOEDANLRFTTEAMTRYSAPPGDPQPEYDL 396

Qy 365 ELITSCSSNVSVAHDAKSRRVYLTTRDPTVPLARAANETRHTPVPNSLGNLIMYAPTLW 424

Db 397 ELITSCSSNVSVAHDAKSRRVYLTTRDPTVPLARAANETRHTPVPNSLGNLIMYAPTLW 456

Qy 425 ARMLTMTHPSILLAQEQLEKALDCQIGACYSTEPLDLPQIIRLHLSAFSLHSYSPG 484

Db 457 ARMLTMTHPSILLAQEQLEKALDCQIGACYSTEPLDLPQIIRLHLSAFSLHSYSPG 516

Qy 485 EINRVASCLRKLGVPPLRWRHARSVRAKLSQGGRAATCGYLFNVAVRTKLUKLTPIP 544

Db 517 EINRVASCLRKLGVPPLRWRHARSVRAKLSQGGRAATCGYLFNVAVRTKLUKLTPIP 576

Qy 545 AASRLDLSGMFVAGYNGDIYHSLSLRARPWFMLCLLISVGVGIYLLP.NR 595

Db 577 AASRLDLSGMFVAGYNGDIYHSLSLRARPWFMLCLLISVGVGIYLLP.NR 627

Search completed: September 22, 2005, 14:49:31

Job time : 79 secs

This Page Blank (uspto)

is active, adding a fluorescent dye capable of binding double-stranded nucleic acid molecules to the reaction mixture, and measuring the fluorescence of the reaction mixture. The RNA polymerase is the Hepatitis C virus (HCV) polymerase, NS5B. The method is useful for treating HCV infection, bone mineral diseases like osteoporosis, carcinomas, cardiovascular diseases, diabetes, ocular disorders, renal dysfunction, lymphomas, lymphoproliferative disorders, metabolic disorders, arthritis, sleep disorders and thyroid disorders. The present sequence represents C-terminally truncated HCV NS5B polymerase (designated Cdelta21 NS5B).

XX Sequence 580 AA;

Query Match 100.0%; Score 3055; DB 8; Length 580;
Best Local Similarity 100.0%; Pred. No. 7e-285;
Matches 580; Conservation 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MASMMSYTWTGALITPCAAEESKLPIINALNSLRLRHNLVYSTTSRSASLRQKVTFDR 60
Db 1 MASMMSYTWTGALITPCAAEESKLPIINALNSLRLRHNLVYSTTSRSASLRQKVTFDR 60

Qy 61 LQVLDHYDVLKEMKAKASTVAKLISVEACKLTPHSASAKSFGYGAQDVSLSRAV 120
Db 61 LQVLDHYDVLKEMKAKASTVAKLISVEACKLTPHSASAKSFGYGAQDVSLSRAV 120

Qy 121 NHISVWQDILEDTPQIPTIMAKNEVPCVQPEKGKPKPARLIVPDLGVRCEKMLY 180
Db 121 NHISVWQDILEDTPQIPTIMAKNEVPCVQPEKGKPKPARLIVPDLGVRCEKMLY 180

Qy 121 NHISVWQDILEDTPQIPTIMAKNEVPCVQPEKGKPKPARLIVPDLGVRCEKMLY 180
Db 121 NHISVWQDILEDTPQIPTIMAKNEVPCVQPEKGKPKPARLIVPDLGVRCEKMLY 180

Qy 181 DVVSTLPOAMGSSYGOYSPKQRYEFLNTWAKRKCPMGFSYDTRCPDSTTENDIRVE 240
Db 181 DVVSTLPOAMGSSYGOYSPKQRYEFLNTWAKRKCPMGFSYDTRCPDSTTENDIRVE 240

Qy 181 DVVSTLPOAMGSSYGOYSPKQRYEFLNTWAKRKCPMGFSYDTRCPDSTTENDIRVE 240
Db 181 DVVSTLPOAMGSSYGOYSPKQRYEFLNTWAKRKCPMGFSYDTRCPDSTTENDIRVE 240

Qy 241 BSIYQCCDLAREAQPAIRSITERYUGGMNTNSKGQNCGYRCBASGVLTTSGNTLTCY 300
Db 241 ESIYQCCDLAREQPAIRSITERYUGGMNTNSKGQNCGYRCBASGVLTTSGNTLTCY 300

Qy 301 LKAANACRAAKLQDCTMLVNGDLVVICSAQGTDAAASLRVFTTEAMTRYSAPPGDPQP 360
Db 301 LKAANACRAAKLQDCTMLVNGDLVVICSAQGTDAAASLRVFTTEAMTRYSAPPGDPQP 360

Qy 361 BYDLELITSCS SNTVAHDASGKRVYLYTRDPTVPLARAWEARHPTPNWSLGNNTIYMA 420
Db 361 BYDLELITSCS SNTVAHDASGKRVYLYTRDPTVPLARAWEARHPTPNWSLGNNTIYMA 420

Qy 421 PTIWARMLTMTHFSIIAQQLQKALDQIYGACYSTEPLDIQQLIPLHGLSAFSLHS 480
Db 421 PTIWARMLTMTHFSIIAQQLQKALDQIYGACYSTEPLDIQQLIPLHGLSAFSLHS 480

Qy 481 YSPGEINRVASCLRKLGVPPLRWRHRSVRAKULSQGRAALCGKYLFWNAVRTKKL 540
Db 481 YSPGEINRVASCLRKLGVPPLRWRHRSVRAKULSQGRAALCGKYLFWNAVRTKKL 540

Qy 541 TPIPAASRLDLSGNFVAGTSGGDIYHSLSRAPRHHHHH 580
Db 541 TPIPAASRLDLSGNFVAGTSGGDIYHSLSRAPRHHHHH 580

RESULT 2
ID AA026417 standard; protein; 576 AA.
AC AA026417;
XX 30-JAN-2003 (first entry)
DE Mutant RNA polymerase NUT-2 protein.
XX Antiviral; hepatitis C virus; HCV; NS5B RNA polymerase.
XX Unidentified.
OS ENEVASCRLKGVPPLRWRHRSVRAKULSQGRAALCGKYLFWNAVRTKKLTPIP 544
PN EP1256628-A2.
XX

PD 13-NOV-2002.
XX
PF 07-MAY-2002; 2003EP-00009387.
XX
PR 10-MAY-2001; 2001US-0289829P.
PA (AGOU-) AGOURON PHARM INC.
XX
PI Love RA, Yu X, Diehl W, Hickey MJ, Parge HB, Gao J, Fuhrman S;
XX
WPI; 2003-031968/03.
DR
XX
Isolated nucleic acid encoding a mutant hepatitis C virus (HCV) NS5B RNA polymerase, useful for producing the mutant RNA polymerase which can be used for identifying inhibitors that can treat HCV infection.

Claim 7; Page; 32pp; English.

PS
XX
The invention relates to an isolated, purified nucleic acid molecule, which encodes a mutant hepatitis C virus (HCV) NS5B RNA polymerase, where a point mutation occurs at least one or all of positions 47, 101, 106, and/or 114 of the native RNA polymerase sequence not defined in the specification. The method of the invention is utilised to identify inhibitors of the polymerase. The inhibitors serving as lead compounds for the design of potentially therapeutic compounds for the treatment of HCV. The mutant HCV NS5B RNA polymerase has improved crystallisation properties as compared to a native HCV NS5B RNA polymerase. This sequence represents a mutant RNA polymerase protein of the invention. NOTE: This sequence is not shown in the specification. It is, however, described in the specification and its sequence has been obtained from an electronic data file.

CC
XX
Sequence 576 AA;
Query Match 96.6%; Score 2951; DB 6; Length 576;
Best Local Similarity 96.5%; Pred. No. 7.4e-275;
Matches 556; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWTGALITCAAEBSKLPIINALNSLRLRHNLVYSTTSRSASLRSOKKTTEDRQLV 64
Db 1 SMSYTWTGALITCAAEBSKLPIINALNSLRLRHNLVYSTTSRSASLRSOKKTTEDRQLV 64

Qy 65 DDHYRDVKEMKAKASTVAKLISVEACKLTPHSASAKSFGYGAQDVSLSRAVNHT 124
Db 61 DDHYRDVKEMKAKASTVAKLISVEACKLTPHSASAKSFGYGAQDVSLSRAVNHT 124

Qy 125 SWKDLLEDTPPIQTTIMAKNEVPCVQPEKGKPKPARLIVFDPDGLVRCVKAQYDVS 184
Db 121 SWKDLLEDTPVDPDTIMAKNEVPCVQPEKGKPKPARLIVFDPDGLVRCVKAQYDVS 180

Qy 185 TLPOAVMGSYGFQYSPKQRYEFLNTWAKRKCPMGFSYDTRCPDSTTENDIRVEESLY 244
Db 181 TLPOAVMGSYGFQYSPKQRYEFLNTWAKRKCPMGFSYDTRCPDSTTENDIRVEESLY 240

Qy 245 QCCDLAPEAROARSLTTRLYVGPMFTSKGONGCGYRCRASGVLTTSGNTLTCYKRA 304
Db 241 QCCDLAPEAROARSLTTRLYVGPMFTSKGONGCGYRCRASGVLTTSGNTLTCYKRA 300

Qy 305 AACRAAKLQDCTMLVNGDLVVICSAQGTDAAASLRVFTTEAMTRYSAPPGDPQP 364
Db 361 ELTSCSSNVSVAHDASGKRVYLYTRDPTVPLARAWEARHPTPNWSLGNNTIYAPTLW 420
Db 301 AACRAAKLQDCTMLVNGDLVVICSAQGTDAAASLRVFTTEAMTRYSAPPGDPQP 360

Qy 365 ELTSCSSNVSVAHDASGKRVYLYTRDPTVPLARAWEARHPTPNWSLGNNTIYAPTLW 424
Db
XX
AC
XX
DE
XX
KW
XX
OS
PN
XX

CC the specification and its sequence has been obtained from an electronic
CC data file

XX Sequence 576 AA;

CC (NISB) JAPAN TOBACCO INC.
CC Ago H, Miyano M, Adachi T;
XX PA
XX PI
XX DR WPI ; 2001-104834/12.
XX New polypeptide, derived from hepatitis C virus (HCV) polymerase NSSB, having a HCV polymerase activity, useful for crystal structure analysis and for rational identification of HCV polymerase inhibitors.
XX Disclosure; Page 279-282; 295pp; English.
XX
CC The present invention provides the hepatitis C virus (HCV) NSSB polymerase protein and its structure. It also provides methods for identifying inhibitors of the protein which can be used in the treatment of HCV infection. HCV can lead to cirrhosis and hepatoma in its chronic form.
XX Sequence 579 AA;
CC
Query Match 96.4%; Score 2944; DB 6; Length 576;
Best Local Similarity 96.2%; Pred. No. 3.5e-274;
Matches 554; Conservative 13; Mismatches 9; Indels 0; Gaps 0;
Db 5 SMTWTGALLPAAEESKLPIINALSNSLRRHNLVSTTSRASLRLQKVKTFDRLOVL 64
1 SMTWTGALLPAAEESKLPIINALSNSLRRHNLVSTTSRASLRLQKVKTFDRLOVL 60
Qy 65 DHYRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSFKGAKDVRSSRAVNHIR 124
61 DHYRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSFKGAKDVRNLSSRAVNIR 120
Qy 125 SWKDLLEDTPQIOTTIMAKNEVFCQPEKGRKPARLIVPDLGIVRCERKMLADYDVS 184
121 SWKDLLEDTPQIOTTIMAKNEVFCQPEKGRKPARLIVPDLGIVRCERKMLADYDVS 180
Qy 185 TLPOAVMGSSYQFQSPKORVFLVNTWAKKCPMGFSIDTCPDSTTENDRVEESTY 244
Db 181 TLPOVYMGSSYQFQSPGQRFVFLVNTWAKKCPMGFSIDTCPDSTTENDRVEESTY 240
Qy 245 QCCDLAPEARQAISSLTERLYVGGFMNTNSKGQNCYRRCRASGVLTSCGNTLTCYKAA 304
Db 241 QCCDLAPEARQAISSLTERLYVGGFMNTNSKGQNCYRRCRASGVLTSCGNTLTCYKAS 300
Qy 305 AACRAAKLQDCTMLYNGDDLIVVICESAGTOEADAASLRVFTTEAMTRYSAPPGDPQQPEYDL 364
Db 301 AACRAAKLQDCTMLYNGDDLIVVICESAGTOEADAASLRVFTTEAMTRYSAPPGDPQQPEYDL 360
Qy 365 ELITSCSSNVSAHDAASGKRVYILTRDPTVPLARAWEAHTPVNSLGNIMYAPLW 424
Db 361 ELITSCSSNVSAHDAASGKRVYILTRDPTVPLARAWEAHTPVNSLGNIMYAPLW 420
Qy 425 ARMLTMTHFSPILLAQOLEKALDQIYGACYSEPLDLQPIITERLHGLSAFSLHYSPG 484
Db 421 ARMLTMTHFSPILLAQOLEKALDQIYGACYSEPLDLQPIITERLHGLSAFSLHYSPG 480
Qy 485 EINRVASCLRKLGVPPLRVWRHARSYRAKLISQCGRAAICGKYLENNAVRKTLKLTPP 544
Db 481 EINRVASCLRKLGVPPLRVWRHARSYRAKLISQCGRAAICGKYLENNAVRKTLKLTPP 540
Qy 545 AASQDLLSGMFVAGYSGGDLYTHSLSRARPHEHHHH 580
Db 541 AASQDLLSGMFVAGYSGGDLYTHSLSRARPHEHHHH 576
RESULT 5
AAB60131 standard; protein; 579 AA.
XX AAB60131; AC AAB60131;
XX DT 03-APR-2001 (first entry)
XX DE Hepatitis C virus NSSB polymerase related protein.
XX PR Hepatitis C virus; HCV; NSSB polymerase; protein coordinate data;
KW Hepatitis C virus; hepatoma; inhibitor.
XX OS Hepatitis C virus.
PN EP1065213-A2.
XX PD 03-JAN-2001.
XX PP 30-JUN-2000; 2000EP-00113955.
XX PR 02-JUL-1999; 99JP-00188630.
PR 07-JUL-1999; 99JP-00124488.
XX
RESULT 6
AAG79558 standard; protein; 578 AA.
ID AAG79558
XX AC AAG79558;
XX DT 09-DEC-2002 (first entry)

XX	HCV decrease-affinity NS5B polymerase, NSSB _{delta21C} -HT.	Db	241 QCCDLAPEARQAISLTERLYGGPLTNSKGQNCYRRCRASGVLTSCNTLTCYLKAS 300
XX	Enzyme; hepatitis C virus; HCV; decreased affinity; NS5B; polymerase; inhibitor; RNA-dependent RNA polymerase.	QY	305 AACRAAKLQDCTMLVNGDLIVVCESAQGTOQDAASLRVTEAMTRYSAPGDPPPEYDLY 364
KW	Hepatitis C virus.	Db	301 AACRAAKLQDCTMLVNGDLIVVCESAQGTOQDAANLRVTEAMTRYSAPGDLPPEYDLY 360
OS		QY	365 ELITSCSNYSVADASGRVYILTRDPTPLARAWEARHTPNSLGNNTMAYAPTLY 424
PN	WO200270739-A2.	Db	361 ELITSCSNYSVADASGRVYILTRDPTPLARAWEARHTPNSLGNNTMAYAPTLY 420
XX	PD 12-SEP-2002.	QY	425 ARMLTMTHPSFSLAQEQLEKALDQIYGACYSTEPLDLPQIERLHGSAFSLHSYSPG 484
XX	PP 06-MAR-2002; 2002WO-CA000323.	Db	421 ARMLTMTHPSFSLAQEQLEKALDQIYGACYSTEPLDLPQIERLHGSAFSLHSYSPG 480
XX	PR 08-MAR-2001; 2001US-0274374P.	QY	485 BINRVASCLRKLGYPPLRWRHRSVRAXLSSCGGAAICGKYLFWAVRTKULKLTPTP 544
PA	(BOEH) BOEHRINGER INGELHEIM CANADA LTD.	Db	481 BINRVASCLRKLGYPPLRWRHRSVRAXLSSCGGAAICGKYLFWAVRTKULKLTPTP 540
XX	Kukolj G, McErcher G;	QY	545 AASRLDLSGMWVAGYSGGDIYHSLSRARPR -HHHHHH 580
XX	WPI; 2002 698/59/75.	Db	541 AASRLDLSGMWVAGYSGGDIYHSLSRARPRLEHHHHHH 578
PT	Identifying inhibitors HCV NS5B RNA-dependent RNA polymerase, comprises	RESULT 7	
PT	incubating an HCV NS5B polymerase having decreased affinity for the	ABP71662	
PT	primer template relative to the native polymerase, with a potential	1D ABP71662 standard; protein; 578 AA.	
XX	inhibitor.	XX	ABP71662;
PS	Claim 9; Page 47-48; 52pp; English.	XX	DT 29-MAY-2003 (first entry)
XX	The sequences given in AAG79556-61 are hepatitis C virus (HCV) decreased affinity NS5B polymerases. These enzymes are used in the method of the invention for identifying a potential inhibitor of the binding between a HCV NS5B RNA-dependent RNA polymerase and an appropriate primer-template. The method comprises incubating the HCV NS5B polymerase with the primer-template in the presence and absence of a potential inhibitor. The HCV NS5B polymerase has a decreased affinity for the primer-template relative to that of native HCV NS5B RNA-dependent RNA polymerase. The method is useful for identifying a potential inhibitor of the binding between HCV NS5B RNA-dependent RNA polymerase and a primer-template. Use of polymerase constructs having a lower affinity towards the primer-template than that of native NS5B polymerase is particularly useful for identifying potential inhibitors in screening large libraries of compounds. The new method reduces the difficulties and disadvantages of prior art. The present method provides an assay that is easy to perform on large libraries of compounds, and has improved sensitivity for detecting inhibitors that would not be identified as such using native HCV NS5B polymerase. This protein represents a soluble form of mature HCV NS5B which lacks the C-terminal 21 amino acids and has an C-terminal hexa-histidine tag.	XX	DE HCV NS5B _{delta121} -His protein sequence.
XX	Sequence 578 AA;	XX	XX
Db	Query Match 96.1%; Score 2936; DB 5; Length 578;	XX	XX
Db	Best Local Similarity 95.5%; Pred. No. 2.1e-273;	XX	XX
Matches 552; Conservative 18; Mismatches 6; Indels 2; Gaps 1;	XX	XX	XX
QY	5 SMSTWTGALITPCAAEESKIPINALNSLRLRHNLYSTSRSRASLRLKVKTFDRLOVL 64	XX	XX
Db	1 SMSMTWTGALITPCAAEESKIPINALNSLRLRHNLYSTSRSRASLRLKVKTFDRLOVL 60	CC	CC
QY	65 DHYTRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHIR 124	CC	CC
Db	61 DHYTRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHIR 120	CC	CC
QY	125 SWKDLLEDTPIOTTIMAKNEVPCVQPEKGGKPKARLIVPDLGVRVCEKMLDYVY 184	CC	CC
Db	121 SWKDLLEDTPIOTTIMAKNEVPCVQPEKGGKPKARLIVPDLGVRVCEKMLDYVY 180	CC	CC
QY	185 TLPOAVMGSSYGFQYSKPKQRFVLYNTWKAKKCPMGFSYDTRCPDSTTENDRVEESTY 244	CC	CC
Db	181 TLPOAVMGSSYGFQYSKPKQRFVLYNAWKSCKKCPMGFSYDTRCPDSTTENDRVEESTY 240	CC	CC
QY	245 QCCDLAPEARQAISLTERLYGGMNTNSKGQNCYRRCRASGVLTSCGNTLTCYLKAA 304	CC	CC
Query Match	96.1%; Score 2936; DB 6; Length 578;	SQ	Sequence 578 AA;
Best Local Similarity	95.5%; Pred. No. 2.1e-273;	XX	XX
Matches	552; Conservative 18; Mismatches 6; Indels 2; Gaps 1;	XX	XX
QY	5 SMSTWTGALITPCAAEESKIPINALNSLRLRHNLYSTSRSRASLRLKVKTFDRLOVL 64	PS	PS
Db	1 SMSMTWTGALITPCAAEESKIPINALNSLRLRHNLYSTSRSRASLRLKVKTFDRLOVL 60	CC	CC
QY	65 DHYTRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHIR 124	CC	CC
Db	61 DHYTRDVLKEMKAKASTVKAKLSSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHIR 120	CC	CC
QY	125 SWKDLLEDTPIOTTIMAKNEVPCVQPEKGGKPKARLIVPDLGVRVCEKMLDYVY 184	CC	CC
Db	121 SWKDLLEDTPIOTTIMAKNEVPCVQPEKGGKPKARLIVPDLGVRVCEKMLDYVY 180	CC	CC
QY	185 TLPOAVMGSSYGFQYSKPKQRFVLYNTWKAKKCPMGFSYDTRCPDSTTENDRVEESTY 244	CC	CC
Db	181 TLPOAVMGSSYGFQYSKPKQRFVLYNAWKSCKKCPMGFSYDTRCPDSTTENDRVEESTY 240	CC	CC
QY	245 QCCDLAPEARQAISLTERLYGGMNTNSKGQNCYRRCRASGVLTSCGNTLTCYLKAA 304	CC	CC
Query Match	96.1%; Score 2936; DB 6; Length 578;	XX	XX

		RESULT 11
Db	121	SWKDLLEETEPIDTTIMARNEFCVQPKGGKPARLIVPDIGVRCEKMLAYDVVS 18
QY	185	TLPAVMGSSYGPQYSPKORVEFLVNTWAKKCPMGFSYDTRCFDSTVENDIVVEESIV 24
Db	181	TLPAVMGSSYGPQYSPKORVEFLVNAWKSKKCPMGFSYDTRCFDSTVTESDIVVEESIV 24
QY	245	QCCRLAPEAROAIRSLTERLYVGGPMTNSKGQNQGYRCPASGLTTSGNTLTCYLKAA 30

non-A-non-B type hepatitis virus fragment of the invention. NOTE: This sequence is given in the sequence listing as an embedded protein and is not further referred to in the specification.

XX Sequence 462 AA;

Query Match 74.6%; Score 2279; DB 8; Length 462;

Best Local Similarity 93.0%; Pred. No. 3.2e-210;

Matches 426; Conservative 18; Mismatches 14; Indels 0; Gaps 0;

Db 1 SAVNHIRSTWKDILLEDNTVPTDITTMASSEVFCVQPEKGKPARLIVFPDGVRYTEK 60

Qy 117 5AVNHIRSTWKDILLEDNTVPTDITTMASSEVFCVQPEKGKPARLIVFPDGVRYTEK 176

Db 1 SAVNHIRSTWKDILLEDNTVPTDITTMASSEVFCVQPEKGKPARLIVFPDGVRYTEK 60

Qy 177 MALDVVSTLPQAYMGSSXYGFOYSPKRVYELVNTWKAKKCPMGFSYDTRCFDSTVTEEND 236

Db 61 MALVNVSITLPQAYMGSSXYGFOYSPKRVYELVNTWKAKKCPMGFSYDTRCFDSTVTEEND 120

Qy 237 IREVEISIYQOCQDLAEPARQKSLTTERLYTGPMNTNSKGQNCGYRRCRASGVLTSGCNT 296

Db 121 IREVEISIYQOCQDLAEPARQKSLTTERLYTGPMNTNSKGQNCGYRRCRASGVLTSGCNT 180

Qy 297 LTCYLUKAAACRAAKLQDCTMLVNGDDLVVICSAAGTQDAAASLRVFTTEAMTRYSAPPD 356

Db 181 LTCYLUKAAACRAAKLQDCTMLVNGDDLVVICSAAGTQDAAASLRVFTTEAMTRYSAPPD 240

Qy 357 PPOEYDLELTISCSNSVSYAHDASGKRVYVLTDRDPTPLARAWEWAHRTIPNSWICNI 416

Db 241 PPRPEYDLELTISCSNSVSYAHDASGKRVYVLTDRDPTPLARAWEWAHRTIPNSWICNI 300

Qy 417 IMYAPTLWARMILMTHAFLFSTLIAQEQLEKALDCQIYGACTSIEPDQLQIITERLHGLSAF 476

Db 301 IMYAPTLWARMILMTHAFLFSTLIAQEQLEKALDCQIYGACTSIEPDQLQIITERLHGLSAF 360

Qy 477 SLHSSYSPGEBINRVASCLRKLGVPPLRVWHRARSYRAKLLSQGSGRAATCGKYLFNWAVRT 536

Db 361 SLHSSYSPGEBINRVASCLRKLGVPPLRVWHRARSYRAKLLSQGSGRAATCGKYLFNWAVRT 420

Qy 537 KKLKTPIPASRDLQSGWVAGYSGCGDIYTHSLSPRARPR 574

Db 421 KKLKTPIPASRDLQSGWVAGYSGCGDIYTHSLSPRARPR 458

RESULT 14

AAR67630 ID AAR67630 standard; protein; 547 AA.

XX AC AAR67630;

XX DT 27-AUG-2003 (revised)

XX DT 25-MAR-2003 (first entry)

XX DE Non-A Non-B hepatitis virus non-structural protein.

XX KW Non-A Non-B hepatitis virus; structural region; cDNA to genomic RNA;

XX KW detection; reagent; anti-Non-A Non-B hepatitis virus antibody; vaccine;

XX KW antigen; epitope; diagnosis.

XX OS Non-A.

OS non-B hepatitis virus.

XX FH Key Location/Qualifiers

FT Peptide 52..72

FT /note= "putative epitope site (see AAR67641)"

XX PN EP628572-A2.

XX PD 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

XX PR 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

XX PR 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

XX PR 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

XX PR 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

XX PR 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

XX PR 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

XX PR 14-DEC-1994.

XX PR 27-MAY-1994; 94EP-00108256.

XX PR 28-MAY-1993; 93JP-00126709.

PR 02-MAR-1994; 94JP-00032201.

XX (EISA) BISAI CO LTD.

XX Aoyama M, Obara T, Tohmatu J, Sawada T, Hosoda T, Iwasaki Y;

XX Arima T;

XX WPI; 1995-015655/03.

DR N-PSDB; AAQ75819.

XX New non-A non-B hepatitis virus sub-type - used to develop prods. for

PR detection, diagnosis, prevention and treatment of non-A non-B hepatitis.

XX PS Claim 1; Page 33-37; 59pp; English.

XX AAR67630 is the structural protein of the Non-A Non-B (NANB) hepatitis

CC virus encoded by a partial cDNA to genomic RNA sequence. Regions of the

CC polypeptide were studied for suitability as an epitope. The novel

CC epitopes are effective in the diagnosis of NANB hepatitis. The nucleotide

CC sequences (see AAO75817-19) were isolated from the plasma of donors in

CC Japan with high s-GPT levels, and were found to be different from

CC previously reported NANB hepatitis viruses. The DNA can be used as a

CC reagent for detecting the NANB hepatitis viral gene. The polypeptides can

CC be used as reagents for detecting anti-NANB hepatitis antibodies or as a

CC NANB hepatitis viral vaccine. (Updated on 25-MAR-2003 to correct PN

XX field.) (Updated on 27-AUG-2003 to correct OS field.)

XX Sequence 547 AA;

SQ

Query Match 70.2%; Score 2144; DB 2; Length 547;

Best Local Similarity 75.5%; Pred. No. 4.4e-197;

Matches 397; Conservative 55; Mismatches 74; Indels 0; Gaps 0;

Db 49 ASLRAKCTTDFRQVLDHYDYLKEMKAKASTYKAKLISVERBACKLTTPHSAKSKTGYG 108

Db 1 ASLRAKCTTDFRQVLDHYDYLKEMKAKASTYKAKLISVERBACKLTTPHSAKSKTGYG 60

Db 109 AKDVRSLSSRAVNHIRSTWKDILLEDPTIQTITMAKNEVFCVQPEKGKRPKARLIVPPD 168

Db 61 AKETRSLSSRAVNHIRSTWKDILLEDQHTEVFCIDPAKGRKPKARLIVPPD 120

Db 121 LGYRVCEMAYLQDYLQVSTLPOAVMGSSYGFQYSPKQRYVERFLVNTWKAKKCPMGFSYDTRCF 228

Db 169 LGYRVCEMAYLQDYLQVSTLPOAVMGSSYGFQYSPKQRYVERFLVNTWKAKKCPMGFSYDTRCF 228

Db 122 LGYRVCEMAYLQDYLQVSTLPOAVMGSSYGFQYSPKQRYVERFLVNTWKAKKCPMGFSYDTRCF 180

Db 229 DSTTYTENDTIVRESEIYQCCDLAPARQIIRSLTERLYGGPMNTNSKGQNCGYRCRASGV 288

Db 181 DSTTYTENDTIRTSIYQCCSLPQEARTYHSLTERLYGGPMNTNSKGQNCGYRCRASGV 240

Db 289 LTTSQGNLTTCYLUAAACRAAKLQDCTMLVNGDDLVVICASQTQEDASLRVFTTEAMT 348

Db 241 FTISMGNTMTCTYKALACKAAGIKDPMLVCGDDLVVICASQTQEDASLRVFTTEAMT 300

Db 349 RYSAPPGDPOPOEYDLELTITSCSSNVSYAHDASGKRVYVYLTRDPTPVLARAAMETARHTP 408

Db 301 RYSAPPGDPRPEYDLELTITSCSSNVSYAHDASGKRVYVYLTRDPTPVLARAAMETARHTP 360

Db 469 RLGLSAFLSLSLHSSPGEBINRVAACLKGVPPLRVWRERARSYVRAKLUQGGAAICCKY 528

Db 421 RLGDAFLSLSLHSSPGEBINRVAACLKGVPPLRVWRERARSYVRAKLUQGGAAICCKY 468

Db 361 VNSWLGNLTIQYAPLWVNRNIMTHFFAQLTLNQNLNFENYGAIVSVPNPLDPLAIE 420

Db 529 LFNWAVRLDKLKTPIPAASRLDLSGWFVAGYSGGDDIYHSLSRPR 574

Db 481 LFNWAVKTKLKTPLPEAARLDLSGWFVAGGDDIYHSLSRPR 526

RESULT 15
AR29906 standard; protein; 389 AA.

ID AAR29906

ID AAR29906 standard; protein; 389 AA.

XX AAR29906;
 AC 25-MAR-2003 (revised)
 DT 26-APR-1993 (first entry)
 XX HCV NS4-NS5 peptide O30-4.
 XX Clone; polypeptide; NS4-NS5; Hepatitis C; virus; HCV; serum; HC;
 KW transcriptase; cDNA; primer; allele; core; region; upstream; hydrophilic;
 KW turn structure; alpha helix; beta sheet; antigen; determinant; antisera.
 OS Hepatitis C virus.
 XX Key Location/Qualifiers
 PT Misc-difference 377 /note= "Nonsense mutation"
 PT Misc-difference 381 /note= "Nonsense mutation"
 XX EP518313-A2.
 XX PD 16-DEC-1992.
 XX PF 11-JUN-1992; 92EP-00109812.
 XX PR 11-JUN-1991; 91JP-00139268.
 PR 12-JUL-1991; 91JP-00172794.
 PR 07-OCT-1991; 91JP-00287008.
 PR 16-DEC-1991; 91JP-0032329.
 PR 20-APR-1992; 92JP-0009957.
 XX PA (MITU) MITSUBISHI KASEI CORP.
 XX PI Seki M, Honda Y, Takahashi K, Murakami T, Teranishi Y, Hayashi N;
 XX WPI: 1992-417213/51.
 DR N-PSDB; AAQ32337.
 XX PT New hepatitis C virus gene and its encoded protein - used for diagnosing
 PT and vaccinating against hepatitis C virus infections.
 XX Disclosure: Page 257-59; 305pp; English.
 XX CC The sequences given in AAR29871-906 and AAR29533 are encoded by various
 CC clones of the NS4-NS5 regions of the Hepatitis C Virus (HCV) gene of the
 CC invention. These NS4-NS5 RNA sequences were isolated from the serum of a
 CC patient suffering from hepatitis C (HCV). The isolated RNA sequences were
 CC converted into cDNA using transcriptase in the presence of one of the
 CC primer sequences given in AAQ32565-77. The sequences were then amplified
 CC using primer pairs. The cDNA sequences isolated represent different
 CC alleles of the same region of the HCV gene. Sequence analysis shows that
 CC these clones represent the core region and some upstream hydrophilic
 CC sequences of the HCV. These polypeptides are thought to contain a highly hydrophilic
 CC region which can adopt a "turn structure" which is not an alpha helix or
 CC a beta sheet. These polypeptides are thought to act as antigen
 CC determinants and are highly reactive with antisera raised against HCV-
 CC associated antigens. See also AAQ32436. (updated on 25-MAR-2003 to
 CC correct PN field.)
 XX SQ Sequence 389 AA;
 Query Match 59.3%; Score 1812; DB 2; Length 389;
 Best Local Similarity 96.1%; Pred. No. 2.6e-165;
 Matches 341; Conservative 6; Mismatches 8;
 Indels 0; Gaps 0;
 Qy 220 GFSYDTRCPDSTWENDIVVEESIYQCDLAPEARQAIISLTERLYVGPMNTNSKGONGC 279
 Db 1 GIPYDTRCPFSTWENDIVVEESIYQCDLAPEARQAIISLTERLYVGPMNTNSKGONGC 60
 Qy 280 YRRCRASGVLTTSCTNTLTCYKAAAACAAKLODCTMLVNGDOLVVICBAGTQEDAS 339
 Db 61 YRRCRASGVLTTSCTNTLTCYKAAAACAAKLODCTMLVNGDOLVVICBAGTQEDAS 120

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: September 22, 2005, 14:47:55 ; Search time 43 Seconds

(without alignments)
1297.808 Million cell updates/sec

Title: US-10-712-479-4

Perfect score: 3055

Sequence: 1 MASMSMSYTWTGALITPCAA.....GGDIYHSLSRARPRHHHHH 580

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched:

283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 248019

Minimum DB seq length: 0

Maximum DB seq length: 585

Post-processing: Minimum Match 0% ; Maximum Match 100% ;

Listing first 45 summaries

Database : PIR_79.1

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	1777	58.2	365	2	JQ0879		NS5 protein - hep
2	1655	54.2	365	2	JQ0880		NS5 protein - hep
3	951	31.1	189	2	PS0104		non-structural pro
4	774	25.3	284	2	PS0102		Genome polyprotein
5	744	24.4	259	2	PS0121		Genome polyprotein
6	667	21.8	135	2	PS0124		Genome polyprotein
7	630	20.6	156	2	PS0109		Genome polyprotein
8	569	18.6	113	2	PC1278		Genome polyprotein
9	563	18.4	113	2	PC1274		Genome polyprotein
10	562	18.4	113	2	PC1275		Genome polyprotein
11	562	18.4	113	2	PC1276		Genome polyprotein
12	560	18.3	113	2	PC1277		Genome polyprotein
13	513	16.8	113	2	PC1279		Genome polyprotein
14	426	13.9	113	2	PC1282		Genome polyprotein
15	426	13.9	113	2	PQ0275		Genome polyprotein
16	425	13.9	113	2	PQ0276		Genome polyprotein
17	424	13.9	113	2	PC1281		Genome polyprotein
18	422	13.8	113	2	PC1283		Genome polyprotein
19	409	13.4	113	2	PC1280		Genome polyprotein
20	408	13.4	113	2	PO0273		Genome polyprotein
21	406	13.3	113	2	PQ0274		Genome polyprotein
22	402	13.2	78	2	PS0085		Genome polyprotein
23	336	11.0	266	2	PO0393		Genome polyprotein
24	300	9.8	132	2	PQ0394		Genome polyprotein
25	298	9.8	132	2	PQ0394		Genome polyprotein
26	296	9.7	60	2	S44215		Genome polyprotein
27	264	8.6	71	2	PC1300		Genome polyprotein
28	261	8.5	71	2	PC1302		Genome polyprotein
29	260	8.5	71	2	PC1301		Genome polyprotein

RESULT 2
JQ0880
NS5 protein - hepatitis C virus (strain J1) (fragment)
C;Species: hepatitis C virus
C;Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004
C;Accession: JQ0880

ALIGNMENTS

QY	231	TVTENDIVRYBESTYQCCDLAPEAQAIISLTERLYVGPMNTSKQNCQNCQYRCRASGVLT	290
Db	1	TVTENDIVRYBESTYQCCDLAPEAQAIISLTERLYVGPMNTSKQNCQNCQYRCRASGVLT	60
QY	291	TSGCNTLTCYKAAAACRAAKLQDCTMLYNGDDLVVICCESAGTQEDAAASLURVTEAMTRY	350
Db	61	TSGCNTLTCYKAAAACRAAKLQDCTMLYNGDDLVVICCESAGTQEDAAASLURVTEAMTRY	120
QY	351	SAPPDDPPOPEYDLELITLITCSNSNVVAHDASGKRVYLTLDPTPLARAWEETARHPPN	410
Db	121	SAPPDDPPOPEYDLELITLITCSNSNVVAHDASGKRVYLTLDPTPLARAWEETARHPPN	180
QY	411	SWLGNITIYAPLWARMILMTHFFSILAQOBELAKDQIYGACYSIEPLDLPOIERTL	470
Db	181	SWLGNITIYAPLWARMILMTHFFSILAQOBELAKDQIYGACYSIEPLDLPOIERTL	240
QY	471	HGLSAFSLHSYSPEBIRNRYASCLRKLGPPRLYWRHARSVRAKLQSQGRRAAICGKYL	530
Db	241	HGLSAFSLHSYSPEBIRNRYASCLRKLGPPRLYWRHARSVRAKLQSQGRRAAICGKYL	300
QY	531	NWAVRTKLKLTPIPAAASRJLDSGMFVGSGGGDIYHSLSRARPR	574
Db	301	NWAVRTKLKLTPIPAAASRJLDSGMFVGSGGGDIYHSLSRARPR	344

Db	118	LTRDPTVPLARAWEETARHTTPVNSNLGNIMIYAPTLWARMILMTHFFSTIILAQELEKAL	177	Db	66	RHRARSVRKLLSQQGRAATCGKYLFWNAVTRKLLPPIAAGQDLSGMFTAGYSGGDI	125
Qy	448	DCQIYGACYSSBPLDQIQLERLHGSASFISHSYSSGEINRVASCLRKLGVPPIRVWRHR	507	Qy	565	YHSLSRARPR	574
Db	178	DCQIYGACYSSBPLDQIQLERLHGSASFISHSYSSGEINRVASCLRKLGVPPIRVWRHR	237	Db	126	YHSVSHARPR	135
Qy	508	RSVRKLLSQQGRAATCGKYL	529				
Db	238	RSVRKLLSQQGRAATCGKYL	259				
				RESULT 8			
				PC1278			
				NS5 protein - hepatitis C virus (strain K1-4) (fragment)			
				C;Species: hepatitis C virus			
				C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004			
				C;Accession: PC1278			
				R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.			
				Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990			
				A;Title: There are two major types of hepatitis C virus in Japan.			
				A;Reference number: PC1274; MUID:90358793; PMID:2117923			
				A;Accession: PC1278			
				A;Molecule type: mRNA			
				A;Residues: 1-113 <END>			
				A;Cross-references: UNIPROT:Q01187; GB:D10645; GB:D90554; PIDN:3221668; PIDN:BA001492.1; E			
				C;Genetics:			
				A;Gene: NS5			
				C;Superfamily: hepatitis C virus genome polyprotein			
				C;Keywords: capsid protein			
				Query Match 18.6%; Score 569; DB 2; Length 113;			
				Best Local Similarity 95.6%; Pred. No. 1.1e-36;			
				Matches 108; Conservative 3; Mismatches 2; Indels 0; Gaps 0;			
				Qy 230 STVENDIRVEEISYQCCDLAPEARQAIISRSLTERLYGGPMTNISKQONGCYRRCRASGVL 289			
				Db 1 STVENDIRVEEISYQCCDLAPEARQVITRSLTERLYGGPLTNISKQONGCYRRCRASGVL 60			
				Qy 290 TTSGNTLTCYLKAAACRAAKLQDCTMLVNGDDLVVICESAGTQDASLRV 342			
				Db 61 TTSGNTLTCYLKAAACRAAKLQDCTMLVCGDDLVVICESAGTQDASLRV 113			
				RESULT 9			
				PC1277			
				NS5 protein - hepatitis C virus (strain K1-3) (fragment)			
				C;Species: hepatitis C virus			
				C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004			
				C;Accession: PC1277			
				R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.			
				Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990			
				A;Title: There are two major types of hepatitis C virus in Japan.			
				A;Reference number: PC1274; MUID:90358793; PMID:2117923			
				A;Accession: PC1277			
				A;Molecule type: mRNA			
				A;Residues: 1-113 <END>			
				A;Cross-references: UNIPROT:O70640; GB:D10644; GB:D90553; PIDN:9221666; PIDN:BA001491.1; E			
				C;Genetics:			
				A;Gene: NS5			
				C;Superfamily: hepatitis C virus genome polyprotein			
				C;Keywords: capsid protein			
				Query Match 18.4%; Score 563; DB 2; Length 113;			
				Best Local Similarity 94.7%; Pred. No. 3.2e-36;			
				Matches 107; Conservative 4; Mismatches 2; Indels 0; Gaps 0;			
				Qy 230 STVENDIRVEEISYQCCDLAPEARQSLRSLTERLYGGPMTNISKQONGCYRRCRASGVL 289			
				Db 1 STVENDIRVEEISYQCCDLAPEARQSLRSLTERLYGGPLTNISKQONGCYRRCRASGVL 60			
				Qy 290 TTSGNTLTCYLKAAACRAAKLQDCTMLVNGDDLVVICESAGTQDASLRV 342			
				Db 61 TTSGNTLTCYLKAAACRAAKLQDCTMLVCGDDLVVICESAGTQDASLRV 113			
				RESULT 10			
				PC1277			
				NS5 protein - hepatitis C virus (fragment)			
				C;Species: hepatitis C virus			
				C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004			
				C;Accession: PC1277			
				R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.			
				Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990			
				A;Title: There are two major types of hepatitis C virus in Japan.			
				A;Reference number: PC1274; MUID:90358793; PMID:2117923			
				A;Accession: PC1277			
				A;Molecule type: mRNA			
				A;Residues: 1-116 <END>			
				A;Cross-references: GB:MS8406; GB:M58407			
				C;Superfamily: hepatitis C virus genome polyprotein			
				C;Keywords: polyprotein			
				Query Match 20.6%; Score 630; DB 2; Length 156;			
				Best Local Similarity 89.2%; Pred. No. 3.5e-41;			
				Matches 116; Conservative 8; Mismatches 6;			
				Indels 0; Gaps 0;			
				Qy 445 KALDQIYGACYSSBPLDQIQLERLHGSASFISHSYSSGEINRVASCLRKLGVPPIRVWRHR 504			
				Db 6 KALDCEIYGACYSSIEPLDLPPIQLRHLGSASFISHSYSGEINRVAACRLKGVPPLRAW 65			
				Qy 505 RHRARSVRKLLSQQGRAATCGKYLFWNAVTRKLLPPIPAASRLDLSGMFTAGYSGGDI 564			

PC1274 NS5 protein - hepatitis C virus (strain K1) (fragment)
 C:Species: hepatitis C virus
 C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
 C:Accession: PC1274
 R:Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
 Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
 A;Title: There are two major types of hepatitis C virus in Japan.
 A;Reference number: PC1274; MUID:90358793; PMID:2117923
 A;Molecule type: mRNA
 A;Residues: 1-113 <END>
 A;Cross-references: UNIPROT:Q01192; GB:D10641; DB:90550; NID:9221658; PIDN:BAA01488.1;
 C:Genetics:
 A;Gene: NS5
 C:Superfamily: hepatitis C virus genome polyprotein
 C:Keywords: capsid protein

Query Match 18.4%; Score 562; DB 2; Length 113;
 Best Local Similarity 95.6%; Pred. No. 3.8e-36;
 Matches 109; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 230 STTVENDIVRESYQCCDLAPEARQATRSLTERLYVGPMNTNSKGONGYRRCRASGV 289
 Db 1 STTVENDIVRESYQCCDLAPEARQATRSLTERLYVGPMNTNSKGONGYRRCRASGV 60

QY 290 TTSGCNTLTCYLKAAAACRAAKLQDCTMLVNGDDLVVICESAGTQEDASLRV 342
 Db 61 TTSGCNTLTCYLKAAAACRAAKLQDCTMLVNGDDLVVICESAGTQEDASLRV 113

RESULT 11
 PC1275 NS5 protein - hepatitis C virus (strain K1-1) (fragment)
 C:Species: hepatitis C virus
 C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
 C:Accession: PC1275
 R:Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
 Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
 A;Title: There are two major types of hepatitis C virus in Japan.
 A;Reference number: PC1274; MUID:90358793; PMID:2117923
 A;Molecule type: mRNA
 A;Residues: 1-113 <END>
 A;Cross-references: UNIPROT:Q01184; GB:D10642; DB:90551; NID:9221662; PIDN:BAA01489.1;
 C:Genetics:
 A;Gene: NS5
 C:Superfamily: hepatitis C virus genome polyprotein
 C:Keywords: capsid protein

Query Match 18.4%; Score 562; DB 2; Length 113;
 Best Local Similarity 94.7%; Pred. No. 3.8e-36;
 Matches 107; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 230 STTVENDIVRESYQCCDLAPEARQATRSLTERLYVGPMNTNSKGONGYRRCRASGV 289
 Db 1 STTVENDIVRESYQCCDLAPEARQATRSLTERLYVGPMNTNSKGONGYRRCRASGV 60

QY 290 TTSGCNTLTCYLKAAAACRAAKLQDCTMLVNGDDLVVICESAGTQEDASLRV 342
 Db 61 TTSGCNTLTCYLKAAAACRAAKLQDCTMLVNGDDLVVICESAGTQEDASLRV 113

RESULT 12
 PC1276 NS5 protein - hepatitis C virus (strain K1-2) (fragment)
 C:Species: hepatitis C virus
 C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
 C:Accession: PC1276
 R:Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
 Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
 A;Title: There are two major types of hepatitis C virus in Japan.
 A;Reference number: PC1274; MUID:90358793; PMID:2117923
 A;Accession: PC1282
 A;Molecule type: mRNA
 A;Residues: 1-113 <END>
 A;Cross-references: UNIPROT:Q01189; GB:D10649; DB:90558; NID:9221676; PIDN:BAA01496.1; I
 C:Genetics:
 A;Gene: NS5
 C:Superfamily: hepatitis C virus genome polyprotein
 C:Keywords: capsid protein

This Page Blank (uspto)

Qy	245 QCCDLAPEARQAISSLTERLYVGPMNTNSKGQNCYRRCPASGVLTTSCTNLTCYLKAA	304	Db	185 TLPOAVMGSSYGFQYSPQRVERFLVNAWKSKKVPMGFAVDTRCFDSTVTENDIRVEESIY	244
Db	245 QCCDLAPEARQAISSLTERLYVGPMNTNSKGQNCYRRCPASGVLTTSCTNLTCYLKAA	304	Qy	245 QCCDLAPEARQAISSLTERLYVGPMNTNSKGQNCYRRCPASGVLTTSCTNLTCYLKAA	304
Db	245 QCCDLAPEARQAISSLTERLYVGPMNTNSKGQNCYRRCPASGVLTTSCTNLTCYLKAT	304	Db	245 QCCDLAPEARQAISSLTERLYVGPMNTNSKGQNCYRRCPASGVLTTSCTNLTCYLKAT	304
Qy	305 AACRAAKLQDQTMVLNGDDLVVICESAGTQDAASLRLVFTTEAMTRYSAPPGDPQQPEYDL	364	Qy	305 AACRAAKLQDQTMVLNGDDLVVICESAGTQDAASLRLVFTTEAMTRYSAPPGDPQQPEYDL	364
Db	305 AACRAAKLQDQTMVLNGDDLVVICESAGTQDAASLRLVFTTEAMTRYSAPPGDPQQPEYDL	364	Db	305 AACRAAKLQDQTMVLNGDDLVVICESAGTQDAASLRLVFTTEAMTRYSAPPGDPQQPEYDL	364
Qy	365 BLITSCSSNYSVAHDASGRKVVYLTRDPTPLARAWEETARHTPWNWLGNIMYAPTLW	424	Qy	365 BLITSCSSNYSVAHDASGRKVVYLTRDPTPLARAWEETARHTPWNWLGNIMYAPTLW	424
Db	365 BLITSCSSNYSVAHDASGRKVVYLTRDPTPLARAWEETARHTPWNWLGNIMYAPTLW	424	Db	365 BLITSCSSNYSVAHDASGRKVVYLTRDPTPLARAWEETARHTPWNWLGNIMYAPTLW	424
Qy	425 ARMLMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLFQIIRLHGSASFSLHSYSPG	484	Qy	425 ARMLMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLFQIIRLHGSASFSLHSYSPG	484
Db	425 ARMLMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLFQIIRLHGSASFSLHSYSPG	484	Db	425 ARMLMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLFQIIRLHGSASFSLHSYSPG	484
Qy	485 BINVASCLRKLGYPPLRWRARSVRAKLISQGRAAICGKLFNWNAVTRKLTPIP	544	Qy	485 BINVASCLRKLGYPPLRWRARSVRAKLISQGRAAICGKLFNWNAVTRKLTPIP	544
Db	485 BINVASCLRKLGYPPLRWRARSVRAKLISQGRAAICGKLFNWNAVTRKLTPIP	544	Db	485 BINVASCLRKLGYPPLRWRARSVRAKLISQGRAAICGKLFNWNAVTRKLTPIP	544
Qy	545 AASRDLSSGMWVAGYSGGDIYHSLSRA	571	Qy	545 AASRDLSSGMWVAGYSGGDIYHSLSRA	571
Db	545 AASRDLSSGMWVAGYSGGDIYHSLSRA	571	Db	545 AASRDLSSGMWVAGYSGGDIYHSLSRA	571
RESULT 4					
Q66NA6	Q66NA6 PRELIMINARY;	571 AA.	Q66NA6	Q66NA6 PRELIMINARY;	571 AA.
ID	Q66NA6		ID	Q66NA6	
AC	Q66NA6;		AC	Q66NA6;	
DT	25-OCT-2004 (TREMBLrel. 28, Created)		DT	25-OCT-2004 (TREMBLrel. 28, Created)	
DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)		DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)	
DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)		DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)	
DE	Hepadnavirus (Fragment).		DE	Hepadnavirus (Fragment).	
OS	Hepaditis C Virus.		OS	Hepaditis C virus.	
OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;		OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;	
OX	NCBI_TaxID=11103;		OX	NCBI_TaxID=11103;	
RN			RN		
RP	SEQUENCE FROM N.A.		RP	SEQUENCE FROM N.A.	
RA	Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,		RA	Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,	
RA	Kleiner D., Holman S., Augenbraun M., Taylor J.,		RA	Kleiner D., Holman S., Augenbraun M., Taylor J.,	
RT	"Sequence Analysis of Hepatitis C Virus Replication Functions in HCV/HIV Coinfected Subjects."		RT	"Sequence Analysis of Hepatitis C Virus Replication Functions in HCV/HIV Coinfected Subjects."	
RL	Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.		RL	Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.	
DR	EMBL; AY682756; AAU08313.1; -		DR	EMBL; AY682779; AAU08335.1; -	
DR	InterPro; IPR002156; HCV_Rdrp;		DR	InterPro; IPR002166; HCV_Rdrp;	
DR	InterPro; IPR007055; RNA_pol_DS_PS;		DR	InterPro; IPR007095; RNA_pol_DS_PS;	
DR	InterPro; IPR007094; RNA_pol_PSVr.		DR	InterPro; IPR007094; RNA_pol_PSVr.	
KW	Pfam; PF09998; Viral_Rdrp; 1.		KW	Pfam; PF0998; Viral_Rdrp; 1.	
FT	NON_TER	1	FT	NON_TER	1
FT	571 AA;	571	FT	571 AA;	571
SQ	SEQUENCE	571 AA;	SQ	SEQUENCE	571 AA;
		631.83 MW;		633.93 MW;	CDOFEE085358BEE67 CRC64;
Query Match	5 SMSYTTWGLITPCAAEBSKLPTNALSLSLRRHNLVYSTTSSASLQQKTTFDRLQLV	64	Query Match	5 SMSYTTWGLITPCAAEBSKLPTNALSLSLRRHNLVYSTTSSASLQQKTTFDRLQLV	64
Best Local Similarity	93.5%;	Score 2857; DB 2;	Best Local Similarity	93.5%;	Score 2856; DB 2;
Matches	540	Mismatches 15; Indels 0; Gaps 0;	Matches	539	Mismatches 17; Indels 0; Gaps 0;
Qy	5 SMSYTTWGLITPCAAEBSKLPTNALSLSLRRHNLVYSTTSSASLQQKTTFDRLQLV	64	Qy	5 SMSYTTWGLITPCAAEBSKLPTNALSLSLRRHNLVYSTTSSASLQQKTTFDRLQLV	64
Db	5 SMSYTTWGLITPCAAEBSKLPTNALSLSLRRHNLVYSTTSSASLQQKTTFDRLQLV	64	Db	5 SMSYTTWGLITPCAAEBSKLPTNALSLSLRRHNLVYSTTSSASLQQKTTFDRLQLV	64
Qy	65 DDHYDVLKEMKAKASTYKAKLSSVEACKLTPHSARKSKFGTKAKDYSLSRAVNHR	124	Qy	65 DDHYDVLKEMKAKASTYKAKLSSVEACKLTPHSARKSKFGTKAKDYSLSRAVNHR	124
Db	65 DDHYDVLKEMKAKASTYKAKLSSVEACKLTPHSARKSKFGTKAKDYSLSRAVNHR	124	Db	65 DDHYDVLKEMKAKASTYKAKLSSVEACKLTPHSARKSKFGTKAKDYSLSRAVNHR	124
Qy	125 SWKDLLEDPTDPIOTTIMAKNEYFCQPEKGKRPKARLIVFPLGIVRCYCEKMLADYDVS	184	Qy	125 SWKDLLEDPTDPIOTTIMAKNEYFCQPEKGKRPKARLIVFPLGIVRCYCEKMLADYDVS	184
Db	125 SWKDLLEDPTDPIOTTIMAKNEYFCQPEKGKRPKARLIVFPLGIVRCYCEKMLADYDVS	184	Db	125 SWKDLLEDPTDPIOTTIMAKNEYFCQPEKGKRPKARLIVFPLGIVRCYCEKMLADYDVS	184
Qy	185 TLPOAVMGSSYGFQYSPQRVERFLVNAWKSKKVPMGFAVDTRCFDSTVTENDIRVEESIY	244	Qy	185 TLPOAVMGSSYGFQYSPQRVERFLVNAWKSKKVPMGFAVDTRCFDSTVTENDIRVEESIY	244

Db	185	TLPQAVMGSSYGFQYSPAQRVEFLVNAWTSKCKCPMGPAVTRCFDSTVTESDIRVEESTY	244	QY	125	SWKDLLEDTDTPIQTTIMAKQEVFCYDPEKGGRKPKARLIVFDPDLGVRCVCEKHALYDVVS	184
Qy	245	QCCDLAPEARQAI8TERLYVGGMPTNSRGQNCYRRGRASGVLTTSGNLTTCYLKAA	304	Db	125	SWKDLLEDTATPDTTMARNEVFCYDPEKGGRKPKARLIVFDPDLGVRCVCEKHALYDVVS	184
Db	245	QCCDLAPEARQAI8TERLYIGBLTNSKGQNCYRRGRASGVLTTSGNLTTCYLKAT	304	QY	185	TLPQAVMGSSYGFQYSPKORVEFLVNTWAKKCPMGFSYDTRCFDSTVTESDIRVEESTY	244
Qy	305	AACRAAKLQDCTMVLNGDDLIVVICESAGTOQDAAASLRVTEAMTRYSAPPGDPQPEYDYL	364	Db	185	TLPQAVMGSSYGFQYSPGRVEFLVNAWTSKCKCPMGFSYDTRCFDSTVTESDIRVEESTY	244
Db	305	AACRAAKLQDCTMVLNGDDLIVVICESAGTOQDAAASLRVTEAMTRYSAPPGDPQPEYDYL	364	QY	245	QCCDLAPEARQAI8TERLYVGPMTNSKGQNCYRRGRASGVLTTSGNLTTCYLKAA	304
Qy	365	ELITSCSSNVSVAADASGRVYVLTTRDPTPLARAATWARTFHFPVNSLGNIMYAPTLW	424	Db	245	QCCDLAPEARQAI8TERLYVGPMTNSKGQNCYRRGRASGVLTTSGNLTTCYLKAS	304
Db	365	ELITSCSSNVSVAADASGRVYVLTTRDPTPLARAATWARTFHFPVNSLGNIMYAPTLW	424	QY	305	AACRAAKLQDCTMVLNGDDLIVVICESAGTOQDAAASLRVTEAMTRYSAPPGDPQPEYDYL	364
Qy	425	ARMILMTHFSSILAAQEOLEKALDQCIQYACYSIEPLDLPQIITERLHGLSAFSLHSSYSPG	484	Db	305	AACRAAKLQDCTMVLNGDDLIVVICESAGTOQDAAASLRVTEAMTRYSAPPGDPQPEYDYL	364
Db	425	ARMILMTHFSSILAAQEOLEKALDQCIQYACYSIEPLDLPQIITERLHGLSAFSLHSSYSPG	484	QY	365	ELITSCSSNVSVAADASGRVYVLTTRDPTPLARAATWARTFHFPVNSLGNIMYAPTLW	424
Qy	485	EINRVASCLRKGVYPLRVRHRARSVRAKLLSQGGRAIKGKYLENFWAVRTKLKLTPIP	544	Db	365	ELITSCSSNVSVAADASGRVYVLTTRDPTPLARAATWARTFHFPVNSLGNIMYAPTLW	424
Db	485	EINRVASCLRKGVYPLRVRHRARSVRAKLLSQGGRAIKGKYLENFWAVRTKLKLTPIP	544	QY	425	ARMILMTHFSSILAAQEOLEKALDQCIQYACYSIEPLDLPQIITERLHGLSAFSLHSSYSPG	484
Qy	545	AASRLDLSGMWVAGYSGGDIYHSLRSA	571	Db	425	ARMILMTHFSSILAAQEOLEKALDQCIQYACYSIEPLDLPQIITERLHGLSAFSLHSSYSPG	484
Db	545	AASRLDLSGMWVAGYSGGDIYHSLRSA	571	QY	485	EINRVASCLRKGVYPLRVRHRARSVRAKLLSQGGRAIKGKYLENFWAVRTKLKLTPIP	544
Db	545	AASRLDLSGMWVAGYSGGDIYHSLRSA	571	Db	485	EINRVASCLRKGVYPLRVRHRARSVRAKLLSQGGRAIKGKYLENFWAVRTKLKLTPIP	544
<hr/>							
RESULT 6							
Q6B4Q2		PRELIMINARY;					
ID	Q6B4Q2						
AC	Q6B4Q2;						
DT	25-OCT-2004	(TREMBLrel. 28, Created)					
DT	25-OCT-2004	(TREMBLrel. 28, Last sequence update)					
DT	25-OCT-2004	(TREMBLrel. 28, Last annotation update)					
DE	NS5b (Fragment).						
OS	Hepatitis C virus.						
OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;						
OC	Hepatitis C virus.						
OX	NCBI_TaxID=11103;						
RN							
RP	SEQUENCE FROM N.A.						
RA	Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,						
RA	Kleiner D., Holman S., Augenbraun M., Taylor J.						
RT	"Sequence Analysis of Hepatitis C Virus Replication Functions in						
RT	HCV/HIV Coinfected Subjects";						
RT	Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.						
DR	EMBL: AY682461; AAF84166.1;	-					
DR	GO: GO:000524; F-ATP binding; IEA.						
DR	GO: GO:0003723; F-RNA binding; IEA.						
DR	GO: GO:0003968; F-RNA-directed RNA polymerase activity; IEA.						
DR	GO: GO:0006354; Pitranscription; IEA.						
DR	GO: GO:0019079; P-viral genome replication; IEA.						
DR	InterPro: IPR002166; HCV_RdRP.						
DR	InterPro: IPR007035; RNA_pol_DS_PS.						
DR	InterPro: IPR007094; RNA_pol_PsVr.						
DR	Pfam: PF00998; viral_RdRP; 1.						
FT	NON_TER 1						
FT	NON_TER 571	571					
SQ	SEQUENCE	571 AA; 63123 MW;	931743E7C7819F36 CRC64;				
Query Match	93.4%;	Score 2853;	DB 2;	Length 571;			
Best Local Similarity	95.2%;	Pred. No. 2.6e-216;	Indels 0;	Gaps 0;			
Matches 540;	Conservative 15;	Mismatches 12;					
Qy	5	SMSTWTGALLTCPAAEESKLPINALSNSLRRHNLVYSTTSRSASLRKKVTFDRLQYL	64				
Db	5	SMSTWTGALLTCPAAEESKLPINALSNSLRRHNLVYSTTSRSASLRKKVTFDRLQYL	64				
Qy	65	DDHYRDVLKEMMKAKASTVKAULLSVEACKLTPPHSAISKPKYGAOKDVSLSRAVNIR	124				
Db	65	DDHYRDVLKEMMKAKASTVKAULLSVEACKLTPPHSAISKPKYGAOKDVSLSRAVNIR	124				
Qy	65	DDHYRDVLKEMMKAKASTVKAULLSVEACKLTPPHSAISKPKYGAOKDVSLSRAVNIR	124				
Db	65	DDHYRDVLKEMMKAKASTVKAULLSVEACKLTPPHSAISKPKYGAOKDVSLSRAVNIR	124				

Qy	125 SWKQDILEDTPPIQTTIMAKNEVFCVOPKGGRKPARLIVPPDGLVRYCEKMALEYDVVS	Db	65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSFKFGYAKDVRNLSSKAVKHIR 124
Db	125 SWKQDILEDTPPIQTTIMAKNEVFCVOPKGGRKPARLIVPPDGLVRYCEKMALEYDVVS	Qy	125 SWWDLLEDTPIDTTIPIQTTIMAKNEVFCVOPKGGRKPARLIVPPDGLVRYCEKMALEYDVVS 184
Qy	185 TLPOAVMGSSYGGFQSPKQVBFLYNTWKAKKCPNGFSTDRCFDSTVENDIRVEESIY 244	Db	125 SWWDLLEDTPIDTTIPIQTTIMAKNEVFCVOPKGGRKPARLIVPPDGLVRYCEKMALEYDVVS 184
Db	185 TLPOAVMGSSYGGFQSPGVRVEFLVNAWTSKVKVPMGFAIDRCFDSTVENDIRVEESIY 244	Qy	185 TLPOAVMGSSYGGFQSPKORVEFLVNTWKAKKCPNGFSTDRCFDSTVENDIRVEESIY 244
Qy	245 QCCDLAPEARQAISSLTERLYVGGMNTSKQNCQCYRRCRASGVLTTSCNTLTCYLKA 304	Db	185 TLPOAVMGSSYGGFQSPGVRVEFLVNAWTSKVKVPMGFAIDRCFDSTVENDIRVEESIY 244
Db	245 QCCDLAPEARQAISSLTERLYVGGPBLTSKQNCQCYRRCRASGVLTTSCNTLTCYLKA 304	Qy	185 TLPOAVMGSSYGGFQSPKORVEFLVNTWKAKKCPNGFSTDRCFDSTVENDIRVEESIY 244
Qy	305 AACRAAKLQDQCTMLVNGDDLVVICESAGTOQDAASLRLVETEAMTRYSAPPGDPQPEYDL 364	Db	245 QCCDLAPEARQAISSLTERLYVGGPBLTSKQNCQCYRRCRASGVLTTSCNTLTCYLKA 304
Db	305 AACRAAKLQDQCTMLVNGDDLVVICESAGTOQDAASLRLVETEAMTRYSAPPGDPQPEYDL 364	Qy	305 AACRAAKLQDQCTMLVNGDDLVVICESAGTOQDAASLRLVETEAMTRYSAPPGDPQPEYDL 364
Qy	365 ELITSCSSNVSVAHDAASGRKVVYLTRDPTVPLARAWEETARHTPVNSLGNIMYAPTLW 424	Db	305 AACRAAKLQDQCTMLVNGDDLVVICESAGTOQDAASLRLVETEAMTRYSAPPGDPQPEYDL 364
Db	365 ELITSCSSNVSVAHDAASGRKVVYLTRDPTVPLARAWEETARHTPVNSLGNIMYAPTLW 424	Qy	365 ELITSCSSNVSVAHDAASGRKVVYLTRDPTVPLARAWEETARHTPVNSLGNIMYAPTLW 424
Qy	425 ARMLIMTHFSSILLAQEQLEKALDCQIYGACYSIPEPLDLPQIILERLHGLSAFSLHSYSPG 484	Db	365 ELITSCSSNVSVAHDAASGRKVVYLTRDPTVPLARAWEETARHTPVNSLGNIMYAPTLW 424
Db	425 ARMLIMTHFSSILLAQEQLEKALDCQIYGACYSIPEPLDLPQIILERLHGLSAFSLHSYSPG 484	Qy	425 ARMLIMTHFSSILLAQEQLEKALDCQIYGACYSIPEPLDLPQIILERLHGLSAFSLHSYSPG 484
Qy	485 EINRYASCLRKLGVPPLRVWRHARSVRAXLISQCGRAAIKGKYLENNAVTRKLUKLTPIP 544	Db	425 ARMLIMTHFSSILLAQEQLEKALDCQIYGACYSIPEPLDLPQIILERLHGLSAFSLHSYSPG 484
Db	485 EINRYASCLRKLGVPPLRVWRHARSVRAXLISQCGRAAIKGKYLENNAVTRKLUKLTPIP 544	Qy	485 EINRYASCLRKLGVPPLRVWRHARSVRAXLISQCGRAAIKGKYLENNAVTRKLUKLTPIP 544
Qy	545 AASRLDLSGMFVAGYSGGDTIYHSLRA 571	Db	485 EINRYASCLRKLGVPPLRVWRHARSVRAXLISQCGRAAIKGKYLENNAVTRKLUKLTPIP 544
Db	545 AASRLDLSGMFVAGYSGGDTIYHSLRA 571	Qy	545 AASRLDLSGMFVAGYSGGDTIYHSLRA 571
Qy	545 DASRLDLSGMFVAGYSGGDTIYHSLRA 571	Db	545 AASQLDLSGMFVAGYSGGDTIYHSSHA 571
RESULT 8			
Q66N83	PRELIMINARY;	PRT;	571 AA.
ID	Q66N83	PRELIMINARY;	571 AA.
AC	Q66N83;	PRELIMINARY;	571 AA.
DT	25-OCT-2004 (TREMBLrel. 28, Created)	AC	Q66N82
DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)	ID	Q66N82;
DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)	DT	25-OCT-2004 (TREMBLrel. 28, Created)
DB	Polyprotein (Fragment).	DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)
OS	Hepatitis C virus.	DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)
OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae; Hepacivirus.	DE	Polyprotein (Fragment).
OC	OC	OS	Hepatitis C virus.
NCBI_TaxID	11103;	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae; Hepacivirus.	OC
NCBI_TaxID	11103;	OC	Hepacivirus.
RN	[1]	NCBI_TaxID=11103;	NCBI_TaxID=11103;
RP	SEQUENCE FROM N.A.	RN	RN
RA	PARKER M., LAMSON D., WROBLEWSKI D., REILLY A., PHILPOTT S.,	RA	SEQUENCE FROM N.A.
RA	KLEINER D., HOLMAN S., AUGENBRAUN M., TAYLOR J.,	RA	PARKER M., LAMSON D., WROBLEWSKI D., REILLY A., PHILPOTT S.,
RT	"Sequence Analysis of Hepatitis C Virus Replication Functions in	RA	KLEINER D., HOLMAN S., AUGENBRAUN M., TAYLOR J.;
RT	HCV/HIV Coinfected Subjects";	RA	"Sequence Analysis of Hepatitis C Virus Replication Functions in
RL	Submitted (JUL 2004) to the EMBL/GenBank/DBJ databases.	RT	HCV/HIV Coinfected Subjects";
DR	EMBL; AY682780; AAU08336.1; -.	RT	Submitted (JUL 2004) to the EMBL/GenBank/DBJ databases.
DR	InterPro; IPR002166; HCV_RdRP.	RL	EMBL; AY682760; AAU08317.1; -.
DR	InterPro; IPR007095; RNA_Pol_DS_Ps.	DR	InterPro; IPR007094; RNA_Pol_DS_Ps.
DR	InterPro; IPR007094; RNA_Pol_PsVir.	DR	InterPro; IPR007095; RNA_Pol_PsVir.
KW	Pfam; PF00998; Viral_RdRP; 1.	DR	Pfam; PF00998; Viral_RdRP; 1.
FT	Polyprotein.	FT	KW
FT	NON TER 1 1	FT	Polyprotein.
SQ	SEQUENCE 571 AA; 63177 MW;	NON TER 571 1	NON TER 571 1
		SQ	SEQUENCE 571 AA; 63227 MW;
			F54BDE550ACDDEBC CRC64;
Query	93 2%; Score 2846; DB 2; Length 571;	Query	F54BDE550ACDDEBC CRC64;
Best Local Similarity	94.9%; Pred. No. 9.3e-216;	Query Match	92.9%; Score 2839; DB 2; Length 571;
Matches	536; Conservative 17; Mismatches 12;	Best Local Similarity	94.5%; Pred. No. 3.3e-215;
		Matches	536; Conservative 19; Mismatches 12;
Qy	5 SMSYTWGALITPCAAEESKLPIINALSNSLRLHNLVYSTTSRASILRKKVTFDRLQVL 64	Qy	5 SMSYTWGALITPCAAEESKLPIINALSNSLRLHNLVYSTTSRASILRKKVTFDRLQVL 64
Db	5 SMSYTWGALITPCAAEESKLPIINALSNSLRLHNLVYSTTSRASILRKKVTFDRLQVL 64	Db	5 SMSYTWGALITPCAAEESKLPIINALSNSLRLHNLVYSTTSRASILRKKVTFDRLQVL 64
Qy	65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSFKFGYAKDVRSLSSRAVNHIR 124	Qy	65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSFKFGYAKDVRSLSSRAVNHIR 124

Db	65 DHYRDVKEIKAKASTVAKLISITEBACTLTPHSARKFYGAKDVRNLSSKATNIR	124	Qy	65 DDHYRDVKEIKAKASTVAKLISITEBACTLTPHSARKFYGAKDVRNLSSKATNIR	124
Qy	125 SWVDLLEDTPDQTTINAKNEFCVQPEBGGKRPARIIFPDLGVRCEKALYDVVS	184	Db	65 DDHYRDVKEIKAKASTVAKLISITEBACTLTPHSARKFYGAKDVRNLSSKATNIR	124
Db	125 SWVDLLEDTPDQTTINAKNEFCVQPEBGGKRPARIIFPDLGVRCEKALYDVVS	184	Qy	125 SWVKDLLEDTPDQTTINAKNEFCVQPEBGGKRPARIIFPDLGVRCEKALYDVVS	184
Qy	185 TLPOAVMGSSYGFQYSPKRVEFLYNTWKAKKCPMGFSYDTRCDSTVENDIRVEESY	244	Qy	185 TLPOAVMGSSYGFQYSPKRVEFLYNTWKAKKCPMGFSYDTRCDSTVENDIRVEESY	244
Db	185 TLPOAVMGSSYGFQYSPKRVEFLYNTWKAKKCPMGFSYDTRCDSTVENDIRVEESY	244	Db	125 SWVKDLQDTPDQTTINAKNEFCVQPEBGGKRPARIIFPDLGVRCEKALYDVVS	184
Qy	245 QCCDLAPEARQAISSLTERLYGGPMNTSKQNGCYRRCRASGVLTTSCGNTLTCYKAA	304	Qy	185 TLPOAVMGSSYGFQYSPKRVEFLYNTWKAKKCPMGFSYDTRCDSTVENDIRVEESY	244
Db	245 QCCDLAPEARQAISSLTERLYGGPMNTSKQNGCYRRCRASGVLTTSCGNTLTCYKAA	304	Qy	245 QCCDLAPEARQAISSLTERLYGGPMNTSKQNGCYRRCRASGVLTTSCGNTLTCYKAA	304
Qy	305 AACRAAKLQDCTMLVGGDLVVICESAGTOQDAASLRVFTTEAMTRYSAPPGDPPQPEYDL	364	Qy	245 QCCDLAPEARQAISSLTERLYGGPMNTSKQNGCYRRCRASGVLTTSCGNTLTCYKAA	304
Db	305 AACRAAKLQDCTMLVGGDLVVICESAGTOQDAASLRVFTTEAMTRYSAPPGDPPQPEYDL	364	Db	245 QCCDLAPEARQAISSLTERLYGGPMNTSKQNGCYRRCRASGVLTTSCGNTLTCYKAA	304
Qy	365 ELITSCSSNVSVAHDASGRVYYLTTRDPTVPLARAAWETARHTFVNWSLGNIIIMYAPTLW	424	Qy	365 ELITSCSSNVSVAHDASGRVYYLTTRDPTVPLARAAWETARHTFVNWSLGNIIIMYAPTLW	424
Db	365 ELITSCSSNVSVAHDASGRVYYLTTRDPTVPLARAAWETARHTFVNWSLGNIIIMYAPTLW	424	Db	365 ELITSCSSNVSVAHDASGRVYYLTTRDPTVPLARAAWETARHTFVNWSLGNIIIMYAPTLW	424
Qy	425 ARMLTMTHFFSIIIAQEQLEKALDCQIYGACYSTEPLDLPQIILERLHGLSAFSLHSYSPG	484	Qy	425 ARMLTMTHFFSIIIAQEQLEKALDCQIYGACYSTEPLDLPQIILERLHGLSAFSLHSYSPG	484
Db	425 ARMLTMTHFFSIIIAQEQLEKALDCQIYGACYSTEPLDLPQIILERLHGLSAFSLHSYSPG	484	Db	425 ARMLTMTHFFSIIIAQEQLEKALDCQIYGACYSTEPLDLPQIILERLHGLSAFSLHSYSPG	484
Qy	485 EINRVAASCRLKGYPPRLWRHRSVRAKLSQSGGRAICGKYLFWAVRTKLKLTPIP	544	Qy	485 EINRVAASCRLKGYPPRLWRHRSVRAKLSQSGGRAICGKYLFWAVRTKLKLTPIP	544
Db	485 EINRVAASCRLKGYPPRLWRHRSVRAKLSQSGGRAICGKYLFWAVRTKLKLTPIP	544	Db	485 EINRVAASCRLKGYPPRLWRHRSVRAKLSQSGGRAICGKYLFWAVRTKLKLTPIP	544
Qy	545 AASRLDLSGMFVAGYSGGDLYHSLRSA	571	Qy	545 AASRLDLSGMFVAGYSGGDLYHSLRSA	571
Db	545 AASRLDLSGMFVAGYSGGDLYHSLRSA	571	Db	545 AASRLDLSGMFVAGYSGGDLYHSLRSA	571
<hr/>					
RESULT 10					
Q66N78	PRELIMINARY;	PRT;	571 AA.		
ID	Q66N78	PRELIMINARY;	PRT;	571 AA.	
AC	Q66N78;	PRELIMINARY;	PRT;	571 AA.	
DT	25-OCT-2004 (TREMBLrel. 28, Created)	AC	Q66N78;	PRELIMINARY;	PRT;
DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)	DT	Q66N78;	PRELIMINARY;	PRT;
DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)	DT	Q66N78;	PRELIMINARY;	PRT;
DE	Polypeptide (Fragment).	DT	Q66N78;	PRELIMINARY;	PRT;
OS	Hepatitis C virus.	DT	Q66N78;	PRELIMINARY;	PRT;
OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;	DT	Q66N78;	PRELIMINARY;	PRT;
OC	Reoviruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;	DT	Q66N78;	PRELIMINARY;	PRT;
OX	NCBI_TaxID=11103;	DT	Q66N78;	PRELIMINARY;	PRT;
RN	[1]	RNA	[1]	SEQUENCE FROM N.A.	
RP	SEQUENCE FROM N.A.	RA	Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,		
RA	Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,	RA	Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,		
RA	Kleiner D., Holman S., Augenbraun M., Taylor J.,	RA	Kleiner D., Holman S., Augenbraun M., Taylor J.,		
RT	"Sequence Analysis of Hepatitis C Virus Replication Functions in	RT	"Sequence Analysis of Hepatitis C Virus Replication Functions in		
RT	HCV/HIV Coinfected Subjects";	RT	HCV/HIV Coinfected Subjects";		
RL	Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.	RL	Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.		
DR	InterPro; IPR002166; HCV_RdRP.	DR	InterPro; IPR002166; HCV_RdRP.		
DR	InterPro; IPR007095; RNA_pol_DS_PS.	DR	InterPro; IPR007095; RNA_pol_DS_PS.		
DR	InterPro; IPR007094; RNA_pol_PSVir.	DR	InterPro; IPR007094; RNA_pol_PSVir.		
DR	PFam; PF00998; Viral_RdRP; 1.	DR	PFam; PF00998; Viral_RdRP; 1.		
KW	Polypeptide.	KW	Polypeptide.		
FT	NON_TER	FT	NON_TER	1	
FT	NON_TER	FT	NON_TER	1	
SQ	SEQUENCE 571 AA; 63360 MW;	SQ	SEQUENCE 571 AA; 63254 MW;	475D81341A64631B CRC64;	
Query Match	92.9%	Score 2837; DB 2;	Score 2837; DB 2;	Length 571;	
Best Local Similarity	94.7%	Pred. No. 4 8e-215;	Best Local Similarity 94.5%;	Pred. No. 4 8e-215;	
Matches 537;	Conservative 17;	Indels 0; Gaps 0;	Matches 536;	Mismatches 18; Indels 0; Gaps 0;	
Qy	5 SMSYTWTGALLTCAAEESKLPINALSNSLRRHENLYSTTSSASLRRQKTYFDRQYL	64	5 SMSYTWTGALLTCAAEESKLPINALSNSLRRHENLYSTTSSASLRRQKTYFDRQYL	64	
Db	5 SMSYTWTGALLTCAAEESKLPINALSNSLRRHENLYSTTSSASLRRQKTYFDRQYL	64	5 SMSYTWTGALLTCAAEESKLPINALSNSLRRHENLYSTTSSASLRRQKTYFDRQYL	64	

Qy	65 DDHYRDVLKEMKAKASTVKAKLSSVEBACKUTPPHSAKSFKGYAKDVSLSRAVNHIR 124	5 SMSYTTWGTGALITPCAAEESKLPIINALNSLRLRHNLVYSTTSRASLROCKVTFDRLQVL 64
Db	65 DKHYQDVLKEMKAKASTVKAKLSSVEACKUTPPHSAKSFKGYAKDVSLSRAVNHIR 124	65 DDHYRDVLKEMKAKASTVKAKLSSVEACKUTPPHSAKSFKGYAKDVSLSRAVNHIR 124
Qy	125 SWWDQDLEDTPIOPTIMMANEVFCVOPKEKGKRPARLIVTPDILGVRVCEKMLDYVS 184	65 DDHYRDVLKEMKAKASTVKAKLSSVEACKUTPPHSAKSFKGYAKDVSLSRAVNHIR 124
Db	125 SWWDQDLEDNPIDTTIMMANEVFCVOPKEKGKRPARLIVTPDILGVRVCEKMLDYVS 184	125 SWWDQDLEDTPIOPTIMMANEVFCVOPKEKGKRPARLIVTPDILGVRVCEKMLDYVS 184
Qy	185 TLPOAVMGSSYGFQSPKQVRVFBELVNTWKAKKCPMGFSYDTRCFUSTVENDIRVEESTY 244	125 SWWDQDLEDTPIOPTIMMANEVFCVOPKEKGKRPARLIVTPDILGVRVCEKMLDYVS 184
Db	185 TLPOAVMGSSYGFQSPKQVRVFBELVNTWKAKKCPMGFSYDTRCFUSTVENDIRVEESTY 244	125 SWWDQDLEDTPIOPTIMMANEVFCVOPKEKGKRPARLIVTPDILGVRVCEKMLDYVS 184
Qy	245 QCCDLAPEARQAISSLTERLYVGPMNTSKQNCQGYRRCAASGLTTSCNTLTCYLKAA 304	185 TLPOAVMGSSYGFQSPKQVRVFBELVNTWKAKKCPMGFSYDTRCFUSTVENDIRVEESTY 244
Db	245 QCCDLAPEARQAISSLTERLYVGPMNTSKQNCQGYRRCAASGLTTSCNTLTCYLKAA 304	185 TLPOAVMGSSYGFQSPKQVRVFBELVNTWKAKKCPMGFSYDTRCFUSTVENDIRVEESTY 244
Qy	305 AACRAAKLQDQTMVLNGDDLVVICESAGTQDAASLRVFTBAMTRYSAPPGDPPQEYDL 364	245 QCCDLAPEARQAISSLTERLYVGPMNTSKQNCQGYRRCAASGLTTSCNTLTCYLKAA 304
Db	305 AACRAAKLQDQTMVLNGDDLVVICESAGTQDAASLRVFTBAMTRYSAPPGDPPQEYDL 364	245 QCCDLAPEARQAISSLTERLYVGPMNTSKQNCQGYRRCAASGLTTSCNTLTCYLKAA 304
Qy	365 ELITSCSNVSYVAHDASGKRVVYLTRDPTPLARAWEARTHTPNSLGNINIYAPTLM 424	305 AACRAAKLQDQTMVLNGDDLVVICESAGTQDAASLRVFTBAMTRYSAPPGDPPQEYDL 364
Db	365 ELITSCSNVSYVAHDASGKRVVYLTRDPTPLARAWEARTHTPNSLGNINIYAPTLM 424	365 ELITSCSNVSYVAHDASGKRVVYLTRDPTPLARAWEARTHTPNSLGNINIYAPTLM 424
Qy	425 ARMILMTHFFSILLAQEQLKALDCQIYGACYSISPLDLQPIIERTLHGLSAPSLSLHSYSPG 484	365 ELITSCSNVSYVAHDASGKRVVYLTRDPTPLARAWEARTHTPNSLGNINIYAPTLM 424
Db	425 ARMILMTHFFSILLAQEQLKALDCQIYGACYSISPLDLQPIIERTLHGLSAPSLSLHSYSPG 484	365 ELITSCSNVSYVAHDASGKRVVYLTRDPTPLARAWEARTHTPNSLGNINIYAPTLM 424
Qy	485 EINRVASCLRLGVPPPLRVHRARSVRAKLSQSGRAATGKYLLENWAVTRKLTKLTPIP 544	425 ARMILMTHFFSILLAQEQLKALDCQIYGACYSISPLDLQPIIERTLHGLSAPSLSLHSYSPG 484
Db	485 EINRVASCLRLGVPPPLRVHRARSVRAKLSQSGRAATGKYLLENWAVTRKLTKLTPIP 544	425 ARMILMTHFFSILLAQEQLKALDCQIYGACYSISPLDLQPIIERTLHGLSAPSLSLHSYSPG 484
Qy	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571	485 EINRVASCLRLGVPPPLRVHRARSVRAKLSQSGRAATGKYLLENWAVTRKLTKLTPIP 544
Db	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571	485 EINRVASCLRLGVPPPLRVHRARSVRAKLSQSGRAATGKYLLENWAVTRKLTKLTPIP 544
RESUL 12		545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571
Q66N74	PRELIMINARY;	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571
ID	Q66N74	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571
AC	Q66N74;	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571
DT	25-OCT-2004 (TREMBLrel. 28, Created)	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571
DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571
DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)	545 AASRLDLSGMWVAGYSGGGDTYHSLSRA 571
DB		
OS		
OC		
OC		
OC		
OX		
RN		
RP	SEQUENCE FROM N.A.	
RA	Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S., Kleiner D., Holman S., Augenbraun M., Taylor J.,	
RA	"Sequence Analysis of Hepatitis C Virus Replication Functions in HCV/HIV Coinfected Subjects.",	
RT	Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.	
RL	EMBL: AY82789; AAU08345; 1.	
DR	InterPro: IPR002166; HCV_RdrP;	
DR	InterPro: IPR007095; RNA_Pol_DS_Ps.	
DR	InterPro: IPR007094; RNA_Pol_PsVir.	
DR	Pfam: PF09998; Viral_RdrP; 1.	
KW	Polyprotein.	
FT	NON_TER 1	1
FT	NON_TER 571	571
SQ	SEQUENCE 571 AA; 63220 MW;	63492 MW; 111E17000D53EBBC CRC64;
Query Match	92.8%; Score 2836; DB 2; Length 571;	92.3%; Score 2820; DB 2; Length 571;
Best Local Similarity	94.0%; Fred. No. 5.7e-215;	Best Local Similarity 94.0%; Pred. No. 1e-213;
Matches	533; Conservative 23; Mismatches 11; Indels 0; Gaps 0;	Matches 533; Conservative 20; Mismatches 14; Indels 0; Gaps 0;
Qy	5 SMSYTTWGTGALITPCAAEESKLPIINALNSLRLRHNLVYSTTSRASLROCKVTFDRLQVL 64	5 SMSYTTWGTGALITPCAAEESKLPIINALNSLRLRHNLVYSTTSRASLROCKVTFDRLQVL 64

5 SMSYTWTGALLTPCAAEESKLPINALNSLRRHNMVYATTSRSASQRKQVTFDRMQLV 64
 5 SMSYTWTGALLTPCAAEESKLPINALNSLRRHNMVYATTSRSASQRKQVTFDRMQLV 64
 Db 65 DDHYRDVLKEMKAKASTVKLILSVEACKLTTPHSASAKSKPGYAKDVSLSRAVNHIR 124
 QY 65 DDHYRDVLKEMKAKASTVKLILSVEACKLTTPHSASAKSKPGYAKDVSLSRAVNHIR 124
 Db 125 SWVQKOLLEDTPLOTTIMAKNEYFCVQPKPGKPKPARLIVFPLGIVRCERKALYDVVS 184
 QY 125 SWVQKOLLEDTPLOTTIMAKNEYFCVQPKPGKPKPARLIVFPLGIVRCERKALYDVVS 184
 Db 125 SWVQKOLLEDTPLOTTIMAKNEYFCVQPKPGKPKPARLIVFPLGIVRCERKALYDVVS 184
 QY 185 TLPOAVMGSSYGFQYSPKQRFVLYNTWAKKCPMGFSYDTRCPDSTVENDIRVEESLY 244
 Db 185 TLPOAVMGSSYGFQYSPKQRFVLYNTWAKKCPMGFSYDTRCPDSTVENDIRVEESLY 244
 QY 185 TLPOAVMGSSYGFQYSPKQRFVLYNTWAKKCPMGFSYDTRCPDSTVENDIRVEESLY 244
 Db 185 TLPOAVMGSSYGFQYSPKQRFVLYNTWAKKCPMGFSYDTRCPDSTVENDIRVEESLY 244
 QY 245 QCCDLAPEARQAIRSLTLLRVLQYGGPMTNSKQNGCYRRCRASGVLTTSGNTLTCYLKA 304
 Db 245 QCCDLAPEARQAIRSLTLLRVLQYGGPMTNSKQNGCYRRCRASGVLTTSGNTLTCYLKA 304
 QY 305 AACRAAKLQDCTMLVNGDDIVICESAGTOQDAASLRVTEAMTRYSAPPGDPQPEYDL 364
 Db 305 AACRAAKLQDCTMLVNGDDIVICESAGTOQDAASLRVTEAMTRYSAPPGDPQPEYDL 364
 QY 365 ELITSCSSNSVVAHDASGRVYLTTRDTPVPLARAANWTAHTPVNSLGN1IMYAPLW 424
 Db 365 ELITSCSSNSVVAHDASGRVYLTTRDTPVPLARAANWTAHTPVNSLGN1IMYAPLW 424
 QY 365 ELITSCSSNSVVAHDASGRVYLTTRDTPVPLARAANWTAHTPVNSLGN1IMYAPLW 424
 Db 365 ELITSCSSNSVVAHDASGRVYLTTRDTPVPLARAANWTAHTPVNSLGN1IMYAPLW 424
 QY 425 ARMLLMTHFFSILLAQOLEKALDQIYACYSTEPLDLPQIYERLHGSAFSLHSYSPG 484
 Db 425 ARMLLMTHFFSILLAQOLEKALDQIYACYSTEPLDLPQIYERLHGSAFSLHSYSPG 484
 QY 485 EINRVASCLRKLGVPPLRWRHARSVRAKLSOGRAATCGYLFENAVRTKLKLTP 544
 Db 485 EINRVASCLRKLGVPPLRWRHARSVRAKLSOGRAATCGYLFENAVRTKLKLTP 544
 QY 545 AASRLDLSGMWVAGYSGGDIYHSLRA 571
 Db 545 AASRLDLSGMWVAGYSGGDIYHSLRA 571
 QY 545 AASRLDLSGMWVAGYSGGDIYHSLRA 571
 Db 545 AASRLDLSGMWVAGYSGGDIYHSLRA 571

RESULT 14
 Q66NB0 PRELIMINARY; PRT; 571 AA.
 ID Q66NB0 PRELIMINARY; PRT; 571 AA.
 AC Q66NA7 PRELIMINARY; PRT; 571 AA.
 DT 25-OCT-2004 (TREMBLrel. 28, Created)
 DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)
 DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)
 DE Polyprotein (Fragment).
 OS Hepatitis C virus.
 OC Viruses; ssRNA positive-strand viruses, no DNA stage: Flaviviridae;
 OC Hepacivirus.
 OX NCBI_TaxID=11103;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
 RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
 RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
 RT HCV/HIV Coinfected Subjects.", Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY682752; AAU08309; 1.
 DR InterPro; IPR002166; HCV_RdRP.
 DR InterPro; IPR007095; RNA_pol_DS_PS.
 DR InterPro; IPR007094; RNA_pol_PSVir.
 KW Pfam; PF00998; Viral_RdRP; 1.
 FT NON_TER 1 1
 FT NON_TER 571 571
 SQ SEQUENCE 571 AA; 63097 MW; C02E7328F3417842 CRC64;

Query Match 91.8%; Score 2803; DB 2; Length 571;
 Best Local Similarity 9.5%; Pred. No. 2.3e-212;
 Matches 530; Conservative 21; Mismatches 16; Indels 0; Gaps 0;
 SQ SEQUENCE 571 AA; 62829 MW; 1EB09F6368B4B729 CRC64;
 Query Match 87.7%; Score 2679; DB 2; Length 571;
 Best Local Similarity 88.7%; Pred. No. 1.4e-202;
 Matches 503; Conservative 29; Mismatches 35; Indels 0; Gaps 0;

RESULT 15
 Q66NA7 PRELIMINARY; PRT; 571 AA.
 ID Q66NA7 PRELIMINARY; PRT; 571 AA.
 AC Q66NA7 PRELIMINARY; PRT; 571 AA.
 DT 25-OCT-2004 (TREMBLrel. 28, Created)
 DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)
 DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)
 DE Polyprotein (Fragment).
 OS Hepatitis C virus.
 OC Viruses; ssRNA positive-strand viruses, no DNA stage: Flaviviridae;
 OC Hepacivirus.
 OX NCBI_TaxID=11103;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
 RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
 RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
 RT HCV/HIV Coinfected Subjects.", Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY682755; AAU08312; 1.
 DR InterPro; IPR002166; HCV_RdRP.
 DR InterPro; IPR007095; RNA_pol_DS_PS.
 DR InterPro; IPR007094; RNA_pol_PSVir.
 KW Pfam; PF00998; Viral_RdRP; 1.
 FT NON_TER 1 1
 FT NON_TER 571 571
 SQ SEQUENCE 571 AA; 62829 MW; 1EB09F6368B4B729 CRC64;

Query Match 87.7%; Score 2679; DB 2; Length 571;
 Best Local Similarity 88.7%; Pred. No. 1.4e-202;
 Matches 503; Conservative 29; Mismatches 35; Indels 0; Gaps 0;

Qy	5	SMSYTWTGALITPCAAEESKPKINALNSLIRHNLVYSTSRSASLROKKVTPDRQLV	64
Db	5	SMSYSMTGALITPCAAEESKPKINALNSLIRHNLVYSTSRSASLROKKVTPDRQLV	64
Qy	65	DHYRDVLKEMKAKASTVKRLLSYEACLTTPHSAKSXKGYAKDVSLSRAVNHIR	124
Db	65	DHYRDVLKEMKAKASTVKRLLSYEACLTTPHSAKSXKGYAKDVSLSRAVNHIR	124
Qy	125	SYWDOLLEDTPICOTIMARNEVCQPKGGREPARLIVFPD1GVRVCEKMLYDVVS	184
Db	125	SYWDOLLEDTPICOTIMARNEVCQPKGGREPARLIVFPD1GVRVCEKMLYDVVS	184
Qy	185	TLPOAVMGSSSYGFOYSPKQRYEFLINTWKCKPMGSYDTRCPDSTVENDIRYESTY	244
Db	185	KLPOAVMGSSSYGFOYSPKQRYEFLINTWKCKPMGSYDTRCPDSTVENDIRYESTY	244
Qy	245	QCCDLAPEAROAIRSSTERLYGGPMNTNSKGQNCCSYRRCASGVLTSCNTLTCYKAA	304
Db	245	QCCDLDPQARVAIKSLITERLYGGPLTSRGENCYRRCAASGVLTSCNTLTCYKAA	304
Qy	305	AACRAAKLQDQTMLYNGDDLVVICSAGTQDAAASURVTEAMTRYSAPEGDPPQPEYDL	364
Db	305	AACRAAGLQDQTMLYCGDDLVVICSAGTQDAAASURVTEAMTRYSAPEGDPPQPEYDL	364
Qy	365	ELITSCSSNVSYAHADSGKRYVYLTRDPTPLARAWETARTHPTNSWGNINMAYPTW	424
Db	365	ELITSCSSNVSYAHADSGKRYVYLTRDPTPLARAWETARTHPTNSWGNINMAYPTW	424
Qy	425	ARMILMTHFFSILLAQOLEKALDQOYGAQCYSTEPLDIPQIITERLHGLSAFSLHSYSPG	484
Db	425	ARMILMTHFFSILLAQOLEKALDQOYGAQCYSTEPLDIPQIITERLHGLSAFSLHSYSPG	484
Qy	485	EINRYAACLRLGVPPLRVRHRAVSRAKLSQSGRAAICGKYLNFNWAUTKULKLTPIP	544
Db	485	EINRYAACLRLGVPPLRVRHRAVSRAKLSQSGRAAICGKYLNFNWAUTKULKLTPIP	544
Qy	545	ASRDLLSGMFVAGYSGGDYHISRA	571
Db	545	AAGQDLSGMFVAGYSGGDYHISRA	571

This Page Blank (uspto)

BLOSUM62						
Gapext 10.0 , Gapext 0.5						
513545 seqs, 74649064 residues						
al number of hits satisfying chosen parameters: 489056						
Maximum Match 0%						
Listing first 45 summaries						
Database : Issued Patents AA.*						
1:	/cgn2_6/prodata/1/iaa/SA_COMB.pep:*					Sequence 1, Appli
2:	/cgn2_6/prodata/1/iaa/5B_COMB.pep:*					Sequence 10, Appli
3:	/cgn2_6/prodata/1/iaa/6A_COMB.pep:*					Sequence 15, Appli
4:	/cgn2_6/prodata/1/iaa/6B_COMB.pep:*					Sequence 6, Appli
5:	/cgn2_6/prodata/1/iaa/PCTRUS_COMB.pep:*					Sequence 6, Appli
6:	/cgn2_6/prodata/1/iaa/backfile1.pep:*					Sequence 6, Appli
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.						
SUMMARIS						
Query	Match	Length	DB	ID	Description	
No.	Score					
1	2879	94.2	576	4	US-09-541-990A-1	
2	1124	36.8	496	3	US-09-867-611-10	
3	1124	36.8	496	4	US-09-690-359-10	
4	1124	36.8	496	5	PCT-US92-0965A15	
5	908	29.7	504	1	US-07-853-985A-6	
6	908	29.7	504	1	US-07-681-703B-6	
7	908	29.7	504	1	US-08-184-236-6	
8	908	29.7	504	1	US-08-407-410B-6	
9	908	29.7	504	2	US-08-485-500-6	
10	908	29.7	504	5	PCT-US91-02370-6	
11	908	29.7	504	5	PCT-US94-04174-6	
12	884	28.9	187	1	US-07-853-385A-2	
13	884	28.9	187	1	US-07-681-703B-2	
14	884	28.9	187	1	US-08-184-236-2	
15	884	28.9	187	2	US-08-407-510B-2	
16	884	28.9	187	2	US-08-485-500-2	
17	884	28.9	187	5	PCT-US91-02370-2	
18	884	28.9	187	5	PCT-US94-04174-2	
19	759	24.8	152	3	US-08-444-818-62	
20	748	24.5	171	3	US-08-444-818-58	
21	686	22.5	387	3	US-08-867-611-12	
22	686	22.5	387	4	US-09-690-359-12	
23	686	22.5	387	5	PCT-US92-06965A17	
24	678	22.2	156	5	PCT-US94-04174-19	
25	621	20.3	133	3	US-08-444-818-60	
26	20.1	393	133	3	US-08-867-611-14	
27	613.5	20.1	393	4	US-09-690-359-14	

RESULT 1
US-09-541-990A-1
; Sequence 1, Application US/09541990A
; Patent No. 6434489
; GENERAL INFORMATION:
; APPLICANT: Lesburg, Charles A.
; APPLICANT: Cable, Michael
; APPLICANT: Hong, Zhi
; APPLICANT: Manarino, Anthony
; APPLICANT: Weber, Patricia
; TITLE OF INVENTION: Compositions of Hepatitis C Virus NSSB Polymerase and Methods for Crystallizing Same
; TITLE OF INVENTION: Methods for Crystallizing Same
; FILE REFERENCE: IN0998 US
; CURRENT APPLICATION NUMBER: US/09/541, 990A
; CURRENT FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn ver. 2.1
SEQ ID NO 1
; LENGTH: 576
; TYPE: PRT
; ORGANISM: Hepatitis C virus
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (335)
; OTHER INFORMATION: amino acids at 335, 344 and 550 may be threonine
; OTHER INFORMATION: or valine at 335, valine or alanine at 344 and
; OTHER INFORMATION: arginine or glutamine at 550
US-09-541-990A-1

ALIGNMENTS

Query	Match	Score	Length	Best Local Similarity	Best Local Similarity	Best Local Similarity	Best Local Similarity
Qy	7 SYWTGALITPCAAESEKLPINALSNLLRHNLYVSTTSRSASLRQKVTFDLQLVQDD	94.2%	576	96.0%	96.0%	96.0%	96.0%
Db	9 SYWTGALITPCAAESEKLPINALSNLLRHNMYATTTSRSASLRQKVTFDLQLVQDD	94.2%	576	96.0%	96.0%	96.0%	96.0%
Qy	67 HYRDLIKEMKAKASTYKAKLISVEACKLTPPHSAKSFKPGKPARLIVPDLGVRCEKMAVYVSTL	94.2%	576	96.0%	96.0%	96.0%	96.0%
Db	69 HYRDLIKEMKAKASTYKAKLISVEACKLTPPHSAKSFKPGKPARLIVPDLGVRCEKMAVYVSTL	94.2%	576	96.0%	96.0%	96.0%	96.0%
Qy	127 WKDLIILEDTPDPIQTTIMAKNEVFCVQPEKGGKPKPARLIVPDLGVRCEKMAVYVSTL	94.2%	576	96.0%	96.0%	96.0%	96.0%
Db	129 WKDLIILEDTPDPIQTTIMAKNEVFCVQPEKGGKPKPARLIVPDLGVRCEKMAVYVSTL	94.2%	576	96.0%	96.0%	96.0%	96.0%
Qy	187 PQAVNGSSYKQYSPQSPQRVEFLVNTWKAKKCPMGFSYDTRCFDSTVENDIRVEESIYQC	94.2%	576	96.0%	96.0%	96.0%	96.0%
Db	189 PQVNGSSYKQYSPQSPQRVEFLVNTWKSCKNPMGFSYDTRCFDSTVENDIRVEESIYQC	94.2%	576	96.0%	96.0%	96.0%	96.0%
Ov	247 CDLAEAROAIRSLSTERLYVCGPMTNSKGONGCYRRCASGVLTTSCGNTLTTCYKAAAA	94.2%	576	96.0%	96.0%	96.0%	96.0%

RESULT 2
US-08-867-611-10
Application US/08667611
Patent No. 6172.189
GENERAL INFORMATION:
APPLICANT: DEVARE, SUSHIL G
APPLICANT: DESAI, SURESH M
APPLICANT: CASEY, JAMES M
APPLICANT: DAILEY, STEPHEN H
APPLICANT: DAWSON, GEORGE J
APPLICANT: GUTIERREZ, ROBIN A
APPLICANT: LESNIOWSKI, RICHARD R
APPLICANT: STEWART, JAMES L
APPLICANT: RUPRECHT, KEVIN R
TITLE OF INVENTION: HEPATITIS C ASSAY UTILIZING RECOMBINANT
TITLE OF INVENTION: HEPATITIS C ASSAY UTILIZING RECOMBINANT
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: ABBOTT LABORATORIES
STREET: ONE ABBOTT PARK ROAD, CHAD377/AP6D2
CITY: ABBOTT PARK
STATE: IL
COUNTRY: USA
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/867,611
FILING DATE: 02-JUN-1997
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/08/646,757
FILING DATE:
APPLICATION NUMBER: US/08/179,896
FILING DATE:
APPLICATION NUMBER: US/07/572,822
FILING DATE: 24-AUG-1990
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/07/614,069
FILING DATE: 07-NOV-1990
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/07/748,561
FILING DATE: 21-AUG-1991
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/07/748,565
FILING DATE: 21-AUG-1991

FILING DATE: 21-AUG-1991
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/07/748,566
FILING DATE: 21-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: POREMBSKI, PRISCILLA B
REGISTRATION NUMBER: 33,207
REFERENCE/DOCKET NUMBER: 4834.US.E6
TELECOMMUNICATION INFORMATION:
TELEPHONE: 708-937-6365
TELEFAX: 708-937-9856
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 496 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-867-611-10

Query Match 36.8% Score 1124; DB 3; Length 496;
Best Local Similarity 84.8% Pred. No. 2, 4e-10;
Matches 212; Conservative 14; Mismatches 24; Indels 0; Gaps 0;

Qy 64 LDHYDHYDYLKEMKAKASTYKAKLSSVERACKLTPPHSAKSFKPGYAKDVKRSLSRVAVTHI 123
Db 247 LDHYDHYDYLKEMKAKASTYKAKLSSVERACKLTPPHSAKSFKPGYAKDVKRSLSRVAVTHI 306

Qy 124 RSWKDLILEDTOPIQITIMAKNEVFCQPEKGGRKPKRLLIVPDIGTRVCEMAYVY 183
Db 307 NSWWDLILEDNTVNPIDTFCQPEKGGRKPKRLLIVPDIGTRVCEMAYVY 366

Qy 184 STLFQAVNMGSSYGFQSPQRVEFLVNTWKAKKCPMGFSYDTRCFSDSTVENDRVESSI 243
Db 367 TQCDLAVWGSIGPQYSQRVEFLVQAWKSXKTPMGFSYDTRCFSDSTVENDRVESSI 426

Qy 244 YQCCDLPAAEORATRSLTERLYGPGMTNSKGONGYTRCRASGVLTSGNTLTCY1KA 303
Db 427 YQCCDLPDPQARVAKSLTERLYGGPLNTSGNTLTCY1KA 486

Qy 304 AAACRAAQLQ 313
Db 487 AAACRAAQLQ 496

RESULT 3
US-09-690-359-10
Sequence 10, Application US/09690359
Patent No. 6591083
GENERAL INFORMATION:
APPLICANT: DEVARE, SUSHIL G
APPLICANT: DESAI, SURESH M
APPLICANT: CASEY, JAMES M
APPLICANT: DAILEY, STEPHEN H
APPLICANT: DAWSON, GEORGE J
APPLICANT: GUTIERREZ, ROBIN A
APPLICANT: LESNIOWSKI, RICHARD R
APPLICANT: STEWART, JAMES L
APPLICANT: RUPRECHT, KEVIN R
TITLE OF INVENTION: HEPATITIS C ASSAY UTILIZING RECOMBINANT
TITLE OF INVENTION: HEPATITIS C ASSAY UTILIZING RECOMBINANT
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: ABBOTT LABORATORIES
STREET: ONE ABBOTT PARK ROAD, CHAD377/AP6D2
CITY: ABBOTT PARK
STATE: IL
COUNTRY: USA
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/867,611
FILING DATE: 02-JUN-1997
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/08/646,757
FILING DATE:
APPLICATION NUMBER: US/08/179,896
FILING DATE:
APPLICATION NUMBER: US/07/572,822
FILING DATE: 24-AUG-1990
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/07/614,069
FILING DATE: 07-NOV-1990
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/07/748,561
FILING DATE: 21-AUG-1991
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/07/748,565
FILING DATE: 21-AUG-1991

COMPUTER: IBM PC compatible
 SOFTWARE: PC-DOS/MS-DOS
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/853, 985A
 FILING DATE: 1992/03/20
 CLASSIFICATION: 435
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US/07/505, 611
 FILING DATE: 06/APR/1990
 APPLICATION NUMBER: US/07/594, 854
 FILING DATE: 09/OCT/1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Dehlinger, Peter J.
 REGISTRATION NUMBER: 28, 006
 REFERENCE/DOCKET NUMBER: 4600-0076-22
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415-324-0880
 TELEFAX: 415-324-0960
 MOLECULE TYPE: protein
 US-07-853-985A-6

SEQUENCE CHARACTERISTICS:
 LENGTH: 504 amino acids
 TYPE: AMINO ACID
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-07-681-703B-6

Query Match 29.7% Score 908; DB 1; Length 504;
 Best Local Similarity 87.2%; Pred. No. 3.9e-84;
 Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

Qy 5 SWSYTTWGLITPAEAEESLPIALNSLRLRHNLVYSTTSRASLQQKTTFDRLOVL 64
 Db 302 SWSYTTWGLITPAEAEESLPIALNSLRLRHNLVYSTTSRASLQQKTTFDRLOVL 361
 Qy 65 DDHYRDVILKEMKAKASTVAKLISVEACKLTPPHSAKSFKGIGAKDVRSLSSRAVNHIR 124
 Db 362 DSHYQDVKEVKAASAKTVKANLISVEACSLTPPHSAKSFKGIGAKDVRCHARKAVTHIN 421
 Qy 125 SWKDLLEDTDTPIQTTIMAKNEVFCVQPEKGRKPKPARLIVFDDLGVRCEKMALYDVVS 184
 Db 422 SWKDLLEDNTVPLDTTIPDTTMAKNEVFCVQPEKGRKPKPARLIVFDDLGVRCEKMALYDVVT 481
 Qy 185 TLPOAVMGSSYGFQYSPKQRFEF 207
 Db 482 KUPLAVMGSSYGFQYSPQRFEF 504

RESULT 7
 US-08-184-236-6
 Sequence 6, Application US/08184236
 Patent No. 5538865

GENERAL INFORMATION:
 APPLICANT: Reyes, Gregory
 APPLICANT: Kim, Jungsuh P
 APPLICANT: Moekkli, Randolph
 TITLE OF INVENTION: Hepatitis C Virus Epitopes
 NUMBER OF SEQUENCES: 10
 ZIP: 94306

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Dehlinger & Associates
 STREET: 350 Cambridge Ave., Suite 250
 CITY: Palo Alto
 STATE: CA
 COUNTRY: USA

NUMBER OF SEQUENCES: 55
 ZIP: 94306

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.24
 APPLICATION NUMBER: US/08/184,236

CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/07/505, 611
 FILING DATE: 06/APR/1990
 APPLICATION NUMBER: US/07/594, 854
 FILING DATE: 09/OCT/1990

APPLICATION NUMBER: US 07/853,985
 PILING DATE: 20-MAR-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Fabian, Gary R.
 REGISTRATION NUMBER: 33,875
 REFERENCE/DOCKET NUMBER: 4600-0113
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415-324-0880
 TELEFAX: 415-324-0960
 INFORMATION FOR SEQ ID NO: 6:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 504 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-184-236-6

Query Match 29.7%; Score 908; DB 1; Length 504;
 Best Local Similarity 87.2%; Pred. No. 3.9e-84;
 Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;
 US-08-407-410B-6

Query Match 29.7%; Score 908; DB 2; Length 504;
 Best Local Similarity 87.2%; Pred. No. 3.9e-84;
 Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;
 US-08-407-410B-6

Query 5 SMSSYWTGALITPCKAEEESKLPIINALNSLRLRHNLVYSTTSRASLRLRKVTKTFRDLQVL 64
 Db 302 SMSSYWTGALITPCKAEEESKLPIINALNSLRLRHNLVYSTTSRACQRQKCKVTFRDLQVL 361

Query 5 SMSSYWTGALITPCKAEEESKLPIINALNSLRLRHNLVYSTTSRASLRLRKVTKTFRDLQVL 64
 Db 362 DSHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHR 421

Query 65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHR 124
 Db 422 SWWDLLEDTDTPIOTTIMAKNEVFCVQPEKGGRKPKARLIVFPDYGVRCEKMLDYVS 184

Query 65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHR 124
 Db 422 SWWDLLEDTDTPIOTTIMAKNEVFCVQPEKGGRKPKARLIVFPDYGVRCEKMLDYVS 184

Query 362 DSHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYAKDVRSLSSRAVNHR 421
 Db 482 KLPЛАVMGSSYGFQYSPQRVEF 504

Query 125 SWWDLLEDTDTPIOTTIMAKNEVFCVQPEKGGRKPKARLIVFPDYGVRCEKMLDYVS 184
 Db 482 KLPЛАVMGSSYGFQYSPQRVEF 504

Query 185 TLPQAVMGSYYGFQYSPQRVEF 207
 Db 482 KLPЛАVMGSSYGFQYSPQRVEF 504

RESULT 9

US-08-485-500-6
 Sequence 6, Application US/08485500
 Patent No. 584339

GENERAL INFORMATION:
 APPLICANT: Reyes, Gregory
 APPLICANT: Kim, Jungsub P.
 APPLICANT: Moekli, Randolph
 APPLICANT: Moekli, Randolph
 APPLICANT: Simonsen, Christian C.
 TITLE OF INVENTION: Hepatitis C Virus Epitopes
 NUMBER OF SEQUENCES: 26
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Peter J. Dehlinger
 STREET: 350 Cambridge Ave., Suite 100
 STATE: CA
 ZIP: 94306
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/407,410B
 FILING DATE:
 CLASSIFICATION: 435
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 505,611
 FILING DATE: 06-APR-1990
 PRIORITY APPLICATION NUMBER: US 594,854
 FILING DATE: 09-OCT-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Fabian, Gary R.
 REGISTRATION NUMBER: 33,875
 REFERENCE/DOCKET NUMBER: 4600-076-21
 TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 323-8302
 INFORMATION FOR SEQ ID NO: 6:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 504 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-485-500-6

Query Match 29.7%; Score 908; DB 5; Length 504;
 Best Local Similarity 87.2%; Pred. No. 3.9e-84;
 Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

Qy 5 SMSYTWTGALITCPAAEESKLPIINALSNSLRRHNLVYSTSRSASLRQKVTEDRQLV 64
 Db 302 SMSYTWTGALITCPAAEESKLPIINALSNSLRRHNLVYSTSRSASLRQKVTEDRQLV 361

Qy 65 DDHYRDVLKEMKAKASTYKAKLISVEACKLTPPHSAKSKEFGYAKDVSRSRAVNHIR 124
 Db 362 DSHYQDVLKEMKAKASTYKAKLISVEACKLTPPHSAKSKEFGYAKDVSRSRAVNHIR 421

Qy 125 SWKDLLEDTPDPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCERMALYDVS 184
 Db 422 SWKDLLEDNPVTPDITIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCERMALYDVT 481

Qy 185 TLPOAVMGSSYGFQYSPKQRFV 207
 Db 482 KLPЛАVMGSSYGFQYSPGQRFV 504

RESULT 11
 PCT/US94-04174-6
 Sequence 6 Application PC/TUS9404174
 GENERAL INFORMATION:
 APPLICANT: Reyes, Gregory
 APPLICANT: Kim, Jungsub P.
 APPLICANT: Moekli, Randolph
 TITLE OF INVENTION: HCV Immunodiagnostic Antigens and Antibodies
 NUMBER OF SEQUENCES: 28
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Law Offices of Peter J. Dehlinger
 STREET: 350 Cambridge Avenue, Suite 300
 CITY: Palo Alto
 STATE: CA
 COUNTRY: US
 ZIP: 94306
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US91/02370
 FILING DATE: 19910405
 CLASSIFICATION: 435.5
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 505, 611
 FILING DATE: 06-APR-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 594, 854
 FILING DATE: 09-OCT-1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Fabian, Gary R.
 REGISTRATION NUMBER: 4600-0107
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415-324-0880
 TELEFAX: 415-324-0960
 INFORMATION FOR SEQ ID NO: 6:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 504 amino acids
 TYPE: AMINO ACID
 TOPOLOGY: linear

Qy 5 SMSYTWTGALITCPAAEESKLPIINALSNSLRRHNLVYSTSRSASLRQKVTEDRQLV 64
 Best Local Similarity 87.2%; Pred. No. 3.9e-84;
 Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

Db 302 S M S Y S P T G A L Y T P C A A E Q K Q L P I N A L S N S L I R H N L V Y S T T S R S A C Q R Q K K V T P D R L Q V L 361
 Qy 65 D D H Y D R V L K E M K A K A S T V K A K L L S V E B A C K T P P H I S A K S K F G Y G A K D V S L S S A R V N H R 124
 Db 362 D S H Y D V L K E Y T K A A S K V K A N L L S V E A C S T P P H I S A K S K F G Y G A K D V S L S S A R V N H R 124
 Qy 125 S W V D Q D L E D T P I O T T M A R N E V C V Q P E K G G R K P A R L I V F P D L G V R Y C E K M A L Y D V Y S 184
 Db 422 S W V D Q D L E D T P I D T I M A N E V C V Q P E K G G R K P A R L I V F P D L G V R Y C E K M A L Y D V V T 481
 Qy 185 T L P Q A V M G S S Y G R O Y S P K Q R V B F 207
 Db 482 K L P L A V M G S S Y G R O Y S P G Q R V B F 504

RESULT 13
 US-07-681-703B-2
 ; Sequence 2, Application US/07681703B
 ; Patent No. 5443965
 ; GENERAL INFORMATION:
 ; APPLICANT: Reyes, Gregory
 ; APPLICANT: Kim, Jungsub P.
 ; APPLICANT: Mocekli, Randolph
 ; TITLE OF INVENTION: Hepatitis C Virus Epitopes
 ; NUMBER OF SEQUENCES: 55
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Dehlinger & Associates
 ; STREET: 350 Cambridge Ave., Suite 250
 ; CITY: Palo Alto
 ; STATE: CA
 ; COUNTRY: USA
 ; ZIP: 94306
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/07/681,703B
 ; FILING DATE: 05-APR-1991
 ; CLASSIFICATION: 435
 ; PRIORITY APPLICATION DATA:
 ; NAME: Fabian, Gary R.
 ; REGISTRATION NUMBER: 33,875
 ; REFERENCE/DOCKET NUMBER: 4600-076-21
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (415) 324-0890
 ; INFORMATION FOR SEQ ID NO: 2:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 187 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 US-07-681-703B-2

Query Match 28.9%; Score 884; DB 1; Length 187;
 Best Local Similarity 87.6%; Pred. No. 2.2e-82;
 Matches 163; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
 ; MOLECULE TYPE: protein

US-07-853-985A-2

Query Match 28.9%; Score 884; DB 1; Length 187;
 Best Local Similarity 87.6%; Pred. No. 2.2e-82;
 Matches 163; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
 ; MOLECULE TYPE: protein

Db 206 E F L Y N T W A R K C P M G F S T D R C F D S T V T E N D I R V E S I V Q C C D L A P E A R Q A I R S L T E R Y 265
 Qy 1 E F L Y Q A W K S K K T P M G F S Y D T R C F D S T V T E S I V Q C C D L D P Q A R V A I R S L T E R Y 60
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 187 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein

Db 266 V G G P M T N S K C Q N C G Y T R C R A S G V I T T S C E N T L T C Y L K A A A C R A K Q D C T M L V N G D D L V 325
 Qy 61 V G G P L T N S G E N C G Y T R C R A S G V I T T S C E N T L T C Y L K A A A C R A G L Q D C T M L V C G D D L V 120
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 187 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein

Db 326 V I C R S A G T Q D A A S L R V F E A M T R Y S A P G R Q D P P O P E Y D L E I T S C S S N V S V A H D A S G K R V 385
 Qy 121 V I C R S A G V Q E D A A S L R A T E M T R Y S A P G D P P O P E Y D L E I T S C S S N V S V A H D A S G K R V 180
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 187 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein

Db 386 Y Y L T R D 391

Db 181 YYLTR 186

RESULT 14 US-08-407-410B-2

Sequence 2, Application US/08184236
 Patent No. 5538865
 GENERAL INFORMATION:
 APPLICANT: Reyes, Gregory
 APPLICANT: Kim, Jungsun P.
 APPLICANT: Moekkli, Randolph
 APPLICANT: Simonsen, Christian C.
 TITLE OF INVENTION: Hepatitis C Virus Epitopes
 NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Peter J. Dehlinger
 STREET: 350 Cambridge Ave., Suite 100
 CITY: Palo Alto
 STATE: CA
 COUNTRY: USA
 ZIP: 94306

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.24

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/184,236

FILING DATE: 06-APR-1990

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/505,611

FILING DATE: 09-OCT-1990

APPLICATION NUMBER: US 07/594,854

FILING DATE: 09-OCT-1990

APPLICATION NUMBER: US 07/853,985

FILING DATE: 20-MAR-1992

ATTORNEY/AGENT INFORMATION:

NAME: Fabian, Gary R.

REGISTRATION NUMBER: 33,875

REFERENCE/DOCKET NUMBER: 4600-0113

TELEPHONE: 415-324-0880

TELEFAX: 415-324-0960

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 187 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-407-410B-2

Query Match 28.9%; Score 884; DB 2; Length 187;
 Best Local Similarity 87.6%; Pred. No. 2.2e-82;
 Matches 163; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

Qy 206 EFLINTWAKKCPNGFSYDTRCPDSTVENDIRVEESTYQCDLAPARQASLTERLY 265

Db 1 EFLVQAWNSKTPNGFSYDTRCPDSTVENDIRVEESTYQCDLAPARQASLTERLY 60

Qy 266 VGGPMNTSKQNGYRRCRASGVLTSGNTLTCYLKAAAACRAAKLQDCTMLVNGDOLV 325

Db 61 VGGPLTNRGENCEYRRCRASGVLTSGNTLTCYKARAACAAAGLQDCTMLVCGDOLV 120

Qy 326 VICESAGTQEDASLRLVTEAMTRYSAAPGDPPOPEYDLELITSCSSSNVVAHDGGRV 385

Db 121 VICESAGTQEDASLRAFTEAMTRYSAAPGDPPOPEYDLELITSCSSSNVVAHDGGRV 180

Qy 386 YYLTRD 391

Db 181 YYLTR 186

Qy 326 VICESAGTQEDASLRSVFTTEAMTRYSAAPGDPPOPEYDLELITSCSSSNVVAHDGGRV 385

Db 121 VICESAGTQEDASLRAFTEAMTRYSAAPGDPPOPEYDLELITSCSSSNVVAHDGGRV 180

Qy 386 YYLTRD 391

Db 181 YYLTR 186

Search completed: September 22, 2005, 14:55:37
 Job time : 44 secs

Qy	61	LQVLDHYDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV	120	Qy	185	TLPQAVMGSYGYFOYSPKORVEFLAVNTMRAKCPMGFSYDTRCPDSTENDIRVEESIY	244				
Db	61	LQVLDHYDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV	120	Db	181	TLPQAVMGSYGYFOYSPKORVEFLAVNTMRAKCPMGFSYDTRCPDSTENDIRVEESIY	240				
Qy	121	NHRSVWDLLEDTPQIOTTIMARNEVFCVQPEKKGRKPARLIVFPDGVRYCEKMLY	180	Qy	245	QCCDLAPEAROAQARSLSLTRLYVGGPMTSISKGONGCYRCRASGLTTSAGNTLTCYLKAA	304				
Db	121	NHRSVWDLLEDTPQIOTTIMARNEVFCVQPEKKGRKPARLIVFPDGVRYCEKMLY	180	Db	241	QCCDLAPEAROAQARSLSLTRLYVGGPMTSISKGONGCYRCRASGLTTSAGNTLTCYLKAT	300				
Qy	181	DVVSUPLQAMGSYGYFOYSPKORVEFLAVNTMRAKCPMGFSYDTRCPDSTENDIRVE	240	Qy	305	ACRAAKLQDCTMLVNGDLVIVICESACTQEDASLRYVETAMTRYSPKGDPBQPEYDL	364				
Db	181	DVVSUPLQAMGSYGYFOYSPKORVEFLAVNTMRAKCPMGFSYDTRCPDSTENDIRVE	240	Db	301	ACRAAKLQDCTMLVNGDLVIVICESACTQEDASLRYVETAMTRYSPKGDPBQPEYDL	360				
Qy	241	BSYIQCDDAPEAROAQARSLTERLYVGGPMTSISKGONGCYRCRASGLTTSAGNTLTCY	300	Qy	365	ELTSCSNSVADASGRKVYLTRDPTVPLARAWEETARHTPVNSLGNIMYAPLW	424				
Db	241	BSYIQCDDAPEAROAQARSLTERLYVGGPMTSISKGONGCYRCRASGLTTSAGNTLTCY	300	Db	361	ELTSCSNSVADASGRKVYLTRDPTVPLARAWEETARHTPVNSLGNIMYAPLW	420				
Qy	301	LKAACACRAAKLQDCTMLVNGDLVIVICESACTGDEAASLRVFTTEAMTRYSPKGDPPOP	360	Qy	425	ARMLTMHFFSISLIAQEOLEKALDCQIYACYSIETPLPQIERRHGLSAFLHSYSPG	484				
Db	301	LKAACACRAAKLQDCTMLVNGDLVIVICESACTGDEAASLRVFTTEAMTRYSPKGDPPOP	360	Db	421	ARMLTMHFFSISLIAQEOLEKALDCQIYACYSIETPLPQIERRHGLSAFLHSYSPG	480				
Qy	361	BYDLELITSCSNSVADASGRKVYLTTRDPTVPLARAWEETARHTPVNSLGNINTMY	420	Qy	485	EINRVAACLRLKLYPPFLWPMRHPARSVAKLISQGGRPAICGKYLLENFAVRTKUKLTIP	544				
Db	361	BYDLELITSCSNSVADASGRKVYLTTRDPTVPLARAWEETARHTPVNSLGNINTMY	420	Db	481	EINRVAACLRLKLYPPFLWPMRHPARSVAKLISQGGRPAICGKYLLENFAVRTKUKLTIP	540				
Qy	421	PTIWARMLMTHFFSISLQEQLEKALDQIYACYSIPLDQIERRHGLSAPSLSH	480	Qy	545	AASRLDLSWAVYSGGDIYHSLSRAPRHHHH	580				
Db	421	PTIWARMLMTHFFSISLQEQLEKALDQIYACYSIPLDQIERRHGLSAPSLSH	480	Db	541	AASQDLSWAVYSGGDIYHSLSRAPRHHHH	576				
Qy	481	YSPGBINRVASCLRKLGVPPLWHRARSVAKLISQSGRAATCGKYLFNWAVRTKUKL	540	RESULT 3							
Db	481	YSPGBINRVASCLRKLGVPPLWHRARSVAKLISQSGRAATCGKYLFNWAVRTKUKL	540	US-10-211-455-1							
Qy	541	TPIPASRIDLSSGMFVAGYSGGDIYHSLSRAPRHHHH	580	; Sequence 1, Application US/10211455							
Db	541	TPIPASRIDLSSGMFVAGYSGGDIYHSLSRAPRHHHH	580	; Publication No US20030108862A1							
RESULT 2								; GENERAL INFORMATION:			
; Sequence 1, Application US/10842046								; APPLICANT: Behringher Ingelheim (Canada) Ltd.			
; GENERAL INFORMATION:								; TITLE OF INVENTION: DIRECT BINDING ASSAY FOR IDENTIFYING			
; APPLICANT: Behringher Ingelheim International GmbH								; TITLE OF INVENTION: INHIBITORS OF HCV POLYMERASE			
; TITLE OF INVENTION: Hepatitis C Virus NS5B Polymerase Inhibitor Binding Pocket								; FILE REFERENCE: 13/088			
; FILE REFERENCE: 13/1233								; CURRENT APPLICATION NUMBER: US/10/211,455			
; CURRENT FILING DATE: 2002-08-02								; CURRENT FILING DATE: 2002-08-02			
; PRIOR APPLICATION NUMBER: 60/310,272								; PRIOR FILING DATE: 2001-08-07			
; NUMBER OF SEQ ID NOS: 4								; NUMBER OF SEQ ID NOS: 4			
; SOFTWARE: FastSEQ for Windows Version 4.0								; SEQ ID NO: 1			
; SEQ ID NO: 1								; LENGTH: 578;			
; LENGTH: 576;								; Score: 2958; DB 17; Length 576;			
; TYPE: PRT								; Best Local Similarity: 96.0%; Pred. No. 2.8e-260; Mismatches: 7; Indels: 0; Gaps: 0;			
; ORGANISM: Hepatitis C virus								; Best Local Similarity: 96.8%; Score: 2958; DB 17; Length 576;			
; US-10-842-046-1								; Best Local Similarity: 96.0%; Pred. No. 2.9e-258; Mismatches: 6; Indels: 2; Gaps: 1;			
; Query Match: 5MSYTWTGALITCPAAEESKLPIINALSNSLIRHNLVTTSRASLQQKTFDRLQLV								; Query Match: 5MSYTWTGALITCPAAEESKLPIINALSNSLIRHNLVTTSRASLQQKTFDRLQLV			
; Best Local Similarity: 95.5%; Pred. No. 2.9e-258; Mismatches: 6; Indels: 2; Gaps: 1;								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; Matches: 552; Conservative: 553; Length: 576;								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 61 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 61 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 121 SWWDLLEDTEPDTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 125 SWWDLLEDTPPIQTTMAKNEVFCVPEKGRKPARLIVFDLGVRVCNLYDVS								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 65 DDHYRDVLKEMKAKASTVKAKLISVEEACKLTPPHSAKSFKGYGAKDVSLSRAV								; Best Local Similarity: 95.1%; Score: 2936; DB 14; Length 578;			
; DB: 1											

305 AACRAAKLQDCMTLVLVVICESAGTQDAASLRVFTTEAMTRYSAPPGDPQPEYDL 364
 301 AACRAAKLQDCMTLVLVVICESAGTQDAASLRVFTTEAMTRYSAPPGDPQPEYDL 360
 365 BLITSCSSNVSVAHDAKGRRVYTLTRDPVPLARAATWARTHPVNSWGNITIMAPTLW 424
 361 BLITSCSSNVSVAHDAKGRRVYTLTRDPVPLARAATWARTHPVNSWGNITIMAPTLW 420
 425 ARMLMTMFFPSILLAQEQLEKALDCQIYCACYCSTEPPLDLPQIERRHGLSAFLSHSYSPG 544
 421 ARMLMTMFFPSILLAQEQLEKALDCQIYCACYCSTEPPLDLPQIERRHGLSAFLSHSYSPG 480
 485 EINRVASCLRKLYGPPPLRVWRHARSVRAKLLSGGRAATCGKYLFLNWAVRTKLUKLTP 544
 481 EINRVASCLRKLYGPPPLRVWRHARSVRAKLLSGGRAATCGKYLFLNWAVRTKLUKLTP 540
 545 AASRLDLSWVAGYSGDIYHSLSRAPER-RRHHHHH 580
 421 ARMLMTMFFPSILLAQEQLEKALDCQIYCACYCSTEPPLDLPQIERRHGLSAFLSHSYSPG 480
 541 AASRLDLSWVAGYSGDIYHSLSRAPER-RRHHHHH 578

RESULT 5
 US-10-170-131-1
 ; Sequence 1, Application US/10170131
 ; Publication No. US20030171874A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Leisburg, Charles A.
 ; APPLICANT: Cable, Michael
 ; APPLICANT: Hong, Zhi
 ; APPLICANT: Manariño, Anthony
 ; APPLICANT: Weber, Patricia
 ; TITLE OF INVENTION: Compositions of Hepatitis C Virus NSSB Polymerase and Methods for Crystallizing Same
 ; FILE REFERENCE: IN0988 US
 ; CURRENT APPLICATION NUMBER: US/10/170,131
 ; CURRENT FILING DATE: 2002-06-12
 ; NUMBER OF SEQ ID NOS: 1
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO: 1
 ; LENGTH: 576
 ; TYPE: PRT
 ; ORGANISM: Hepatitis C virus
 ; FEATURE: VARIANT
 ; NAME/KEY: LOCATION, (335)
 ; OTHER INFORMATION: or valine at 335, 344 and 550 may be threonine
 ; OTHER INFORMATION: arginine or glutamine at 335
 ; OTHER INFORMATION: alanine at 344 and
 ; OTHER INFORMATION: glutamine at 550
 US-10-170-131-1

RESULT 4
 US-10-471-164-3
 ; Sequence 3, Application US/10471164
 ; Publication No. US20040110126A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GEORGE KUKOLJ and Ginette MCKERCHER
 ; TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY
 ; FILE REFERENCE: 13,094
 ; CURRENT APPLICATION NUMBER: US/10/471,164
 ; CURRENT FILING DATE: 2003-09-05
 ; PRIORITY APPLICATION NUMBER: 60/274,374
 ; PRIOR FILING DATE: 2001-03-08
 ; NUMBER OF SEQ ID NOS: 6
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 3
 ; LENGTH: 578
 ; TYPE: PRT
 ; ORGANISM: HCV
 US-10-471-164-3

Query Match 96.1%; Score 2936; DB 16; Length 578;
 Best Local Similarity 95.5%; Pred. No. 2.9e-259; Mismatches 6; Indels 2; Gaps 1;
 Matches 552; Conservative 18; Mismatches 6; Indels 2; Gaps 0;

5 SMSYTWTGALITPCAAEESKLPINALNSLRLHNLVYSTTSRSASLRQKTTFDRQLV 64
 1 SMSYTWTGALITPCAAEESQLPINALNSLVRHNMVYSTTSRSALRQKTTFDRQLV 60
 65 DHYRDVLKEMAKASTVKAKLISVEACKLTPPHSAKSFKFGYAKDVRSLSSRAVHIR 124
 61 DHYRDVLKEMAKASTVKAKLISVEACKLTPPHSAKSFKFGYAKDVRNLSSKAVIDH 120
 125 SWKDLLEDTPIQTTIMAKNEYFCVOPKEGKRPKARLIVFDPGLGVRCENALYDV 184
 121 SWKDLLEDTPIQTTIMAKNEYFCVOPKEGKRPKARLIVFDPGLGVRCENALYDV 180
 185 TLPQAVMGSYYGFOYSPKORVEFLVNTKAKKCPMGFSYDTRCFDSTVENDIRVEESIY 244
 181 TLPQAVMGSYYGFOYSPKORVEFLVNAWKSCKCPMGFSYDTRCFDSTVENDIRVEESIY 240
 245 QCCDLAPERQATFSLTBLVYGGPMNTSKGQNGCYRCRASGVLTTSCGNTTCYKAA 304
 241 QCCDLAPERQATFSLTBLVYGGPMNTSKGQNGCYRCRASGVLTTSCGNTTCYKAA 300
 305 AACRAAKLQDCMTLVLVVICESAGTQDAASLRVFTTEAMTRYSAPPGDPQPEYDL 364
 301 AACRAAKLQDCMTLVLVVICESAGTQDAASLRVFTTEAMTRYSAPPGDPQPEYDL 360
 365 BLITSCSSNVSVAHDAKGRRVYTLTRDPVPLARAATWARTHPVNSWGNITIMAPTLW 424
 361 BLITSCSSNVSVAHDAKGRRVYTLTRDPVPLARAATWARTHPVNSWGNITIMAPTLW 420

Query Match 94.2%; Score 2879; DB 14; Length 576;
 Best Local Similarity 96.0%; Pred. No. 4.5e-253;
 Matches 545; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

7 SYWTGALITPCAAEESKLPINALNSLRLHNLVYSTTSRSASLRQKTTFDRQLV 66
 9 SYWTGALITPCAAEESKLPINALNSLRLHNLVYSTTSRSASLRQKTTFDRQLV 68
 67 HYRVLKEMAKASTVKAKLISVEACKLTPPHSAKSFKFGYAKDVRSLSSRAVHIR 126
 69 HYRVLKEMAKASTVKAKLISVEACKLTPPHSAKSFKFGYAKDVRNLSSKAVIDH 128
 127 WKOLLEDTPIQTTIMAKNEYFCVOPKEGKRPKARLIVFDPGLGVRCENALYDV 186
 60 DB 129 WKOLLEDTPIQTTIMAKNEYFCVOPKEGKRPKARLIVFDPGLGVRCENALYDV 188
 187 PQAVMGSYYGFOYSPKORVEFLVNTKAKKCPMGFSYDTRCFDSTVENDIRVEESIY 246
 189 PQAVMGSYYGFOYSPKORVEFLVNTKAKKCPMGFSYDTRCFDSTVENDIRVEESIY 248
 247 CDLAPERQATFSLTBLVYGGPMNTSKGQNGCYRCRASGVLTTSCGNTTCYKAA 306
 249 CDLAPERQATFSLTBLVYGGPMNTSKGQNGCYRCRASGVLTTSCGNTTCYKAA 308
 307 CRAAKLQDCMTLVLVVICESAGTQDAASLRVFTTEAMTRYSAPPGDPQPEYDL 366
 309 CRAAKLQDCMTLVLVVICESAGTQDAASLRVFTTEAMTRYSAPPGDPQPEYDL 368
 367 ITSCSSNVSVAHDAKGRRVYTLTRDPVPLARAATWARTHPVNSWGNITIMAPTLW 426
 361 ITSCSSNVSVAHDAKGRRVYTLTRDPVPLARAATWARTHPVNSWGNITIMAPTLW 420

Db 369 ITSCSSNVSYAHADASGKRVYYLTTRDPTPLARAATWHTPVNSWLGNINIYAPTLW 428 Db 481 EINRVASSLRKUGVPPPLWRHARSVAKLISQGGRATCGKYLFWAVRTKL---- 534

Qy 427 MILMTHFFSILLAOQLEKALDCOIGACYSIEPLDIPOLIERUHLGSLAFAFSLHSYSPGRI 486 Qy 545 AASRLDLISGWFVAGYSGGDIYHSLSRAPRPRHHHHH 580

Db 429 MILMTHFFSILLAOQLEKALDCOIGACYSIEPLDIPOLIERUHLGSLAFAFSLHSYSPBEI 488 Db 535 :-----HHHHHH 545

Db 487 NRVASCLRKLGVPPLRWRHARSVAKLISQGGRATCGKYLFWAVRTKLKLTPTPA 546

Db 489 NRVASCLRKLGVPPLRWRHARSVAKLISQGGRATCGKYLFWAVRTKLKLTPTPA 548

Qy 547 SRLDLISGWFVAGYSGGDIYHSLSRARPR 574

Db 549 SXDLISGWFVAGYSGGDIYHSLSRARPR 576

RESULT 6

Query Match 89.5%; Score 2734.5; DB 16; Length 545;

Best Local Similarity 90.1%; Pred. No. 6.2e-240; Mismatches 19; Indels 7; Gaps 2; Matches 519; Conservative

Qy 5 SMSYTWTGALITPCAAEESKPLPINALSNSLREHNLYSTTSSEASLRQKKTTFDRLQVL 64

Db 1 SMSYTWTGALITPCAAEESKPLPINALSNSLVRNMYSTTSSEASLRQKKTTFDRLQVL 60

Qy 65 DDHRYDVKEMAKASTVKAKLISVEACKLTPPHSAKSFKGAKDVRSLSSRAVNHIR 124

Db 61 DDHRYDVKEMAKASTVKAKLISVEACKLTPPHSAKSFKGAKDVRNLSSRAVDHIR 120

Qy 125 SWKDLDEDTPIQTTIMAKNEVFCYDPEKGKRPKPARLIVFPLGVRCEKMAKYDVVS 184

Db 121 SWKDLDEDTPIQTTIMAKNEVFCYDPEKGKRPKPARLIVFPLGVRCEKMAKYDVVS 180

Qy 185 TLPQAVMGSYSGFQYSKPOREFLVNTVKAKKCPMGFSYDTRCFDSTVENDIRVEESIY 244

Db 181 TLPQAVMGSYSGFQYSKPOREFLVNAVKSKCPMGFSYDTRCFDSTVENDIRVEESIY 240

Qy 245 QCCDLAPERQAFSRLTERLYGGPMNSKGONGYRCRASGVLTSCGNLTICYKAA 304

Db 241 QCCDLAPERQAFSRLTERLYGGPLTSKGONGYRCRASGVLTSCGNLTICYKAS 300

Qy 305 ACRAAKQDCTMVLVNGDDLVVICESAGTOEASLRYFTTEAMTRYSAPPGDPQPEYDL 164

Db 301 ACRAAKQDCTMVLVNGDDLVVICESAGTOEAAWETRHTPPVNSLGNITMYAPLW 360

Qy 365 ELTSCSSNVSYAHADASGKRVYYLTTRDPTPLARAATWHTPVNSLGNITMYAPLW 424

Db 361 ELTSCSSNVSYAHADASGKRVYYLTTRDPTPLARAATWHTPVNSLGNITMYAPLW 420

Qy 425 ARMLMTHFFSILLAOQLEKALDCQIYGACYSTEPLDIPOLIERLHLSAFLHSYSPG 484

Db 421 ARMLMTHFFSILLAOQLEKALDCQIYGACYSTEPLDIPOLIERLHLSAFLHSYSPG 480

Qy 485 EINRVASSLRKUGVPPPLWRHARSVAKLISQGRAIGKYLFWAVRTKLKLTPTPA 544

RESULT 7

Query Match 89.5%; Score 2734.5; DB 16; Length 545;

Best Local Similarity 90.1%; Pred. No. 6.2e-240; Mismatches 19; Indels 7; Gaps 2; Matches 519; Conservative

Qy 549 AASRLDLISGWFVAGYSGGDIYHSLSRAPRPRHHHHH 580

Db 535 :-----HHHHHH 545

GENERAL INFORMATION:

APPLICANT: HYBRIGENICS

TITLE OF INVENTION: S1D nucleic acids and polypeptides selected from a hepatitis C virus and applications thereof

CURRENT APPLICATION NUMBER: US/09/921397

CURRENT FILING DATE: 2001-08-02

PRIOR APPLICATION NUMBER: EP 00402225.7

PRIOR FILING DATE: 2000-08-03

NUMBER OF SEQ ID NOS: 156

FILE REFERENCE: B409A - JAZ

SEQUENCE 4, Application US/10471164

Publication No. US20040110126A1

GENERAL INFORMATION:

APPLICANT: George KUKOLJ and Ginevra MCKERCHER

TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY

FILE REFERENCE: 13/094

CURRENT APPLICATION NUMBER: US/10/471,164

CURRENT FILING DATE: 2003-09-05

PRIOR APPLICATION NUMBER: 60/274,374

PRIOR FILING DATE: 2001-03-08

NUMBER OF SEQ ID NOS: 6

SOFTWARE: fastSEQ for Windows Version 4.0

SEQ ID NO 4

TYPE: PRT

ORGANISM: Hepatitis C virus

US-09-921-397-107

Query Match 89.5%; Score 2734.5; DB 16; Length 545;

Best Local Similarity 90.1%; Pred. No. 7.4e-118; Mismatches 13; Indels 0; Gaps 0; Matches 263; Conservative

Qy 84 AKLISVEACKLTPPHSAKSFKGAKDVRSLSSRAVNHIRSTWKLDEDTPIQTTIM 143

Db 1 ANLISVEEACSLTPPHSAKSFKGAKDVRCHARKAVHNSWKLDEDTPIQTTIM 60

Qy 144 ARNEVFCVQPERGKRPALIVPDGLVRCEKMAVTDVSTLPQAVNGSSYSGOYSKQ 203

Db 61 ARNEVFCVQPERGKRPALIVPDGLVRCEKMAVTDVSTLPQAVNGSSYSGOYSKQ 120

Db 121 RVEFLVQWKSRTKTPMGFSYDTRCFDSTVENDIRVEESIYOCOCDLAPEAROAIRSLTER 263

Qy 204 RVEFLVNTWKAKKKCPMGFSYDTRCFDSTVENDIRVEESIYOCOCDLAPEAROAIRSLTER 263

Db 181 LYVGGPLTSRGNCYRCRASGVLTSCGNLTICYKARAACRAAGLQDCTMLVCCDD 240

Qy 324 LVVICESAGTQDAAASLVETEAMTRYSAPPGDPQPEYDLITSCSSNVSYAHDAQK 383

Db 241 LVVICESAGQDAAASLRAFTEAMTRYSAPPGDPQPEYDLITSCSSNVSYAHDAQK 300

RESULT 8

Query Match 89.5%; Score 2734.5; DB 16; Length 545;

Best Local Similarity 90.1%; Pred. No. 6.2e-240; Mismatches 19; Indels 7; Gaps 2; Matches 519; Conservative

Qy 264 LYVGGPLTSRGNCYRCRASGVLTSCGNLTICYKAAAACRAAKLQDCTMLVNCDD 323

Db 181 LYVGGPLTSRGNCYRCRASGVLTSCGNLTICYKARAACRAAGLQDCTMLVCCDD 240

Qy 61 DDHRYDVKEMAKASTVKAKLISVEACKLTPPHSAKSFKGAKDVRNLSSRAVDHIR 120

Db 121 DDHRYDVKEMAKASTVKAKLISVEACKLTPPHSAKSFKGAKDVRNLSSRAVDHIR 120

Qy 125 SWKDLDEDTPIQTTIMAKNEVFCYDPEKGKRPKPARLIVFPLGVRCEKMAKYDVVS 184

Db 121 SWKDLDEDTPIQTTIMAKNEVFCYDPEKGKRPKPARLIVFPLGVRCEKMAKYDVVS 180

Qy 185 TLPQAVMGSYSGFQYSKPOREFLVNTVKAKKCPMGFSYDTRCFDSTVENDIRVEESIY 244

Db 181 TLPQAVMGSYSGFQYSKPOREFLVNAVKSKCPMGFSYDTRCFDSTVENDIRVEESIY 240

Qy 245 QCCDLAPERQAFSRLTERLYGGPMNSKGONGYRCRASGVLTSCGNLTICYKAA 304

Db 241 QCCDLAPERQAFSRLTERLYGGPLTSKGONGYRCRASGVLTSCGNLTICYKAS 300

Qy 305 ACRAAKQDCTMVLVNGDDLVVICESAGTOEASLRYFTTEAMTRYSAPPGDPQPEYDL 164

Db 301 ACRAAKQDCTMVLVNGDDLVVICESAGTOEAAWETRHTPPVNSLGNITMYAPLW 360

Qy 365 ELTSCSSNVSYAHADASGKRVYYLTTRDPTPLARAATWHTPVNSLGNITMYAPLW 424

Db 361 ELTSCSSNVSYAHADASGKRVYYLTTRDPTPLARAATWHTPVNSLGNITMYAPLW 420

Qy 425 ARMLMTHFFSILLAOQLEKALDCQIYGACYSTEPLDIPOLIERLHLSAFLHSYSPG 484

Db 421 ARMLMTHFFSILLAOQLEKALDCQIYGACYSTEPLDIPOLIERLHLSAFLHSYSPG 480

Qy 485 EINRVASSLRKUGVPPPLWRHARSVAKLISQGRAIGKYLFWAVRTKLKLTPTPA 544

Query Match 42.0%; Score 1283; DB 17; Length 352;

Qy :-----HHHHHH 545

Best Local Similarity 71.5%; Pred. No. 6.5e-108;
 Matches 243; Conservative 38; Mismatches 59; Indels 0; Gaps 0;

Qy 5 SMSTWTGALITPCLAAEBSKPLPINALSNSLRRHNLVYSTTSEASLRLRKTTFDRLOVL 64
 Db 13 SMSTWTGALITPCLAAEBSKPLPINALSNSLRRHNLVYSTTSEASLRLRKTTFDRLOVL 72

Qy 65 DHYRDVKEKMKAKASTVKAKLISVERACKLTPPHSAKSFKFGKAKDVSLSRAVNHR 124
 Db 73 DHYKRTLDDVKAAGTARLLTEAALTPHSARFKFGKAKDVLAKAVTDIK 132

Qy 125 SWVQDLLEDTPDPIOTTIMAKNEVFCVQPKGKPKPARLIVPDLGVRCERKALYDVVS 184
 Db 133 GWNRLLTDTKTPPIPTSIMAKNEVFCVNPAGKCKPKARLIVPDLGVRCERKALYDQA 192

Qy 185 TLPOAVMGESYGFQYSKPKRVEFLVNTWAKKCPCMGSFSDTRCPDSTTENDRVEESYY 244
 Db 193 KLPQAVMGESYGFQYSKPKRVEFLVNTWAKKCPCMGSFSDTRCPDSTTENDRVEESYY 252

Qy 245 QCCDLAPEARQAIISLTERLYVGGMPTNSKGQNCGYRRCRASGVLTSGNTLTCYKAA 304
 Db 253 QCCNLDPEARQAIISLTERLYVGGMPTNSKGQNCGYRRCRASGVFTSMGNTMTCYIK 312

Qy 305 ACRAAKLGQDCMTLYNGDDLVICESAGTQDAAASLRVT 344
 Db 313 ASASAAGLGSADFLVCGDDLVICESKGVDQDRAALRAFT 352

RESULT 9
 US-09-921-397-109
 Sequence 109, Application US/09921397
 Patent No. US2002151484A1
 GENERAL INFORMATION:
 APPLICANT: HYBRIGENICS
 TITLE OF INVENTION: S1D nucleic acids and polypeptides selected from a
 TITLE OF INVENTION: Pathogenic strain of the hepatitis C virus and
 TITLE OF INVENTION: applications thereof
 FILE REFERENCE: B4809A - JAZ
 CURRENT APPLICATION NUMBER: US/09/921,397
 CURRENT FILING DATE: 2001-08-02
 PRIOR APPLICATION NUMBER: EP 004 02225.7
 PRIOR FILING DATE: 2000-08-03
 NUMBER OF SEQ ID NOS: 156
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 109
 LENGTH: 260
 TYPE: PRT
 ORGANISM: Hepatitis C virus
 US-09-921-397-109

Best Local Similarity 89.2%; Pred. No. 1.9e-103;
 Matches 232; Conservative 11; Mismatches 11; Indels 0; Gaps 0;

Qy 130 LLEDDTPDPIOTTIMAKNEVFCVQPKGKPKPARLIVPDLGVRCERKALYDVSTLPOA 189
 Db 1 LLEDDTPDPIOTTIMAKNEVFCVQPKGKPKPARLIVPDLGVRCERKALYDVSTLPOA 60

Qy 190 VMGSSYGFQYSKPKRVEFLVNTWAKKCPCMGSFSDTRCPDSTTENDRVEESYQCCDL 249
 Db 61 VMGSSYGFQYSKPKRVEFLVNTWAKKCPCMGSFSDTRCPDSTTENDRVEESYQCCDL 120

Qy 250 APEARQAIISLTERLYVGGMPTNSKGQNCGYRRCRASGVLTSGNTLTCYKAAACA 309
 Db 121 DPOQRAVAKSLSLTERLYVGGMPTNSKGQNCGYRRCRASGVLTSGNTLTCYKAAACA 180

Qy 310 AKLQDCMTLYNGDDLVICESAGTQDAAASLRVTEAMTRYSAPPGDPFQPEYDELELITS 369
 Db 181 AGLQDCMTLYNGDDLVICESAGTQDAAASLRVTEAMTRYSAPPGDPFQPEYDELELITS 240

Qy 370 CSSNVSAHDASKRKYVLT 389
 Db 241 CSSNVSAHDGAGKCRKYVLT 260

RESULT 10
 US-10-211-455-3
 Sequence 3, Application US/10211455
 Publication No. US20030108862A1
 GENERAL INFORMATION:
 APPLICANT: Boehringer Ingelheim (Canada) Ltd.
 TITLE OF INVENTION: DIRECT BINDING ASSAY FOR IDENTIFYING
 FILE REFERENCE: 13-088
 CURRENT APPLICATION NUMBER: US/10/211,455
 CURRENT FILING DATE: 2002-03-02
 PRIOR APPLICATION NUMBER: 60/310,272
 PRIOR FILING DATE: 2001-08-07
 NUMBER OF SEQ ID NOS: 4
 SOFTWARE: FastSeq For Windows Version 4.0
 SEQ ID NO: 3

Length: 576
 TYPE: PRT
 ORGANISM: HCV

US-10-211-455-3

Query Match 31.9%; Score 975.5; DB 14;
 Best Local Similarity 38.7%; Pred. No. 1.4e-79;
 Matches 230; Conservative 93; Mismatches 236; Indels 35; Gaps 12;

Qy 4 MMSXYTWTGALITPCLAAEBSKPLPINALSNSLRRHNLVYSTTSEASLRLRKTTFDRLOVL 63
 Db 1 MMSXYTWD-VISPKTAKSVLSTAATTSGLKRSLLVTEPDAELRKQKUTINRQPL 59

Qy 64 LDDHYRDVLKEMKAKASTVKAKLISVERACKLTPPHSAKSFKF-GYGAKDVRSLSSR-AYN 121
 Db 60 FPPSYHKOYVTLAKEKASKVGVNMDYDVEAHTPSKSKAKSHITSLRGTDVRSGLAKAVL 119

Qy 122 HIRSVWDLLEDTPDPI---QTTIMAKNEVFCVQPKGKPKPARLIVPDLGVRCERKAA 178
 Db 120 DLQR----CVAEGRIPSPHYROTVIPVKEEVVKTPQKPKKPPRLISVPHLRCVERNY 175

Qy 179 LYDVVSTLFOAVGNGSYGQYSKPKRVEFLVNTWAKKCPCMGSFSDTRCPDSTTENDR 238
 Db 176 YGQVAPDVYKAVMDAYE-VDPTRVRLLSMSWSPD-AVGATCDTVCEDSTTIPEDIM 232

Qy 239 VEBSIYQCCDLAPEARQAIISLTERLYVGGMPTNSKGQNCGYRRCRASGVLTSGNTLT 298
 Db 233 VETDIYSAAKLSDHOHAGHTIARQLYAGGPMIAYDGRIGYHCRSSGVYTSSNSLT 292

Qy 299 CYLKAAGAACRAAKLQDCTMLVNGDDLVICESAGTQDAAASLRVTEAMTRYSAPPGDP 358
 Db 293 CWLKVNAAAEQAQMKNPRLICGDDCTIWKSAGADAKQAMRVFASNMKVMGAQDCVY 352

RESULT 11
 US-09-921-397-108
 Sequence 108, Application US/09921397
 Patent No. US20120151484A1
 GENERAL INFORMATION:
 APPLICANT: Boehringer Ingelheim (Canada) Ltd.
 TITLE OF INVENTION: DIRECT BINDING ASSAY FOR IDENTIFYING
 FILE REFERENCE: 13-088
 CURRENT APPLICATION NUMBER: US/10/211,455
 CURRENT FILING DATE: 2002-03-02
 PRIOR APPLICATION NUMBER: 60/310,272
 PRIOR FILING DATE: 2001-08-07
 NUMBER OF SEQ ID NOS: 4
 SOFTWARE: FastSeq For Windows Version 4.0
 SEQ ID NO: 3

Length: 576
 TYPE: PRT
 ORGANISM: HCV

US-09-921-397-108

Best Local Similarity 89.2%; Pred. No. 1.9e-103;
 Matches 232; Conservative 11; Mismatches 11; Indels 0; Gaps 0;

Qy 359 QPEYDLEITTSCSNVNTVYAHASQKRYVLTREDFVPLARAANETARPTPVNSWIGNITM 418
 Db 353 QPKSLEBTCSNVNTVYAHASQKRYVLTREDFVPLARAANETARPTPVNSWIGNITM 412

Qy 419 YAPTLWAMILMTHFFSIIAQOQLEKALDCQIYGACYSIEPLDLPQIILERLGLSASFSL 478
 Db 413 HYPLWVSRVLAHFMEQMLFEDKLPEYTFDNYGKNTVPEVDLPSITAGVHGEAFSV 472

Qy 479 HSYSPGEINRVAASLRLKGVPFRVWRHARSYRAKLSQGGRAAIGKYLFLNVAVRTKL 538
 Db 473 VRTNAEILRVLQSLSLTDMPPLRAWRKKARAVLASAKRGRRGAAHKLARFLL-WHATSR- 530

Qy 539 KLTTPAASRLDLSGWFYAGS-----GDIYHLSR-ARPRAHHHHH 580
 Db 531 ---BLP-----DLDKTSVARYTFNYCDVYSPGDFVFTPQRRLQKLEHHHHH 576

APPLICANT: HYBRIGENICS
 TITLE OF INVENTION: S1D nucleic acids and polypeptides selected from a
 TITLE OF INVENTION: pathogenic strain of the hepatitis C virus and
 FILE REFERENCE: B4809A - JAZ
 CURRENT APPLICATION NUMBER: US/09/921,397
 CURRENT FILING DATE: 2001-08-02
 PRIOR APPLICATION NUMBER: EP 00402225.7
 PRIOR FILING DATE: 2000-08-03
 NUMBER OF SEQ ID NOS: 156
 SEQ ID NO: 108
 LENGTH: 199
 TYPE: PRT
 ORGANISM: Hepatitis C virus
 US-09-921-397-108

Query Match 30.0%; Score 915; DB 9; Length 199;
 Best Local Similarity 85.9%; Pred. No. 9.9e-75;
 Matches 171; Conservative 11; Mismatches 17; Indels 0; Gaps 0;

Qy 90 BEACKLTPPHASAKSKFGYAKDVKRSLSRAVNHTRSWKDLLEDTPDQTIMAKNEVF 149
 1 BEACSLTPPHASAKSKFGYAKDVKRCHARGAVAHINSWKDLLEDSTPDTIMAKNEVF 60

Qy 150 CVQPEKGGKPKPARLIVPDLGVRCEKVALYDVVSTLPQAVMGSSYGROYSKPKRVEFLV 209
 Db 61 CVQPKGGKPKARLIVPDLGVRCEKVALYDVVSKPLAVMGSSYGROYSKPKRVEFLV 120

Qy 210 NTWKAKKCPMGFSYDTRCDFSTVENDIRVEESTYQCCDLPEARQATRSLTERLYWGGP 269
 Db 121 QAWSKKTKPMGFSYDTRCDFSTVENDIRVEESTYQCCDLDPQARVAKSLTERLYWGGP 180

Qy 270 MTNSKGQNGCYRRCRASGV 288
 Db 181 LTNSRGNCYRRCRASGV 199

RESULT 12
 US-09-921-397-110
 Application US/09921397
 Patent No. US20020151484A1
 GENERAL INFORMATION:
 APPLICANT: HYBRIGENICS
 TITLE OF INVENTION: S1D nucleic acids and polypeptides selected from a
 TITLE OF INVENTION: pathogenic strain of the hepatitis C virus and
 FILE REFERENCE: B4809A - JAZ
 CURRENT APPLICATION NUMBER: US/09/921,397
 CURRENT FILING DATE: 2001-08-02
 PRIOR APPLICATION NUMBER: EP 00402225.7
 PRIOR FILING DATE: 2000-08-03
 NUMBER OF SEQ ID NOS: 156
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 110
 LENGTH: 127
 TYPE: PRT
 ORGANISM: Hepatitis C virus
 US-09-921-397-110

Query Match 20.4%; Score 623; DB 9; Length 127;
 Best Local Similarity 89.8%; Pred. No. 2.1e-48;
 Matches 114; Conservative 9; Mismatches 4; Indels 0; Gaps 0;

Qy 326 VICESAGTOBDAASLRVFTTEAMTRYSAPPGDPPEYDLELTSCSSNSVADASGKRV 385
 1 VICESAGQDAAASLRVFTTEAMTRYSAPPGDPPEYDLELTSCSSNSVADASGKRV 60

Qy 386 YYLTRDPTPLARAWARETARHTPVNSLGNINMAYPTLWARMILMTHFSISLIAOELEK 445
 Db 61 YYLTRDPTPLARAWARETARHTPVNSLGNINMAYPTLWARMILMTHFSISLIAOELEK 120

Qy 446 ALDCQIV_

Db 121 ALNCETIV 127

RESULT 13
 US-09-921-397-106
 Sequence 106, Application US/09921397
 Patent No. US20020151484A1
 GENERAL INFORMATION:
 APPLICANT: HYBRIGENICS
 TITLE OF INVENTION: S1D nucleic acids and polypeptides selected from a
 TITLE OF INVENTION: pathogenic strain of the hepatitis C virus and
 FILE REFERENCE: B4809A - JAZ
 CURRENT APPLICATION NUMBER: US/09/921,397
 CURRENT FILING DATE: 2001-08-02
 PRIOR APPLICATION NUMBER: EP 00402225.7
 NUMBER OF SEQ ID NOS: 156
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 106
 LENGTH: 137
 TYPE: PRT
 ORGANISM: Hepatitis C virus
 US-09-921-397-106

Query Match 19.1%; Score 595; DB 9; Length 137;
 Best Local Similarity 83.9%; Pred. No. 6.3e-45;
 Matches 115; Conservative 7; Mismatches 15; Indels 0; Gaps 0;

Qy 9 TWTGALITPCAAEESKLPIINALNSLLEHHNLVYSTTSRSASLRQKKTTFDRLQVLDHY 68
 Db 1 SWTGALITPCAAEESKLPIINALNSLLEHHNLVYSTTSRSACQKKTTFDRLQVLDHY 60

Qy 69 RDVYLKEMAKASTYKAKLISVEACKLTTPHSAKSKFGYAKDVRSLHNSLLEHHNLVYSTTSRSAVNHIRSTWK 128
 Db 61 QDVYLKEMAKASTYKAKLISVEACKLTTPHSAKSKFGYAKDVRSLHNSLLEHHNLVYSTTSRSAVNHIRSTWK 120

Qy 129 DJLEDTPQIQTIMAK 145
 Db 121 DJLEDTPQIQTIMAK 137

RESULT 14
 US-09-294-121A-82
 Sequence 82, Application US/09294121A
 Patent No. US20020059422A1
 GENERAL INFORMATION:
 APPLICANT: MAERTENS, GERT; STUYVER, LIEVEN;
 APPLICANT: ROSSAU, RUDI; VAN HEUVERWYN, HUGO
 TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
 TITLE OF INVENTION: ISOLATES
 NUMBER OF SEQUENCES: 97
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: BIERMAN & MUSERLIAN
 STREET: 600 THIRD AVENUE
 CITY: NEW YORK
 STATE: NEW YORK
 COUNTRY: USA
 ZIP: 10016

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/294,121A
 FILING DATE:
 CLASSIFICATION:
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 08/256,568
 FILING DATE: 18-JUL-1994
 APPLICATION NUMBER: PCT/EP93/03325

FILING DATE: 26-NOV-1993
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: EP/93/402,129.6
 FILING DATE: 31-AUG-1993
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: EP/93/402,129.6
 FILING DATE: 27-NOV-1992
 TELECOMMUNICATION INFORMATION:
 NAME: CHARLES A. MUSERLIAN
 REGISTRATION NUMBER: 19,683
 REFERENCE/DOCKET NUMBER: 410.0.004
 TELEFAX: (212) 661-8000
 TELEPHONE: (212) 661-8002
 INFORMATION FOR SEQ ID NO: 82:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 113 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 IMMEDIATE SOURCE: protein
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 POSITION IN GENOME:
 MAP POSITION: n/a
 IMMEDIATE SOURCE:
 LENGTH: 113 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 IMMEDIATE SOURCE: protein
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 POSITION IN GENOME:
 MAP POSITION: n/a
 US-09-294-121a-82

Query Match 18.7%; Score 570; DB 9; Length 113;
 Best Local Similarity 95.6%; Pred. No. 1.2e-43;
 Matches 108; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 230 STTVENDIRVESTIYQCCDLAPEARQAIRSLTTERLYVGPPMTNSKGONGYRRCRASGVL 289
 Db 1 STTVENDIRVESTIYQCCDLAPEARQAIRSLTTERLYVGPPMTNSKGONGYRRCRASGVL 60

Qy 290 TTISCGNTLTCYKAAAACRAAKLQDDCTMLVNGDDLVVICESAGTQEDASLRV 342
 Db 61 TTISCGNTLTCYKAAAACRAAKLQDDCTMLVNGDDLVVICESAGTQEDASLRV 113

Search completed: September 22, 2005, 14:58:37

Job time : 175 secs

APPLICATION NUMBER: EP/93/402,129.6
 FILING DATE: 31-AUG-1993
 PRIORITY APPLICATION DATA:
 NAME: CHARLES A. MUSERLIAN
 REGISTRATION NUMBER: 19,683
 REFERENCE/DOCKET NUMBER: 410.0.004
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 661-8000
 TELEFAX: (212) 661-8002
 INFORMATION FOR SEQ ID NO: 82:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 113 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 IMMEDIATE SOURCE: protein
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 POSITION IN GENOME:
 MAP POSITION: n/a
 US-09-899-082a-82

Query Match 18.7%; Score 570; DB 9; Length 113;
 Best Local Similarity 95.6%; Pred. No. 1.2e-43;
 Matches 108; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 230 STTVENDIRVESTIYQCCDLAPEARQAIRSLTTERLYVGPPMTNSKGONGYRRCRASGVL 289
 Db 1 STTVENDIRVESTIYQCCDLAPEARQAIRSLTTERLYVGPPMTNSKGONGYRRCRASGVL 60

Qy 290 TTISCGNTLTCYKAAAACRAAKLQDDCTMLVNGDDLVVICESAGTQEDASLRV 342
 Db 61 TTISCGNTLTCYKAAAACRAAKLQDDCTMLVNGDDLVVICESAGTQEDASLRV 113

Search completed: September 22, 2005, 14:58:37

Job time : 175 secs

RESULT 15
 US-09-899-082a-82

Sequence 82, Application US/09899082A
 ; Patent No. US20020106638A1
 ; GENERAL INFORMATION:
 ; APPLICANT: MARTEENS, GEBERT; STUYVER, LIEVEN;
 ; ROSSAU, RUDI; VAN HEUVERSWN, HUGO
 ; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
 ; ISOLATES
 ; NUMBER OF SEQUENCES: 97
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEER: BIERMAN & MUSERLIAN
 ; STREET: 600 THIRD AVENUE
 ; CITY: NEW YORK
 ; STATE: NEW YORK
 ; COUNTRY: USA
 ; ZIP: 10016
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: ASCII
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/899,082A
 ; FILING DATE: 06-Jul-2001
 ; CLASSIFICATION: <Unknown>
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/378,900
 ; FILING DATE: <Unknown>
 ; APPLICATION NUMBER: 08/256,568
 ; FILING DATE: 18-JUL-1994
 ; APPLICATION NUMBER: PCT/EP93/03325
 ; FILING DATE: 26-NOV-1993

This Page Blank (uspto)